"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtWith_AU_IN_FIRST","meanArtWith_AU_IN_LAST","meanArtWith_AU_IN_CORR","mean_articles_per_internal_author","mean_articles_per_internal_first_author","mean_articles_per_internal_last_author","mean_articles_per_internal_corresponding_author","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","meanCitationTrend","InternCoauthorship","AffCoauthorship","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"IRCCS_SPALLANZANIROMA",2000,55,8.72727272727273,2.09090909090909,0.2,0.309090909090909,0.2,1.41975308641975,1.1,1.88888888888889,1.1,0.363636363636364,0,30,6,5,14,0.55,0.11,0.09,0.25,45.67,1.00753898702243,NA,0.272727272727273,0.945454545454545,0.45,0.559,0.539,0.559,"GIUSEPPE IPPOLITO;ANDREA DE LUCA;A. CINGOLANI;ENRICO GIRARDI;ANTONELLA D’ARMINIO MONFORTE;GIOVANNI REZZA;ANDREA ANTINORI;ADRIANA AMMASSARI;CARLO FEDERICO PERNO;STEFANO AQUARO;ADRIANO LAZZARIN;PATRIZIO PEZZOTTI;RITA MURRI;GUIDO ANTONELLI;MARIA GRAZIA PAGLIA;F. DIANZANI;MAURO MORONI;R CALIÒ;F AIUTI;NICOLA PETROSILLO","16;7;6;6;6;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3","GIUSEPPE IPPOLITO;VINCENZO PURO;ENRICO GIRARDI;ANDREA DE LUCA;A. CINGOLANI;RAE S;JOAN MONTANER;JANET RABOUD;ADRIANA AMMASSARI;ANDREA ANTINORI;RITA MURRI;NICOLA MAGNAVITA;A. FILENI;CARLO FEDERICO PERNO;ANTONELLA D’ARMINIO MONFORTE;STEFANO AQUARO;PAOLO VISCA;GUIDO ANTONELLI;GIOVANNI REZZA;GIORGIO ANTONUCCI","2.65;1.14;0.92;0.73;0.69;0.67;0.67;0.67;0.58;0.55;0.55;0.5;0.5;0.49;0.39;0.39;0.37;0.36;0.36;0.34","GIUSEPPE IPPOLITO;ANDREA DE LUCA;A. CINGOLANI;ENRICO GIRARDI;ANDREA ANTINORI;ADRIANA AMMASSARI;CARLO FEDERICO PERNO;STEFANO AQUARO;RITA MURRI;MARIA GRAZIA PAGLIA;NICOLA PETROSILLO;VINCENZO PURO;M CASARINI;MASSIMO AMICOSANTE;FEDERICA FORBICI;RAE S;S GIOSUÈ;ERIK DE CLERCQ;PAOLO VISCA;MARIA LETIZIA GIANCOLA","16;7;6;6;5;5;5;4;4;3;3;3;2;2;2;2;2;2;2;2","GIUSEPPE IPPOLITO;VINCENZO PURO;ENRICO GIRARDI;ANDREA DE LUCA;A. CINGOLANI;RAE S;ADRIANA AMMASSARI;ANDREA ANTINORI;RITA MURRI;A. FILENI;CARLO FEDERICO PERNO;STEFANO AQUARO;PAOLO VISCA;GIORGIO ANTONUCCI;MARIA GRAZIA PAGLIA;NICOLA PETROSILLO;MARIA LETIZIA GIANCOLA;M CASARINI;S GIOSUÈ;A BISETTI","2.65;1.14;0.92;0.73;0.69;0.67;0.58;0.55;0.55;0.5;0.49;0.39;0.37;0.34;0.32;0.26;0.26;0.25;0.25;0.25","GIUSEPPE IPPOLITO;ANDREA DE LUCA;ANDREA ANTINORI;ANTONELLA D’ARMINIO MONFORTE;GIOVANNI REZZA;PATRIZIO PEZZOTTI;MAURO MORONI;GIOACCHINO ANGARANO;ALESSANDRO COZZI‐LEPRI;ANDREW N. PHILLIPS;FABRICE GRITTI;FABRIZIO SOSCIA;G. FILICE;L CAGGESE;PASQUALE NARCISO;UMBERTO TIRELLI;VINCENZO COLANGELI;ENRICO GIRARDI;A. CINGOLANI;GIORGIO ANTONUCCI","1095;928;833;746;643;631;622;559;550;550;550;550;550;550;550;550;550;392;340;317","GIUSEPPE IPPOLITO;ANDREA ANTINORI;PASQUALE NARCISO;ADRIANA AMMASSARI;LIONETTI;MARCO GENTILE;PAOLO GROSSI;MARIA GRAZIA PAGLIA;CARLO FEDERICO PERNO;GIORGIO ANTONUCCI;MARIO RAVIǴLIONE;PETER GODFREY‐FAUSSETT;S GIOSUÈ;PAOLO VISCA;GIUSEPPINA LIUZZI;SUSANNA GRISETTI;ALESSANDRO SAMPAOLESI;GIUSEPPINA NURRA;CHIARA RAMPAZZO;CHRIS MEIER","1060;696;550;195;185;181;181;172;154;142;142;142;131;128;111;111;63;63;59;59","GIUSEPPE IPPOLITO;CARLO FEDERICO PERNO;ANDREA ANTINORI;MARCO GENTILE;ADRIANA AMMASSARI;MARIA GRAZIA PAGLIA;NICOLA PETROSILLO;VINCENZO PURO;ENRICO GIRARDI;FEDERICA FORBICI;GIORGIO MANCINO;PAOLO VISCA;RAE S;S GIOSUÈ;A BISETTI;A. CINGOLANI;A. FILENI;ADRIANO PELLICELLI;ALBERTO ANGELICI;ALBERTO FRANCHI","13;5;4;3;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;ECONOMICS;POLITICAL SCIENCE;BUSINESS;ENGINEERING;SOCIOLOGY","41;27;6;5;3;2;2;2;1;1;1","IMMUNOLOGY;INTERNAL MEDICINE;BIOCHEMISTRY;VIROLOGY;PATHOLOGY;GASTROENTEROLOGY;GENETICS;SURGERY;MICROBIOLOGY;MOLECULAR BIOLOGY;ENVIRONMENTAL HEALTH;FAMILY MEDICINE;PHARMACOLOGY;CELL BIOLOGY;INTENSIVE CARE MEDICINE;ASTRONOMY;BIOTECHNOLOGY;CLINICAL PSYCHOLOGY;COMPUTATIONAL BIOLOGY;ECONOMIC GROWTH;ENDOCRINOLOGY;GYNECOLOGY;LAW;OPTICS;PALEONTOLOGY;RADIOLOGY;WORLD WIDE WEB","34;31;19;18;13;12;12;6;5;5;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2","HUMAN IMMUNODEFICIENCY VIRUS (HIV);GENE;VIRUS;IN VITRO;CONFIDENCE INTERVAL;TUBERCULOSIS;COHORT;IMMUNE SYSTEM;REGIMEN;APOPTOSIS;CANCER;IN VIVO;CHEMOTHERAPY;CYTOKINE;INTERFERON;INTRACELLULAR;LYMPHOCYTE;ADIPOSE TISSUE;ADVERSE EFFECT;ANTIBIOTICS;ANTIBODY;ANTIGEN;ASYMPTOMATIC;CENTRAL NERVOUS SYSTEM;CHOLESTEROL;CONTEXT (ARCHAEOLOGY);CROSS-SECTIONAL STUDY;DISCONTINUATION;DRUG;ENZYME;HEPATITIS C;INCIDENCE (GEOMETRY);INFLAMMATION;MALARIA;MONOCYTE;MULTIPLE SCLEROSIS;NUCLEOSIDE;PARASITE HOSTING;POPULATION;RECEPTOR;YOUNG ADULT","24;16;13;10;6;6;5;5;5;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","VIRAL LOAD;VIRAL DISEASE;PERIPHERAL BLOOD MONONUCLEAR CELL;VIRAL REPLICATION;ALPHA INTERFERON;CD8;GENOTYPE;MYCOBACTERIUM TUBERCULOSIS;POLYMERASE CHAIN REACTION;CERVICAL CANCER;CHRONIC HEPATITIS;CYTOTOXIC T CELL;GENOME;HAZARD RATIO;HEPATITIS B VIRUS;NUCLEOTIDE;PLASMODIUM FALCIPARUM;PROGRAMMED CELL DEATH;PROTEASE;RELATIVE RISK;RNA;SEROCONVERSION;TUBERCULIN;VIREMIA","20;14;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;SIDA;LENTIVIRUS;REVERSE TRANSCRIPTASE;CERVICAL INTRAEPITHELIAL NEOPLASIA;GAMETOCYTE;INTERFERON ALFA;LAMIVUDINE;RIBAVIRIN;ZIDOVUDINE;ACTIVE IMMUNIZATION;ALPHA (FINANCE);ANNEXIN A5;CASPASE 3;CD40;CONDOM;CULTURE CONVERSION;CYTOLYSIS;DNA FRAGMENTATION;FAS RECEPTOR;GENOTYPING;HERPESVIRIDAE;HSP70;INTEGRON;INTERNAL TRANSCRIBED SPACER;JC VIRUS;MAMMOGRAPHY;MOLECULAR MEDICINE;MYELIN BASIC PROTEIN;NESTED POLYMERASE CHAIN REACTION;OPPORTUNISTIC INFECTION;ORNITHINE;PROVIRUS;RAPID UREASE TEST;REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;SALMONELLA ENTERICA;SEROSTATUS;SEROTONIN TRANSPORTER;SLOW VIRUS;SPLENIC DISEASE;SUBTELOMERE;THYMIDYLATE SYNTHASE;TINIDAZOLE;UREA BREATH TEST;VINCRISTINE","15;8;6;4;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HIV INFECTIONS;HUMANS;ANTI-HIV AGENTS;FEMALE;ADULT;HIV-1;MALE;RNA, VIRAL;MIDDLE AGED;HIV PROTEASE INHIBITORS;MACROPHAGES;HIV SEROPOSITIVITY;INDINAVIR;RITONAVIR;ACQUIRED IMMUNODEFICIENCY SYNDROME;AGED;ANTIVIRAL AGENTS;DRUG THERAPY, COMBINATION;INTERFERON-ALPHA;PLASMODIUM FALCIPARUM","65;47;37;26;25;23;22;18;16;15;15;12;12;12;11;11;11;10;10;10","HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;HEPATITIS C INFECTION AND TREATMENT;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;MALARIA;TUBERCULOSIS;CLINICOPATHOLOGY OF FIBROUS TUMORS AND TREATMENT STRATEGIES;DIAGNOSIS AND MANAGEMENT OF ABDOMINAL TUBERCULOSIS;DIAGNOSIS AND MANAGEMENT OF CARDIAC TUMORS;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;EPIDEMIOLOGY AND PATHOGENESIS OF PNEUMOCYSTIS PNEUMONIA;ERRORS AND COMMUNICATION IN RADIOLOGY IMAGING;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;GUILLAIN-BARRÉ SYNDROME AND RELATED NEUROPATHIES;HEALTHCARE POLICY REFORMS AND INEQUALITIES IN FRANCE;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;IMMUNOBIOLOGY OF DENDRITIC CELLS","11;6;4;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","HIV;ANTIRETROVIRAL THERAPY;HIV INFECTION;HIV TRANSMISSION;INDINAVIR;REGIMEN;AIDS;ANTIBODIES;PROTEASE INHIBITOR (PHARMACOLOGY);RITONAVIR;TREATMENT;ANTIRETROVIRAL TREATMENT;CROSS-SECTIONAL STUDY;DISCONTINUATION;HEPATITIS C;HIV EPIDEMIOLOGY;IMMUNE RESPONSES;INTERFERON ALFA;KOILOCYTE;MONOCYTE","18;13;10;6;5;5;4;4;4;4;4;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;HUMAN IMMUNODEFICIENCY;HIV INFECTION;IMMUNODEFICIENCY VIRUS;ACTIVE ANTIRETROVIRAL;ANTIRETROVIRAL AGENTS;ANTIRETROVIRAL CLINICAL;CHRONIC HEPATITIS;CLINICAL TRIALS;COMBINATION ANTIRETROVIRAL;EXPOSURE CATEGORIES;HEALTHY HIV-NEGATIVE;HEART SURGERY;HIGHLY ACTIVE;HIV RNA;HIV- INFECTION;HIV- PROTEASE;HIV-NEGATIVE INDIVIDUALS;LOAD CONCENTRATIONS;PLASMA VIRAL;PLASMODIUM FALCIPARUM;PREDICTING HIV;PROTEASE INHIBITOR;RNA VIROLOGIC;SUBSET COUNTS;T-LYMPHOCYTE SUBSET;TYPE INFECTION;VIRAL LOAD;VIROLOGIC OUTCOME;VIRUS TYPE","7;6;5;5;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;HIV RNA;PLASMA HIV;TOTAL CHOLESTEROL;VIRAL LOAD;RNA CONCENTRATIONS;TRIGLYCERIDE LEVELS;CONFIDENCE INTERVAL;RH CI;EBV DNA;HIV-INFECTED PATIENTS;SOT RECIPIENTS;HIV INFECTION;INTERVAL CI;SYMPTOMATIC EBV;CD COUNT;CHRONIC HEPATITIS;DNA LEVELS;EBV INFECTIONS;HODGKINS DISEASE;LOG COPIESML;MG BD;PSEUDOMONAS STRAIN;REGIMENS RH;RESPONSE OCCURRED;STANDARD ABVD;CD CELL;COHORT STUDY;COMBINATION THERAPY;DRUG USERS","17;10;9;9;9;8;8;7;7;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3",7,0.13,4.5,3,0,0,0,0,12.5,0,1,3.5,0,0,0,0,0,0,0,0,0,0,0,43,43.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,4914917,175532.75,5,28,10,1,32,35106.55,1.56665921316677,"AUTONOMOUS UNIVERSITY OF BARCELONA;BIOMEDICAL PRIMATE RESEARCH CENTRE;DEPARTMENT FOR ENVIRONMENT, FOOD AND RURAL AFFAIRS;DÉLÉGATION MIDI PYRÉNÉES;DÉLÉGATION PARIS 11;GLAXOSMITHKLINE (BELGIUM);HELMHOLTZ CENTRE FOR INFECTION RESEARCH;IMPERIAL COLLEGE LONDON;INSTITUT PASTEUR;ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI;LEIDEN UNIVERSITY;LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE;MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS;PASTEUR INSTITUTE OF LILLE;PUBLIC HEALTH AGENCY OF SWEDEN;PUBLIC HEALTH ENGLAND;QUEEN'S UNIVERSITY BELFAST;ROYAL VETERINARY COLLEGE;SANOFI (FRANCE);STATENS SERUM INSTITUT","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CSC - COST-SHARING CONTRACTS (FUNDING SCHEME);FP5-LIFE QUALITY - SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""QUALITY OF LIFE AND MANAGEMENT OF LIVING RESOURCES"", 1998-2002 (PROGRAMME)","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY","1;1","BIOTECHNOLOGY;EMERGING INFECTIOUS DISEASES;HIV/AIDS;IMMUNIZATION;INFECTIOUS DISEASES;PREVENTION;RARE DISEASES;TUBERCULOSIS;TUBERCULOSIS VACCINE;VACCINE RELATED","1;1;1;1;1;1;1;1;1;1","INFECTION","1","3.4 VACCINES","1",NA,NA,NA,NA,"A06 AGRICULTURE, VETERINARY AND FOOD SCIENCE","1","3 GOOD HEALTH AND WELL BEING","1",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SPALLANZANIROMA",2001,88,7.79545454545455,3.23863636363636,0.5,0.454545454545455,0.534090909090909,2.08888888888889,1.46666666666667,2.5,1.38235294117647,0.352272727272727,3,40,7,7,29,0.45,0.08,0.08,0.33,39.25,0.859004453036004,NA,0.193181818181818,0.806818181818182,0.574,0.534,0.546,0.515,"GIUSEPPE IPPOLITO;ANDREA ANTINORI;NICOLA PETROSILLO;ENRICO GIRARDI;DIEGO SERRAINO;VINCENZO PURO;GABRIELLA DE CARLI;ADRIANA AMMASSARI;ANDREA DE LUCA;A. CINGOLANI;PASQUALE NARCISO;PAOLO VISCA;MAURO PIACENTINI;LAURA FALASCA;GIOVANNI REZZA;CHIARA AGRATI;FABRIZIO POCCIA;NICOLETTA ORCHI;EMANUELE NICASTRI;RITA MURRI","34;14;11;11;10;9;8;7;6;6;6;5;5;5;4;4;4;4;4;4","GIUSEPPE IPPOLITO;ENRICO GIRARDI;NICOLA PETROSILLO;ANDREA ANTINORI;DIEGO SERRAINO;VINCENZO PURO;GABRIELLA DE CARLI;ADRIANA AMMASSARI ANDREA ANTINORI;ADRIANA AMMASSARI;PAOLO VISCA;A. CINGOLANI;EMANUELE NICASTRI;LAURA FALASCA;PASQUALE NARCISO;MAURO PIACENTINI;E. BORDI;ANDREA DE LUCA;PIERLUCA PISELLI;CHIARA AGRATI;FABRIZIO POCCIA","7.08;2.51;1.85;1.78;1.46;1.43;1.26;1;0.98;0.94;0.84;0.83;0.73;0.73;0.62;0.6;0.57;0.56;0.55;0.55","GIUSEPPE IPPOLITO;ANDREA ANTINORI;NICOLA PETROSILLO;ENRICO GIRARDI;DIEGO SERRAINO;VINCENZO PURO;GABRIELLA DE CARLI;ADRIANA AMMASSARI;PASQUALE NARCISO;PAOLO VISCA;MAURO PIACENTINI;LAURA FALASCA;CHIARA AGRATI;FABRIZIO POCCIA;NICOLETTA ORCHI;EMANUELE NICASTRI;VITTORIO COLIZZI;PASQUALE NARCISO;GIANPIERO D’OFFIZI;VALERIO TOZZI","34;14;11;11;10;9;8;7;6;5;5;5;4;4;4;4;4;3;3;3","GIUSEPPE IPPOLITO;ENRICO GIRARDI;NICOLA PETROSILLO;ANDREA ANTINORI;DIEGO SERRAINO;VINCENZO PURO;GABRIELLA DE CARLI;ADRIANA AMMASSARI ANDREA ANTINORI;ADRIANA AMMASSARI;PAOLO VISCA;EMANUELE NICASTRI;LAURA FALASCA;PASQUALE NARCISO;MAURO PIACENTINI;E. BORDI;PIERLUCA PISELLI;CHIARA AGRATI;FABRIZIO POCCIA;ANTONINO DI;VITTORIO COLIZZI","7.08;2.51;1.85;1.78;1.46;1.43;1.26;1;0.98;0.94;0.83;0.73;0.73;0.62;0.6;0.56;0.55;0.55;0.53;0.51","GIUSEPPE IPPOLITO;ANDREA ANTINORI;ADRIANA AMMASSARI;PASQUALE NARCISO;GIOVANNI REZZA;MAURO MORONI;DIEGO SERRAINO;ANDREA DE LUCA;RITA MURRI;PATRIZIO PEZZOTTI;PATRIZIO DE LONGIS;A. CINGOLANI;ALBERT W. WU;NICOLA PETROSILLO;ANTONELLA D'ARMINIO MONFORTE;CRESCENZO MARIA IZZO;GIAMPIERO CAROSI;LAURA RAVASIO;MARIA PAOLA TROTTA;MIRIAM LICHTNER","1600;1257;852;728;710;671;623;618;569;558;536;525;497;489;464;464;464;464;464;464","GIUSEPPE IPPOLITO;ANDREA ANTINORI;ADRIANA AMMASSARI;PASQUALE NARCISO;PATRIZIO DE LONGIS;NICOLA PETROSILLO;MARIA PAOLA TROTTA;DIEGO SERRAINO;FABRIZIO PALMIERI;VINCENZO PURO;MAURO PIACENTINI;LUCIA ALBA;LUIGI RUCO;VALERIO TOZZI;ALESSANDRA AMENDOLA;ENRICO GIRARDI;ROBERTA NARDACCI;TONINO ALONZI;GABRIELLA DE CARLI;ALFONSO MELE","1539;1180;819;728;536;475;464;395;311;289;212;211;211;188;185;175;170;160;152;151","GIUSEPPE IPPOLITO;ANDREA ANTINORI;ENRICO GIRARDI;NICOLA PETROSILLO;PASQUALE NARCISO;VINCENZO PURO;DIEGO SERRAINO;GABRIELLA DE CARLI;ADRIANA AMMASSARI;VALERIO TOZZI;LAURA FALASCA;MAURO PIACENTINI;ANNA ROSA GARBUGLIA;C CARVELLI;E. BORDI;EMANUELE NICASTRI;FABRIZIO PALMIERI;FABRIZIO POCCIA;GIANPIERO D’OFFIZI;LAURA VINCENZI","31;12;11;10;9;8;8;7;6;5;4;4;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;POLITICAL SCIENCE;PSYCHOLOGY;SOCIOLOGY;ECONOMICS;ENGINEERING;GEOGRAPHY;MATHEMATICS;HISTORY;PHILOSOPHY","68;39;8;7;6;4;4;4;3;3;2;2;1;1","INTERNAL MEDICINE;IMMUNOLOGY;VIROLOGY;GENETICS;BIOCHEMISTRY;PATHOLOGY;FAMILY MEDICINE;SURGERY;ENVIRONMENTAL HEALTH;PEDIATRICS;INTENSIVE CARE MEDICINE;GASTROENTEROLOGY;MICROBIOLOGY;OPTICS;CELL BIOLOGY;EMERGENCY MEDICINE;PSYCHIATRY;DEMOGRAPHY;LAW;PHARMACOLOGY","45;40;29;24;16;15;10;10;9;9;8;7;7;7;5;5;5;4;4;4","HUMAN IMMUNODEFICIENCY VIRUS (HIV);VIRUS;GENE;IMMUNE SYSTEM;PROSPECTIVE COHORT STUDY;DISEASE;ANTIGEN;CONFIDENCE INTERVAL;ENZYME;IN VITRO;INCIDENCE (GEOMETRY);ANTIBIOTICS;APOPTOSIS;HEPATITIS C;BACTERIA;CANCER;CYTOKINE;EPIDEMIOLOGY;ODDS RATIO;POPULATION","37;26;12;12;10;8;7;7;7;7;7;6;6;6;5;5;5;5;5;5","VIRAL LOAD;VIRAL DISEASE;HEPATITIS C VIRUS;T CELL;HEPATITIS B VIRUS;PERIPHERAL BLOOD MONONUCLEAR CELL;INFECTIOUS DISEASE (MEDICAL SPECIALTY);POLYMERASE CHAIN REACTION;VIRAL REPLICATION;HUMAN LEUKOCYTE ANTIGEN;SEROCONVERSION;TISSUE TRANSGLUTAMINASE;ALPHA INTERFERON;ANTIBIOTIC RESISTANCE;BACTEREMIA;COINFECTION;GENOME;GENOTYPE;HAZARD RATIO;HEART RATE;INTERFERON GAMMA;MUCOCUTANEOUS ZONE;MULTIPLE DRUG RESISTANCE;MYCOBACTERIUM TUBERCULOSIS;NEUROCOGNITIVE;PHYLOGENETIC TREE;PHYLOGENETICS;PLASMID;PROGRAMMED CELL DEATH;PROTEASE;SALMONELLA;SEROLOGY;STAPHYLOCOCCUS AUREUS;UNIVARIATE ANALYSIS","17;12;8;7;5;5;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;LENTIVIRUS;SIDA;REVERSE TRANSCRIPTASE;CLADE;HBSAG;INTEGRON;LAMIVUDINE;SALMONELLA ENTERICA;T-CELL RECEPTOR;ALPHA (FINANCE);ANTIBODY TITER;AUTONOMIC NERVOUS SYSTEM;BILIARY CIRRHOSIS;BREAST CARCINOMA;BRONCHOPULMONARY DYSPLASIA;CARDIAC INDEX;CASPASE 3;CEFTAZIDIME;CENTRAL VENOUS PRESSURE;CONDOM;CORONAVIRUS DISEASE 2019 (COVID-19);CYCLIN;CYCLIN D1;FLAVIVIRIDAE;GANCICLOVIR;GENOTYPE-PHENOTYPE DISTINCTION;GENOTYPING;HEART RATE VARIABILITY;HEPACIVIRUS;HERPESVIRIDAE;HYPERTRIGLYCERIDEMIA;IL-2 RECEPTOR;INTERFERON ALFA;INTERLEUKIN 21;INTRAVENOUS DRUG;LONG TERMINAL REPEAT;MOLECULAR EPIDEMIOLOGY;MYCOBACTERIUM BOVIS;ORTHOSTATIC INTOLERANCE;PAROXETINE;PROVIRUS;RETINITIS;RIBAVIRIN;SEROPREVALENCE;SEROTONERGIC;SEROTONIN TRANSPORTER;SEXUAL TRANSMISSION;SLOW VIRUS;TAUROURSODEOXYCHOLIC ACID;VANCOMYCIN;VIRAL EVOLUTION;VIRAL QUASISPECIES;ZIDOVUDINE","15;5;5;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HIV INFECTIONS;HUMANS;FEMALE;MALE;ADULT;HIV-1;ACQUIRED IMMUNODEFICIENCY SYNDROME;ANTI-HIV AGENTS;ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE;MIDDLE AGED;HEPATITIS C;ITALY;;LYMPHOMA, AIDS-RELATED;LYMPHOMA, NON-HODGKIN;CROSS INFECTION;AIDS-RELATED OPPORTUNISTIC INFECTIONS;RNA, VIRAL;AGED;ADOLESCENT","86;70;40;36;35;33;25;22;20;20;17;17;14;14;14;13;12;12;11;10","HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;NATURAL KILLER CELLS IN IMMUNITY;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;EPIDEMIOLOGY AND PATHOGENESIS OF PNEUMOCYSTIS PNEUMONIA;HEPATITIS C INFECTION AND TREATMENT;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;INFECTION CONTROL IN HEALTHCARE SETTINGS;TUBERCULOSIS;BIOAVAILABILITY AND HEALTH EFFECTS OF CURCUMIN;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND MANAGEMENT OF LIVER DISEASES;DIAGNOSIS AND TREATMENT OF SPINAL INFECTIONS;ECONOMICS OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT;EMERGING ZOONOTIC DISEASES AND ONE HEALTH APPROACH;ENGINEERING BACTERIA FOR CANCER TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NEONATAL SEPSIS","13;6;6;5;4;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1","HIV;ANTIRETROVIRAL THERAPY;HIV INFECTION;HEPATITIS C;REGIMEN;HIV TRANSMISSION;ADHERENCE TO MEDICATION;HUMAN HERPESVIRUS 8;IMMUNE ACTIVATION;MEMORY T CELLS;RITONAVIR;SEROCONVERSION;TISSUE TRANSGLUTAMINASE;TREATMENT;ANTIMICROBIAL RESISTANCE GENES;APOPTOSIS;BACTEREMIA;DIAGNOSIS;ETIOLOGY;HEPATITIS B","19;16;7;5;5;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;ACTIVE ANTIRETROVIRAL;HIGHLY ACTIVE;HUMAN IMMUNODEFICIENCY;HIV INFECTION;IMMUNODEFICIENCY VIRUS;PATIENTS TREATED;INFECTIOUS DISEASES;CHRONIC HEPATITIS;DRUG RESISTANCE;LAZZARO SPALLANZANI;TISSUE TRANSGLUTAMINASE;TRANSGLUTAMINASE EXPRESSION;BACTERIAL PNEUMONIA;CELL SUBSET;CHANGING PATTERNS;DISEASES LAZZARO;EXPANDING DRUG;HCV-INFECTED PERSONS;HEALTHCARE WORKERS;HIV TYPE;HIV- STRAINS;HUMAN HERPESVIRUS;INCFI PLASMIDS;INCREASING PREVALENCE;INFECTED PATIENTS;INTEGRON ACQUISITION;LYMPHOCYTES EXPRESSING;MULTIPLE LETTERS;NATIONAL INSTITUTE","11;10;10;6;5;5;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","IL- MEDIAN;MEDIAN PGML;PGML NA;PGML RANGE;ANTIRETROVIRAL THERAPY;ACTIVE ANTIRETROVIRAL;HIGHLY ACTIVE;POL GENE;VIRAL LOAD;RESISTANCE MUTATIONS;SOURCE PATIENT;CRP MEDIAN;HIV- SUBTYPES;IL- LEVELS;MEDIAN MGL;OUTBREAK PATIENTS;PGML CRP;RNA COPIESML;ALT LEVELS;CHRONIC HEPATITIS;CONFIDENCE INTERVAL;HR CI;HUMAN IMMUNODEFICIENCY;IMMUNODEFICIENCY VIRUS;MGL NA;MGL RANGE;PGML IL-;SALVAGE THERAPY;BOOTSCAN ANALYSIS;COHORT NAIVE","12;12;12;12;10;8;8;8;8;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;4;4",15,0.17,6,2,0,1,0,0,2.25,0,2,4,0,1,1,0,1,0,0,1,0,0,0,37,37,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,0,16,0.8,0,0,51,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,"United States","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY","1;1","CLINICAL RESEARCH;HIV/AIDS;INFECTIOUS DISEASES","1;1;1","INFECTION","1","6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,2,1595434,294478.07,5.5,5.5,4,1,15,141468.816666667,0.622045211612595,"ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI;ALFASIGMA (ITALY);HOSPITAL UNIVERSITARIO SANTA CRISTINA;ISTITUTO SUPERIORE DI SANITÀ;JENNER INSTITUTE;KAROLINSKA INSTITUTET;KU LEUVEN;SPANISH NATIONAL RESEARCH COUNCIL;UNIVERSITY OF OXFORD;UNIVERSITY OF PADUA","2;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","FP5-LIFE QUALITY - SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""QUALITY OF LIFE AND MANAGEMENT OF LIVING RESOURCES"", 1998-2002 (PROGRAMME);CSC - COST-SHARING CONTRACTS (FUNDING SCHEME);DEM - DEMONSTRATION CONTRACTS (FUNDING SCHEME)","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","2;1;1;1","BIOTECHNOLOGY;CANCER;DIGESTIVE DISEASES;GENETICS;HEPATITIS;HEPATITIS - B;IMMUNIZATION;INFECTIOUS DISEASES;LIVER DISEASE;PREVENTION;VACCINE RELATED","1;1;1;1;1;1;1;1;1;1;1","CANCER;INFECTION","1;1","3.4 VACCINES;6.1 PHARMACEUTICALS","1;1","NOT SITE-SPECIFIC CANCER","1","5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","1","A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1;1","3 GOOD HEALTH AND WELL BEING","1",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SPALLANZANIROMA",2002,80,10.5375,3.4875,0.4125,0.4375,0.5,2.17647058823529,1.19230769230769,1.65,1.31034482758621,0.5,0,39,12,13,15,0.49,0.15,0.16,0.19,43.76,0.793248556840608,NA,0.3875,0.8625,0.427,0.378,0.429,0.371,"GIUSEPPE IPPOLITO;ANDREA ANTINORI;NICOLA PETROSILLO;LEOPOLDO PAOLO PUCILLO;CARLO FEDERICO PERNO;PAOLO VISCA;ENRICO GIRARDI;MARIA ROSARIA CAPOBIANCHI;GIOVANNI REZZA;GIANPIERO D’OFFIZI;FABRIZIO POCCIA;MAURO ZACCARELLI;EMANUELE NICASTRI;DIEGO SERRAINO;MASSIMO ANDREONI;ANTONELLA D’ARMINIO MONFORTE;CHIARA AGRATI;LOREDANA SARMATI;ANDREA DE LUCA;CORRADO BIBBOLINO","17;13;9;8;8;7;6;6;5;5;5;5;5;5;5;5;4;4;4;4","GIUSEPPE IPPOLITO;ANDREA ANTINORI;PAOLO VISCA;NICOLA PETROSILLO;DIEGO SERRAINO;LEOPOLDO PAOLO PUCILLO;ANDREA FRUSTACI;CARLO FEDERICO PERNO;CORRADO BIBBOLINO;GIANPIERO D’OFFIZI;FRANCESCO GIUSEPPE DE ROSA;LIVIA LEONI;CECILIA AMBROSI;MARIA ROSARIA CAPOBIANCHI;ENRICO GIRARDI;VINCENZO SCHININÀ;ADRIANA AMMASSARI;MAURO ZACCARELLI;ANDREA PETRUCCA;ELISA BUSI RIZZI","1.63;1.36;1.33;1.13;1.05;0.98;0.83;0.81;0.71;0.62;0.6;0.58;0.58;0.58;0.55;0.54;0.54;0.53;0.53;0.52","GIUSEPPE IPPOLITO;ANDREA ANTINORI;NICOLA PETROSILLO;LEOPOLDO PAOLO PUCILLO;CARLO FEDERICO PERNO;PAOLO VISCA;ENRICO GIRARDI;MARIA ROSARIA CAPOBIANCHI;GIANPIERO D’OFFIZI;FABRIZIO POCCIA;MAURO ZACCARELLI;EMANUELE NICASTRI;DIEGO SERRAINO;CHIARA AGRATI;CORRADO BIBBOLINO;MAURO PIACENTINI;ADRIANA AMMASSARI;ALESSANDRA AMENDOLA;CARLA MONTESANO;VITTORIO COLIZZI","17;13;9;8;8;7;6;6;5;5;5;5;5;4;4;4;4;4;4;4","GIUSEPPE IPPOLITO;ANDREA ANTINORI;PAOLO VISCA;NICOLA PETROSILLO;DIEGO SERRAINO;LEOPOLDO PAOLO PUCILLO;ANDREA FRUSTACI;CARLO FEDERICO PERNO;CORRADO BIBBOLINO;GIANPIERO D’OFFIZI;LIVIA LEONI;CECILIA AMBROSI;MARIA ROSARIA CAPOBIANCHI;ENRICO GIRARDI;VINCENZO SCHININÀ;ADRIANA AMMASSARI;MAURO ZACCARELLI;ANDREA PETRUCCA;ELISA BUSI RIZZI;FABRIZIO POCCIA","1.63;1.36;1.33;1.13;1.05;0.98;0.83;0.81;0.71;0.62;0.58;0.58;0.58;0.55;0.54;0.54;0.53;0.53;0.52;0.52","ANDREA ANTINORI;CARLO FEDERICO PERNO;GIUSEPPE IPPOLITO;MAURO PIACENTINI;NICOLA PETROSILLO;ANDREA DE LUCA;ANTONELLA D’ARMINIO MONFORTE;ROBERTA NARDACCI;ADRIANA AMMASSARI;A. CINGOLANI;ENRICO GIRARDI;MARIA PAOLA TROTTA;PASQUALE NARCISO;ALESSANDRO COZZI‐LEPRI;FRANCESCA BERNASSOLA;GERRY MELINO;SERAFINA OLIVERIO;TONINO ALONZI;LEOPOLDO PAOLO PUCILLO;ALESSANDRA AMENDOLA","831;602;571;475;471;436;398;374;360;350;328;323;312;308;307;307;307;299;277;271","ANDREA ANTINORI;CARLO FEDERICO PERNO;GIUSEPPE IPPOLITO;MAURO PIACENTINI;NICOLA PETROSILLO;ROBERTA NARDACCI;ADRIANA AMMASSARI;MARIA PAOLA TROTTA;PASQUALE NARCISO;ENRICO GIRARDI;TONINO ALONZI;ALESSANDRA AMENDOLA;PAOLO VISCA;LEOPOLDO PAOLO PUCILLO;MAURO ZACCARELLI;FABRIZIO POCCIA;CHIARA AGRATI;UBALDO VISCO‐COMANDINI;DELIA GOLETTI;EMANUELE NICASTRI","831;602;530;475;471;374;332;323;312;300;299;271;225;221;218;205;189;171;170;159","GIUSEPPE IPPOLITO;ANDREA ANTINORI;NICOLA PETROSILLO;CARLO FEDERICO PERNO;PAOLO VISCA;LEOPOLDO PAOLO PUCILLO;PASQUALE NARCISO;EMANUELE NICASTRI;ENRICO GIRARDI;MARIA ROSARIA CAPOBIANCHI;MAURO ZACCARELLI;ALESSANDRA AMENDOLA;CORRADO BIBBOLINO;DIEGO SERRAINO;FABRIZIO POCCIA;GIANPIERO D’OFFIZI;MAURO PIACENTINI;ADRIANA AMMASSARI;ANDREA PETRUCCA;CARLA MONTESANO","15;13;9;8;7;6;6;5;5;5;5;4;4;4;4;4;4;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;ENGINEERING;PSYCHOLOGY;COMPUTER SCIENCE;ECONOMICS;MATHEMATICS;BUSINESS;PHILOSOPHY;POLITICAL SCIENCE;SOCIOLOGY","57;49;9;6;4;4;3;2;2;1;1;1;1","IMMUNOLOGY;INTERNAL MEDICINE;VIROLOGY;GENETICS;BIOCHEMISTRY;MICROBIOLOGY;PATHOLOGY;CELL BIOLOGY;GASTROENTEROLOGY;ENDOCRINOLOGY;MOLECULAR BIOLOGY;PEDIATRICS;ENVIRONMENTAL HEALTH;FAMILY MEDICINE;SURGERY;CANCER RESEARCH;ELECTRICAL ENGINEERING;OPTICS;PSYCHIATRY;ANATOMY;INTENSIVE CARE MEDICINE;RADIOLOGY","38;37;28;26;23;15;13;12;7;6;6;6;5;5;5;4;4;4;4;3;3;3","HUMAN IMMUNODEFICIENCY VIRUS (HIV);GENE;VIRUS;DISEASE;ANTIBODY;IMMUNE SYSTEM;APOPTOSIS;COHORT;CONFIDENCE INTERVAL;DRUG RESISTANCE;ENZYME;RECEPTOR;ANTIBIOTICS;ODDS RATIO;TUBERCULOSIS;ANTIGEN;CELL CULTURE;COHORT STUDY;IN VITRO;INCIDENCE (GEOMETRY);POPULATION;REGIMEN;SIGNAL TRANSDUCTION;TRANSMISSION (TELECOMMUNICATIONS)","27;23;16;11;9;7;6;6;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4","VIRAL LOAD;VIRAL DISEASE;GENOTYPE;MYCOBACTERIUM TUBERCULOSIS;POLYMERASE CHAIN REACTION;SEROLOGY;T CELL;ERYTHROMYCIN;GENE EXPRESSION;HEPATITIS C VIRUS;VIRAL REPLICATION;CD8;CELL CYCLE;CYTOTOXIC T CELL;ESCHERICHIA COLI;GENOME;HAZARD RATIO;HEPATITIS B VIRUS;NEURODEGENERATION;PROGRAMMED CELL DEATH;PROTEIN KINASE C;PSEUDOMONAS;RNA;STREPTOCOCCUS PNEUMONIAE;TISSUE TRANSGLUTAMINASE;TRANSCRIPTION FACTOR;VIREMIA","20;9;6;5;5;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;REVERSE TRANSCRIPTASE;LENTIVIRUS;SEROPREVALENCE;SIDA;CRYOGLOBULINEMIA;CTL*;PROMOTER;SEROSTATUS;ZIDOVUDINE;ANEUPLOIDY;ANTIBODY TITER;AZOOSPERMIA;BACTERIOPHAGE;C-MET;CASPASE 1;CD28;CHLAMYDOPHILA PNEUMONIAE;CYCLIN-DEPENDENT KINASE 1;DNA VIRUS;DNA-BINDING DOMAIN;DNA-BINDING PROTEIN;EXTRAPULMONARY TUBERCULOSIS;FABRY'S DISEASE;GENETICALLY MODIFIED MOUSE;HAPLOTYPE;HSP70;IBMX;IL-2 RECEPTOR;INTEGRON;INTERLEUKIN 21;INTESTINAL MALABSORPTION;INTRACYTOPLASMIC SPERM INJECTION;INTRAVENOUS DRUG;INVERTED REPEAT;IRF1;JANUS KINASE 1;LAMIVUDINE;LATENT TUBERCULOSIS;LDL RECEPTOR;MALE INFERTILITY;MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS;MEN WHO HAVE SEX WITH MEN;MITOCHONDRIAL APOPTOSIS-INDUCED CHANNEL;MOLECULAR EPIDEMIOLOGY;MOLECULAR MEDICINE;NATURAL KILLER T CELL;ONCOGENE;PERFORIN;PHORBOL;PSEUDOMONADACEAE;PSEUDOMONADALES;PULSED-FIELD GEL ELECTROPHORESIS;PYOVERDINE;RECEPTOR ANTAGONIST;REPRESSOR;RESTRICTIVE CARDIOMYOPATHY;RETINOID;SALMONELLA ENTERICA;SERUM AMYLOID P COMPONENT;SEXUAL TRANSMISSION;SOCS3;SPIRAMYCIN;SPUTUM CULTURE;STAT;STAT PROTEIN;STAT6;STAUROSPORINE;TOCOPHEROL;TORQUE TENO VIRUS;TRANSCRIPTIONAL REGULATION;TRANSPOSABLE ELEMENT;TROPHERYMA WHIPPLEI;VERY LOW-DENSITY LIPOPROTEIN","12;5;4;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HIV INFECTIONS;HUMANS;HIV-1;FEMALE;MALE;ADULT;ANTI-HIV AGENTS;ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE;MIDDLE AGED;RNA, VIRAL;APOPTOSIS;AIDS-RELATED OPPORTUNISTIC INFECTIONS;REVERSE TRANSCRIPTASE INHIBITORS;BACTERIAL PROTEINS;RISK FACTORS;TRANSCRIPTION FACTORS;CD4-POSITIVE T-LYMPHOCYTES;ACQUIRED IMMUNODEFICIENCY SYNDROME;ANIMALS;HEPATITIS C","75;62;38;33;31;29;24;23;21;19;15;14;14;13;13;12;11;10;10;10","HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;HEPATITIS C INFECTION AND TREATMENT;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;EPIDEMIOLOGY AND PATHOGENESIS OF PNEUMOCYSTIS PNEUMONIA;MANAGEMENT AND EPIDEMIOLOGY OF PNEUMONIA;NATURAL KILLER CELLS IN IMMUNITY;ROLE OF RETINOIC ACID IN BIOLOGICAL PROCESSES;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;APELIN SIGNALING AND PHYSIOLOGY;BACTERIAL PHYSIOLOGY AND GENETICS;BIOLOGICAL, EPIDEMIOLOGICAL, AND CLINICAL ASPECTS OF ECHINOCOCCOSIS;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;CLASSIFICATION AND TREATMENT OF SPONDYLOARTHRITIS;DIAGNOSIS AND MANAGEMENT OF ABDOMINAL TUBERCULOSIS;ECOLOGY AND EVOLUTION OF VIRUSES IN ECOSYSTEMS;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;EPIDEMIOLOGY AND MANAGEMENT OF FUNGAL INFECTIONS;EPIDEMIOLOGY AND PATHOGENESIS OF BACTERIAL MENINGITIS","13;10;4;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","HIV;ANTIRETROVIRAL THERAPY;HIV INFECTION;IMMUNE RESPONSES;ADHERENCE TO MEDICATION;HIV EPIDEMIOLOGY;HIV TRANSMISSION;NEVIRAPINE;REVERSE-TRANSCRIPTASE INHIBITOR;T CELL;PROTEASE INHIBITOR (PHARMACOLOGY);REGIMEN;RESISTANCE MUTATION;SEROPREVALENCE;STRAIN (INJURY);AIDS;APOPTOSIS;CTL*;DIAGNOSIS;DISCONTINUATION","22;13;8;5;4;4;4;4;4;4;3;3;3;3;3;2;2;2;2;2","ANTIRETROVIRAL THERAPY;HUMAN IMMUNODEFICIENCY;CHRONICALLY INFECTED;DRUG RESISTANCE;HHV- INFECTION;HIV-INFECTED PATIENTS;ACTIVE ANTIRETROVIRAL;CELLULAR OXIDATIVE;COHORT NAIVE;DISEASE PROGRESSION;HCV INFECTION;HIGHLY ACTIVE;HIV DISEASE;HIV--INFECTED PATIENTS;HUMAN HERPESVIRUS;IMMUNODEFICIENCY VIRUS;IMMUNODEFICIENCY VIRUS-INFECTED;ITALIAN COHORT;MIXED CRYOGLOBULINEMIA;NON-HODGKINS LYMPHOMA;OXIDATIVE STRESS;PREVALENCE TREND;PULMONARY TUBERCULOSIS;REVERSE TRANSCRIPTASE;STRUCTURED TREATMENT;TRANSCRIPTASE INHIBITORS;TREATMENT INTERRUPTION;VIROLOGICAL RESPONSE;A-INDUCED LYSIS;ABDOMINAL TUBERCULOSIS","8;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1","DE LA;ANTIRETROVIRAL THERAPY;FRANCE SEARCH;PS PHOSPHORYLATION;CAMILLE-DESMOULINS F-;CENTRE NATIONAL;F- VILLEJUIF;GUSTAVE ROUSSY;INSTITUT GUSTAVE;LA RECHERCHE;NATIONAL DE;RECHERCHE SCIENTIFIQUE;ROUSSY RUE;RUE CAMILLE-DESMOULINS;SCIENTIFIQUE UMR;UMR INSTITUT;VILLEJUIF FRANCE;VIRAL LOAD;LYMPHOCYTE COUNT;ACTIVE ANTIRETROVIRAL;HIGHLY ACTIVE;MALATTIE INFETTIVE;ROME ITALY;HUMAN HERPESVIRUS;ISTITUTO NAZIONALE;POSITIVE TST;BIOLOGY UNIVERSITY;HERPESVIRUS TYPE;NUCLEAR FUSION;SPALLANZANI ROME","26;23;22;20;19;19;19;19;19;19;19;19;19;19;19;19;19;13;11;10;10;10;10;9;9;9;8;8;8;8",19,0.24,4.5,2,0,1.75,0,0,2,1,1,2.5,0,0,1,0,0,0,0,1,0,0,0,43,43.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,2056205,293743.57,5,7,6,1,32,200217.530952381,0.399565410778275,"DÉLÉGATION RÉGIONALE PROVENCE-ALPES-CÔTE D’AZUR ET CORSE;IRCCS OSPEDALE SAN RAFFAELE;ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI;UNIVERSITY OF DEBRECEN;UNIVERSITY OF EDINBURGH;UNIVERSITY OF ERLANGEN-NUREMBERG;UNIVERSITY OF ZURICH","1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CSC - COST-SHARING CONTRACTS (FUNDING SCHEME);FP5-LIFE QUALITY - SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""QUALITY OF LIFE AND MANAGEMENT OF LIVING RESOURCES"", 1998-2002 (PROGRAMME)","1;1","31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;32 BIOMEDICAL AND CLINICAL SCIENCES","1;1;1","AUTOIMMUNE DISEASE;BIOTECHNOLOGY;GENETICS;PREVENTION","1;1;1;1","INFLAMMATORY AND IMMUNE SYSTEM","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS","1;1","NOT SITE-SPECIFIC CANCER","1","1.1 NORMAL FUNCTIONING","1","A01 CLINICAL MEDICINE","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SPALLANZANIROMA",2003,84,8.03571428571429,2.5952380952381,0.44047619047619,0.321428571428571,0.452380952380952,2.08035714285714,1.18181818181818,2.07142857142857,1.21212121212121,0.297619047619048,4,29,9,13,26,0.35,0.11,0.15,0.31,44.92,0.848638718189927,NA,0.321428571428571,0.785714285714286,0.512,0.462,0.399,0.438,"GIUSEPPE IPPOLITO;ANDREA ANTINORI;NICOLA PETROSILLO;MARIA ROSARIA CAPOBIANCHI;CARLO FEDERICO PERNO;FABRIZIO POCCIA;EMANUELE NICASTRI;LEOPOLDO PAOLO PUCILLO;FRANCA DEL NONNO;ORESTE LO IACONO;RITA MURRI;DIEGO SERRAINO;MAURO PIACENTINI;VINCENZO PURO;PASQUALE NARCISO;CRISTIANA GIOIA;PASQUALE NARCISO;GIOVANNI REZZA;VALERIO TOZZI;ANDREA DE LUCA","19;12;9;8;8;7;6;6;5;5;5;5;5;5;5;4;4;4;4;4","GIUSEPPE IPPOLITO;VINCENZO PURO;NICOLA PETROSILLO;EMANUELE NICASTRI;GIUSEPPINA LIUZZI;ANDREA ANTINORI;PURO;CARLO FEDERICO PERNO;PASQUALE NARCISO;MARIA ROSARIA CAPOBIANCHI;FABRIZIO POCCIA;MAURO PIACENTINI;DIEGO SERRAINO;PAOLO ASCENZI;UBALDO VISCO‐COMANDINI;CLAUDIO ANGELETTI;LEOPOLDO PAOLO PUCILLO;GIOVANNI REZZA;ADRIANO LAZZARIN;CLAUDIA BALOTTA","4.43;1.89;1.43;1.39;1.19;1.01;1;0.99;0.85;0.8;0.79;0.77;0.72;0.71;0.69;0.64;0.61;0.59;0.5;0.5","GIUSEPPE IPPOLITO;ANDREA ANTINORI;NICOLA PETROSILLO;MARIA ROSARIA CAPOBIANCHI;CARLO FEDERICO PERNO;FABRIZIO POCCIA;EMANUELE NICASTRI;LEOPOLDO PAOLO PUCILLO;FRANCA DEL NONNO;ORESTE LO IACONO;DIEGO SERRAINO;MAURO PIACENTINI;VINCENZO PURO;PASQUALE NARCISO;CRISTIANA GIOIA;PASQUALE NARCISO;VALERIO TOZZI;MAURO ZACCARELLI;MARIACARMELA SOLMONE;MARIA PAOLA TROTTA","19;12;9;8;8;7;6;6;5;5;5;5;5;5;4;4;4;4;4;4","GIUSEPPE IPPOLITO;VINCENZO PURO;NICOLA PETROSILLO;EMANUELE NICASTRI;GIUSEPPINA LIUZZI;ANDREA ANTINORI;PURO;CARLO FEDERICO PERNO;PASQUALE NARCISO;MARIA ROSARIA CAPOBIANCHI;FABRIZIO POCCIA;MAURO PIACENTINI;DIEGO SERRAINO;PAOLO ASCENZI;UBALDO VISCO‐COMANDINI;CLAUDIO ANGELETTI;LEOPOLDO PAOLO PUCILLO;F. LAURIA;GABRIELLA DE CARLI;RENATA MANCINI","4.43;1.89;1.43;1.39;1.19;1.01;1;0.99;0.85;0.8;0.79;0.77;0.72;0.71;0.69;0.64;0.61;0.5;0.5;0.5","ANDREA FRUSTACI;ATTILIO MASERI;CRISTINA CHIMENTI;GIUSEPPE IPPOLITO;ANDREA ANTINORI;FIORELLA CALABRESE;GAETANO THIENE;MAURIZIO PIERONI;FABRIZIO POCCIA;FRANÇOIS H.T. DUONG;MARCO TRIPODI;MARKUS H. HEIM;NICOLA LA MONICA;RITA MURRI;ANNAROSA LERI;BERNARDO NADAL‐GINARD;CLAUDIA COLUSSI;DANIELE TORELLA;FRANCA DI MEGLIO;HUBERT HELENIAK","834;834;834;584;563;456;456;456;435;405;405;405;405;396;378;378;378;378;378;378","MARCO TRIPODI;ANDREA ANTINORI;GIUSEPPE IPPOLITO;FABRIZIO POCCIA;VALERIO TOZZI;MARIA PAOLA TROTTA;CARLO FEDERICO PERNO;NICOLA PETROSILLO;TONINO ALONZI;PIERLUCA PISELLI;PATRIZIA LORENZINI;MAURO PIACENTINI;VINCENZO PURO;PASQUALE NARCISO;ILARIA UCCELLA;MARIA LETIZIA GIANCOLA;BRUNO DEL GROSSO;SUSANNA GRISETTI;MARIA ROSARIA CAPOBIANCHI;EMANUELE NICASTRI","405;368;360;358;293;210;201;182;182;175;168;165;164;158;156;156;154;154;145;130","GIUSEPPE IPPOLITO;ANDREA ANTINORI;MARIA ROSARIA CAPOBIANCHI;CARLO FEDERICO PERNO;NICOLA PETROSILLO;PASQUALE NARCISO;VINCENZO PURO;FRANCA DEL NONNO;EMANUELE NICASTRI;FABRIZIO POCCIA;MARIA PAOLA TROTTA;MARIACARMELA SOLMONE;MAURO PIACENTINI;VALERIO TOZZI;GIORGIO ANTONUCCI;GIUSEPPINA LIUZZI;MARIO ANTONINI;ALESSANDRA AMENDOLA;ENRICO GIRARDI;EVANGELO BOUMIS","15;10;8;8;7;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ENGINEERING;COMPUTER SCIENCE;ECONOMICS;SOCIOLOGY;BUSINESS;PSYCHOLOGY","67;49;13;5;4;2;2;2;1;1","IMMUNOLOGY;INTERNAL MEDICINE;VIROLOGY;PATHOLOGY;GENETICS;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;MICROBIOLOGY;OPTICS;PEDIATRICS;INTENSIVE CARE MEDICINE;CELL BIOLOGY;SURGERY;ONCOLOGY;PSYCHIATRY;CANCER RESEARCH;MOLECULAR BIOLOGY;PHARMACOLOGY;ECOLOGY;ELECTRICAL ENGINEERING","43;43;35;23;22;16;12;10;10;10;10;9;8;8;6;5;4;4;4;3;3","HUMAN IMMUNODEFICIENCY VIRUS (HIV);VIRUS;GENE;DISEASE;POPULATION;INCIDENCE (GEOMETRY);ANTIBODY;DRUG RESISTANCE;ENZYME;REGIMEN;TUBERCULOSIS;ANTIGEN;APOPTOSIS;CANCER;CHEMOTHERAPY;EPIDEMIOLOGY;IMMUNE SYSTEM;IN VITRO;INTERFERON;LYMPHOMA","21;21;17;13;9;8;7;6;6;6;6;5;5;5;5;5;5;5;5;5","VIRAL LOAD;VIRAL DISEASE;HEPATITIS C VIRUS;GENOTYPE;HEPATITIS B VIRUS;CD8;LIVER TRANSPLANTATION;POLYMERASE CHAIN REACTION;PROGRAMMED CELL DEATH;RESPIRATORY TRACT INFECTIONS;RNA;T CELL;VIRAL REPLICATION;VIREMIA;BACILLUS ANTHRACIS;BACTEREMIA;CANCER REGISTRY;CERVICAL CANCER;DILATED CARDIOMYOPATHY;EPITOPE;INFECTIOUS DISEASE (MEDICAL SPECIALTY);MACROPHAGE;MYCOBACTERIUM TUBERCULOSIS;NEUTROPENIA;PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA;RECOMBINANT DNA;RETINOIC ACID;UNIVARIATE ANALYSIS","19;10;9;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;REVERSE TRANSCRIPTASE;SIDA;LENTIVIRUS;RIBAVIRIN;LAMIVUDINE;FLAVIVIRIDAE;HEPACIVIRUS;RETINOID;AMINOPEPTIDASE;ANTIGEN-PRESENTING CELL;ANTIMYCOBACTERIAL;BACILLACEAE;BACILLALES;CORONAVIRUS DISEASE 2019 (COVID-19);CRYOGLOBULINEMIA;DNA METHYLATION;DNA VACCINATION;ESAT-6;FLUDARABINE;FUSION PROTEIN;HBSAG;HETEROCHROMATIN;INFLAMMATORY BOWEL DISEASES;INTESTINAL MALABSORPTION;JAK-STAT SIGNALING PATHWAY;KAPOSI'S SARCOMA;LIVE ATTENUATED INFLUENZA VACCINE;LYMPHOCYTIC CHORIOMENINGITIS;MEMORY T CELL;MEN WHO HAVE SEX WITH MEN;NEUROPSYCHOLOGICAL TEST;NITROGENASE;ORNITHINE;ORTHOTOPIC LIVER TRANSPLANTATION;PHARMACOGENETICS;PYOVERDINE;REACTOGENICITY;S-NITROSOGLUTATHIONE;SEROPREVALENCE;STAPHYLOCOCCAL INFECTIONS;STAT PROTEIN;STEATOHEPATITIS;SULFURTRANSFERASE;TENIPOSIDE;TRIVALENT INFLUENZA VACCINE;TROPHERYMA WHIPPLEI;V3 LOOP;VACCINIA;VIRAL QUASISPECIES","12;6;6;5;4;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HIV INFECTIONS;HUMANS;HIV-1;MALE;FEMALE;ADULT;MIDDLE AGED;ANTI-HIV AGENTS;HEPATITIS C, CHRONIC;ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE;BACTEREMIA;CROSS INFECTION;HEPACIVIRUS;ITALY;LIVER;RNA, VIRAL;AGED;HEPATITIS C;DRUG RESISTANCE, VIRAL;ACQUIRED IMMUNODEFICIENCY SYNDROME","81;72;45;43;42;32;30;29;23;22;19;19;19;18;18;18;17;17;15;13","EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;HEPATITIS C INFECTION AND TREATMENT;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;TUBERCULOSIS;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;EPIDEMIOLOGY AND PATHOGENESIS OF PNEUMOCYSTIS PNEUMONIA;BIOLOGICAL AGENTS FOR BIOTERRORISM;INFECTION CONTROL IN HEALTHCARE SETTINGS;LYMPHOID NEOPLASMS;NATURAL KILLER CELLS IN IMMUNITY;POLYOMAVIRUS-ASSOCIATED CARCINOGENESIS AND CLINICAL MANIFESTATIONS;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;BACTERIAL PHYSIOLOGY AND GENETICS;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;CELLULAR SENESCENCE AND AGING-RELATED DISEASES;COMPREHENSIVE APPROACH TO SCHOOL HEALTH PROMOTION;CORONAVIRUS DISEASE 2019;DIAGNOSIS AND MANAGEMENT OF ABDOMINAL TUBERCULOSIS;DIAGNOSIS AND TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA","9;9;7;4;4;4;3;2;2;2;2;2;1;1;1;1;1;1;1;1","HIV;ANTIRETROVIRAL THERAPY;HIV INFECTION;REGIMEN;HEPATITIS C;IMMUNOSUPPRESSION;CANCER INCIDENCE;HIV EPIDEMIOLOGY;HIV TRANSMISSION;RESISTANCE MUTATION;TREATMENT;VIREMIA;ADHERENCE TO MEDICATION;ANTIBODIES;ANTIRETROVIRAL DRUG;BACILLUS ANTHRACIS;BACTEREMIA;BIOLOGICAL WARFARE;EFAVIRENZ;FENRETINIDE","18;10;7;7;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;GENOTYPIC RESISTANCE;ACTIVE ANTIRETROVIRAL;HIGHLY ACTIVE;RESISTANCE TESTS;HUMAN IMMUNODEFICIENCY;IMMUNODEFICIENCY VIRUS;NOSOCOMIAL INFECTIONS;ANTIRETROVIRAL TREATMENT;CEREBROSPINAL FLUID;DRUG RESISTANCE;HIV INFECTION;HIV POSITIVE;INHIBITOR-CONTAINING REGIMENS;INHIBITS INTERFERON;KAPOSIS SARCOMA;LIVER TRANSPLANTATION;NON-HODGKINS LYMPHOMA;PATIENTS AFFECTED;PATIENTS UNDERGOING;PERIPHERAL BLOOD;PULMONARY TUBERCULOSIS;THERAPY HAART;TYPE REPLICATION;UTERINE CERVIX;VIRUS TYPE;AB ABROGATES;ABROGATES MACROPHAGE-MEDIATED;ACTIVE LYMPHOCYTIC;ACTIVE PULMONARY","7;5;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","ASTALT ALTERATION;STUDY POPULATION;ACTIVE ANTIRETROVIRAL;ACTIVE TB;CD CELL;HIGHLY ACTIVE;HIV INFECTION;INTERQUARTILE RANGE;SEXUAL DYSFUNCTION;TRANSGENIC MICE;AGE CATEGORY;ANTIRETROVIRAL THERAPY;CELL COUNT;GRADE ASTALT;HHV- INFECTION;HIV RNA;HIV SEROCONVERSION;LOGISTIC REGRESSION;REVERSE TRANSCRIPTASE;VIROLOGICAL OUTCOMES;AGE CATEGORIES;CHRONIC HEPATITIS;EXPOSURE CATEGORY;GENOTYPIC RESISTANCE;LIVER BIOPSIES;PERIPHERAL BLOOD;VIRAL LOAD;AGED DISEASED;DISEASED HEARTS;DRUG RESISTANCE","10;10;7;7;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;4;4;4",12,0.14,6,4,0,1,0,0,4.5,1,1,4,0,0,1,0,0,0,0,1,0,0,0,40.25,40.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SPALLANZANIROMA",2004,93,11.1182795698925,3.67741935483871,0.53763440860215,0.419354838709677,0.612903225806452,2.23870967741935,1.25,1.625,1.23913043478261,0.462365591397849,2,49,8,17,17,0.53,0.09,0.18,0.18,48.38,1.02811114697826,NA,0.365591397849462,0.806451612903226,0.503,0.455,0.455,0.459,"ANDREA ANTINORI;GIUSEPPE IPPOLITO;NICOLA PETROSILLO;ANTONELLA D’ARMINIO MONFORTE;ENRICO GIRARDI;PAOLO VISCA;CARLO FEDERICO PERNO;PAOLO ASCENZI;MAURO ZACCARELLI;VINCENZO PURO;EVANGELO BOUMIS;MARIA PAOLA TROTTA;FABRIZIO PALMIERI;ALESSANDRO COZZI‐LEPRI;GIANPIERO D’OFFIZI;FABRIZIO POCCIA;ANDREA DE LUCA;CLAUDIA BALOTTA;FEDERICA FORBICI;ALESSIO BOCEDI","20;14;13;12;10;9;9;8;8;8;7;6;6;6;5;5;5;5;5;5","PAOLO VISCA;NICOLA PETROSILLO;GIUSEPPE IPPOLITO;PAOLO ASCENZI;ANDREA ANTINORI;VINCENZO PURO;ENRICO GIRARDI;VALERIO TOZZI;LUCIA FRATINO;MARIA GRAZIA PAGLIA;ALESSIO BOCEDI;FABRIZIO PALMIERI;MAURO PIACENTINI;LUIGI GRADONI;FABRIZIO POCCIA;EVANGELO BOUMIS;MAURO ZACCARELLI;GIANPIERO D’OFFIZI;STEFANIA CICALINI;ANTONELLA D’ARMINIO MONFORTE","2.1;1.88;1.85;1.82;1.53;1.52;1.27;1.06;1;0.92;0.92;0.81;0.73;0.7;0.69;0.67;0.65;0.64;0.59;0.59","ANDREA ANTINORI;GIUSEPPE IPPOLITO;NICOLA PETROSILLO;ANTONELLA D’ARMINIO MONFORTE;ENRICO GIRARDI;PAOLO VISCA;CARLO FEDERICO PERNO;PAOLO ASCENZI;MAURO ZACCARELLI;VINCENZO PURO;EVANGELO BOUMIS;MARIA PAOLA TROTTA;FABRIZIO PALMIERI;GIANPIERO D’OFFIZI;FABRIZIO POCCIA;FEDERICA FORBICI;ALESSIO BOCEDI;RITA MURRI;DIEGO SERRAINO;MAURO PIACENTINI","20;14;13;12;10;9;9;8;8;8;7;6;6;5;5;5;5;5;5;5","PAOLO VISCA;NICOLA PETROSILLO;GIUSEPPE IPPOLITO;PAOLO ASCENZI;ANDREA ANTINORI;VINCENZO PURO;ENRICO GIRARDI;VALERIO TOZZI;LUCIA FRATINO;MARIA GRAZIA PAGLIA;ALESSIO BOCEDI;FABRIZIO PALMIERI;MAURO PIACENTINI;FABRIZIO POCCIA;EVANGELO BOUMIS;MAURO ZACCARELLI;GIANPIERO D’OFFIZI;STEFANIA CICALINI;ANTONELLA D’ARMINIO MONFORTE;DIEGO SERRAINO","2.1;1.88;1.85;1.82;1.53;1.52;1.27;1.06;1;0.92;0.92;0.81;0.73;0.69;0.67;0.65;0.64;0.59;0.59;0.57","ANTONELLA D’ARMINIO MONFORTE;ANDREA ANTINORI;PAOLO ASCENZI;PAOLO VISCA;NICOLA PETROSILLO;FILIPPO ACCONCIA;MARIA MARINO;ADRIANA AMMASSARI;ENRICO GIRARDI;ALESSIO BOCEDI;RITA MURRI;GIUSEPPE IPPOLITO;MARIA PAOLA TROTTA;ALBERT W. WU;MARIA STELLA ALOISI;A. TRENTALANCE;ENZO SPISNI;VITTORIO TOMASI;CARLO FEDERICO PERNO;PASQUALE NARCISO","985;932;761;678;634;573;573;561;551;536;505;499;462;437;430;409;409;409;353;337","ANDREA ANTINORI;PAOLO VISCA;PAOLO ASCENZI;ENRICO GIRARDI;ALESSIO BOCEDI;MARIA PAOLA TROTTA;GIUSEPPE IPPOLITO;MARIA STELLA ALOISI;NICOLA PETROSILLO;CARLO FEDERICO PERNO;PASQUALE NARCISO;ADRIANA AMMASSARI;ALBERT W. WU;ANTONELLA D’ARMINIO MONFORTE;FABRIZIO STARACE;LUCA BARTOLI;RITA MURRI;ANDREA FRUSTACI;ANDREA RUSSO;ATTILIO MASERI","897;664;597;548;536;462;451;430;382;353;303;276;276;276;276;276;276;267;267;267","ANDREA ANTINORI;GIUSEPPE IPPOLITO;NICOLA PETROSILLO;CARLO FEDERICO PERNO;ENRICO GIRARDI;PASQUALE NARCISO;MAURO ZACCARELLI;PAOLO ASCENZI;VINCENZO PURO;EVANGELO BOUMIS;PAOLO VISCA;MARIA PAOLA TROTTA;FEDERICA FORBICI;FABRIZIO PALMIERI;GIANPIERO D’OFFIZI;MARIA ROSARIA CAPOBIANCHI;VALERIO TOZZI;DIEGO SERRAINO;ALESSIO BOCEDI;ANNA ROSA GARBUGLIA","18;10;10;9;9;8;7;7;7;6;6;6;5;5;5;5;5;4;4;4","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ECONOMICS;POLITICAL SCIENCE;ENGINEERING;SOCIOLOGY;BUSINESS;MATHEMATICS;PHILOSOPHY;MATERIALS SCIENCE;PSYCHOLOGY","72;52;14;9;6;6;6;5;3;2;2;2;1;1","IMMUNOLOGY;INTERNAL MEDICINE;VIROLOGY;GENETICS;BIOCHEMISTRY;PATHOLOGY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;SURGERY;MICROBIOLOGY;FAMILY MEDICINE;INTENSIVE CARE MEDICINE;PEDIATRICS;EMERGENCY MEDICINE;GASTROENTEROLOGY;LAW;MOLECULAR BIOLOGY;OPTICS;ECONOMIC GROWTH;ENDOCRINOLOGY;PALEONTOLOGY","42;38;35;26;25;20;13;12;11;10;9;9;7;5;5;5;5;5;4;4;4","HUMAN IMMUNODEFICIENCY VIRUS (HIV);GENE;VIRUS;DISEASE;ENZYME;IMMUNE SYSTEM;TUBERCULOSIS;CONFIDENCE INTERVAL;IN VITRO;POPULATION;ANTIBODY;DRUG RESISTANCE;INCIDENCE (GEOMETRY);ANTIGEN;APOPTOSIS;CANCER;COHORT;HEALTH CARE;HEPATITIS C;ODDS RATIO;REGIMEN","32;31;23;12;12;11;8;7;7;7;6;6;5;4;4;4;4;4;4;4;4","VIRAL LOAD;VIRAL DISEASE;HEPATITIS C VIRUS;GENOTYPE;POLYMERASE CHAIN REACTION;RNA;CD8;PROTEASE;T CELL;VIRAL REPLICATION;CYSTEINE;CYTOTOXIC T CELL;HEPATITIS B VIRUS;MYCOBACTERIUM TUBERCULOSIS;PLASMODIUM FALCIPARUM;VIREMIA;ACTIVE SITE;BREAST CANCER;CHEMOKINE;CHRONIC INFECTION;DIRECTLY OBSERVED THERAPY;ENCEPHALITIS;HAZARD RATIO;INFECTIOUS DISEASE (MEDICAL SPECIALTY);LIVER TRANSPLANTATION;MULTICENTER STUDY;MUTATION;NEUROCOGNITIVE;NEUROPSYCHOLOGY;PEPTIDE SEQUENCE;POST-EXPOSURE PROPHYLAXIS;PROGRAMMED CELL DEATH;SALVAGE THERAPY;SEROCONVERSION;SEROLOGY;SYPHILIS;TACROLIMUS;TRANSCRIPTION FACTOR;TRANSFECTION","22;13;11;8;6;5;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;LENTIVIRUS;REVERSE TRANSCRIPTASE;SIDA;HIV-1 PROTEASE;VIRAL QUASISPECIES;ZIDOVUDINE;ESTROGEN RECEPTOR;HEPACIVIRUS;LAMIVUDINE;PALMITOYLATION;RIBAVIRIN;T-CELL RECEPTOR;VIRAL EVOLUTION;AMINO ACID RESIDUE;AMPLICON;APICOMPLEXA;BDNA TEST;CD4 T CELL;CERAMIDE SYNTHASE;CEREBRAL MALARIA;CHEMOKINE RECEPTOR;CHLAMYDOPHILA PNEUMONIAE;CLADE;CONDOM;CONSERVED SEQUENCE;CORONAVIRUS DISEASE 2019 (COVID-19);CRYOGLOBULINEMIA;DMT1;DNA EXTRACTION;EPSTEIN–BARR VIRUS INFECTION;EUKARYOTE;GENETICALLY MODIFIED MOUSE;GENOTYPING;GRANZYME B;HERPESVIRIDAE;MALE INFERTILITY;MEMORY T CELL;MEN WHO HAVE SEX WITH MEN;MITOCHONDRIAL APOPTOSIS-INDUCED CHANNEL;MOLECULAR EPIDEMIOLOGY;MYCOBACTERIUM BOVIS;NESTED POLYMERASE CHAIN REACTION;NEUROGLOBIN;NFKB1;PERFORIN;PERIPHERAL T-CELL LYMPHOMA;PLASTID;PLEURAL DISEASE;POMALIDOMIDE;RESPIRATORY RATE;RETINOID;REVERSION;SPHINGOMYELIN PHOSPHODIESTERASE;TRANSACTIVATION;TUBERCULOID LEPROSY;YERSINIA PSEUDOTUBERCULOSIS","17;5;5;4;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HIV INFECTIONS;HUMANS;HIV-1;ANTI-HIV AGENTS;MALE;ADULT;FEMALE;HEPATITIS C;ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE;MIDDLE AGED;ITALY;ACQUIRED IMMUNODEFICIENCY SYNDROME;RNA, VIRAL;DRUG RESISTANCE, VIRAL;REVERSE TRANSCRIPTASE INHIBITORS;HIV PROTEASE INHIBITORS;TUBERCULOSIS, PULMONARY;;ANIMALS;ANTIVIRAL AGENTS","90;75;49;41;41;38;36;30;28;25;23;21;21;20;17;13;12;11;11;11","EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;HEPATITIS C INFECTION AND TREATMENT;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;TUBERCULOSIS;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;EPIDEMIOLOGY AND PATHOGENESIS OF PNEUMOCYSTIS PNEUMONIA;HEMOGLOBIN FUNCTION AND REGULATION IN VERTEBRATES;MANAGEMENT AND EPIDEMIOLOGY OF INFECTIVE ENDOCARDITIS;MECHANISMS OF ESTROGEN RECEPTOR SIGNALING;AMOEBIASIS: PATHOGENESIS AND CLINICAL MANAGEMENT;CHALLENGES IN UNDERSTANDING AND TREATING LEPROSY;CORONAVIRUS DISEASE 2019 RESEARCH;CYANOGENIC GLYCOSIDES IN PLANTS AND INDUSTRIAL WASTEWATERS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;DIAGNOSIS AND TREATMENT OF SPINAL INFECTIONS;EPIDEMIOLOGY AND MANAGEMENT OF OCULAR INFLAMMATORY DISEASES;EPIDEMIOLOGY AND MOLECULAR CHARACTERIZATION OF PARASITIC DISEASES;GENETIC AND PATHOGENIC STUDY OF PLAGUE BACTERIA","14;9;9;6;4;4;2;2;2;2;2;1;1;1;1;1;1;1;1;1","HIV;ANTIRETROVIRAL THERAPY;HIV INFECTION;TREATMENT;HIV EPIDEMIOLOGY;HIV TRANSMISSION;ADHERENCE TO MEDICATION;DIAGNOSIS;HEPATITIS C;IMMUNE RESPONSES;MONOCYTE;REGIMEN;VIRAL QUASISPECIES;VIREMIA;CHRONIC INFECTION;DIRECTLY OBSERVED THERAPY;EFAVIRENZ;ENDOCARDITIS GUIDELINES;ESTROGEN RECEPTOR ALPHA;HBV INFECTION","26;15;10;8;7;7;4;4;4;4;3;3;3;3;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;ACTIVE ANTIRETROVIRAL;HIGHLY ACTIVE;HIV-INFECTED PATIENTS;HIV-INFECTED PERSONS;VIRUS INFECTION;CARE WORKERS;HCV INFECTION;HEALTH CARE;HEALTHCARE WORKERS;HIV TYPE;HIV-INFECTED PATIENT;HUMAN IMMUNODEFICIENCY;INFECTIVE ENDOCARDITIS;ITALIAN HOSPITALS;LIVER TRANSPLANTATION;MULTICENTER STUDY;NEUROCOGNITIVE IMPAIRMENT;REPLICATIVE CAPACITY;REVERSE TRANSCRIPTASE;RISK FACTORS;VIRUS TYPE;ABACAVIR EUROSIDA;ACCESS SITE-RELATED;ACIDIC SPHINGOMYELINASE-MEDIATED;ACTIVITY VOLUMES;ACUTE FATAL;ACUTE HCV;ACUTE HIV;ACUTE RESPIRATORY","8;7;7;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","PUBMED SCOPUS;CROSSREF PUBMED;ANTIRETROVIRAL THERAPY;CELL DEATH;BH DOMAIN;AMINO ACID;BCL- FAMILY;CELL BIOL;ACTIVE ANTIRETROVIRAL;HCV INFECTION;HIGHLY ACTIVE;HUMAN IMMUNODEFICIENCY;IMMUNODEFICIENCY VIRUS;MITOCHONDRIAL MEMBRANE;MOLECULAR PROBES;BIOL -CROSSREF;ENZYMATIC ACTIVITY;HIV INFECTION;THERAPY HAART;VIROLOGICAL FAILURE;CHAPS-IP BUFFER;DELAYED PRESENTATION;MEMBRANE POTENTIAL;MOL CELL;ODDS RATIO;BIOL CHEM;CERIONE RA;CHEM -ABSTRACT;CONFIDENCE INTERVAL;DEATH INDUCTION","33;25;18;14;11;10;10;9;8;8;8;8;8;8;8;7;7;7;7;7;6;6;6;6;6;5;5;5;5;5",18,0.19,6,2.75,0,1,0,7,2.5,0,1.25,4.5,0,1,13,0,1.25,1,0,10,2,0,0,49.5,49.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,2,900,0.7,1,1,101,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","1;1","CHRONIC LIVER DISEASE AND CIRRHOSIS;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COMPARATIVE EFFECTIVENESS RESEARCH;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;HEPATITIS;HEPATITIS - C;INFECTIOUS DISEASES;LIVER DISEASE","1;1;1;1;1;1;1;1;1;1",NA,NA,"6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,1,1.7e+07,548387.1,6,31,12,1,3,291615.380414747,0.318913220104275,"ARMAUER HANSEN RESEARCH INSTITUTE;ASTON UNIVERSITY;BIOMEDICAL PRIMATE RESEARCH CENTRE;CHEIKH ANTA DIOP UNIVERSITY;DÉLÉGATION PARIS 11;FRENCH NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;GLAXOSMITHKLINE (BELGIUM);IMPERIAL COLLEGE LONDON;INSTITUT PASTEUR;ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI;LEIDEN UNIVERSITY MEDICAL CENTER;LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE;MAX PLANCK SOCIETY;MEDICAL RESEARCH COUNCIL;PUBLIC HEALTH ENGLAND;STATENS SERUM INSTITUT;TECHNICAL UNIVERSITY OF MUNICH;UNIVERSITY HOSPITAL OF BASEL;UNIVERSITY HOSPITAL ULM;UNIVERSITY OF BIRMINGHAM","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","FP6-2002-LIFESCIHEALTH (CALL FOR PROPOSAL);FP6-LIFESCIHEALTH - LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH: THEMATIC PRIORITY 1 UNDER THE FOCUSING AND INTEGRATING COMMUNITY RESEARCH PROGRAMME 2002-2006. (PROGRAMME);IP - INTEGRATED PROJECT (FUNDING SCHEME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY","1;1","BIODEFENSE;BIOTECHNOLOGY;EMERGING INFECTIOUS DISEASES;IMMUNIZATION;INFECTIOUS DISEASES;ORPHAN DRUG;PREVENTION;RARE DISEASES;TUBERCULOSIS;TUBERCULOSIS VACCINE;VACCINE RELATED","1;1;1;1;1;1;1;1;1;1;1","INFECTION","1","3.4 VACCINES","1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1","3 GOOD HEALTH AND WELL BEING","1",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SPALLANZANIROMA",2005,97,10.5360824742268,3.68041237113402,0.494845360824742,0.391752577319588,0.494845360824742,2.27741935483871,1.41176470588235,1.9,1.41176470588235,0.515463917525773,3,46,12,17,17,0.47,0.12,0.18,0.18,41.54,0.784532626335315,NA,0.371134020618557,0.855670103092783,0.608,0.449,0.412,0.434,"ANDREA ANTINORI;GIUSEPPE IPPOLITO;MARIA ROSARIA CAPOBIANCHI;PAOLO ASCENZI;FABRIZIO POCCIA;CLAUDIO ANGELETTI;CARLO FEDERICO PERNO;CHIARA AGRATI;EMANUELE NICASTRI;DIEGO SERRAINO;NICOLA PETROSILLO;STEFANIA CICALINI;VINCENZO PURO;ALESSIO BOCEDI;PAOLO VISCA;ENRICO GIRARDI;GIANPIERO D’OFFIZI;CONCETTA CASTILLETTI;MAURO FASANO;MAURO PIACENTINI","18;16;14;12;10;8;8;7;7;7;7;7;7;6;6;6;5;5;5;5","PAOLO ASCENZI;ANDREA ANTINORI;GIUSEPPE IPPOLITO;MARIA ROSARIA CAPOBIANCHI;DOUGLAS HOREJSH;FABRIZIO POCCIA;ALESSIO BOCEDI;LORENZA PUTIGNANI;PAOLO VISCA;NICOLA PETROSILLO;FEDERICO MARTINI;VINCENZO PURO;STEFANIA CICALINI;CHIARA AGRATI;CARLO FEDERICO PERNO;MAURO FASANO;CLAUDIO ANGELETTI;EMANUELE NICASTRI;PAOLA CINQUE;DIEGO SERRAINO","3.44;1.98;1.86;1.76;1.6;1.41;1.2;1.2;1.07;1.04;0.96;0.96;0.93;0.92;0.9;0.9;0.88;0.85;0.66;0.65","ANDREA ANTINORI;GIUSEPPE IPPOLITO;MARIA ROSARIA CAPOBIANCHI;PAOLO ASCENZI;FABRIZIO POCCIA;CLAUDIO ANGELETTI;CARLO FEDERICO PERNO;CHIARA AGRATI;EMANUELE NICASTRI;DIEGO SERRAINO;NICOLA PETROSILLO;STEFANIA CICALINI;VINCENZO PURO;ALESSIO BOCEDI;PAOLO VISCA;ENRICO GIRARDI;GIANPIERO D’OFFIZI;CONCETTA CASTILLETTI;MAURO PIACENTINI;PIERLUCA PISELLI","18;16;14;12;10;8;8;7;7;7;7;7;7;6;6;6;5;5;5;5","PAOLO ASCENZI;ANDREA ANTINORI;GIUSEPPE IPPOLITO;MARIA ROSARIA CAPOBIANCHI;DOUGLAS HOREJSH;FABRIZIO POCCIA;ALESSIO BOCEDI;LORENZA PUTIGNANI;PAOLO VISCA;NICOLA PETROSILLO;FEDERICO MARTINI;VINCENZO PURO;STEFANIA CICALINI;CHIARA AGRATI;CARLO FEDERICO PERNO;CLAUDIO ANGELETTI;EMANUELE NICASTRI;DIEGO SERRAINO;ALESSANDRA SACCHI;GIANPIERO D’OFFIZI","3.44;1.98;1.86;1.76;1.6;1.41;1.2;1.2;1.07;1.04;0.96;0.96;0.93;0.92;0.9;0.88;0.85;0.65;0.65;0.63","ANDREA ANTINORI;GIUSEPPE IPPOLITO;PASQUALE NARCISO;FABRIZIO POCCIA;MAURO PIACENTINI;PATRIZIA LORENZINI;UBALDO VISCO‐COMANDINI;VALERIO TOZZI;VINCENZO PURO;CARLO FEDERICO PERNO;EMANUELE NICASTRI;ANDREA FRUSTACI;CARLO NAPOLITANO;CRISTINA CHIMENTI;FULVIO BELLOCCI;ILARIA RIVOLTA;MATTEO ANTONIO RUSSO;MAURIZIO PIERONI;SILVIA G. PRIORI;TOMMASO SANNA","856;689;443;413;368;367;367;367;363;362;361;354;354;354;354;354;354;354;354;354","GIUSEPPE IPPOLITO;ANDREA ANTINORI;FABRIZIO POCCIA;MAURO PIACENTINI;VINCENZO PURO;CARLO FEDERICO PERNO;PAOLO ASCENZI;GABRIELLA DE CARLI;PASQUALE NARCISO;FEDERICA FORBICI;MARIA ROSARIA CAPOBIANCHI;ANGELA CORPOLONGO;CHRYSOULA VLASSI;MARINELLA GIULIANELLI;PASQUALE NOTO;PATRIZIA LORENZINI;PIETRO BALESTRA;RITA BELLAGAMBA;UBALDO VISCO‐COMANDINI;VALERIO TOZZI","689;664;412;368;363;362;337;316;311;286;266;240;235;235;235;235;235;235;235;235","GIUSEPPE IPPOLITO;ANDREA ANTINORI;MARIA ROSARIA CAPOBIANCHI;PAOLO ASCENZI;FABRIZIO POCCIA;CARLO FEDERICO PERNO;CLAUDIO ANGELETTI;CHIARA AGRATI;NICOLA PETROSILLO;DIEGO SERRAINO;VINCENZO PURO;STEFANIA CICALINI;EMANUELE NICASTRI;ALESSIO BOCEDI;ENRICO GIRARDI;PASQUALE NARCISO;MAURO PIACENTINI;FEDERICO MARTINI;GIANPIERO D’OFFIZI;PAOLO VISCA","16;15;12;11;9;8;8;7;7;7;7;6;6;6;6;6;5;5;5;5","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;PHILOSOPHY;ENGINEERING;SOCIOLOGY;ECONOMICS;POLITICAL SCIENCE;ART;BUSINESS;GEOLOGY;HISTORY;MATERIALS SCIENCE;PSYCHOLOGY","58;55;17;6;6;5;3;3;2;2;1;1;1;1;1;1","IMMUNOLOGY;VIROLOGY;INTERNAL MEDICINE;GENETICS;BIOCHEMISTRY;PATHOLOGY;CELL BIOLOGY;MICROBIOLOGY;ENVIRONMENTAL HEALTH;MOLECULAR BIOLOGY;ORGANIC CHEMISTRY;GASTROENTEROLOGY;CARDIOLOGY;CANCER RESEARCH;INTENSIVE CARE MEDICINE;PSYCHIATRY;DEMOGRAPHY;ENDOCRINOLOGY;LIBRARY SCIENCE;PHARMACOLOGY;QUANTUM MECHANICS;RADIOLOGY;STEREOCHEMISTRY","51;42;31;28;27;16;12;12;10;9;8;7;5;4;4;4;3;3;3;3;3;3;3","VIRUS;GENE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNE SYSTEM;DISEASE;ENZYME;ANTIGEN;IN VITRO;POPULATION;ANTIBODY;APOPTOSIS;HEPATITIS C;DNA;DRUG RESISTANCE;CONFIDENCE INTERVAL;BACTERIA;CELL CULTURE;CEREBROSPINAL FLUID;COHORT STUDY;EPIDEMIOLOGY;PULMONARY HYPERTENSION","34;26;26;13;11;11;9;9;9;8;8;7;6;6;5;4;4;4;4;4;4","VIRAL DISEASE;VIRAL LOAD;HEPATITIS C VIRUS;T CELL;HEPATITIS B VIRUS;HEME;ALLOSTERIC REGULATION;CD8;CYTOTOXIC T CELL;GENOTYPE;INFECTIOUS DISEASE (MEDICAL SPECIALTY);PERIPHERAL BLOOD MONONUCLEAR CELL;PROGRAMMED CELL DEATH;PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;RNA;SEROLOGY;VIRAL REPLICATION;DENDRITIC CELL;GENOME;HAZARD RATIO;HEPATITIS A VIRUS;HUMAN HERPESVIRUS;NUCLEOSIDE ANALOGUE;POLYMERASE CHAIN REACTION","16;16;9;7;6;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3","ANTIRETROVIRAL THERAPY;LENTIVIRUS;SIDA;REVERSE TRANSCRIPTASE;JC VIRUS;LAMIVUDINE;CORONAVIRUS DISEASE 2019 (COVID-19);HERPESVIRIDAE;ANTIGEN PRESENTATION;ANTIGEN-PRESENTING CELL;ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA;BK VIRUS;CASPASE;HBSAG;MEN WHO HAVE SEX WITH MEN;MOLECULAR BEACON;ZIDOVUDINE;ALLOSTERIC ENZYME;AMPLICON;AMPLIFIED FRAGMENT LENGTH POLYMORPHISM;APICOMPLEXA;CASPASE 3;CD86;CELL MEDIATED IMMUNITY;CLADE;CTL*;DEOXYCYTIDINE;DIGITOXIN;DIRECT AGGLUTINATION TEST;DNA METHYLATION;DNA MICROARRAY;EPSTEIN–BARR VIRUS INFECTION;EUKARYOTE;FLAVIVIRIDAE;FLUDARABINE;GENOTYPING;HAPLOTYPE;HEPACIVIRUS;INTERLEUKIN 12;INTERLEUKIN 21;INTRAVENOUS DRUG;ISOPENTENYL PYROPHOSPHATE;LIPOTEICHOIC ACID;LYMPHOPROLIFERATIVE RESPONSE;MELTING CURVE ANALYSIS;MEMORY T CELL;MERKEL CELL POLYOMAVIRUS;MHC CLASS I;MHC CLASS II;MONOCLONAL;MUTAGENESIS;MYCOBACTERIUM SMEGMATIS;NATURAL KILLER T CELL;NEOPLASTIC TRANSFORMATION;NEUROGLOBIN;NUCLEIC ACID THERMODYNAMICS;P38 MITOGEN-ACTIVATED PROTEIN KINASES;PAROMOMYCIN;PERIPLASMIC SPACE;PEROXYNITRITE;POINT MUTATION;PROMOTER;PROTEIN QUATERNARY STRUCTURE;PSEUDOMONADACEAE;PSEUDOMONADALES;PYOVERDINE;RETINOID;SEROSTATUS;SH-SY5Y;SUBGENOMIC MRNA;T-CELL RECEPTOR;THYMIDINE KINASE;WILD TYPE;YERSINIA PSEUDOTUBERCULOSIS","9;8;7;5;4;4;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HIV INFECTIONS;HUMANS;ADULT;MALE;FEMALE;HIV-1;HEPATITIS C;MIDDLE AGED;ANTI-HIV AGENTS;HEPATITIS C, CHRONIC;ITALY;HEPACIVIRUS;INTERFERON-GAMMA;AIDS DEMENTIA COMPLEX;RNA, VIRAL;ANIMALS;;APOPTOSIS;TH1 CELLS;VIRUS REPLICATION","81;74;37;35;33;28;26;25;24;18;16;15;15;14;14;13;12;12;12;12","HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;HEPATITIS C INFECTION AND TREATMENT;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;NATURAL KILLER CELLS IN IMMUNITY;POLYOMAVIRUS-ASSOCIATED CARCINOGENESIS AND CLINICAL MANIFESTATIONS;PROTEIN BINDING SPECIFICITY IN HUMAN SERUM ALBUMIN;CORONAVIRUS DISEASE 2019 RESEARCH;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;EPIDEMIOLOGY AND MOLECULAR CHARACTERIZATION OF PARASITIC DISEASES;HEMOGLOBIN FUNCTION AND REGULATION IN VERTEBRATES;MOLECULAR MECHANISMS OF CARDIAC ARRHYTHMIAS;BRUCELLOSIS: A RE-EMERGING ZOONOSIS;CHALLENGES IN UNDERSTANDING AND TREATING LEPROSY;CYANOGENIC GLYCOSIDES IN PLANTS AND INDUSTRIAL WASTEWATERS;DIAGNOSIS AND TREATMENT OF LUNG CANCER;DNA NANOTECHNOLOGY AND BIOANALYTICAL APPLICATIONS;EBOLA VIRUS RESEARCH AND OUTBREAKS;ELECTRON SPIN RESONANCE IN BIOMOLECULAR STUDIES","12;9;8;6;5;4;4;3;3;2;2;2;2;1;1;1;1;1;1;1","HIV;ANTIRETROVIRAL THERAPY;HEPATITIS C;HEPATITIS C VIRUS;HIV EPIDEMIOLOGY;HIV INFECTION;HIV TRANSMISSION;HUMAN HERPESVIRUS 8;JC VIRUS;MEMORY T CELLS;REVERSE-TRANSCRIPTASE INHIBITOR;RITONAVIR;ANTIGEN PRESENTATION;APOPTOSIS;DISCONTINUATION;EFAVIRENZ;FATTY ACID BINDING;HEPATITIS B;IMMUNE ACTIVATION;INTERQUARTILE RANGE","19;10;7;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3","ANTIRETROVIRAL THERAPY;CEREBROSPINAL FLUID;HIV-INFECTED PATIENTS;HUMAN HERPESVIRUS;PULMONARY HYPERTENSION;VIRUS INFECTION;ALLOSTERIC MODULATION;FLOW CYTOMETRY;HIV INFECTION;HUMAN IMMUNODEFICIENCY;HUMAN SERUM;SERUM ALBUMIN;ANTIRETROVIRAL TREATMENT;ANTIRETROVIRAL-NAIVE HIV-INFECTED;APOPTOSIS INDUCED;BRUGADA SYNDROME;CARDIAC HISTOLOGICAL;CELL DEATH;CLINICAL PHENOTYPE;DENDRITIC CELLS;FLUID HIV-;HISTOLOGICAL SUBSTRATE;HIV- INFECTION;HIVINFECTED PATIENTS;NEUROBLASTOMA CELLS;NEUROCOGNITIVE IMPAIRMENT;REVERSE TRANSCRIPTASE;RISK FACTORS;SOUTHERN ITALY;VIRUS REPLICATION","4;4;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;HUMAN IMMUNODEFICIENCY;IMMUNODEFICIENCY VIRUS;MED -CROSSREF;EXP MED;CELL DEATH;ESTE JA;FERRI KF;HCV INFECTION;HIV-INFECTED INDIVIDUALS;VIRUS HCV;WHITE MATTER;ANTIHIV DRUGS;GIANT CELLS;HIV-ASSOCIATED DEMENTIA;HIV-INFECTED PATIENTS;MAMMALIAN TARGET;PERFETTINI JL;PERIPHERAL BLOOD;PULMONARY HYPERTENSION;BIOLOGY UNIVERSITY;BRAIN SECTIONS;CDT CELLS;DISCONTINUATION DUE;ENVELOPE GLYCOPROTEIN;ENVELOPEJ EXP;FERROUS NITROSYLATED;FULL-TEXT VERSION;HEALTH CARE","46;43;22;19;12;11;8;8;8;8;8;8;8;7;7;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6",19,0.2,4.04,2,0,1,0,0,2,0,1,2.5,0,0,0,0,0,0,0,0,0,0,0,62,62,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SPALLANZANIROMA",2006,100,9.81,3.72,0.35,0.39,0.39,1.80288461538462,1.20689655172414,1.69565217391304,1.25806451612903,0.44,0,43,21,17,12,0.43,0.21,0.17,0.12,68.82,1.34734564502048,NA,0.33,0.9,0.574,0.421,0.38,0.42,"PAOLO ASCENZI;ANDREA ANTINORI;CARLO FEDERICO PERNO;DIEGO SERRAINO;PAOLO VISCA;GIUSEPPE IPPOLITO;FABRIZIO POCCIA;MARIA ROSARIA CAPOBIANCHI;ANTONELLA D’ARMINIO MONFORTE;PASQUALE NARCISO;VALERIO TOZZI;MAURO ZACCARELLI;ENRICO GIRARDI;VITTORIO COLIZZI;ANGELO MARTINO;S SQUARCIONE;ENRICA TAMBURRINI;GIAN MARÍA FIMIA;PIERLUCA PISELLI;M. RAVIZZA","13;10;10;8;8;8;7;7;7;7;6;6;6;6;5;5;5;5;5;5","PAOLO ASCENZI;PAOLO VISCA;FABRIZIO POCCIA;CARLO FEDERICO PERNO;GIUSEPPE IPPOLITO;ANGELO MARTINO;MAURO FASANO;MARIA MARINO;PASQUALE NARCISO;DIEGO SERRAINO;MARIA ROSARIA CAPOBIANCHI;ENRICO GIRARDI;ANDREA ANTINORI;VITTORIO COLIZZI;ALESSIO BOCEDI;RITA CASETTI;MARIA GRAZIA PAGLIA;S SQUARCIONE;GIAN MARÍA FIMIA;PAOLA GALLUZZO","3.46;1.45;1.04;0.99;0.98;0.91;0.87;0.87;0.86;0.84;0.84;0.79;0.74;0.72;0.68;0.62;0.59;0.55;0.55;0.53","PAOLO ASCENZI;ANDREA ANTINORI;CARLO FEDERICO PERNO;DIEGO SERRAINO;PAOLO VISCA;GIUSEPPE IPPOLITO;FABRIZIO POCCIA;MARIA ROSARIA CAPOBIANCHI;PASQUALE NARCISO;VALERIO TOZZI;MAURO ZACCARELLI;ENRICO GIRARDI;ANGELO MARTINO;S SQUARCIONE;GIAN MARÍA FIMIA;PIERLUCA PISELLI;MARIA GRAZIA PAGLIA;PASQUALE NARCISO;ROBERTA D’ARRIGO;UBALDO VISCO‐COMANDINI","13;10;10;8;8;8;7;7;7;6;6;6;5;5;5;5;4;4;4;4","PAOLO ASCENZI;PAOLO VISCA;FABRIZIO POCCIA;CARLO FEDERICO PERNO;GIUSEPPE IPPOLITO;ANGELO MARTINO;PASQUALE NARCISO;DIEGO SERRAINO;MARIA ROSARIA CAPOBIANCHI;ENRICO GIRARDI;ANDREA ANTINORI;ALESSIO BOCEDI;RITA CASETTI;MARIA GRAZIA PAGLIA;S SQUARCIONE;GIAN MARÍA FIMIA;FRANCA DEL NONNO;STEFANO LICCI;PIERLUCA PISELLI;NICOLA PETROSILLO","3.46;1.45;1.04;0.99;0.98;0.91;0.86;0.84;0.84;0.79;0.74;0.68;0.62;0.59;0.55;0.55;0.53;0.53;0.51;0.5","GIAN MARÍA FIMIA;MAURO PIACENTINI;ANTOINE TESNIÈRE;DIDIER MÉTIVIER;FABIOLA CICCOSANTI;FRANÇOIS GHIRINGHELLI;GRÉGOIRE MIGNOT;GUIDO KROEMER;JEAN‐LUC PERFETTINI;LAURENCE ZITVOGEL;LIONEL APÉTOH;MARIA CASTEDO;MICHEL OBÉID;NATHANAËL LAROCHETTE;NOËLIA CASARES;PETER VAN ENDERT;THEOCHARIS PANARETAKIS;PAOLO ASCENZI;MARIA MARINO;PAOLA GALLUZZO","2959;2939;2763;2763;2763;2763;2763;2763;2763;2763;2763;2763;2763;2763;2763;2763;2763;992;599;595","GIAN MARÍA FIMIA;MAURO PIACENTINI;FABIOLA CICCOSANTI;PAOLO ASCENZI;PASQUALE NARCISO;GIUSEPPE IPPOLITO;ROSARIO RUSSO;PAOLO VISCA;ANDREA ANTINORI;FABRIZIO POCCIA;MARIA ROSARIA CAPOBIANCHI;VALERIO TOZZI;CARLO FEDERICO PERNO;ENRICO GIRARDI;ROBERTA D’ARRIGO;ALESSIO BOCEDI;RITA BELLAGAMBA;ANTONINO DI;CONCETTA CASTILLETTI;STEFANIA NOTARI","2959;2884;2763;992;537;350;322;315;291;282;274;257;249;244;224;212;210;197;197;193","PAOLO ASCENZI;PASQUALE NARCISO;ANDREA ANTINORI;CARLO FEDERICO PERNO;GIUSEPPE IPPOLITO;PAOLO VISCA;MAURO ZACCARELLI;FABRIZIO POCCIA;VALERIO TOZZI;ENRICO GIRARDI;MARIA ROSARIA CAPOBIANCHI;PIERLUCA PISELLI;ANGELO MARTINO;GIAN MARÍA FIMIA;S SQUARCIONE;ALESSIO BOCEDI;DIEGO SERRAINO;FRANCA DEL NONNO;MARIA GRAZIA PAGLIA;PATRIZIA LORENZINI","13;11;9;8;8;8;6;6;6;6;5;5;5;5;5;4;4;4;4;4","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ECONOMICS;POLITICAL SCIENCE;PSYCHOLOGY;SOCIOLOGY;ENGINEERING;BUSINESS;GEOGRAPHY;MATHEMATICS","74;62;17;10;8;4;4;4;4;3;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;VIROLOGY;GENETICS;BIOCHEMISTRY;PATHOLOGY;CELL BIOLOGY;MICROBIOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;OBSTETRICS;FAMILY MEDICINE;SURGERY;OPTICS;CANCER RESEARCH;DERMATOLOGY;ENDOCRINOLOGY;GYNECOLOGY;PEDIATRICS;PHARMACOLOGY","48;44;35;34;24;22;14;14;11;11;8;7;7;6;5;5;5;5;5;5","HUMAN IMMUNODEFICIENCY VIRUS (HIV);GENE;VIRUS;IMMUNE SYSTEM;CANCER;POPULATION;ENZYME;IN VITRO;DISEASE;REGIMEN;ANTIBODY;CONFIDENCE INTERVAL;PREGNANCY;TUBERCULOSIS;BACTERIA;DRUG RESISTANCE;INCIDENCE (GEOMETRY);ODDS RATIO;RECEPTOR;ANTIGEN;APOPTOSIS;CHOLESTEROL;COHORT;HEALTH CARE;HEPATITIS C;IN VIVO","27;24;22;13;10;10;9;9;8;8;7;7;7;7;6;6;6;5;5;4;4;4;4;4;4;4","VIRAL LOAD;VIRAL DISEASE;GENOTYPE;T CELL;HEPATITIS B VIRUS;HEPATITIS C VIRUS;MYCOBACTERIUM TUBERCULOSIS;POLYMERASE CHAIN REACTION;VIRAL REPLICATION;CERVICAL CANCER;MUTATION;SEROLOGY;SUPEROXIDE;BREAST CANCER;CYTOTOXIC T CELL;DENDRITIC CELL;GENE EXPRESSION;LEISHMANIA;PROGRAMMED CELL DEATH;VIRULENCE;VISCERAL LEISHMANIASIS","18;11;7;7;5;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3","ANTIRETROVIRAL THERAPY;LAMIVUDINE;PEROXYNITRITE;ESTROGEN RECEPTOR;REVERSE TRANSCRIPTASE;SIDA;ZIDOVUDINE;CASPASE;CORONAVIRUS DISEASE 2019 (COVID-19);HEPACIVIRUS;HERPESVIRIDAE;HPV INFECTION;LEISHMANIA INFANTUM;LENTIVIRUS;NUCLEAR RECEPTOR;SEROPREVALENCE;SPHINGOSINE-1-PHOSPHATE;VIRAL EVOLUTION;ACTIVE TUBERCULOSIS;ALPHA (FINANCE);ALTERNATIVE SPLICING;ANTIGEN-PRESENTING CELL;ANTIMYCOBACTERIAL;ATTENUATED VACCINE;BACILLACEAE;BACILLALES;CASPOFUNGIN;CD40;CD86;CELL FATE DETERMINATION;CERVICAL CANCER SCREENING;COMPLEMENTATION;DISCRIMINANT VALIDITY;ELECTRON TRANSPORT COMPLEX I;ELECTRON TRANSPORT COMPLEX IV;ELISPOT;EPITHELIAL–MESENCHYMAL TRANSITION;FLAVIVIRIDAE;GENE EXPRESSION PROFILING;GERMINAL CENTER;GP41;HEALTH FACILITY;HEMEPROTEIN;HEMOPEXIN;HEPATOCYTE NUCLEAR FACTORS;HYPERTRIGLYCERIDEMIA;IL-2 RECEPTOR;IMMUNOGENIC CELL DEATH;IN SITU HYBRIDIZATION;INTERLEUKIN 12;INTERLEUKIN 21;KAPOSI'S SARCOMA;LATENT TUBERCULOSIS;LOSARTAN;MATRIX-ASSISTED LASER DESORPTION/IONIZATION;MEGLUMINE ANTIMONIATE;MIMOTOPE;MYCOBACTERIUM SMEGMATIS;NADH DEHYDROGENASE;NOCARDIOSIS;OPPORTUNISTIC INFECTION;PAPILLOMAVIRIDAE;PERTUSSIS TOXIN;POINT MUTATION;PROMOTER;RIBAVIRIN;SECOND TRIMESTER;SULFURTRANSFERASE;TEMPERATURE GRADIENT GEL ELECTROPHORESIS;THIRD TRIMESTER;TRANSCRIPTOME;TUBERCULOSIS DIAGNOSIS;VERY LOW-DENSITY LIPOPROTEIN;VIRAL QUASISPECIES","14;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HIV INFECTIONS;HUMANS;FEMALE;MALE;ADULT;HIV-1;ANTI-HIV AGENTS;MIDDLE AGED;HEPATITIS C;ITALY;REVERSE TRANSCRIPTASE INHIBITORS;ANIMALS;DENDRITIC CELLS;HEPACIVIRUS;PREGNANCY COMPLICATIONS, INFECTIOUS;ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE;AGED;HIV PROTEASE INHIBITORS;;BACTERIAL PROTEINS","90;75;49;38;36;29;26;26;20;20;18;16;15;15;15;14;13;13;12;12","EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;HEPATITIS C INFECTION AND TREATMENT;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;GLOBAL BURDEN OF LEISHMANIASIS INCIDENCE AND TREATMENT;TUBERCULOSIS;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;IMMUNOBIOLOGY OF DENDRITIC CELLS;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;MECHANISMS OF ESTROGEN RECEPTOR SIGNALING;BIOLOGICAL AGENTS FOR BIOTERRORISM;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;HEMOGLOBIN FUNCTION AND REGULATION IN VERTEBRATES;MECHANOSENSITIVE ION CHANNELS IN PHYSIOLOGY AND DISEASE;MEDICAL EQUIPMENT MAINTENANCE AND MANAGEMENT;REGULATORY T CELL DEVELOPMENT AND FUNCTION;SARCOMA RESEARCH AND TREATMENT;SPHINGOLIPID SIGNALLING AND METABOLISM IN HEALTH AND DISEASE;ADVANCES IN METABOLOMICS RESEARCH","10;8;6;6;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;1","HIV;ANTIRETROVIRAL THERAPY;REGIMEN;TREATMENT;HIV INFECTION;HIV EPIDEMIOLOGY;HEPATITIS C;REVERSE-TRANSCRIPTASE INHIBITOR;STAVUDINE;ABACAVIR;ADHERENCE TO MEDICATION;EFAVIRENZ;ESTROGEN;HIV TRANSMISSION;LEISHMANIASIS;NEVIRAPINE;RESISTANCE MUTATION;BACILLUS ANTHRACIS;CANCER INCIDENCE;CORONAVIRUS","18;14;7;7;6;5;4;4;4;3;3;3;3;3;3;3;3;2;2;2","ANTIRETROVIRAL THERAPY;ACTIVE ANTIRETROVIRAL;DENDRITIC CELLS;HIGHLY ACTIVE;HIV-INFECTED PATIENTS;PREGNANT WOMEN;HIV-INFECTED WOMEN;PATIENTS FAILING;ANTIRETROVIRAL DRUGS;CELL DEATH;HAART ERA;HEMOGLOBIN GLBO;HIV--INFECTED PATIENTS;HIV-POSITIVE PATIENTS;HUMAN PLASMA;IBACILLUS ANTHRACISI;IMMUNE RESPONSE;LIPID PROFILE;MITOCHONDRIAL RESPIRATORY;MYCOBACTERIUM LEPRAE;NITRIC OXIDE;PROTEOMIC ANALYSIS;SPHINGOSINE -PHOSPHATE;TREATED PATIENTS;TRUNCATED HEMOGLOBIN;ABACAVIR MODULATES;ABLATION LEADS;ACTIVATING INTERACTION;ACTIVE TUBERCULOSIS;ACTIVITY DETERMINATION","6;4;4;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","ANTIRETROVIRAL THERAPY;NATIONAL INSTITUTE;ROMA ITALYSEARCH;CONFIDENCE INTERVAL;SELECTED PEPTIDES;DISEASES IRCCS;INFECTIOUS DISEASES;IRCCS LAZZARO;LAZZARO SPALLANZANI;LIPOSOMAL AMPHOTERICIN;PREGNANT WOMEN;SPALLANZANI ROMA;ACTIVE ANTIRETROVIRAL;HIGHLY ACTIVE;INTERVAL CI;LIPID VALUES;LONG-TERM DIALYSIS;MULTIVARIATE ANALYSES;RESPIRATORY CHAIN;THERAPY HAART;VIRAL LOAD;ACTIVE TB;ANTIRETROVIRAL TREATMENT;ANTIVIRAL ACTIVITY;CD INCREASE;ENFUVIRTIDE-TREATED PATIENTS;HIV INFECTION;LEFT VENTRICULAR;ODDS RATIO;PAOLO ASCENZI","8;8;8;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4",26,0.26,6,4,1,4,0,2,4,0,2,5,0,1,4,0,3,0,2,3.5,1.5,0,0,76,76.75,2,0,1,0,0,0,0,0,1,0,0,0,2,0,0,0,8,4.27,1.5,0,1,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"AGRATI CHIARA;ALONZI TONINO;AMICOSANTE MASSIMO;BORDONI VERONICA;CAPOBIANCHI MARIA ROSARIA;CASETTI RITA;D OFFIZI GIANPIERO;GIOIA CRISTIANA;HOREJSH DOUGLAS;IPPOLITO GIUSEPPE","1;1;1;1;1;1;1;1;1;1","ISTITUTO NAZ PER LE MALATTIE I;ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE ""LAZZARO SPALLANZANI"";ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE ""LAZZARO SPALLANZANI"" IRCCS","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3204 IMMUNOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","3;1;1;1;1","BIOTECHNOLOGY;VACCINE RELATED","1;1","5.2 CELLULAR AND GENE THERAPIES","1","A61K35/12;C12N5/00;C12N5/06;C12N5/0783;C12N5/0789;G01N33/50;G01N33/569;G01N33/571;G01N33/576","1;1;1;1;1;1;1;1;1","A61K35/12;C12N2502/14;C12N5/0018;C12N5/0647;G01N33/505;G01N33/56911;G01N33/56972;G01N33/56977;G01N33/56983;G01N33/571","1;1;1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SPALLANZANIROMA",2007,106,8.76415094339623,3.15094339622642,0.481132075471698,0.433962264150943,0.471698113207547,1.83977900552486,1.18604651162791,1.76923076923077,1.21951219512195,0.452830188679245,0,61,15,14,11,0.58,0.14,0.13,0.1,59.75,1.13205421546356,NA,0.273584905660377,0.820754716981132,0.441,0.401,0.423,0.398,"ANDREA ANTINORI;ENRICO GIRARDI;MARIA ROSARIA CAPOBIANCHI;CARLO FEDERICO PERNO;PAOLO ASCENZI;GIUSEPPE IPPOLITO;MARCO CORAZZARI;MAURO PIACENTINI;CLAUDIO ANGELETTI;ANDREA FRUSTACI;GIANPIERO D’OFFIZI;FABRIZIO POCCIA;DIEGO SERRAINO;GIAN MARÍA FIMIA;PASQUALE NARCISO;PATRIZIA MARCONI;ANGELA CORPOLONGO;GIOVANNI REZZA;UBALDO VISCO‐COMANDINI;MARCO TRIPODI","14;11;11;10;7;7;6;6;6;6;5;5;5;5;5;4;4;4;4;4","PAOLO ASCENZI;MARIA ROSARIA CAPOBIANCHI;ANDREA ANTINORI;ANDREA FRUSTACI;ENRICO GIRARDI;GIUSEPPE IPPOLITO;PAOLO VISCA;CARLO FEDERICO PERNO;MAURO PIACENTINI;MAURO FASANO;GABRIELLA FANALI;MASSIMO COLETTA;MARCO CORAZZARI;FABRIZIO POCCIA;ISABELLA ABBATE;CLAUDIO ANGELETTI;GIAN MARÍA FIMIA;NICOLA PETROSILLO;RITA CASETTI;EMANUELE NICASTRI","1.9;1.47;1.4;1.27;1.05;1;1;0.94;0.86;0.83;0.83;0.74;0.73;0.72;0.68;0.67;0.66;0.65;0.59;0.59","ANDREA ANTINORI;ENRICO GIRARDI;MARIA ROSARIA CAPOBIANCHI;CARLO FEDERICO PERNO;PAOLO ASCENZI;GIUSEPPE IPPOLITO;MARCO CORAZZARI;MAURO PIACENTINI;CLAUDIO ANGELETTI;ANDREA FRUSTACI;GIANPIERO D’OFFIZI;FABRIZIO POCCIA;GIAN MARÍA FIMIA;PASQUALE NARCISO;PATRIZIA MARCONI;ANGELA CORPOLONGO;UBALDO VISCO‐COMANDINI;MARCO TRIPODI;ALESSANDRA SACCHI;ANTONINO DI","14;11;11;10;7;7;6;6;6;6;5;5;5;5;4;4;4;4;4;4","PAOLO ASCENZI;MARIA ROSARIA CAPOBIANCHI;ANDREA ANTINORI;ANDREA FRUSTACI;ENRICO GIRARDI;GIUSEPPE IPPOLITO;PAOLO VISCA;CARLO FEDERICO PERNO;MAURO PIACENTINI;MARCO CORAZZARI;FABRIZIO POCCIA;ISABELLA ABBATE;CLAUDIO ANGELETTI;GIAN MARÍA FIMIA;NICOLA PETROSILLO;RITA CASETTI;EMANUELE NICASTRI;ALESSANDRA SACCHI;GIANPIERO D’OFFIZI;PASQUALE NARCISO","1.9;1.47;1.4;1.27;1.05;1;1;0.94;0.86;0.73;0.72;0.68;0.67;0.66;0.65;0.59;0.59;0.58;0.57;0.52","ANDREA FRUSTACI;ARTHUR M. FELDMAN;JAGAT NARULA;JEFFREY A. TOWBIN;KENNETH L. BAUGHMAN;LESLIE T. COOPER;MARIELL JESSUP;RANDALL C. STARLING;RENU VIRMANI;UWE KÜHL;GLENN N. LEVINE;MARCO CORAZZARI;MAURO PIACENTINI;GIAN MARÍA FIMIA;ROBERTA NARDACCI;ALESSANDRA ROMAGNOLI;ANASTASSIA STOYKOVA;CLAUDIA FUOCO;FRANCESCO CECCONI;KAMAL CHOWDHURY","2121;2014;2014;2014;2014;2014;2014;2014;2014;2014;1582;1385;1217;1177;1073;1033;1033;1033;1033;1033","MARCO CORAZZARI;GIAN MARÍA FIMIA;ANDREA FRUSTACI;ROBERTA NARDACCI;ALESSANDRA ROMAGNOLI;ANDREA ANTINORI;ENRICO GIRARDI;PASQUALE NARCISO;ANGELA CORPOLONGO;RITA BELLAGAMBA;VALERIO TOZZI;UBALDO VISCO‐COMANDINI;MARIA FLORA SALVATORI;PIETRO BALESTRA;CHRYSOULA VLASSI;MARINELLA GIULIANELLI;MARCO TRIPODI;CARLA CICCHINI;CORINNA STEINDLER;MARIA ROSARIA CAPOBIANCHI","1385;1177;1157;1073;1033;636;440;378;360;360;352;318;316;316;315;315;289;227;227;222","ANDREA ANTINORI;CARLO FEDERICO PERNO;ENRICO GIRARDI;MARIA ROSARIA CAPOBIANCHI;PAOLO ASCENZI;PASQUALE NARCISO;MARCO CORAZZARI;GIUSEPPE IPPOLITO;ANDREA FRUSTACI;VALERIO TOZZI;GIAN MARÍA FIMIA;ALESSANDRA SACCHI;ANNA ROSA GARBUGLIA;CLAUDIO ANGELETTI;FABRIZIO POCCIA;FEDERICO MARTINI;ISABELLA ABBATE;MARCO TRIPODI;MARIA PAOLA TROTTA;MAURO PIACENTINI","14;10;10;8;7;7;6;5;5;5;5;4;4;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;ENGINEERING;SOCIOLOGY;COMPUTER SCIENCE;POLITICAL SCIENCE;ART;MATHEMATICS;PSYCHOLOGY;BUSINESS;GEOGRAPHY;HISTORY;PHILOSOPHY","77;65;15;11;6;6;3;3;2;2;2;1;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;VIROLOGY;GENETICS;BIOCHEMISTRY;PATHOLOGY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;MICROBIOLOGY;CANCER RESEARCH;CARDIOLOGY;ELECTRICAL ENGINEERING;OPTICS;PEDIATRICS;SURGERY;DEMOGRAPHY;MOLECULAR BIOLOGY;ORGANIC CHEMISTRY;RADIOLOGY","51;49;38;37;28;16;10;10;9;8;8;6;6;6;6;6;6;5;5;5;5","GENE;VIRUS;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNE SYSTEM;DISEASE;POPULATION;IN VITRO;ANTIGEN;CONFIDENCE INTERVAL;ENZYME;ANTIBODY;BACTERIA;APOPTOSIS;COHORT;INCIDENCE (GEOMETRY);TUBERCULOSIS;CANCER;DRUG RESISTANCE;HEPATITIS C;LOGISTIC REGRESSION;ODDS RATIO;PROSPECTIVE COHORT STUDY;TRANSMISSION (TELECOMMUNICATIONS)","28;26;24;13;12;11;10;9;8;8;7;7;6;6;6;6;5;5;5;5;5;5;5","VIRAL LOAD;HEPATITIS C VIRUS;VIRAL DISEASE;GENOTYPE;HEME;POLYMERASE CHAIN REACTION;PROGRAMMED CELL DEATH;T CELL;CYTOTOXIC T CELL;EPITOPE;MYCOBACTERIUM TUBERCULOSIS;HEPATITIS B VIRUS;VIREMIA;CD8;ENDOMYOCARDIAL BIOPSY;REACTION RATE CONSTANT;REAL-TIME POLYMERASE CHAIN REACTION;RNA;STAPHYLOCOCCUS AUREUS;TUBERCULIN","16;8;7;6;6;6;6;6;5;5;5;4;4;3;3;3;3;3;3;3","ANTIRETROVIRAL THERAPY;REVERSE TRANSCRIPTASE;HEMEPROTEIN;ELISPOT;GP41;LAMIVUDINE;LATENT TUBERCULOSIS;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;RIBAVIRIN;SIDA;STAPHYLOCOCCAL INFECTIONS;TUBERCULOSIS DIAGNOSIS;VIRAL QUASISPECIES;ACTINOBACTERIA;ACUTE BRONCHIOLITIS;AMPLICON;ANTHRACYCLINE;ATG8;AUTOPHAGOSOME;BAG3;BDNA TEST;BECN1;BK VIRUS;CD28;CHOLESTERYL ESTER;CONGENITAL CYSTIC ADENOMATOID MALFORMATION;CORONAVIRUS DISEASE 2019 (COVID-19);CTL*;CTLA-4;CYTOREDUCTIVE SURGERY;DNA FRAGMENTATION;EBOLAVIRUS;EPITHELIAL–MESENCHYMAL TRANSITION;ETHAMBUTOL;EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS;FLAVIVIRIDAE;GENOTYPING;HALOARCHAEA;HEMANGIOBLAST;HEMOPEXIN;HEPACIVIRUS;HEPTAD REPEAT;HERPESVIRIDAE;IL-2 RECEPTOR;IMMUNOGENIC CELL DEATH;INTRAVENOUS DRUG;LASER CAPTURE MICRODISSECTION;LENTIVIRUS;MANIA;MEN WHO HAVE SEX WITH MEN;MICROCOCCACEAE;MICROSATELLITE;MOLECULAR EPIDEMIOLOGY;MYCOBACTERIUM BOVIS;NEUROEPITHELIAL CELL;NITROGENASE;PAS DOMAIN;PERITONEAL CARCINOMATOSIS;PEROXYNITRITE;PROMOTER;PYOVERDINE;PYRAZINAMIDE;REPLICON;RETINOID;RICKETTSIOSIS;RNA POLYMERASE;SEROPREVALENCE;SEXUAL PARTNER;SEXUAL TRANSMISSION;SINGLE-NUCLEOTIDE POLYMORPHISM;SPOTTED FEVER;SYBR GREEN I;T-CELL RECEPTOR;TANDEM REPEAT;TAQMAN;VACCINIA;VARIABLE NUMBER TANDEM REPEAT;VERY LOW-DENSITY LIPOPROTEIN;VIRAL ENCEPHALITIS;VIRAL EVOLUTION","14;5;4;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HIV INFECTIONS;HUMANS;MALE;HIV-1;FEMALE;ADULT;ITALY;MIDDLE AGED;ANTI-HIV AGENTS;DNA, VIRAL;ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE;RNA, VIRAL;;BACTERIAL PROTEINS;TREATMENT OUTCOME;AGED;HEPATITIS C, CHRONIC;ANIMALS;NEOPLASMS;VIRAL LOAD","96;82;48;45;43;42;35;35;29;19;15;14;13;13;13;12;12;11;11;11","HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;HEPATITIS C INFECTION AND TREATMENT;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;TUBERCULOSIS;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;HEMOGLOBIN FUNCTION AND REGULATION IN VERTEBRATES;IMMUNOBIOLOGY OF DENDRITIC CELLS;NATURAL KILLER CELLS IN IMMUNITY;EBOLA VIRUS RESEARCH AND OUTBREAKS;ENDOPLASMIC RETICULUM STRESS AND UNFOLDED PROTEIN RESPONSE;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;GLOBAL IMPACT OF ARBOVIRAL DISEASES;HEPATITIS B INFECTION AND TREATMENT;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS;PROTEIN BINDING SPECIFICITY IN HUMAN SERUM ALBUMIN;ROLE OF AUTOPHAGY IN DISEASE AND HEALTH;","14;9;6;5;5;5;4;3;3;3;2;2;2;2;2;2;2;2;2;1","HIV;ANTIRETROVIRAL THERAPY;HIV INFECTION;HEPATITIS C;HIV TRANSMISSION;REVERSE-TRANSCRIPTASE INHIBITOR;CARDIAC IMAGING;ENDOMYOCARDIAL BIOPSY;HEMEPROTEIN;IMMUNE RESPONSES;MYCOBACTERIUM TUBERCULOSIS;TREATMENT;VIREMIA;HBV INFECTION;HIV EPIDEMIOLOGY;INTERQUARTILE RANGE;MYOGLOBIN FUNCTION;REGIMEN;T CELL;AUTOPHAGY","20;12;9;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;2","ANTIRETROVIRAL THERAPY;HIV-INFECTED PATIENTS;ACTIVE ANTIRETROVIRAL;HIGHLY ACTIVE;CARDIOVASCULAR DISEASE;DISEASE PROGRESSION;ENDOMYOCARDIAL BIOPSY;CD CELL;CHAIN REACTION;DENDRITIC CELLS;DENSITY LIPOPROTEIN;DNA QUANTITATION;DRUG-RESISTANT TUBERCULOSIS;ENDOPLASMIC RETICULUM;EUROPEAN SOCIETY;EXTENSIVELY DRUG-RESISTANT;FERROUS NITROSYLATED;GENETIC VARIABILITY;HEART FAILURE;HIV DNA;HIV INFECTION;HIV TYPE;HIV--POSITIVE WOMEN;HIV-RELATED NEUROCOGNITIVE;HUMAN HERPESVIRUS;HUMAN IMMUNODEFICIENCY;HUMAN PAPILLOMAVIRUS;HUMAN SERUM;HYPERTROPHIC CARDIOMYOPATHY;KAPOSIS SARCOMA","5;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;ONLINE PUBLICATION;PUBLICATION DATE;ONLINE NA;FABRY DISEASE;FINAL CONCENTRATION;NP DEFICITS;ER STRESS;PERSISTENT NP;CD CELL;BIOL CHEM;CELL DEATH;CHEM -ABSTRACT;PUBMED GOOGLE;BIOCHIM BIOPHYS;BIOPHYS ACTA;CONDUCTION TISSUE;FAST FORM;HEME-BINDING DOMAIN;SLOW FORM;BACTERIOL -CROSSREF;HEME BINDING;VI MUTATION;ACTA -GOOGLE;ACTIVE TUBERCULOSIS;ANDERSON-FABRY DISEASE;ANTIRETROVIRAL THERAPY;BIOCHEM -CROSSREF;CELL COUNT","42;39;21;21;18;17;16;14;13;12;10;9;9;9;9;8;8;8;8;8;8;7;7;7;6;6;6;6;6;6",21,0.2,6,2,0,1,0,1,2,1,1,2,0,1,1,0,1,0,1,1,0,0,0,79,79,3,0,2,1,0,0,0,0,0,0,0,0,3,0,0,11,6,5.41,1,0,0,3,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"CASETTI RITA;AMICOSANTE ,MASSIMO;AMICOSANTE MASSIMO;CANNAS ANGELA;CARRARA STEFANIA;CARRARA, STEFANIA;GIRARADI,ENRICO;GIRARDI ENRICO;GOLETTI ,DELIA;GOLETTI DELIA","2;1;1;1;1;1;1;1;1;1","ISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI;ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE ""LAZZARO SPALLANZANI"" IRCCS;ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI IRCCS","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY","4;1;1;1;1;1","EMERGING INFECTIOUS DISEASES;INFECTIOUS DISEASES;BIODEFENSE;BIOTECHNOLOGY;GENETICS;IMMUNIZATION;ORPHAN DRUG;PREVENTION;RARE DISEASES;TUBERCULOSIS","2;2;1;1;1;1;1;1;1;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","2","C07H21/04;C07K14/35;G01N33/554;G01N33/569;A61K39/04;C12Q1/68","2;2;2;2;1;1","C07K14/35;G01N33/5695;Y10S435/975;C12Q1/701","2;2;2;1",2,3,14.5,1.21,0,0,4,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,"Italy","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY","2;2;2","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HIV/AIDS;IMMUNIZATION;INFECTIOUS DISEASES;PREVENTION;VACCINE RELATED;EMERGING INFECTIOUS DISEASES","2;2;2;2;2;2;2;1","INFECTION","2","6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,1,1999998,333333,4,6,6,1,3,174731.099462366,0.606646443169842,"FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS;ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI;LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN;NATIONAL INSTITUTE FOR MEDICAL RESEARCH;UNIVERSITY COLLEGE LONDON;UNIVERSITY OF ZAMBIA","1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","FP6-2005-LIFESCIHEALTH-7 (CALL FOR PROPOSAL);FP6-LIFESCIHEALTH - LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH: THEMATIC PRIORITY 1 UNDER THE FOCUSING AND INTEGRATING COMMUNITY RESEARCH PROGRAMME 2002-2006. (PROGRAMME);STREP - SPECIFIC TARGETED RESEARCH PROJECT (FUNDING SCHEME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY","1;1;1","GENETICS;HIV/AIDS;INFECTIOUS DISEASES;LUNG;RARE DISEASES;TUBERCULOSIS","1;1;1;1;1;1","INFECTION","1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1","3 GOOD HEALTH AND WELL BEING","1",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SPALLANZANIROMA",2008,117,9.41880341880342,3.47008547008547,0.376068376068376,0.427350427350427,0.41025641025641,2.14814814814815,1.12820512820513,2.27272727272727,1.17073170731707,0.452991452991453,1,51,19,19,16,0.44,0.16,0.16,0.14,62.02,1.13021650691975,NA,0.307692307692308,0.82051282051282,0.483,0.369,0.316,0.362,"MARIA ROSARIA CAPOBIANCHI;ANDREA ANTINORI;GIUSEPPE IPPOLITO;PAOLO ASCENZI;ENRICO GIRARDI;PASQUALE NARCISO;STEFANO LICCI;VINCENZO PURO;CARLO FEDERICO PERNO;MAURO PIACENTINI;NICOLA PETROSILLO;F. LAURIA;CHIARA AGRATI;EMANUELE NICASTRI;PAOLO VISCA;FEDERICO MARTINI;FABRIZIO POCCIA;FRANCA DEL NONNO;CONCETTA CASTILLETTI;CLAUDIO ANGELETTI","15;12;12;11;11;10;8;8;8;7;7;7;6;6;6;6;5;5;5;5","PAOLO ASCENZI;STEFANO LICCI;PASQUALE NARCISO;MARIA ROSARIA CAPOBIANCHI;DIEGO SERRAINO;VINCENZO PURO;PAOLO VISCA;GIUSEPPE IPPOLITO;ANDREA ANTINORI;ENRICO GIRARDI;MASSIMO COLETTA;FRANCA DEL NONNO;NICOLA PETROSILLO;MAURO PIACENTINI;EMANUELE NICASTRI;FRANCESCO IMPERI;LUCA MORELLI;CARLO FEDERICO PERNO;CLAUDIO ANGELETTI;CHIARA AGRATI","2.25;2.14;1.94;1.46;1.22;1.2;1.17;1.16;0.98;0.95;0.94;0.89;0.89;0.87;0.75;0.73;0.69;0.66;0.65;0.63","MARIA ROSARIA CAPOBIANCHI;ANDREA ANTINORI;GIUSEPPE IPPOLITO;PAOLO ASCENZI;ENRICO GIRARDI;PASQUALE NARCISO;STEFANO LICCI;VINCENZO PURO;CARLO FEDERICO PERNO;MAURO PIACENTINI;NICOLA PETROSILLO;F. LAURIA;CHIARA AGRATI;EMANUELE NICASTRI;PAOLO VISCA;FEDERICO MARTINI;FABRIZIO POCCIA;FRANCA DEL NONNO;CONCETTA CASTILLETTI;CLAUDIO ANGELETTI","15;12;12;11;11;10;8;8;8;7;7;7;6;6;6;6;5;5;5;5","PAOLO ASCENZI;STEFANO LICCI;PASQUALE NARCISO;MARIA ROSARIA CAPOBIANCHI;DIEGO SERRAINO;VINCENZO PURO;PAOLO VISCA;GIUSEPPE IPPOLITO;ANDREA ANTINORI;ENRICO GIRARDI;FRANCA DEL NONNO;NICOLA PETROSILLO;MAURO PIACENTINI;EMANUELE NICASTRI;FRANCESCO IMPERI;CARLO FEDERICO PERNO;CLAUDIO ANGELETTI;CHIARA AGRATI;FEDERICO MARTINI;PASQUALE NOTO","2.25;2.14;1.94;1.46;1.22;1.2;1.17;1.16;0.98;0.95;0.89;0.89;0.87;0.75;0.73;0.66;0.65;0.63;0.62;0.62","MAURO PIACENTINI;GUIDO KROEMER;WALTER MALORNI;BORIS ZHIVOTOVSKY;DOUGLAS R. GREEN;E S ALNEMRI;ERIC H. BAEHRECKE;GABRIEL NÚÑEZ;GERRY MELINO;J TSCHOPP;JOHN ABRAMS;JUNYING YUAN;LORENZO GALLUZZI;MARCUS E. PETER;MICHAEL O. HENGARTNER;MIKHAIL V. BLAGOSKLONNY;PETER VANDENABEELE;PIERRE GOLSTEIN;RICHARD A. KNIGHT;SHARAD KUMAR","3799;3528;3226;3194;3194;3194;3194;3194;3194;3194;3194;3194;3194;3194;3194;3194;3194;3194;3194;3194","MAURO PIACENTINI;PAOLO ASCENZI;GIUSEPPE IPPOLITO;ENRICO GIRARDI;MARIA ROSARIA CAPOBIANCHI;GIAN MARÍA FIMIA;ANDREA ANTINORI;DELIA GOLETTI;F. LAURIA;VINCENZO PURO;PASQUALE NARCISO;MARIACARMELA SOLMONE;CHIARA AGRATI;FABRIZIO POCCIA;ADRIANA AMMASSARI;CARMINE MANCONE;MARCO TRIPODI;PAOLA PIACENTINI;FEDERICO MARTINI;ALESSANDRO BRUSELLES","3465;536;529;485;448;387;348;284;272;268;266;234;221;220;209;192;192;190;163;157","ANDREA ANTINORI;MARIA ROSARIA CAPOBIANCHI;PASQUALE NARCISO;PAOLO ASCENZI;ENRICO GIRARDI;GIUSEPPE IPPOLITO;MAURO PIACENTINI;STEFANO LICCI;VINCENZO PURO;CARLO FEDERICO PERNO;EMANUELE NICASTRI;FEDERICO MARTINI;CHIARA AGRATI;NICOLA PETROSILLO;CONCETTA CASTILLETTI;FABRIZIO POCCIA;FRANCA DEL NONNO;PAOLO VISCA;F. LAURIA;ISABELLA ABBATE","12;12;12;11;10;10;7;7;7;6;6;6;6;5;5;5;5;5;5;5","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;ENGINEERING;COMPUTER SCIENCE;MATHEMATICS;PHILOSOPHY;PSYCHOLOGY;HISTORY;SOCIOLOGY;ECONOMICS;POLITICAL SCIENCE;BUSINESS;GEOGRAPHY;MATERIALS SCIENCE","85;61;17;16;6;5;5;5;5;3;3;2;2;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;VIROLOGY;GENETICS;BIOCHEMISTRY;PATHOLOGY;ENVIRONMENTAL HEALTH;CELL BIOLOGY;OPTICS;FAMILY MEDICINE;GASTROENTEROLOGY;MICROBIOLOGY;PEDIATRICS;INTENSIVE CARE MEDICINE;PHARMACOLOGY;MOLECULAR BIOLOGY;SURGERY;ORGANIC CHEMISTRY;QUANTUM MECHANICS;CANCER RESEARCH;ELECTRICAL ENGINEERING;EMERGENCY MEDICINE;GYNECOLOGY;LINGUISTICS;NURSING;PSYCHIATRY;STEREOCHEMISTRY","55;52;39;34;29;22;14;10;10;9;9;9;9;8;8;7;7;5;5;4;4;4;4;4;4;4;4","HUMAN IMMUNODEFICIENCY VIRUS (HIV);VIRUS;GENE;IMMUNE SYSTEM;POPULATION;ENZYME;DISEASE;CANCER;HEPATITIS C;INCIDENCE (GEOMETRY);ANTIBODY;IN VITRO;TUBERCULOSIS;APOPTOSIS;EPIDEMIOLOGY;HEPATITIS B;ANTIBIOTICS;ANTIGEN;BACTERIA;COHORT","29;27;24;15;13;12;11;10;10;9;8;8;8;7;7;7;6;6;6;6","VIRAL LOAD;HEPATITIS B VIRUS;HEPATITIS C VIRUS;GENOTYPE;PROGRAMMED CELL DEATH;T CELL;VIRAL DISEASE;HEME;MYCOBACTERIUM TUBERCULOSIS;PERIPHERAL BLOOD MONONUCLEAR CELL;POLYMERASE CHAIN REACTION;BREAST CANCER;INFECTIOUS DISEASE (MEDICAL SPECIALTY);VIREMIA;AUTOPHAGY;COINFECTION;IMMUNITY;PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;SEROLOGY;SPUTUM;TISSUE TRANSGLUTAMINASE","16;9;9;8;6;6;6;5;5;5;5;4;4;4;3;3;3;3;3;3;3","ANTIRETROVIRAL THERAPY;HBSAG;SIDA;CASPASE;CORONAVIRUS DISEASE 2019 (COVID-19);HEMEPROTEIN;ACTIVE TUBERCULOSIS;CD3;FLAVIVIRIDAE;HEPACIVIRUS;LATENT TUBERCULOSIS;NESTED POLYMERASE CHAIN REACTION;REVERSE TRANSCRIPTASE;T-CELL RECEPTOR;ALPHA (FINANCE);AMPLICON;ANNEXIN A2;ANTHRACYCLINE;ANTIVIRAL THERAPY;AVIAN INFLUENZA VIRUS;BK VIRUS;CASPASE 3;CD28;CD40;CHLAMYDOMONAS;CHLAMYDOMONAS REINHARDTII;CHROMOPHOBE CELL;COMPLEMENTATION;CROSS-REACTIVITY;CULTURE CONVERSION;DEPERSONALIZATION;ELISPOT;ESOPHAGEAL CANDIDIASIS;ESTROGEN RECEPTOR;ETHAMBUTOL;EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS;FEBRILE NEUTROPENIA;GLOBULES OF FAT;GP41;HEMOPEXIN;HIV VACCINE;HIV-1 PROTEASE;IMIPENEM;IMMUNOGENIC CELL DEATH;INTERNAL TRANSCRIBED SPACER;JC VIRUS;JURKAT CELLS;LAMIVUDINE;LENTIVIRUS;LOWER RESPIRATORY TRACT INFECTION;LY294002;MALARIA VACCINE;MAMMARY GLAND;MASSIVE PARALLEL SEQUENCING;MEN WHO HAVE SEX WITH MEN;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;MHC CLASS I;MITOPHAGY;MITOTIC CATASTROPHE;NARINGENIN;NECROPTOSIS;NON-PHOTOCHEMICAL QUENCHING;NUCLEAR PROTEIN;OPPORTUNISTIC INFECTION;PALMITOYLATION;PAPANICOLAOU STAIN;PARASITEMIA;PEROXYNITRITE;PHYLOGENETIC RELATIONSHIP;PNEUMOCOCCAL INFECTIONS;POLY ADP RIBOSE POLYMERASE;PYOVERDINE;PYROPTOSIS;RETINOID;REVERSION;RIBAVIRIN;RIBOSOMAL DNA;SEXUAL TRANSMISSION;SEXUALLY TRANSMITTED DISEASE;SMALL HAIRPIN RNA;SPUTUM CULTURE;SYPHILIS SERODIAGNOSIS;TAMOXIFEN;THYLAKOID;TIMI;TUBERCULOSIS DIAGNOSIS;VARIMAX ROTATION;VIRAL QUASISPECIES","12;5;4;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;HIV INFECTIONS;ADULT;FEMALE;MALE;MIDDLE AGED;ITALY;;ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE;HIV-1;AGED;RNA, VIRAL;DNA, VIRAL;HEPATITIS C;HEPATITIS B;ANIMALS;ANTI-HIV AGENTS;REVERSE TRANSCRIPTASE INHIBITORS;VIRAL LOAD;ADOLESCENT","86;68;50;50;45;35;32;19;19;19;18;18;17;15;14;13;13;13;13;12","EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;HEPATITIS B INFECTION AND TREATMENT;HEMOGLOBIN FUNCTION AND REGULATION IN VERTEBRATES;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;HEPATITIS C INFECTION AND TREATMENT;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;TUBERCULOSIS;NATURAL KILLER CELLS IN IMMUNITY;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;POLYOMAVIRUS-ASSOCIATED CARCINOGENESIS AND CLINICAL MANIFESTATIONS;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;BIOLOGICAL BASIS AND CLINICAL MANAGEMENT OF SYPHILIS;CLINICAL CHARACTERISTICS AND MANAGEMENT OF SARCOIDOSIS;EPIDEMIOLOGY AND PATHOGENESIS OF PNEUMOCYSTIS PNEUMONIA;EPIDEMIOLOGY AND PATHOGENESIS OF RESPIRATORY VIRAL INFECTIONS;INFLUENZA VIRUS RESEARCH AND EPIDEMIOLOGY;LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;MOLECULAR MECHANISMS OF APOPTOSIS AND CELL DEATH;ROLE OF RETINOIC ACID IN BIOLOGICAL PROCESSES","7;7;6;6;5;5;5;4;3;3;3;3;2;2;2;2;2;2;2;2","HIV;ANTIRETROVIRAL THERAPY;HEPATITIS C;HIV INFECTION;HEPATITIS B;REGIMEN;TREATMENT;HBV INFECTION;MYCOBACTERIUM TUBERCULOSIS;PATHOGENESIS;REVERSE-TRANSCRIPTASE INHIBITOR;VIRAL HEPATITIS;VIREMIA;ADHERENCE TO MEDICATION;CELL DEATH;HEMEPROTEIN;IMMUNOSUPPRESSION;MEMORY T CELLS;PROTEASE INHIBITOR (PHARMACOLOGY);TISSUE TRANSGLUTAMINASE","18;13;10;9;7;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3","ANTIRETROVIRAL THERAPY;CELL DEATH;HIV-INFECTED PATIENTS;BREAST CANCER;INFECTED PATIENTS;INTERFERON RESPONSE;ACTIVE ANTIRETROVIRAL;ACUTE HEPATITIS;ANTIRETROVIRAL REGIMENS;ANTIRETROVIRAL TREATMENT;AVIAN INFLUENZA;CANCER PATIENTS;CELL CARCINOMA;CLINICAL PRACTICE;FABRY DISEASE;HCV GENOTYPE;HEALTHCARE WORKERS;HIGHLY ACTIVE;HIV INFECTED;HIV PATIENTS;HIV RNA;JOB SATISFACTION;MULTIFOCAL LEUKOENCEPHALOPATHY;PERIPHERAL ΓΔ;PREGNANT WOMEN;PROGRESSIVE MULTIFOCAL;PULMONARY TUBERCULOSIS;RENAL CELL;TRUNCATED HEMOGLOBIN;VIRAL HEPATITIS","4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;LEFT VENTRICULAR;FABRY DISEASE;FORCE MEASUREMENTS;ACTIVE TB;CD CELL;CELL COUNT;CELL DEATH;FD CARDIOMYOCYTES;FD CARDIOMYOPATHY;GOLD IN-TUBE;PKA TREATMENT;RUSSO MA;CHEST PAIN;ENDOMYOCARDIAL BIOPSY;QUANTIFERON-TB GOLD;RELAXING SOLUTION;RESTING TENSION;STIENEN GJM;TISSUE DOPPLER;CD T-CELL;DER VELDEN;HCV GENOTYPE;RATE CONSTANT;ADYSPNEA CHEST;CARDIOMYOCYTE CROSS-SECTIONAL;DOPPLER IMAGING;FABRY CARDIOMYOPATHY;FD PATIENTS","24;17;14;12;9;8;8;8;8;8;8;8;8;8;7;7;7;7;7;7;7;6;6;6;6;5;5;5;5;5",22,0.19,8.77,4.75,1,1,0,5,5.75,0,1,5,0,1,1.5,0,5,0,1,1.75,0,0,0,74.75,74.75,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,12,4,0.99,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"CANNAS ANGELA;MILKONYAN HOVSEP;TOMEI LOUIS DAVID;UMANSKY SAMUIL R","1;1;1;1","ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE ""LAZZARO SPALLANZANI"" IRCCS","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY","2;1","EMERGING INFECTIOUS DISEASES;INFECTIOUS DISEASES;KIDNEY DISEASE;PREVENTION","1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT","1;1","C12Q1/68","1","C12Q1/6806;C12Q1/689","1;1",4,5.75,1326.5,2.31,1,0.25,140,0,0,0,1,1,0,0,2,0,2,2,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,0,0,0,0,"United States","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY","4;4;1","CLINICAL RESEARCH;HIV/AIDS;INFECTIOUS DISEASES;ANTIMICROBIAL RESISTANCE;ARTHRITIS;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;GENETICS;PREVENTION;RARE DISEASES;TUBERCULOSIS","4;4;4;1;1;1;1;1;1;1","INFECTION","3","6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","3;1;1;1",NA,NA,NA,NA,2,5530500,269630.43,3.5,12,6,0.5,29.5,300883.273375409,0.388855115432157,"ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI;AIX-MARSEILLE UNIVERSITY;CLAUDE BERNARD UNIVERSITY LYON 1;DANISH CANCER SOCIETY;DÉLÉGATION PARIS 11;EUROPEAN MOLECULAR BIOLOGY LABORATORY;GERMAN CANCER RESEARCH CENTER;INSTITUTE CURIE;INSTITUTE OF GENETICS AND MOLECULAR AND CELLULAR BIOLOGY;INSTITUTE OF MOLECULAR BIOTECHNOLOGY;KAROLINSKA INSTITUTET;MAX PLANCK SOCIETY;ROYAL COLLEGE OF SURGEONS IN IRELAND;TEL AVIV UNIVERSITY;UNIVERSITY HOSPITAL FRANKFURT;UNIVERSITY OF CAMPANIA ""LUIGI VANVITELLI"";UNIVERSITY OF GRAZ;UNIVERSITY OF LAUSANNE;UNIVERSITY OF SOUTHERN DENMARK;UNIVERSITY OF ULM","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;TELETHON FOUNDATION","1;1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CP-IP - LARGE-SCALE INTEGRATING PROJECT (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2007-A (CALL FOR PROPOSAL);TELETHON GRANT PROJECTS - 2008 (PROGRAM)","1;1;1;1","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS;3208 MEDICAL PHYSIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","2;2;1;1;1;1;1","BIOTECHNOLOGY;CANCER;CARDIOVASCULAR;GENETICS;HEART DISEASE;HUMAN GENOME;NEURODEGENERATIVE;ORPHAN DRUG;RARE DISEASES","1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;GENERIC HEALTH RELEVANCE","1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY)","2;1","NOT SITE-SPECIFIC CANCER","1","1.5 RESOURCES AND INFRASTRUCTURE;2.4 RESOURCES AND INFRASTRUCTURE RELATED TO ETIOLOGY;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","1;1;1;1","A01 CLINICAL MEDICINE","2",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SPALLANZANIROMA",2009,123,11.3414634146341,3.94308943089431,0.455284552845528,0.422764227642276,0.479674796747967,2.32057416267943,1.16666666666667,1.67741935483871,1.20408163265306,0.51219512195122,1,66,15,18,14,0.54,0.12,0.15,0.11,52.42,1.13328820256003,NA,0.300813008130081,0.886178861788618,0.507,0.409,0.365,0.4,"ENRICO GIRARDI;ANDREA ANTINORI;MARIA ROSARIA CAPOBIANCHI;DELIA GOLETTI;PIERLUCA PISELLI;GIUSEPPE IPPOLITO;CARLO FEDERICO PERNO;VINCENZO PURO;NICOLA PETROSILLO;PASQUALE NARCISO;PASQUALE NARCISO;PAOLO ASCENZI;CONCETTA CASTILLETTI;PAOLO VISCA;MAURO PIACENTINI;GIANPIERO D’OFFIZI;ANDREA DE LUCA;EMANUELE NICASTRI;DIEGO SERRAINO;FRANCESCA CECCHERINI‐SILBERSTEIN","15;14;14;10;10;10;10;9;8;8;7;7;7;7;7;6;6;6;6;6","NICOLA PETROSILLO;MARIA ROSARIA CAPOBIANCHI;PAOLO VISCA;ENRICO GIRARDI;ANDREA ANTINORI;ANDREA FRUSTACI;PASQUALE NARCISO;PAOLO ASCENZI;VINCENZO PURO;DELIA GOLETTI;CARLO FEDERICO PERNO;GIUSEPPE IPPOLITO;PIERLUCA PISELLI;CONCETTA CASTILLETTI;CRISTINA CHIMENTI;MAURO PIACENTINI;SILVIA D’AREZZO;EMANUELE NICASTRI;ANDREA DE LUCA;ANTONINO DI","2.18;1.52;1.41;1.36;1.33;1.17;1.08;1.05;1.04;0.84;0.79;0.77;0.76;0.68;0.67;0.66;0.65;0.6;0.6;0.59","ENRICO GIRARDI;ANDREA ANTINORI;MARIA ROSARIA CAPOBIANCHI;DELIA GOLETTI;PIERLUCA PISELLI;GIUSEPPE IPPOLITO;CARLO FEDERICO PERNO;VINCENZO PURO;NICOLA PETROSILLO;PASQUALE NARCISO;PASQUALE NARCISO;PAOLO ASCENZI;CONCETTA CASTILLETTI;PAOLO VISCA;MAURO PIACENTINI;GIANPIERO D’OFFIZI;EMANUELE NICASTRI;FRANCESCA CECCHERINI‐SILBERSTEIN;ROBERTA D’ARRIGO;ANTONINO DI","15;14;14;10;10;10;10;9;8;8;7;7;7;7;7;6;6;6;5;5","NICOLA PETROSILLO;MARIA ROSARIA CAPOBIANCHI;PAOLO VISCA;ENRICO GIRARDI;ANDREA ANTINORI;ANDREA FRUSTACI;PASQUALE NARCISO;PAOLO ASCENZI;VINCENZO PURO;DELIA GOLETTI;CARLO FEDERICO PERNO;GIUSEPPE IPPOLITO;PIERLUCA PISELLI;CONCETTA CASTILLETTI;CRISTINA CHIMENTI;MAURO PIACENTINI;SILVIA D’AREZZO;EMANUELE NICASTRI;ANTONINO DI;ALESSANDRO CAPONE","2.18;1.52;1.41;1.36;1.33;1.17;1.08;1.05;1.04;0.84;0.79;0.77;0.76;0.68;0.67;0.66;0.65;0.6;0.59;0.58","DELIA GOLETTI;MAURO PIACENTINI;GIOVANNI BATTISTA MIGLIORI;GIAN MARÍA FIMIA;ENRICO GIRARDI;AIK BOSSINK;PAOLO VISCA;AINARA EGIA;ARKAITZ CARRACEDO;CRISTINA BLÁZQUEZ;FRANCESCO CECCONI;GUILLERMO VELASCO;JONATHAN A. NOWAK;JUAN IOVANNA;LUIS GONZÁLEZ‐FERIA;MANUEL GUZMÁN;MAR LORENTE;MARÍA SALAZAR‐ROA;PATRICIA BOYA;PATRICIA VÁZQUEZ","1244;945;874;861;765;686;655;649;649;649;649;649;649;649;649;649;649;649;649;649","DELIA GOLETTI;MAURO PIACENTINI;GIAN MARÍA FIMIA;PAOLO VISCA;ENRICO GIRARDI;ANDREA FRUSTACI;CRISTINA CHIMENTI;PASQUALE NARCISO;ANDREA ANTINORI;PIERLUCA PISELLI;MARIA ROSARIA CAPOBIANCHI;NICOLA PETROSILLO;SILVIA D’AREZZO;FEDERICA TIBURZI;FRANCESCO IMPERI;GIUSEPPE IPPOLITO;GIANPIERO D’OFFIZI;ALESSANDRO CAPONE;TONINO ALONZI;VALENTINA VANINI","1158;945;861;655;623;567;567;532;482;424;345;336;329;292;292;292;286;272;272;271","PASQUALE NARCISO;ANDREA ANTINORI;MARIA ROSARIA CAPOBIANCHI;ENRICO GIRARDI;PIERLUCA PISELLI;VINCENZO PURO;CARLO FEDERICO PERNO;GIUSEPPE IPPOLITO;MAURO PIACENTINI;NICOLA PETROSILLO;DELIA GOLETTI;CONCETTA CASTILLETTI;PAOLO ASCENZI;PAOLO VISCA;EMANUELE NICASTRI;GIANPIERO D’OFFIZI;MATTIA PROSPERI;ELEONORA LALLE;GIAN MARÍA FIMIA;ROBERTA D’ARRIGO","15;14;14;12;10;9;8;8;8;8;8;7;7;7;6;6;6;5;5;5","MEDICINE;BIOLOGY;CHEMISTRY;ENGINEERING;PHYSICS;COMPUTER SCIENCE;SOCIOLOGY;POLITICAL SCIENCE;PSYCHOLOGY;BUSINESS;ECONOMICS;GEOGRAPHY;HISTORY;MATHEMATICS;PHILOSOPHY","93;74;12;11;11;6;5;2;2;1;1;1;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;VIROLOGY;GENETICS;BIOCHEMISTRY;PATHOLOGY;MICROBIOLOGY;ENVIRONMENTAL HEALTH;SURGERY;CELL BIOLOGY;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;OPTICS;PEDIATRICS;ELECTRICAL ENGINEERING;MECHANICAL ENGINEERING;COMPUTATIONAL BIOLOGY;MOLECULAR BIOLOGY;OBSTETRICS;ONCOLOGY;ORGANIC CHEMISTRY;PHARMACOLOGY;PSYCHIATRY","56;49;47;39;29;26;18;14;12;11;11;9;9;8;6;6;5;5;5;5;5;5;5","GENE;VIRUS;HUMAN IMMUNODEFICIENCY VIRUS (HIV);DISEASE;IMMUNE SYSTEM;POPULATION;TUBERCULOSIS;DRUG RESISTANCE;ENZYME;INCIDENCE (GEOMETRY);ANTIGEN;COHORT;CONFIDENCE INTERVAL;EPIDEMIOLOGY;IN VITRO;REGIMEN;BACTERIA;DNA;HEPATITIS B;RANDOMIZED CONTROLLED TRIAL;TRANSMISSION (TELECOMMUNICATIONS)","36;33;32;16;15;12;12;10;9;9;8;8;8;8;8;8;7;7;7;7;7","VIRAL LOAD;HEPATITIS B VIRUS;GENOTYPE;MUTATION;HEPATITIS C VIRUS;VIRAL DISEASE;MYCOBACTERIUM TUBERCULOSIS;POLYMERASE CHAIN REACTION;INFECTIOUS DISEASE (MEDICAL SPECIALTY);PSEUDOMONAS AERUGINOSA;VIREMIA;GENOME;HAZARD RATIO;RECOMBINANT DNA;T CELL;ACINETOBACTER;COINFECTION;DNA DAMAGE;GENE EXPRESSION;INNATE IMMUNE SYSTEM;INTERFERON GAMMA;MULTIPLE DRUG RESISTANCE;PERIPHERAL BLOOD MONONUCLEAR CELL;PHYLOGENETIC TREE;PROTEASE;RNA;SKIN CANCER","28;10;9;9;8;8;7;7;6;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","ANTIRETROVIRAL THERAPY;REVERSE TRANSCRIPTASE;CORONAVIRUS DISEASE 2019 (COVID-19);HBSAG;LAMIVUDINE;LATENT TUBERCULOSIS;ACINETOBACTER BAUMANNII;ZIDOVUDINE;ACTIVE TUBERCULOSIS;ALPHAVIRUS INFECTION;BACTERIAL OUTER MEMBRANE;ELISPOT;HEMEPROTEIN;HERPESVIRIDAE;HIV-1 PROTEASE;IL-2 RECEPTOR;LENTIVIRUS;PERIPLASMIC SPACE;POINT MUTATION;PROVIRUS;RIBAVIRIN;SIDA;TOLL-LIKE RECEPTOR;TUBERCULOSIS DIAGNOSIS;VIRAL QUASISPECIES","21;6;5;5;5;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HIV INFECTIONS;HUMANS;HIV-1;FEMALE;MALE;ADULT;ANTI-HIV AGENTS;MIDDLE AGED;ITALY;ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE;TUBERCULOSIS;DNA, VIRAL;RNA, VIRAL;VIRAL LOAD;VIREMIA;INTERFERON-GAMMA;RECOMBINANT PROTEINS;ANTIVIRAL AGENTS;DRUG RESISTANCE, VIRAL;AGED","119;100;61;59;56;51;45;37;34;26;24;19;19;19;19;18;17;16;16;15","HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;TUBERCULOSIS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;HEPATITIS B INFECTION AND TREATMENT;HEPATITIS C INFECTION AND TREATMENT;INFLUENZA VIRUS RESEARCH AND EPIDEMIOLOGY;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;MECHANISMS AND TREATMENT OF LIVER FIBROSIS;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;EBOLA VIRUS RESEARCH AND OUTBREAKS;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;EPIDEMIOLOGY AND MOLECULAR CHARACTERIZATION OF PARASITIC DISEASES;EPIDEMIOLOGY AND PATHOGENESIS OF RESPIRATORY VIRAL INFECTIONS;GLOBAL IMPACT OF ARBOVIRAL DISEASES;MOLECULAR MECHANISMS OF DNA DAMAGE RESPONSE;PROTEIN BINDING SPECIFICITY IN HUMAN SERUM ALBUMIN;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS","15;12;11;8;5;5;4;4;3;3;3;2;2;2;2;2;2;2;2;1","HIV;ANTIRETROVIRAL THERAPY;HIV INFECTION;REGIMEN;HBV INFECTION;HEPATITIS B;TREATMENT;NEVIRAPINE;RITONAVIR;EFAVIRENZ;HIV TRANSMISSION;MYCOBACTERIUM TUBERCULOSIS;VIREMIA;ATAZANAVIR;CART;H1N1;HEPATITIS C;LIVER DISEASE;LOPINAVIR;PROTEASE INHIBITOR (PHARMACOLOGY)","26;21;12;8;7;7;7;6;6;5;5;5;5;4;4;4;4;4;4;4","ANTIRETROVIRAL THERAPY;ANTIRETROVIRAL TREATMENT;ACTIVE TUBERCULOSIS;CHRONIC HEPATITIS;DE NOVO;HIV TYPE;HUMAN SERUM;LATENT TUBERCULOSIS;TUBERCULOSIS INFECTION;ACINETOBACTER BAUMANNII;AIDS-RELATED INTESTINAL;ANTIRETROVIRAL DRUGS;AV MUTATION;CHIKUNGUNYA OUTBREAKS;COHORT STUDY;CONSENSUS STATEMENT;CRITICAL REAPPRAISAL;CRYPTOSPORIDIOSIS ROLE;GENOTYPIC RESISTANCE;HAART ERA;HIV INFECTION;HIV- ENVELOPE;HIV-INFECTED PATIENTS;HIV-POSITIVE PATIENTS;HUMAN IMMUNODEFICIENCY;IMMUNODEFICIENCY VIRUS;INCREASED PATHOGENESIS;INFECTIOUS DISEASES;INTESTINAL CRYPTOSPORIDIOSIS;LIVER TRANSPLANTATION","6;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;ACTIVE TB;HIV INFECTION;TB PATIENTS;ACTIVE ANTIRETROVIRAL;GENE EXPRESSION;HIGHLY ACTIVE;QUANTIFERON-TB GOLD;SKIN TEST;TUBERCULIN SKIN;TUBERCULOSIS INFECTION;VIRAL LOAD;VΓVΔ T-CELL;ACTIVE TUBERCULOSIS;ANTIRETROVIRAL TREATMENT;EUROPEAN COUNTRIES;HIV- INFECTION;IMMUNE RESPONSE;INFECTIOUS DISEASES;HEALTHY CONTROLS;INFECTED PATIENTS;LATENT TUBERCULOSIS;PERIPHERAL BLOOD;AV MUTATION;GOLD IN-TUBE;HIV- INFECTED;HIV-INFECTED PATIENTS;IMMUNE RESPONSES;MONONUCLEAR CELLS;MYCOBACTERIUM TUBERCULOSIS","15;11;9;9;8;8;8;8;8;8;8;8;8;7;7;7;7;7;7;6;6;6;6;5;5;5;5;5;5;5",29,0.24,6,3,504.5,1,43,15,3,0,2,5,7,1,3,1,2,2,4.5,3.5,2,0,0,111,136,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,5,0,1.47,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,3,0,0,0,3,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;3204 IMMUNOLOGY","3;3;2","ANTIMICROBIAL RESISTANCE;BIODEFENSE;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;EMERGING INFECTIOUS DISEASES;INFECTIOUS DISEASES;LUNG;PREVENTION;RARE DISEASES;TUBERCULOSIS;VACCINE RELATED","1;1;1;1;1;1;1;1;1;1;1","INFECTION","3","6.1 PHARMACEUTICALS","2",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,"PUBLIC LIBRARY OF SCIENCE","1","31 BIOLOGICAL SCIENCES;3105 GENETICS;32 BIOMEDICAL AND CLINICAL SCIENCES","1;1;1","GENETICS","1",NA,NA,"4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","1","BIOMEDICAL","1",NA,NA,NA,NA,NA,NA
"IRCCS_SPALLANZANIROMA",2010,98,11.1836734693878,3.51020408163265,0.459183673469388,0.357142857142857,0.520408163265306,2.20512820512821,1.28571428571429,2.05882352941176,1.41666666666667,0.683673469387755,3,54,13,9,9,0.55,0.13,0.09,0.09,38.99,0.862785654981625,NA,0.387755102040816,0.826530612244898,0.485,0.491,0.417,0.467,"GIUSEPPE IPPOLITO;MARIA ROSARIA CAPOBIANCHI;F. LAURIA;ANDREA ANTINORI;EMANUELE NICASTRI;ANTONELLA D’ARMINIO MONFORTE;NICOLA PETROSILLO;CARLO FEDERICO PERNO;ISABELLA ABBATE;ANTONINO DI;CONCETTA CASTILLETTI;ENRICO GIRARDI;LEOPOLDO PAOLO PUCILLO;PASQUALE NARCISO;ANDREA DE LUCA;MAURO MORONI;ANTONELLA CASTAGNA;CHIARA TOMMASI;GIAN MARÍA FIMIA;GABRIELLA ROZERA","18;17;15;14;11;9;8;7;7;6;6;6;6;6;5;5;5;5;5;5","MARIA ROSARIA CAPOBIANCHI;F. LAURIA;GIUSEPPE IPPOLITO;ENRICO GIRARDI;NICOLA PETROSILLO;ANDREA ANTINORI;EMANUELE NICASTRI;VALERIO TOZZI;FABRIZIO CARLETTI;CARLO FEDERICO PERNO;PASQUALE NARCISO;ISABELLA ABBATE;ANTONELLA D’ARMINIO MONFORTE;CONCETTA CASTILLETTI;GIAN MARÍA FIMIA;PAOLO VISCA;CHIARA TOMMASI;LEOPOLDO PAOLO PUCILLO;MAURO PIACENTINI;MARIA BEATRICE VALLI","1.69;1.65;1.6;1.43;1.37;1.26;1.24;1;1;0.75;0.69;0.68;0.68;0.61;0.58;0.56;0.54;0.54;0.54;0.53","GIUSEPPE IPPOLITO;MARIA ROSARIA CAPOBIANCHI;F. LAURIA;ANDREA ANTINORI;EMANUELE NICASTRI;NICOLA PETROSILLO;CARLO FEDERICO PERNO;ISABELLA ABBATE;ANTONINO DI;CONCETTA CASTILLETTI;ENRICO GIRARDI;LEOPOLDO PAOLO PUCILLO;PASQUALE NARCISO;CHIARA TOMMASI;GIAN MARÍA FIMIA;GABRIELLA ROZERA;MICHELE BIBAS;MARIA BEATRICE VALLI;SILVIA MESCHI;MAURO PIACENTINI","18;17;15;14;11;8;7;7;6;6;6;6;6;5;5;5;5;4;4;4","MARIA ROSARIA CAPOBIANCHI;F. LAURIA;GIUSEPPE IPPOLITO;ENRICO GIRARDI;NICOLA PETROSILLO;ANDREA ANTINORI;EMANUELE NICASTRI;VALERIO TOZZI;FABRIZIO CARLETTI;CARLO FEDERICO PERNO;PASQUALE NARCISO;ISABELLA ABBATE;CONCETTA CASTILLETTI;GIAN MARÍA FIMIA;CHIARA TOMMASI;LEOPOLDO PAOLO PUCILLO;MAURO PIACENTINI;MARIA BEATRICE VALLI;MICHELE BIBAS;ELISABETTA GRILLI","1.69;1.65;1.6;1.43;1.37;1.26;1.24;1;1;0.75;0.69;0.68;0.61;0.58;0.54;0.54;0.54;0.53;0.51;0.5","ANDREA ANTINORI;GIUSEPPE IPPOLITO;DELIA GOLETTI;ENRICO GIRARDI;ANTONELLA D’ARMINIO MONFORTE;AMANDA MOCROFT;ANDREW PHILLIPS;JENS LUNDGREN;AIK BOSSINK;BEATE KAMPMANN;BERNHARD HELLMICH;CHRISTOPH LANGE;CONNIE ERKENS;ELISABETH H. SCHÖLVINCK;FILIPPO BARTALESI;GIOVANNI BATTISTA MIGLIORI;GIOVANNI SOTGIU;HANS L. RIEDER;HEATHER MILBURN;IVAN SOLOVIČ","739;727;700;671;621;485;485;485;484;484;484;484;484;484;484;484;484;484;484;484","ANDREA ANTINORI;DELIA GOLETTI;GIUSEPPE IPPOLITO;ENRICO GIRARDI;MARIA ROSARIA CAPOBIANCHI;F. LAURIA;EMANUELE NICASTRI;ANTONINO DI;NICOLA PETROSILLO;GIAN MARÍA FIMIA;LEOPOLDO PAOLO PUCILLO;CONCETTA CASTILLETTI;FABRIZIO CARLETTI;ISABELLA ABBATE;FABIOLA CICCOSANTI;PASQUALE NARCISO;SILVIA D’AREZZO;STEFANIA CARRARA;CARLO FEDERICO PERNO;MICHELE BIBAS","739;632;544;523;430;355;286;279;265;259;259;237;222;171;167;150;148;148;144;129","MARIA ROSARIA CAPOBIANCHI;GIUSEPPE IPPOLITO;ANDREA ANTINORI;F. LAURIA;EMANUELE NICASTRI;ISABELLA ABBATE;CARLO FEDERICO PERNO;NICOLA PETROSILLO;PASQUALE NARCISO;CONCETTA CASTILLETTI;ANTONINO DI;CHIARA TOMMASI;GIAN MARÍA FIMIA;LEOPOLDO PAOLO PUCILLO;MICHELE BIBAS;GABRIELLA ROZERA;ENRICO GIRARDI;FABRIZIO CARLETTI;MARIA BEATRICE VALLI;MAURO PIACENTINI","16;15;13;13;11;7;7;7;6;6;5;5;5;5;5;4;4;4;4;4","MEDICINE;BIOLOGY;ENGINEERING;PHYSICS;SOCIOLOGY;POLITICAL SCIENCE;CHEMISTRY;PSYCHOLOGY;COMPUTER SCIENCE;ECONOMICS;GEOGRAPHY;BUSINESS;PHILOSOPHY;HISTORY;MATERIALS SCIENCE;MATHEMATICS;ENVIRONMENTAL SCIENCE","81;42;12;9;9;8;7;5;4;4;4;3;3;2;2;2;1","INTERNAL MEDICINE;VIROLOGY;IMMUNOLOGY;GENETICS;PATHOLOGY;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;SURGERY;GASTROENTEROLOGY;MICROBIOLOGY;CELL BIOLOGY;FAMILY MEDICINE;OPTICS;LAW;PEDIATRICS;ELECTRICAL ENGINEERING;DEMOGRAPHY;PHARMACOLOGY;PSYCHIATRY","47;34;33;26;22;17;15;15;12;11;10;9;9;9;8;7;6;5;5;5","HUMAN IMMUNODEFICIENCY VIRUS (HIV);GENE;VIRUS;DISEASE;POPULATION;INCIDENCE (GEOMETRY);TUBERCULOSIS;COHORT;IMMUNE SYSTEM;ANTIBODY;ANTIBIOTICS;BACTERIA;EPIDEMIOLOGY;LYMPHOMA;OUTBREAK;TRANSMISSION (TELECOMMUNICATIONS);RANDOMIZED CONTROLLED TRIAL;REGIMEN;ALTERNATIVE MEDICINE;DNA;DRUG RESISTANCE;HEALTH CARE;HEPATITIS C;IN VITRO;MEDLINE","29;23;21;13;13;9;9;8;8;7;6;6;6;6;6;6;5;5;4;4;4;4;4;4;4","VIRAL LOAD;GENOTYPE;HEPATITIS C VIRUS;INFECTIOUS DISEASE (MEDICAL SPECIALTY);VIRAL DISEASE;GENE EXPRESSION;INFLUENZA A VIRUS;MYCOBACTERIUM TUBERCULOSIS;SEROLOGY;T CELL;PHYLOGENETICS;PROGRAMMED CELL DEATH;PSEUDOMONAS AERUGINOSA;PYROSEQUENCING;ARDS;BORTEZOMIB;CD8;CYTARABINE;CYTOTOXIC T CELL;DENGUE VIRUS;GENETIC DIVERSITY;HEPATITIS B VIRUS;LIVER TRANSPLANTATION;NON-HODGKIN'S LYMPHOMA;PHYLOGENETIC TREE;POISSON REGRESSION;RECOMBINANT DNA;RIFAMPICIN;SEROCONVERSION;STAPHYLOCOCCUS AUREUS;TRANSCRIPTION FACTOR;TROPISM;UNFOLDED PROTEIN RESPONSE;UNIVARIATE ANALYSIS;VIRAL REPLICATION;WEST NILE VIRUS","18;9;7;6;6;4;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;CORONAVIRUS DISEASE 2019 (COVID-19);VIRAL QUASISPECIES;ACINETOBACTER BAUMANNII;ACTIVE TUBERCULOSIS;CD86;CLADE;ETHAMBUTOL;HERPESVIRIDAE;LATENT TUBERCULOSIS;LENTIVIRUS;MOLECULAR EPIDEMIOLOGY;PYRAZINAMIDE;SEROPREVALENCE;TISSUE TROPISM;VANCOMYCIN;ALTERNATIVE SPLICING;APOMORPHINE;BACTERIAL OUTER MEMBRANE;BK VIRUS;CASPASE;CATIONIC LIPOSOME;CD3;CD38;CD40;COALESCENT THEORY;CYTOLYSIS;DENGUE HAEMORRHAGIC FEVER;FEBRILE NEUTROPENIA;GENOTYPING;GLUTATHIONE PEROXIDASE;HBSAG;HEMEPROTEIN;HISTONE DEACETYLASE;HOUSEKEEPING GENE;IMMUNOGENIC CELL DEATH;KU70;LEVODOPA;MEN WHO HAVE SEX WITH MEN;MICROARRAY ANALYSIS TECHNIQUES;MULTILOCUS SEQUENCE TYPING;NIOSOME;OXALIPLATIN;PERIPHERAL T-CELL LYMPHOMA;PROMOTER;PULSED-FIELD GEL ELECTROPHORESIS;PYOVERDINE;REGULON;REPRESSOR;RETINOID;RIBAVIRIN;RNA SPLICING;RNA-BINDING PROTEIN;SALMONELLA ENTERICA;SEQUESTOSOME 1;SIDA;SMN1;STREPTOCOCCUS SUIS;TANDEM REPEAT;TRANSCRIPTIONAL REGULATION;TUBERCULOSIS DIAGNOSIS;V3 LOOP;VARIABLE NUMBER TANDEM REPEAT;VECTOR (MOLECULAR BIOLOGY);VERY LOW-DENSITY LIPOPROTEIN;VIRAL INTERFERENCE;VIRAL LIFE CYCLE;ZIDOVUDINE","12;6;4;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;HIV INFECTIONS;MALE;FEMALE;ADULT;ITALY;HIV-1;;MIDDLE AGED;VIRAL LOAD;ANTI-BACTERIAL AGENTS;GRAM-POSITIVE BACTERIAL INFECTIONS;INFLUENZA, HUMAN;ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE;INFLUENZA A VIRUS, H1N1 SUBTYPE;MYCOBACTERIUM TUBERCULOSIS;CD4 LYMPHOCYTE COUNT;HEPATITIS C;RNA, VIRAL;TUBERCULOSIS","76;75;35;32;31;30;27;21;21;14;12;12;12;11;11;11;10;10;10;10","HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;TUBERCULOSIS;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;INFLUENZA VIRUS RESEARCH AND EPIDEMIOLOGY;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;GLOBAL IMPACT OF ARBOVIRAL DISEASES;HEPATITIS C INFECTION AND TREATMENT;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;MOLECULAR MECHANISMS OF APOPTOSIS AND CELL DEATH;PHARMACOKINETICS OF ANTIBIOTICS IN CRITICALLY ILL PATIENTS;VIRAL HEMORRHAGIC FEVERS AND ZOONOTIC INFECTIONS;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;BACTERIAL BIOFILMS AND QUORUM SENSING MECHANISMS;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;COPPER AND ZINC IN HEALTH AND DISEASE;DIAGNOSIS AND TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA;DIAGNOSIS AND TREATMENT OF PROSTHETIC JOINT INFECTIONS;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION","12;7;6;6;5;5;4;3;2;2;2;2;1;1;1;1;1;1;1;1","HIV;HIV INFECTION;ANTIRETROVIRAL THERAPY;H1N1;HIV EPIDEMIOLOGY;REGIMEN;HEPATITIS C;VIRAL QUASISPECIES;CART;ETIOLOGY;HEPATITIS B;HIV TRANSMISSION;PANDEMIC;POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE;PYROSEQUENCING;RALTEGRAVIR;TREATMENT;ACINETOBACTER BAUMANNII;ACTIVE TUBERCULOSIS;CANCER INCIDENCE","21;11;9;6;6;5;4;4;3;3;3;3;3;3;3;3;3;2;2;2","HIV INFECTION;ANTIRETROVIRAL THERAPY;ITALIAN SOCIETY;CONSENSUS DOCUMENT;CONTROVERSIAL ISSUES;COMBINED ANTIRETROVIRAL;HIV-INFECTED PATIENTS;SEVERE INFECTIONS;ACINETOBACTER BAUMANNII;ALKHURMA HEMORRHAGIC;ANTAGONIST TREATMENT;CCR ANTAGONIST;CD CELL;CONSENSUS STATEMENT;HEALTH WORKERS;HEMORRHAGIC FEVER;HIV-INFECTED PERSONS;HIVINFECTED PATIENTS;HUMAN SERUM;LATE PRESENTATION;PROVIRAL HIV;RISK FACTOR;TRAVELERS RETURNING;ULTRA-DEEP PYROSEQUENCING;WEST NILE;ACCURATE MARKER;ACID DELIVERY;ACQUIRED WEST;ACTING LIPOSOMAL;ACTIVE ANTIRETROVIRAL","6;5;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","HIV INFECTION;CONTROVERSIAL ISSUES;CD COUNT;INFECTION CONTROL;LATE PRESENTATION;ARTERIAL HYPERTENSION;NOSOCOMIAL INFECTIONS;ANTIRETROVIRAL THERAPY;CLINICAL TRIALS;INCREASED RISK;CELL COUNT;CELL DEATH;CLINICAL MANAGEMENT;CORECEPTOR USAGE;PATIENTS AFFECTED;PROVIRAL DNA;PULMONARY ARTERIAL;QUALITY ASSESSMENT;RISK FACTORS;ACTIVE ANTIRETROVIRAL;ACTIVE TB;ASSESSMENT SCALE;CD CELL;CONSORT METHOD;CONTROLLED TRIALS;DEVELOPED COUNTRIES;EVALUATE RANDOMIZED;HIGHLY ACTIVE;HIV RNA;ITALIAN SOCIETY","15;11;9;9;9;8;8;7;7;7;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5",22,0.22,6,2.75,1,1,1,2.5,1,0,2,3,0,1,3,1,1,0,0,3,0,0,0,67,67,2,0,0,0,0,0,1,2,0,0,0,0,0,3,0,6.33333333333333,5.66666666666667,4.94,1.33333333333333,0,1,2,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"AMICOSANTE MASSIMO;CARRARA STEFANIA;CASETTI RITA;GIRARDI ENRICO;GOLETTI DELIA;POCCIA FABRIZIO;VINCENTI DONATELLA;ALONZI TONINO;BORDONI VERONICA;TRIPODI MARCO","2;2;2;2;2;2;2;1;1;1","ISTITUTO NAZIONALE PER LA MALATTIE INFETTIVE L SPALLANZANI IRCCS;ISTITUTO NAZ DELLE MALATTIE IN;ISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE ""LAZZARO SPALLANZANI""","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;31 BIOLOGICAL SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","5;2;1;1;1","BIODEFENSE;EMERGING INFECTIOUS DISEASES;HIV/AIDS;IMMUNIZATION;INFECTIOUS DISEASES;ORPHAN DRUG;PREVENTION;RARE DISEASES;TUBERCULOSIS;VACCINE RELATED","2;2;2;2;2;2;2;2;2;2","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.2 CELLULAR AND GENE THERAPIES","2;1","C07K14/35;G01N33/569;A01N65/00;A61K35/12;A61K39/04;C12N5/00;C12N5/02;C12N5/0789","2;2;1;1;1;1;1;1","C07K14/35;G01N33/5695;Y10S435/975;A61K35/12;C12N2502/14;C12N5/0018;C12N5/0647","2;2;2;1;1;1;1",4,4.33,629.33,2.67,1,0.25,97.5,0,0,0,0,3,0,1,0,0,3,0,0,0,0,0,0,0,4,0,0,3,1,0,0,0,0,0,0,0,0,"United States","3","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY","4;3;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HIV/AIDS;INFECTIOUS DISEASES","3;3;3;3","INFECTION;RENAL AND UROGENITAL","4;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS","3;1","LIVER CANCER","1","2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER","1",2,6950000,315909.09,5.5,22,12.5,1,22.5,289742.999670619,0.338230777314402,"DÉLÉGATION PARIS 11;ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI;ACADEMIC MEDICAL CENTER;AGENCE NATIONALE DE RECHERCHES SUR LE SIDA ET LES HÉPATITES VIRALES;AUSTRIAN AGENCY FOR HEALTH AND FOOD SAFETY;BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE;CENTRE DE RECHERCHE MÉDICALES DE LAMBARÉNÉ;DEPARTMENT OF HEALTH;EUROVACC FOUNDATION;FRIEDRICH-LOEFFLER-INSTITUT;HACETTEPE UNIVERSITY;IFAKARA HEALTH INSTITUTE;INSERM TRANSFERT;INSTITUTE OF TROPICAL MEDICINE ANTWERP;INSTITUTO DE SALUD CARLOS III;KENYA MEDICAL RESEARCH INSTITUTE;LEIDEN UNIVERSITY MEDICAL CENTER;LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE;LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN;MALARIA CONSORTIUM","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","CP-CSA-INFRA-PP - CONSTRUCTION OF NEW RESEARCH INFRASTRUCTURES - PREPARATORY PHASE (FUNDING SCHEME);CP-IP-SICA - LARGE-SCALE INTEGRATING PROJECT FOR SPECIFIC COOPERATION ACTIONS DEDICATED TO INTERNATIONAL COOPERATION PARTNER COUNTRIES(SICA) (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2009-SINGLE-STAGE (CALL FOR PROPOSAL);FP7-INFRASTRUCTURES - SPECIFIC PROGRAMME ""CAPACITIES"": RESEARCH INFRASTRUCTURES (PROGRAMME);FP7-INFRASTRUCTURES-2010-1 (CALL FOR PROPOSAL)","1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;33 BUILT ENVIRONMENT AND DESIGN;3302 BUILDING","1;1;1;1;1","CLINICAL RESEARCH;HIV/AIDS;IMMUNIZATION;INFECTIOUS DISEASES;MALARIA;PREVENTION;RARE DISEASES;VACCINE RELATED;VECTOR-BORNE DISEASES","1;1;1;1;1;1;1;1;1","INFECTION","1",NA,NA,NA,NA,NA,NA,"A01 CLINICAL MEDICINE;C13 ARCHITECTURE, BUILT ENVIRONMENT AND PLANNING","1;1","3 GOOD HEALTH AND WELL BEING","1",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SPALLANZANIROMA",2011,96,11.15625,3.21875,0.302083333333333,0.375,0.375,2.32330827067669,1.03571428571429,1.5,1.05882352941176,0.666666666666667,0,48,13,17,8,0.5,0.14,0.18,0.08,42.11,0.99013258068244,NA,0.479166666666667,0.885416666666667,0.433,0.389,0.398,0.431,"MARIA ROSARIA CAPOBIANCHI;ANDREA ANTINORI;ENRICO GIRARDI;CARLO FEDERICO PERNO;NICOLA PETROSILLO;FRANCESCA CECCHERINI‐SILBERSTEIN;ANTONELLA D’ARMINIO MONFORTE;VALENTINA SVICHER;DELIA GOLETTI;GIUSEPPE IPPOLITO;ISABELLA ABBATE;ANTONELLA CASTAGNA;GABRIELLA ROZERA;VALERIA CENTO;ROBERTA D’ARRIGO;ANTONINO DI;ANDREA DE LUCA;EMANUELE NICASTRI;ROMINA SALPINI;MAURO PIACENTINI","17;13;11;11;8;8;8;8;7;7;7;6;6;5;5;5;5;5;5;5","MARIA ROSARIA CAPOBIANCHI;NICOLA PETROSILLO;ANDREA ANTINORI;ENRICO GIRARDI;MICHELE BIBAS;CARLO FEDERICO PERNO;FRANCESCA CECCHERINI‐SILBERSTEIN;VALENTINA SVICHER;ANTONELLA D’ARMINIO MONFORTE;GIUSEPPE IPPOLITO;VINCENZO PURO;ISABELLA ABBATE;ANDREA BAIOCCHINI;DELIA GOLETTI;GABRIELLA ROZERA;SILVIA D’AREZZO;F. LAURIA;FEDERICO MARTINI;NAZARIO BEVILACQUA;PAOLO ASCENZI","1.73;1.38;1.26;0.98;0.91;0.91;0.76;0.69;0.66;0.63;0.62;0.62;0.6;0.6;0.58;0.57;0.57;0.56;0.53;0.52","MARIA ROSARIA CAPOBIANCHI;ANDREA ANTINORI;ENRICO GIRARDI;CARLO FEDERICO PERNO;NICOLA PETROSILLO;DELIA GOLETTI;GIUSEPPE IPPOLITO;ISABELLA ABBATE;GABRIELLA ROZERA;ROBERTA D’ARRIGO;ANTONINO DI;EMANUELE NICASTRI;MAURO PIACENTINI;GIAN MARÍA FIMIA;F. LAURIA;CATERINA GORI;PASQUALE NARCISO;MARCO TRIPODI;BARBARA BARTOLINI;E. BORDI","17;13;11;11;8;7;7;7;6;5;5;5;5;5;5;5;5;4;4;4","MARIA ROSARIA CAPOBIANCHI;NICOLA PETROSILLO;ANDREA ANTINORI;ENRICO GIRARDI;MICHELE BIBAS;CARLO FEDERICO PERNO;GIUSEPPE IPPOLITO;VINCENZO PURO;ISABELLA ABBATE;ANDREA BAIOCCHINI;DELIA GOLETTI;GABRIELLA ROZERA;SILVIA D’AREZZO;F. LAURIA;FEDERICO MARTINI;NAZARIO BEVILACQUA;PAOLO ASCENZI;ADRIANA CATALDO;PASQUALE NARCISO;E. BORDI","1.73;1.38;1.26;0.98;0.91;0.91;0.63;0.62;0.62;0.6;0.6;0.58;0.57;0.57;0.56;0.53;0.52;0.5;0.47;0.46","ANDREA ANTINORI;MARIA ROSARIA CAPOBIANCHI;ANTONELLA D’ARMINIO MONFORTE;ANTONELLA CASTAGNA;MAURO PIACENTINI;GIAN MARÍA FIMIA;DELIA GOLETTI;ENRICO GIRARDI;GIUSEPPE IPPOLITO;MARIA CARLA RE;ISABELLA ABBATE;ANTONINO DI;MASSIMO GALLI;VINCENZO PURO;CARLO FEDERICO PERNO;ALESSANDRO COZZI‐LEPRI;CARLO TORTI;CAROLINE SABIN;F. LAURIA;VALENTINA SVICHER","881;815;686;544;479;470;430;412;388;387;366;349;331;326;324;311;310;263;262;249","MARIA ROSARIA CAPOBIANCHI;ANDREA ANTINORI;MAURO PIACENTINI;GIAN MARÍA FIMIA;GIUSEPPE IPPOLITO;ISABELLA ABBATE;DELIA GOLETTI;ANTONINO DI;FABIOLA CICCOSANTI;ORNELLA BUTERA;NICOLA PETROSILLO;VINCENZO PURO;ROBERTA NARDACCI;ENRICO GIRARDI;CATERINA GORI;ALESSANDRA AMENDOLA;PASQUALE NARCISO;MARCO TRIPODI;TONINO ALONZI;LAURA FALASCA","795;684;479;470;388;366;356;349;248;246;243;235;231;208;190;189;188;187;187;172","MARIA ROSARIA CAPOBIANCHI;ANDREA ANTINORI;ENRICO GIRARDI;PASQUALE NARCISO;NICOLA PETROSILLO;GIUSEPPE IPPOLITO;ISABELLA ABBATE;GABRIELLA ROZERA;CARLO FEDERICO PERNO;DELIA GOLETTI;CATERINA GORI;GIAN MARÍA FIMIA;ANTONINO DI;EMANUELE NICASTRI;MAURO PIACENTINI;ROBERTA D’ARRIGO;ALESSANDRO BRUSELLES;BARBARA BARTOLINI;LEOPOLDO PAOLO PUCILLO;SILVIA D’AREZZO","16;12;8;8;8;7;7;6;6;6;5;5;5;5;5;5;4;4;4;4","MEDICINE;BIOLOGY;CHEMISTRY;ENGINEERING;GEOGRAPHY;SOCIOLOGY;COMPUTER SCIENCE;MATHEMATICS;BUSINESS;ECONOMICS;HISTORY;MATERIALS SCIENCE;PHYSICS;POLITICAL SCIENCE","73;60;8;8;5;5;4;3;2;2;1;1;1;1","INTERNAL MEDICINE;VIROLOGY;GENETICS;IMMUNOLOGY;BIOCHEMISTRY;PATHOLOGY;GASTROENTEROLOGY;MICROBIOLOGY;ENVIRONMENTAL HEALTH;PEDIATRICS;CELL BIOLOGY;INTENSIVE CARE MEDICINE;COMPUTATIONAL BIOLOGY;DEMOGRAPHY;CANCER RESEARCH;MECHANICAL ENGINEERING;OBSTETRICS;ORGANIC CHEMISTRY;SURGERY;ARCHAEOLOGY;ELECTRICAL ENGINEERING;MOLECULAR BIOLOGY;PALEONTOLOGY;STATISTICS","46;45;37;36;21;20;12;12;11;7;6;6;5;5;4;4;4;4;4;3;3;3;3;3","GENE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);VIRUS;POPULATION;IMMUNE SYSTEM;ENZYME;TUBERCULOSIS;BACTERIA;CONFIDENCE INTERVAL;DISEASE;ANTIBIOTICS;ANTIBODY;COHORT;IN VITRO;MEDICAL MICROBIOLOGY;REGIMEN;ANTIGEN;COHORT STUDY;EPIDEMIOLOGY;OUTBREAK;PREGNANCY;RECEPTOR;RETROSPECTIVE COHORT STUDY;VACCINATION","33;30;27;10;8;7;7;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4","VIRAL LOAD;GENOTYPE;POLYMERASE CHAIN REACTION;MUTATION;GENOME;VIREMIA;HAZARD RATIO;HEPATITIS B VIRUS;HEPATITIS C VIRUS;INFECTIOUS DISEASE (MEDICAL SPECIALTY);MYCOBACTERIUM TUBERCULOSIS;SEROCONVERSION;AUTOPHAGY;PYROSEQUENCING;RNA;SEROLOGY;TRANSCRIPTION FACTOR;TROPISM;VIRAL DISEASE;ALLELE;CHEMOKINE;EPITOPE;GENE EXPRESSION;HEALTH SERVICES;HEME;HEPATOCYTE;INFLUENZA A VIRUS;KIDNEY TRANSPLANTATION;LINEAGE (GENETIC);MARAVIROC;PEPTIDE SEQUENCE;PERIPHERAL BLOOD MONONUCLEAR CELL;PHENOTYPE;PHYLOGENETICS;PLASMABLASTIC LYMPHOMA;PLASMODIUM FALCIPARUM;PROTEASE;PSEUDOMONAS AERUGINOSA;RECOMBINANT DNA;STAPHYLOCOCCUS AUREUS;SUPEROXIDE;TACROLIMUS;VIRAL REPLICATION;WEST NILE VIRUS","19;11;8;7;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;REVERSE TRANSCRIPTASE;CORONAVIRUS DISEASE 2019 (COVID-19);LATENT TUBERCULOSIS;MULTILOCUS SEQUENCE TYPING;V3 LOOP;ACTIVE TUBERCULOSIS;BASILIXIMAB;CHEMOKINE RECEPTOR;GENOTYPING;GP41;MOLECULAR EPIDEMIOLOGY;NUCLEAR RECEPTOR;PSYCHOLOGICAL REPRESSION;REPRESSOR;TUBERCULOSIS DIAGNOSIS;VARIABLE NUMBER TANDEM REPEAT;VIRAL QUASISPECIES;ACINETOBACTER BAUMANNII;ADENOSINE RECEPTOR;ALPHAVIRUS INFECTION;AMPLICON;ATOVAQUONE;AUTOPHAGOSOME;BK VIRUS;CELL FATE DETERMINATION;CERVICAL INTRAEPITHELIAL NEOPLASIA;CLADE;CONNEXIN;CXCR4;DEEP SEQUENCING;DIAGNOSIS OF MALARIA;ELISPOT;ENTEROCOCCUS FAECALIS;EUKARYOTE;FOCAL SEGMENTAL GLOMERULOSCLEROSIS;GENOMICS;GLOMERULAR BASEMENT MEMBRANE;GLOMERULOSCLEROSIS;GLUTATHIONE PEROXIDASE;HAPLOTYPE;HBSAG;HEALTH FACILITY;HEMEPROTEIN;HEPACIVIRUS;HEPADNAVIRIDAE;HEPATITIS A VACCINE;HEPATOCYTE NUCLEAR FACTORS;HPV INFECTION;HUMAN BOCAVIRUS;HYPOVITAMINOSIS;INTRAEPITHELIAL NEOPLASIA;JC VIRUS;LAMIVUDINE;LENTIVIRUS;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;MG132;MICROBICIDES FOR SEXUALLY TRANSMITTED DISEASES;MICROCOCCACEAE;MICROSATELLITE;NESTED POLYMERASE CHAIN REACTION;OFF-PUMP CORONARY ARTERY BYPASS;PARASITEMIA;PEROXYNITRITE;PLASMACYTOID DENDRITIC CELL;PODOCYTE;RENAL GLOMERULUS;RIBAVIRIN;RUBELLA;SALMONELLA ENTERICA;SEROPREVALENCE;SEXUALLY TRANSMITTED DISEASE;SIDA;STAPHYLOCOCCAL INFECTIONS;TANDEM REPEAT;TISSUE TROPISM;TROUGH LEVEL;VACCINIA;VANCOMYCIN;VECTOR (MOLECULAR BIOLOGY);VIRAL PHYLODYNAMICS;WHOLE GENOME SEQUENCING","12;5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HIV INFECTIONS;HUMANS;HIV-1;FEMALE;MALE;ADULT;ITALY;MIDDLE AGED;ANTI-HIV AGENTS;;TUBERCULOSIS;RNA, VIRAL;DNA, VIRAL;VIRAL LOAD;HEPATITIS B VIRUS;MYCOBACTERIUM TUBERCULOSIS;ACQUIRED IMMUNODEFICIENCY SYNDROME;LIVER;RETROSPECTIVE STUDIES;ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE","82;75;55;39;39;35;33;31;30;16;16;15;14;14;13;13;12;12;12;11","HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;TUBERCULOSIS;GLOBAL IMPACT OF ARBOVIRAL DISEASES;INFLUENZA VIRUS RESEARCH AND EPIDEMIOLOGY;MECHANISMS AND TREATMENT OF LIVER FIBROSIS;EPIDEMIOLOGY AND MOLECULAR CHARACTERIZATION OF PARASITIC DISEASES;HEPATITIS B INFECTION AND TREATMENT;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS;POLYOMAVIRUS-ASSOCIATED CARCINOGENESIS AND CLINICAL MANIFESTATIONS;ROLE OF AUTOPHAGY IN DISEASE AND HEALTH;ATOMIC MAGNETOMETRY TECHNIQUES;ATRIAL FIBRILLATION;BACTERIAL PATHOGENESIS IN ANIMAL AND HUMAN HEALTH;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;CHEMISTRY AND APPLICATIONS OF ANTIMICROBIAL POLYMERS;COPPER AND ZINC IN HEALTH AND DISEASE","13;9;5;5;4;4;4;3;3;3;2;2;2;2;1;1;1;1;1;1","HIV;ANTIRETROVIRAL THERAPY;HIV INFECTION;HIV EPIDEMIOLOGY;MEDICAL MICROBIOLOGY;REGIMEN;VIREMIA;AIDS;H1N1;MYCOBACTERIUM TUBERCULOSIS;SEROCONVERSION;CART;HEPATOCYTE GROWTH FACTOR;INTERQUARTILE RANGE;MULTILOCUS SEQUENCE TYPING;PANDEMIC;PYROSEQUENCING;RITONAVIR;V3 LOOP;ACTIVE TUBERCULOSIS","26;9;7;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;2","HIV-INFECTED PATIENTS;HIV INFECTION;ANTIRETROVIRAL THERAPY;PREGNANCY OUTCOMES;CD CELL;CD T-CELL;CELL COUNT;CHRONIC HEPATITIS;HIV-ASSOCIATED PLASMABLASTIC;HUMAN IMMUNODEFICIENCY;HUMAN SERUM;ITALIAN COHORT;MOLECULAR EPIDEMIOLOGY;NILE VIRUS;PANDEMIC HN;PATIENTS TREATED;PERFORMANCE EVALUATION;PERIPHERAL BLOOD;PLASMABLASTIC LYMPHOMA;PRELIMINARY RESULTS;PSEUDOMONAS AERUGINOSA;REVERSE TRANSCRIPTASE;T-CELL COUNT;TUBERCULOSIS DISEASE;VIRUS ISOLATES;WEST NILE;ABBOTT IMI;ABBOTT REALTIME;ABERRANT METHYLATION;ACID ENHANCES","5;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","ROME ITALY;AUTOPHAGY INDUCTION;CD T-CELL;HEK CELLS;NORMAL CONDITIONS;ITALY SEARCH;ANTIRETROVIRAL THERAPY;CD CELL;HIV INFECTION;ITALY DEPARTMENT;KSHV DNA;ROME TOR;T-CELL COUNT;TOR VERGATA;CELL COUNT;SUPPLEMENTARY FIGURE;VERGATA ROME;ACTIVE TB;FONDAZIONE SANTA;HELA CELLS;INFECTIOUS DISEASES;IRCCS FONDAZIONE;LATE PRESENTATION;LUCIA ROME;MOLECULAR NEUROEMBRYOLOGY;NEUROEMBRYOLOGY IRCCS;SANTA LUCIA;VIROLOGICAL FAILURE;BIOLOGY DULBECCO;CLINICAL PROGRESSION","30;21;16;16;15;14;13;13;11;11;11;11;11;11;10;10;10;9;9;9;9;9;9;9;9;9;9;9;8;8",27,0.28,3.62,2,1,1,1,3,2.75,0,1,2,0,1,2.25,0,1,1,2.5,2,1.25,0,0,123.5,124,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,3,558.67,4.8,1,0.17,55.17,0,0,1,0,4,0,1,0,0,3,0,0,0,0,0,0,0,5,1,0,3,3,0,0,0,0,0,0,0,0,"United States","3","32 BIOMEDICAL AND CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY","6;4;3;3","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HIV/AIDS;INFECTIOUS DISEASES;COMPARATIVE EFFECTIVENESS RESEARCH;PATIENT SAFETY;PREVENTION","4;4;4;4;1;1;1","INFECTION","6","6.1 PHARMACEUTICALS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;5.1 PHARMACEUTICALS","5;1;1","KAPOSI'S SARCOMA;CERVICAL CANCER;NON-HODGKIN'S LYMPHOMA","2;1;1","2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;3.3 CHEMOPREVENTION;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","2;1;1",1,11758352,653241.78,7,18,8,1,290,299730.003638873,0.320288255545029,"AIX-MARSEILLE UNIVERSITY;BALEARIC ISLANDS HEALTH RESEARCH INSTITUTE;FEDERAL DEPARTMENT OF ECONOMIC AFFAIRS EDUCATION AND RESEARCH;FEDERAL DEPARTMENT OF HOME AFFAIRS;FRENCH AGENCY FOR FOOD, ENVIRONMENTAL AND OCCUPATIONAL HEALTH & SAFETY;IMPERIAL COLLEGE LONDON;INSTITUT PASTEUR;INSTITUTE FOR SCIENTIFIC INTERCHANGE;ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI;ISTITUTO SUPERIORE DI SANITÀ;ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLE VENEZIE;KU LEUVEN;MAX PLANCK SOCIETY;PHILIPPS UNIVERSITY OF MARBURG;UNIVERSITY OF BARCELONA;UNIVERSITY OF BOLOGNA;UNIVERSITY OF EDINBURGH;UNIVERSITY OF GOTHENBURG","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CP-IP - LARGE-SCALE INTEGRATING PROJECT (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2011-TWO-STAGE (CALL FOR PROPOSAL)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY","1;1;1","BIODEFENSE;EMERGING INFECTIOUS DISEASES;INFECTIOUS DISEASES;INFLUENZA;PREVENTION;VACCINE RELATED","1;1;1;1;1;1","INFECTION","1","2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;2.5 RESEARCH DESIGN AND METHODOLOGIES (AETIOLOGY)","1;1",NA,NA,NA,NA,"A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE","1","3 GOOD HEALTH AND WELL BEING","1",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SPALLANZANIROMA",2012,119,10.6806722689076,3.66386554621849,0.428571428571429,0.478991596638655,0.621848739495798,2.47159090909091,1.21428571428571,2.11111111111111,1.27586206896552,0.588235294117647,0,53,10,13,13,0.45,0.08,0.11,0.11,32.19,0.770757978372755,5.51491569390402,0.336134453781513,0.907563025210084,0.449,0.407,0.407,0.443,"ANDREA ANTINORI;GIUSEPPE IPPOLITO;ENRICO GIRARDI;MARIA ROSARIA CAPOBIANCHI;ANTONELLA D’ARMINIO MONFORTE;VINCENZO PURO;PASQUALE NARCISO;DELIA GOLETTI;MAURO PIACENTINI;NICOLA PETROSILLO;EMANUELE NICASTRI;GIAN MARÍA FIMIA;CARLO FEDERICO PERNO;ALESSANDRO COZZI‐LEPRI;PASQUALE DE NARDO;PIERLUCA PISELLI;CLAUDIO ANGELETTI;RENÉ GOTTSCHALK;GIOACCHINO ANGARANO;GAETANA STERRANTINO","20;16;15;12;10;10;10;9;8;8;7;7;7;7;6;6;6;5;5;5","ANDREA ANTINORI;GIUSEPPE IPPOLITO;ENRICO GIRARDI;MARIA ROSARIA CAPOBIANCHI;NICOLA PETROSILLO;MAURO PIACENTINI;CARLO FEDERICO PERNO;VINCENZO PURO;PASQUALE NARCISO;CRISTINA CHIMENTI;ANDREA FRUSTACI;PASQUALE DE NARDO;ANTONELLA D’ARMINIO MONFORTE;DELIA GOLETTI;MASSIMO ANDREONI;EMANUELE NICASTRI;GAETANA STERRANTINO;CLAUDIO ANGELETTI;GABRIELLA ROZERA;ALESSANDRO COZZI‐LEPRI","1.81;1.58;1.42;1.4;1.19;1.05;1.04;1.02;0.97;0.96;0.96;0.84;0.84;0.73;0.69;0.67;0.64;0.63;0.63;0.57","ANDREA ANTINORI;GIUSEPPE IPPOLITO;ENRICO GIRARDI;MARIA ROSARIA CAPOBIANCHI;VINCENZO PURO;PASQUALE NARCISO;DELIA GOLETTI;MAURO PIACENTINI;NICOLA PETROSILLO;EMANUELE NICASTRI;GIAN MARÍA FIMIA;CARLO FEDERICO PERNO;PASQUALE DE NARDO;PIERLUCA PISELLI;CLAUDIO ANGELETTI;FRANCESCO MARIA FUSCO;CHIARA TOMMASI;GIOVANNI DELOGU;GABRIELLA ROZERA;ADRIANA AMMASSARI","20;16;15;12;10;10;9;8;8;7;7;7;6;6;6;5;5;5;5;5","ANDREA ANTINORI;GIUSEPPE IPPOLITO;ENRICO GIRARDI;MARIA ROSARIA CAPOBIANCHI;NICOLA PETROSILLO;MAURO PIACENTINI;CARLO FEDERICO PERNO;VINCENZO PURO;PASQUALE NARCISO;ANDREA FRUSTACI;PASQUALE DE NARDO;DELIA GOLETTI;EMANUELE NICASTRI;CLAUDIO ANGELETTI;GABRIELLA ROZERA;GIAN MARÍA FIMIA;PIERLUCA PISELLI;MARIA GRAZIA PAGLIA;ADRIANA AMMASSARI;ELISA GENTILOTTI","1.81;1.58;1.42;1.4;1.19;1.05;1.04;1.02;0.97;0.96;0.84;0.73;0.67;0.63;0.63;0.57;0.56;0.54;0.54;0.51","GIAN MARÍA FIMIA;MAURO PIACENTINI;FABIOLA CICCOSANTI;ALESSANDRA ROMAGNOLI;MARCO CORAZZARI;NICOLA PETROSILLO;DELIA GOLETTI;GIOVANNI DELOGU;ALEXANDER VALENT;ALFREDO CRIOLLO;ALICE BOILÈVE;ANTONELLA SISTIGU;ANTONIO ANTOCCIA;ANTONIO FUEYO;BASTIEN JOB;CARLOS LÓPEZ‐OTÍN;CHRISTOPH RUCKENSTUHL;CHRISTOPHER J. CHAN;CLAIRE PAILLERET;CLARA LOCHER","1056;994;608;524;524;506;485;411;403;403;403;403;403;403;403;403;403;403;403;403","GIAN MARÍA FIMIA;MAURO PIACENTINI;FABIOLA CICCOSANTI;NICOLA PETROSILLO;ALESSANDRO CAPONE;E. BORDI;ENRICO GIRARDI;MADDALENA GIANNELLA;PIERLUCA PISELLI;ANDREA ANTINORI;MARIA ROSARIA CAPOBIANCHI;GIUSEPPE IPPOLITO;PASQUALE NARCISO;ALESSANDRA ROMAGNOLI;MARCO CORAZZARI;MICHELE BIBAS;PIERANGELO CHINELLO;DELIA GOLETTI;VINCENZO PURO;ANNA ROSA GARBUGLIA","761;699;608;506;370;350;321;319;307;299;278;263;262;229;229;197;193;190;152;147","ANDREA ANTINORI;GIUSEPPE IPPOLITO;ENRICO GIRARDI;MARIA ROSARIA CAPOBIANCHI;PASQUALE NARCISO;NICOLA PETROSILLO;VINCENZO PURO;EMANUELE NICASTRI;DELIA GOLETTI;CLAUDIO ANGELETTI;MAURO PIACENTINI;PASQUALE DE NARDO;PIERLUCA PISELLI;RITA BELLAGAMBA;CARLO FEDERICO PERNO;GABRIELLA ROZERA;GIAN MARÍA FIMIA;ADRIANA AMMASSARI;CHIARA TOMMASI;ALESSANDRO CAPONE","20;16;14;12;11;8;8;7;7;6;6;6;6;5;5;5;5;5;5;4","MEDICINE;BIOLOGY;ENGINEERING;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;SOCIOLOGY;ECONOMICS;POLITICAL SCIENCE;BUSINESS;GEOGRAPHY;MATHEMATICS;PSYCHOLOGY;PHILOSOPHY","107;56;13;12;11;6;6;4;4;2;2;2;2;1","INTERNAL MEDICINE;IMMUNOLOGY;VIROLOGY;PATHOLOGY;GENETICS;BIOCHEMISTRY;GASTROENTEROLOGY;MICROBIOLOGY;ENVIRONMENTAL HEALTH;CELL BIOLOGY;INTENSIVE CARE MEDICINE;SURGERY;OPTICS;MECHANICAL ENGINEERING;PEDIATRICS;DEMOGRAPHY;MEDICAL EMERGENCY;ONCOLOGY;CANCER RESEARCH;CARDIOLOGY;ENDOCRINOLOGY;FAMILY MEDICINE","69;47;40;34;32;22;22;21;17;13;11;10;9;8;8;6;6;6;5;5;5;5","HUMAN IMMUNODEFICIENCY VIRUS (HIV);GENE;VIRUS;TUBERCULOSIS;POPULATION;IMMUNE SYSTEM;REGIMEN;BACTERIA;COHORT;DISEASE;ANTIBIOTICS;EPIDEMIOLOGY;INCIDENCE (GEOMETRY);APOPTOSIS;CART;ADVERSE EFFECT;INFECTION CONTROL;ANTIBODY;CANCER;CONFIDENCE INTERVAL;ENZYME;IN VITRO;ISOLATION (MICROBIOLOGY);OUTBREAK","39;32;20;16;12;10;10;9;9;9;8;8;8;7;7;6;6;5;5;5;5;5;5;5","VIRAL LOAD;MYCOBACTERIUM TUBERCULOSIS;GENOTYPE;AUTOPHAGY;HEPATITIS C VIRUS;HEPATITIS B VIRUS;MARAVIROC;STAPHYLOCOCCUS AUREUS;VIRAL DISEASE;ANTIBIOTIC RESISTANCE;INFECTIOUS DISEASE (MEDICAL SPECIALTY);PHENOTYPE;PHYLOGENETIC TREE;ESCHERICHIA COLI;GENOME;HAZARD RATIO;PROTEASE;RNA;TROPISM;AVIDITY;CARDIOMYOPATHY;CD34;CHEMOKINE;COLORECTAL CANCER;DOWNREGULATION AND UPREGULATION;GENE EXPRESSION;HEPATITIS A;INTERFERON GAMMA;MACROPHAGE;MUTATION;MYCOBACTERIUM;NEUROCOGNITIVE;PEPTIDE SEQUENCE;PLASMODIUM FALCIPARUM;POISSON REGRESSION;PROGRAMMED CELL DEATH;PSEUDOMONAS AERUGINOSA;PYROSEQUENCING;RECOMBINANT DNA;SEROLOGY;SYPHILIS;T CELL","32;11;8;7;7;6;5;5;5;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;LATENT TUBERCULOSIS;CORONAVIRUS DISEASE 2019 (COVID-19);REVERSE TRANSCRIPTASE;VANCOMYCIN;ACTIVE TUBERCULOSIS;CHEMOKINE RECEPTOR;HBSAG;KLEBSIELLA PNEUMONIAE;LAMIVUDINE;LENTIVIRUS;MEN WHO HAVE SEX WITH MEN;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;MOLECULAR EPIDEMIOLOGY;SIDA;TISSUE TROPISM;TUBERCULOSIS DIAGNOSIS;V3 LOOP;VIRAL QUASISPECIES;ZIDOVUDINE","27;5;4;4;4;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HIV INFECTIONS;HUMANS;MALE;FEMALE;ADULT;MIDDLE AGED;;ITALY;HIV-1;TUBERCULOSIS;ANTI-HIV AGENTS;AGED;MYCOBACTERIUM TUBERCULOSIS;ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE;YOUNG ADULT;ANTI-BACTERIAL AGENTS;CROSS INFECTION;HIV SEROPOSITIVITY;ADOLESCENT;HEPATITIS C","85;80;55;52;47;43;35;32;30;28;25;23;21;17;15;14;14;14;12;12","EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;TUBERCULOSIS;HEPATITIS C INFECTION AND TREATMENT;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;EPIDEMIOLOGY AND PATHOGENESIS OF PNEUMOCYSTIS PNEUMONIA;HEPATITIS B INFECTION AND TREATMENT;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;INFECTION CONTROL IN HEALTHCARE SETTINGS;ROLE OF AUTOPHAGY IN DISEASE AND HEALTH;EBOLA VIRUS RESEARCH AND OUTBREAKS;HEPATITIS E INFECTION AND TREATMENT;MANAGEMENT AND EPIDEMIOLOGY OF INFECTIVE ENDOCARDITIS;MECHANISMS OF APOPTOTIC CELL CLEARANCE AND IMMUNE REGULATION;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;ATTENTION-DEFICIT/HYPERACTIVITY DISORDER","16;8;8;8;4;4;3;3;3;3;3;2;2;2;2;2;1;1;1;1","HIV;ANTIRETROVIRAL THERAPY;REGIMEN;TREATMENT;CART;RALTEGRAVIR;RITONAVIR;EFAVIRENZ;HIV INFECTION;ISOLATION (MICROBIOLOGY);MARAVIROC;DARUNAVIR;EMTRICITABINE;HBV INFECTION;HEPATITIS B;HEPATITIS C;MEDICAL MICROBIOLOGY;ADHERENCE TO MEDICATION;CROSS-SECTIONAL STUDY;DAPTOMYCIN","24;23;10;8;7;7;7;5;5;5;5;4;4;4;4;4;4;3;3;3","HIV-INFECTED PATIENTS;ANTIRETROVIRAL THERAPY;HIGHLY INFECTIOUS;INFECTIOUS DISEASES;EUROPEAN COUNTRIES;HIVINFECTED PATIENTS;ISOLATION FACILITIES;MYCOBACTERIUM TUBERCULOSIS;ADHERENCE SUPPORTS;AUTOPHAGIC FLUX;CART ERA;CO-RECEPTOR RECOGNITION;CROSS-SECTIONAL STUDY;CURRENT CART;DENDRITIC CELLS;DYNAMICS STUDY;FIRST-LINE ANTIRETROVIRAL;GENOTYPIC RESISTANCE;HEPATOCELLULAR CARCINOMA;HIV GP;HIV PATIENTS;HIVINFECTED NAÏVE;HYPERTROPHIC CARDIOMYOPATHY;INFECTION CONTROL;INFECTIVE ENDOCARDITIS;ITALIAN COHORT;ITALY RESULTS;LIGHT CHAINS;MOLECULAR DYNAMICS;NAIVE PATIENTS","8;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;HIV INFECTION;ADVERSE EVENTS;CD CELL;ESBL GN;MVCLPVR TDFFTCLPVR;CD COUNT;HCV INFECTION;HIV PATIENTS;INFECTIOUS DISEASES;CELL COUNT;HIV-INFECTED PATIENTS;MYCOBACTERIUM TUBERCULOSIS;LOGISTIC REGRESSION;LOWER NONADHERENCE;MOTHERHOOD DESIRE;PROTEASE INHIBITORS;RISK FACTORS;ROME ITALY;VIRAL LOAD;GN UTI;HIGHLY INFECTIOUS;IQR MEDIAN;ISOLATION FACILITIES;JOINT INFECTION;PROSTHETIC JOINT;RATIO CI;REVERSE TRANSCRIPTASE;TUBERCULOSIS TREATMENT;VΓVΔ T-CELLS","14;13;12;12;11;11;9;9;9;9;8;8;8;7;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6",38,0.32,3.44,2.75,1,1,0,1,3.25,0,1,3.75,1,1,4,0,0,1,1.5,4,2,0,0,71.75,71.75,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,7,1.61,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"AMICOSANTE ,MASSIMO;CARRARA, STEFANIA;CASETTI RITA;GIRARADI,ENRICO;GOLETTI ,DELIA;POCCIA FABRIZIO;VINCENTIDONATELLA ,","1;1;1;1;1;1;1","ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI IRCCS","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","2;1","INFECTIOUS DISEASES;RARE DISEASES;TUBERCULOSIS","1;1;1",NA,NA,"A61K39/04;C07H21/04;C07K14/35;G01N33/554;G01N33/569","1;1;1;1;1","C07K14/35;G01N33/5695;Y10S435/975","1;1;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,50000,50000,2,1,1,0,8,324730.003638873,0.366458284317756,"ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI","1","TELETHON FOUNDATION","1",NA,NA,"TELETHON EXPLORATORY PROJECTS 2012 (PROGRAM)","1","31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;34 CHEMICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY","1;1;1;1","BRAIN DISORDERS;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);MUSCULAR DYSTROPHY;RARE DISEASES","1;1;1;1","MUSCULOSKELETAL","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1",NA,NA,1,"AMERICAN CHEMICAL SOCIETY","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","2;1","BIOTECHNOLOGY;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;HEPATITIS;HEPATITIS - C;INFECTIOUS DISEASES;LIVER DISEASE","1;1;1;1;1;1;1;1","INFECTION","1","5.1 PHARMACEUTICALS","1","BIOMEDICAL","1","CLINICAL MEDICINE AND SCIENCE","1","LIVER CANCER","1",NA,NA
"IRCCS_SPALLANZANIROMA",2013,106,12.2641509433962,3.40566037735849,0.358490566037736,0.367924528301887,0.424528301886792,2.24223602484472,1.15151515151515,1.77272727272727,1.18421052631579,0.641509433962264,1,46,11,16,13,0.43,0.1,0.15,0.12,35.36,1.01335315645905,5.36396181384248,0.377358490566038,0.886792452830189,0.461,0.417,0.386,0.436,"GIUSEPPE IPPOLITO;ANDREA ANTINORI;NICOLA PETROSILLO;ENRICO GIRARDI;MARIA ROSARIA CAPOBIANCHI;CARLO FEDERICO PERNO;CARMELA PINNETTI;ANGELA CORPOLONGO;ROBERTA NARDACCI;EMANUELE NICASTRI;MAURO PIACENTINI;DELIA GOLETTI;PIERLUCA PISELLI;ADRIANA AMMASSARI;ANTONELLA D’ARMINIO MONFORTE;FRANCA DEL NONNO;NICOLETTA ORCHI;GIUSEPPINA LIUZZI;MARIA MERCEDES SANTORO;ENRICA TAMBURRINI","13;12;11;11;11;11;6;6;6;6;6;6;6;6;6;5;5;5;5;5","GIUSEPPE IPPOLITO;NICOLA PETROSILLO;CARLO FEDERICO PERNO;A. FILENI;MARIA ROSARIA CAPOBIANCHI;LUCIANO STERPELLONE;ANDREA ANTINORI;PIERLUCA PISELLI;ENRICO GIRARDI;CRISTINA CHIMENTI;ANDREA FRUSTACI;MARIA MERCEDES SANTORO;NICOLA MAGNAVITA;VINCENZO PURO;ROBERTA NARDACCI;MAURO PIACENTINI;GABRIELLA DE CARLI;ANGELA CORPOLONGO;STEFANO DI BELLA;MARCO ANGRIMAN","1.91;1.6;1.22;1.17;1.01;1;0.98;0.8;0.79;0.77;0.77;0.72;0.67;0.65;0.57;0.54;0.51;0.5;0.5;0.5","GIUSEPPE IPPOLITO;ANDREA ANTINORI;NICOLA PETROSILLO;ENRICO GIRARDI;MARIA ROSARIA CAPOBIANCHI;CARLO FEDERICO PERNO;CARMELA PINNETTI;ANGELA CORPOLONGO;ROBERTA NARDACCI;EMANUELE NICASTRI;MAURO PIACENTINI;DELIA GOLETTI;PIERLUCA PISELLI;ADRIANA AMMASSARI;FRANCA DEL NONNO;NICOLETTA ORCHI;GIUSEPPINA LIUZZI;VINCENZO PURO;ANDREA BAIOCCHINI;PASQUALE DE NARDO","13;12;11;11;11;11;6;6;6;6;6;6;6;6;5;5;5;5;4;4","GIUSEPPE IPPOLITO;NICOLA PETROSILLO;CARLO FEDERICO PERNO;A. FILENI;MARIA ROSARIA CAPOBIANCHI;LUCIANO STERPELLONE;ANDREA ANTINORI;PIERLUCA PISELLI;ENRICO GIRARDI;CRISTINA CHIMENTI;ANDREA FRUSTACI;VINCENZO PURO;ROBERTA NARDACCI;MAURO PIACENTINI;GABRIELLA DE CARLI;ANGELA CORPOLONGO;STEFANO DI BELLA;SAMUELE CORTESE;DELIA GOLETTI;EMANUELE NICASTRI","1.91;1.6;1.22;1.17;1.01;1;0.98;0.8;0.79;0.77;0.77;0.65;0.57;0.54;0.51;0.5;0.5;0.5;0.46;0.46","MAURO PIACENTINI;GIAN MARÍA FIMIA;FRANCESCO CECCONI;PAMELA BIELLI;CHRISTINE GRETZMEIER;FLAVIE STRAPPAZZON;FRANCESCA NAZIO;JÖRN DENGJEL;MANUELA ANTONIOLI;MATTEO BORDI;VALENTINA CIANFANELLI;DELIA GOLETTI;MARIA ROSARIA CAPOBIANCHI;FRANCA DEL NONNO;CONCETTA CASTILLETTI;GIUSEPPE IPPOLITO;ENRICO GIRARDI;NICOLA PETROSILLO;CLAUDIA CAGLIOTI;ELEONORA LALLE","934;817;779;772;694;694;694;694;694;694;694;484;470;418;309;300;281;280;279;279","MAURO PIACENTINI;GIAN MARÍA FIMIA;MANUELA ANTONIOLI;DELIA GOLETTI;FRANCA DEL NONNO;GIUSEPPE IPPOLITO;CLAUDIA CAGLIOTI;NICOLA PETROSILLO;CARLO FEDERICO PERNO;ROBERTA NARDACCI;ANDREA ANTINORI;ANDREA FRUSTACI;CRISTINA CHIMENTI;ENRICO GIRARDI;MARIA ROSARIA CAPOBIANCHI;ANGELA CORPOLONGO;VINCENZO PURO;GABRIELLA DE CARLI;LINDA PETRONE;EMANUELE NICASTRI","934;817;694;484;418;300;279;269;249;223;202;180;180;175;169;154;136;135;128;124","GIUSEPPE IPPOLITO;ANDREA ANTINORI;CARLO FEDERICO PERNO;ENRICO GIRARDI;NICOLA PETROSILLO;MARIA ROSARIA CAPOBIANCHI;ADRIANA AMMASSARI;DELIA GOLETTI;ANGELA CORPOLONGO;CARMELA PINNETTI;EMANUELE NICASTRI;MAURO PIACENTINI;ROBERTA NARDACCI;FRANCA DEL NONNO;NICOLETTA ORCHI;GIUSEPPINA LIUZZI;ANDREA BAIOCCHINI;CATERINA GORI;LEOPOLDO PAOLO PUCILLO;MARIO ANTONINI","13;12;9;9;9;7;6;6;6;6;6;6;6;5;5;5;4;4;4;4","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;ENGINEERING;SOCIOLOGY;COMPUTER SCIENCE;PSYCHOLOGY;BUSINESS;ECONOMICS;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE;GEOLOGY;ART;ENVIRONMENTAL SCIENCE;HISTORY;MATERIALS SCIENCE","85;51;12;10;8;6;5;5;4;3;3;3;3;2;1;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;VIROLOGY;GENETICS;PATHOLOGY;BIOCHEMISTRY;GASTROENTEROLOGY;CELL BIOLOGY;MICROBIOLOGY;SURGERY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;OPTICS;PEDIATRICS;DEMOGRAPHY;CARDIOLOGY;NURSING;PSYCHIATRY;CANCER RESEARCH;CLINICAL PSYCHOLOGY;ELECTRICAL ENGINEERING;EMERGENCY MEDICINE;FAMILY MEDICINE;MECHANICAL ENGINEERING;PHARMACOLOGY;RADIOLOGY","57;42;28;27;24;20;13;12;12;12;11;10;7;7;6;5;5;5;4;4;4;4;4;4;4;4","HUMAN IMMUNODEFICIENCY VIRUS (HIV);GENE;VIRUS;POPULATION;IMMUNE SYSTEM;TUBERCULOSIS;ANTIBIOTICS;CONFIDENCE INTERVAL;DISEASE;COHORT;INCIDENCE (GEOMETRY);REGIMEN;MEDICAL MICROBIOLOGY;ODDS RATIO;RETROSPECTIVE COHORT STUDY;BACTERIA;CANCER;DRUG RESISTANCE;ENZYME;EPIDEMIOLOGY","33;30;15;11;9;9;8;8;8;7;7;7;6;6;6;5;5;5;5;5","VIRAL LOAD;HEPATITIS C VIRUS;GENOTYPE;HEPATITIS B VIRUS;SYPHILIS;VIRAL DISEASE;HAZARD RATIO;PHYLOGENETICS;POLYMERASE CHAIN REACTION;PSEUDOMONAS AERUGINOSA;ANTIBIOTIC RESISTANCE;AUTOPHAGY;CD8;MYCOBACTERIUM TUBERCULOSIS;PHENOTYPE;PHYLOGENETIC TREE;SEPTIC SHOCK;T CELL;CARBAPENEM;CELLULAR DIFFERENTIATION;CLOSTRIDIUM DIFFICILE;COLISTIN;DOWNREGULATION AND UPREGULATION;GENE EXPRESSION;HUMAN HERPESVIRUS;INNATE IMMUNE SYSTEM;LIVER TRANSPLANTATION;MESSENGER RNA;MICRORNA;MUTANT;PROGRAMMED CELL DEATH;PROTEASE;PROTEIN KINASE A;PULMONARY TUBERCULOSIS;REAL-TIME POLYMERASE CHAIN REACTION;RECOMBINANT DNA;REGULATOR;SPERMINE;TIGECYCLINE;TRANSGENE;TROPISM;TUBERCULIN;UNFOLDED PROTEIN RESPONSE;VIREMIA;VIRULENCE","21;7;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;LAMIVUDINE;MEN WHO HAVE SEX WITH MEN;REVERSE TRANSCRIPTASE;CLADE;LATENT TUBERCULOSIS;MOLECULAR EPIDEMIOLOGY;RIBAVIRIN;VIRAL QUASISPECIES;ACINETOBACTER BAUMANNII;AMPK;GENETICALLY MODIFIED MOUSE;IMIPENEM;KAPOSI'S SARCOMA;TAQMAN;ZIDOVUDINE;ACTIVE TUBERCULOSIS;ADVANCED MATERNAL AGE;AEDES ALBOPICTUS;ALTERNATIVE SPLICING;ANTIBIOTIC STEWARDSHIP;ANTIGEN-PRESENTING CELL;ANTIMICROBIAL STEWARDSHIP;ARTEMISININ;ATYPICAL ANTIPSYCHOTIC;BAG3;CASPASE;CD3;CHEMICAL CHAPERONE;COLONOSCOPY;COMPLEMENTATION;CONDOM;CORONAVIRUS DISEASE 2019 (COVID-19);CRYPTOCOCCAL MENINGITIS;CTL*;ENDOPLASMIC-RETICULUM-ASSOCIATED PROTEIN DEGRADATION;EPITHELIAL–MESENCHYMAL TRANSITION;EXOCYST;FMR1;HBSAG;HEPACIVIRUS;HIV-1 PROTEASE;IMMUNOGENIC CELL DEATH;INGUINAL CANAL;INTERLEUKIN 21;KLEBSIELLA PNEUMONIAE;LENTIVIRUS;MECHANISTIC TARGET OF RAPAMYCIN;MEROPENEM;MICAFUNGIN;MOLECULAR CLOCK;NOCARDIOSIS;NS3;POLYAMINE OXIDASE;PROGENITOR;PROMOTER;QUORUM SENSING;REPRESSOR;RNA SPLICING;RNA-BINDING PROTEIN;RPTOR;SEXUAL PARTNER;SEXUAL TRANSMISSION;SIDA;SINGLE-NUCLEOTIDE POLYMORPHISM;SMALL FOR GESTATIONAL AGE;TOLL-LIKE RECEPTOR;TRANSCRIPTIONAL REGULATION;TRANSPOSABLE ELEMENT;UBIQUITIN LIGASE;VECTOR (MOLECULAR BIOLOGY)","16;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HIV INFECTIONS;HUMANS;MALE;ANTI-HIV AGENTS;HIV-1;FEMALE;ADULT;MIDDLE AGED;ITALY;;VIRAL LOAD;AGED;RNA, VIRAL;ANTI-BACTERIAL AGENTS;ANTIVIRAL AGENTS;TREATMENT OUTCOME;TUBERCULOSIS;HEPATITIS C, CHRONIC;LUNG;HEPATITIS C","121;82;51;47;47;46;42;36;25;20;20;14;14;13;13;13;13;12;12;10","EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;HEPATITIS C INFECTION AND TREATMENT;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;TUBERCULOSIS;HEPATITIS B INFECTION AND TREATMENT;IMMUNOBIOLOGY OF DENDRITIC CELLS;ROLE OF AUTOPHAGY IN DISEASE AND HEALTH;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;CLOSTRIDIUM DIFFICILE INFECTION AND TREATMENT;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;POLYAMINES AND BIOGENIC AMINES IN BIOLOGY AND HEALTH;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;ANTHELMINTIC RESISTANCE IN VETERINARY PARASITES;ARISTOLOCHIC ACID NEPHROPATHY AND UROTHELIAL CANCER;ATTENTION-DEFICIT/HYPERACTIVITY DISORDER","10;8;8;5;4;4;3;3;3;2;2;2;2;2;2;2;2;1;1;1","HIV;ANTIRETROVIRAL THERAPY;TREATMENT;HIV INFECTION;HIV EPIDEMIOLOGY;REGIMEN;MEDICAL MICROBIOLOGY;KAPOSI'S SARCOMA;LOPINAVIR;EFAVIRENZ;HEPATITIS C;HIV TRANSMISSION;INTERQUARTILE RANGE;LOPINAVIR/RITONAVIR;MOLECULAR EPIDEMIOLOGY;NEVIRAPINE;PRE-EXPOSURE PROPHYLAXIS;RITONAVIR;VIRAL QUASISPECIES;ABACAVIR","21;13;10;8;7;7;6;4;4;3;3;3;3;3;3;3;3;3;3;2","ANTIRETROVIRAL THERAPY;DRUG RESISTANCE;REVERSE TRANSCRIPTASE;VIRAL LOAD;CHRONIC HEPATITIS;CLOSTRIDIUM DIFFICILE;DENDRITIC CELLS;DIFFICILE INFECTION;ENTECAVIR TREATMENT;EXCITOTOXIC INJURY;GIARDIA INTESTINALIS;HIV- INFECTION;HIV- INFECTIONS;HIV-INFECTED PATIENTS;KAPOSIS SARCOMA;LIVER TRANSPLANTATION;MOUSE MODEL;OXIDASE DOSAGE;PARASITE GIARDIA;PATIENTS FAILING;PHYLOGENETIC ANALYSIS;PREGNANCY OUTCOMES;PREGNANT WOMEN;PSEUDOMONAS AERUGINOSA;PULMONARY TUBERCULOSIS;QUANTIFERON-TB GOLD;SCPHIVSCPINFECTED PATIENTS;SPERMINE OXIDASE;TB DIAGNOSIS;TRANSCRIPTASE INHIBITORS","3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;ACTIVE TB;HIV INFECTION;HIV-INFECTED PATIENTS;COMBINATION ANTIRETROVIRAL;CDI EPISODES;GT COPIESML;HIV DIAGNOSIS;HIV RNA;INDICATOR DISEASE;KAPOSIS SARCOMA;PRE-HAART VIRAEMIA;REVERSE TRANSCRIPTASE;RISK FACTORS;SPERMINE OXIDASE;TB DIAGNOSIS;VIRAL LOAD;VIROLOGICAL SUCCESS;EASTERN EUROPE;HUMAN IMMUNODEFICIENCY;IMMUNODEFICIENCY VIRUS;PATIENTS STARTING;ANTIRETROVIRAL TREATMENT;CD T-CELL;CHRONIC INFECTION;DRUG RESISTANCE;INFECTIOUS DISEASES;PATIENTS TREATED;VIROLOGICAL FAILURE;CD CELL","20;17;15;11;9;8;8;8;8;8;8;8;8;8;8;8;8;8;7;7;7;7;6;6;6;6;6;6;6;5",43,0.41,5.17,5.5,1.5,1.75,1,10.25,3,1,1,6,1,1,4,0,2.75,2.25,1,3.25,2.75,0,0,86.5,86.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,4,959.5,1.3,1,0.5,120.5,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,"United States","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY","2;1;1","CLINICAL RESEARCH;HIV/AIDS;INFECTIOUS DISEASES","1;1;1","INFECTION","1","6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,"PUBLIC LIBRARY OF SCIENCE","28","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;34 CHEMICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;49 MATHEMATICAL SCIENCES;3001 AGRICULTURAL BIOTECHNOLOGY;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;38 ECONOMICS;4905 STATISTICS","38;17;4;3;2;2;2;1;1;1;1;1;1;1","INFECTIOUS DISEASES;CLINICAL RESEARCH;PREVENTION;RARE DISEASES;STEM CELL RESEARCH;DIGESTIVE DISEASES;HEMATOLOGY;HEPATITIS;HEPATITIS - B;HIV/AIDS;LIVER DISEASE;BIODEFENSE;BIOTECHNOLOGY;CANCER;CHRONIC LIVER DISEASE AND CIRRHOSIS;EMERGING INFECTIOUS DISEASES;GENETICS;HEALTH SERVICES;INFLUENZA;LUNG","8;5;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","INFECTION;CANCER","5;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","3;2;1","CLINICAL","7","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;HEALTH SERVICES RESEARCH;PUBLIC HEALTH","10;1;1;1","NON-HODGKIN'S LYMPHOMA;BLOOD CANCER;LEUKEMIA / LEUKAEMIA;MYELOMA;NOT SITE-SPECIFIC CANCER","2;1;1;1;1","3 GOOD HEALTH AND WELL BEING","1"
"IRCCS_SPALLANZANIROMA",2014,126,13.1349206349206,3.53174603174603,0.349206349206349,0.341269841269841,0.563492063492063,2.43169398907104,1.25714285714286,1.53571428571429,1.42,0.642857142857143,0,57,15,4,11,0.45,0.12,0.03,0.09,37.22,0.984931113575349,5.15483870967742,0.468253968253968,0.928571428571429,0.492,0.511,0.483,0.482,"ANDREA ANTINORI;MARIA ROSARIA CAPOBIANCHI;GIUSEPPE IPPOLITO;ENRICO GIRARDI;ANTONIO DI BIAGIO;ANTONELLA D’ARMINIO MONFORTE;CARLO FEDERICO PERNO;MAURO PIACENTINI;ADRIANA AMMASSARI;CARMELA PINNETTI;ANDREA DE LUCA;ANTONELLA CASTAGNA;GIAN MARÍA FIMIA;FRANCESCA CECCHERINI‐SILBERSTEIN;CRISTINA MUSSINI;ALESSANDRO COZZI‐LEPRI;GIOACCHINO ANGARANO;DELIA GOLETTI;PIERLUCA PISELLI;MASSIMO ANDREONI","36;20;16;14;12;11;11;9;9;8;8;8;8;8;8;8;7;7;7;7","ANDREA ANTINORI;MARIA ROSARIA CAPOBIANCHI;GIUSEPPE IPPOLITO;CRISTINA CHIMENTI;ANDREA FRUSTACI;ENRICO GIRARDI;DELIA GOLETTI;SIMONE LANINI;CARLO FEDERICO PERNO;ANTONIO DI BIAGIO;ANTONELLA D’ARMINIO MONFORTE;MAURO PIACENTINI;GIAN MARÍA FIMIA;ANNA ROSA GARBUGLIA;CARMELA PINNETTI;FRANCA DEL NONNO;ADRIANA AMMASSARI;STEFANO BONORA;GUIDO ANTONELLI;GIUSEPPE MARIA ETTORRE","2.95;2.2;1.8;1.05;1.05;1.01;0.98;0.92;0.9;0.9;0.9;0.88;0.82;0.71;0.68;0.62;0.61;0.6;0.59;0.58","ANDREA ANTINORI;MARIA ROSARIA CAPOBIANCHI;GIUSEPPE IPPOLITO;ENRICO GIRARDI;CARLO FEDERICO PERNO;MAURO PIACENTINI;ADRIANA AMMASSARI;CARMELA PINNETTI;GIAN MARÍA FIMIA;DELIA GOLETTI;PIERLUCA PISELLI;MASSIMO ANDREONI;RITA BELLAGAMBA;MAURO ZACCARELLI;STEFANO RUSCONI;SIMONE LANINI;ANNA ROSA GARBUGLIA;MASSIMO GALLI;GIANPIERO D’OFFIZI;CHIARA AGRATI","36;20;16;14;11;9;9;8;8;7;7;7;7;6;6;6;6;5;5;5","ANDREA ANTINORI;MARIA ROSARIA CAPOBIANCHI;GIUSEPPE IPPOLITO;CRISTINA CHIMENTI;ANDREA FRUSTACI;ENRICO GIRARDI;DELIA GOLETTI;SIMONE LANINI;CARLO FEDERICO PERNO;MAURO PIACENTINI;GIAN MARÍA FIMIA;ANNA ROSA GARBUGLIA;CARMELA PINNETTI;FRANCA DEL NONNO;ADRIANA AMMASSARI;PIERLUCA PISELLI;RITA BELLAGAMBA;LEOPOLDO PAOLO PUCILLO;CONCETTA CASTILLETTI;MARCO FRANCONE","2.95;2.2;1.8;1.05;1.05;1.01;0.98;0.92;0.9;0.88;0.82;0.71;0.68;0.62;0.61;0.55;0.54;0.53;0.52;0.52","GIAN MARÍA FIMIA;MAURO PIACENTINI;ANDREA ANTINORI;MARCO CORAZZARI;FRANCESCA NAZIO;FRANCESCO CECCONI;VALENTINA CIANFANELLI;CARMELO GARCÍA‐MONZÓN;JAVIER VARGAS‐CASTRILLÓN;JORDI MUNTANÉ;LISARDO BOSCÁ;M. PILAR VALDECANTOS;MARÍA E. MIQUILENA-COLINA;NÉSTOR VÁZQUEZ-AGRA;ORESTE LO IACONO;PALOMA MARTÍN‐SANZ;RAFAEL MAYORAL;VIRGINIA PARDO;ÁGUEDA GONZÁLEZ‐RODRÍGUEZ;ÁNGELA M. VALVERDE","1587;1550;953;882;706;706;573;505;505;505;505;505;505;505;505;505;505;505;505;505","GIAN MARÍA FIMIA;MAURO PIACENTINI;ANDREA ANTINORI;MARCO CORAZZARI;ROBERTA NARDACCI;DELIA GOLETTI;ALESSANDRA ROMAGNOLI;GIUSEPPE IPPOLITO;GIANPIERO D’OFFIZI;PIERLUCA PISELLI;MANUELA ANTONIOLI;ENRICO GIRARDI;ANDREA FRUSTACI;MARIA ROSARIA CAPOBIANCHI;ROMINA VERARDO;FABIOLA CICCOSANTI;FERNANDA SCOPELLITI;ANTONINO DI;FRANCA DEL NONNO;ELISA PETRUCCIOLI","1200;1087;825;716;418;401;340;328;282;273;271;264;256;241;221;216;208;171;170;163","ANDREA ANTINORI;MARIA ROSARIA CAPOBIANCHI;GIUSEPPE IPPOLITO;MAURO ZACCARELLI;ENRICO GIRARDI;ADRIANA AMMASSARI;PIERLUCA PISELLI;ANNA ROSA GARBUGLIA;CARLO FEDERICO PERNO;RITA BELLAGAMBA;SIMONE LANINI;CARMELA PINNETTI;DELIA GOLETTI;GIAN MARÍA FIMIA;FEDERICO MARTINI;GIANPIERO D’OFFIZI;PATRIZIA LORENZINI;ANDREA FRUSTACI;CHIARA AGRATI;CATERINA GORI","31;20;16;12;9;8;7;6;6;6;6;6;6;6;5;5;5;5;5;5","MEDICINE;BIOLOGY;CHEMISTRY;ENGINEERING;PHYSICS;MATHEMATICS;POLITICAL SCIENCE;BUSINESS;PSYCHOLOGY;SOCIOLOGY;COMPUTER SCIENCE;GEOGRAPHY;ECONOMICS;HISTORY;GEOLOGY;PHILOSOPHY","111;55;10;7;7;6;6;4;4;4;3;3;2;2;1;1","INTERNAL MEDICINE;VIROLOGY;IMMUNOLOGY;GENETICS;PATHOLOGY;BIOCHEMISTRY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;CELL BIOLOGY;PEDIATRICS;PHARMACOLOGY;INTENSIVE CARE MEDICINE;SURGERY;CANCER RESEARCH;LAW;OPTICS;CARDIOLOGY;ENDOCRINOLOGY;FAMILY MEDICINE;PSYCHIATRY","76;56;52;26;25;24;24;15;13;10;10;9;7;6;6;6;5;5;5;5","HUMAN IMMUNODEFICIENCY VIRUS (HIV);VIRUS;GENE;REGIMEN;DISEASE;POPULATION;HEPATITIS C;APOPTOSIS;COHORT;DISCONTINUATION;ADVERSE EFFECT;ENZYME;IN VITRO;ANTIBODY;CANCER;CELL;COHORT STUDY;INCIDENCE (GEOMETRY);OUTBREAK;PROPORTIONAL HAZARDS MODEL;RANDOMIZED CONTROLLED TRIAL;TUBERCULOSIS","55;30;26;21;16;13;11;10;10;10;7;7;7;6;6;6;6;6;6;6;6;6","VIRAL LOAD;HEPATITIS C VIRUS;GENOTYPE;AUTOPHAGY;HEPATITIS B VIRUS;CLINICAL ENDPOINT;T CELL;HAZARD RATIO;INFECTIOUS DISEASE (MEDICAL SPECIALTY);MARAVIROC;MYCOBACTERIUM TUBERCULOSIS;PERIPHERAL BLOOD MONONUCLEAR CELL;ALPHA INTERFERON;CARDIOMYOPATHY;CHRONIC HEPATITIS;EBOLA VIRUS;GENOME;LIVER TRANSPLANTATION;SEROLOGY;TENOFOVIR;VIRAL DISEASE;VIRAL REPLICATION","44;15;10;9;9;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","ANTIRETROVIRAL THERAPY;LAMIVUDINE;RIBAVIRIN;CORONAVIRUS DISEASE 2019 (COVID-19);VIRAL QUASISPECIES;GENOTYPING;HBSAG;REVERSE TRANSCRIPTASE;ANTIGEN-PRESENTING CELL;BDNA TEST;CLADE;CYP3A4;CYP3A5;HIV ANTIGENS;LATENT TUBERCULOSIS;MEN WHO HAVE SEX WITH MEN;MITOPHAGY;SINGLE-NUCLEOTIDE POLYMORPHISM;STABLE ISOTOPE LABELING BY AMINO ACIDS IN CELL CULTURE;ACTIVE TUBERCULOSIS;ALPHA (FINANCE);AMPLICON;ANAEROBIC GLYCOLYSIS;ANTIGEN PRESENTATION;ANTIVIRAL TREATMENT;ATF6;BORRELIA;CASSIA;CD11C;CD86;CORRELATION DIMENSION;DEEP SEQUENCING;DENGUE VACCINE;DEPHOSPHORYLATION;EBOLAVIRUS;ELISPOT;ESAT-6;ESTROGEN RECEPTOR;FRONTOTEMPORAL DEMENTIA;HEMAGGLUTINATION ASSAY;HEPACIVIRUS;HEPATITIS DELTA;HEPATITIS E;HEPATITIS E VIRUS;HERPESVIRIDAE;HPV INFECTION;HSP70;IMMUNOGENIC CELL DEATH;INTERFERON ALFA;INVASIVE CANDIDIASIS;ISCHEMIC CARDIOMYOPATHY;LYME;MOLECULAR EPIDEMIOLOGY;MOLECULAR MEDICINE;NEUROGLOBIN;OPEN READING FRAME;P-GLYCOPROTEIN;PARKIN;PEROXIREDOXIN;PEROXYNITRITE;PRENATAL DIAGNOSIS;PROTEIN PHOSPHATASE 2;PROVIRUS;QUALITY MANAGEMENT SYSTEM;QUANTITATIVE PROTEOMICS;RHODAMINE 123;RPTOR;SHOTGUN PROTEOMICS;SOLID ORGAN;STEATOHEPATITIS;TAQMAN;THIOREDOXIN REDUCTASE;TISSUE TROPISM;UBIQUITIN LIGASE;V3 LOOP;VINCRISTINE;VITRONECTIN","36;7;6;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HIV INFECTIONS;HUMANS;MALE;FEMALE;ADULT;MIDDLE AGED;HIV-1;;ANTI-HIV AGENTS;ANTIVIRAL AGENTS;RNA, VIRAL;HEPATITIS C;AGED;HEPACIVIRUS;VIRAL LOAD;RITONAVIR;HEPATITIS C, CHRONIC;AUTOPHAGY;TREATMENT OUTCOME;ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE","102;86;52;49;44;41;40;39;35;27;25;23;19;19;19;18;17;15;14;13","EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;HEPATITIS C INFECTION AND TREATMENT;TUBERCULOSIS;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;ROLE OF AUTOPHAGY IN DISEASE AND HEALTH;EBOLA VIRUS RESEARCH AND OUTBREAKS;HEPATITIS B INFECTION AND TREATMENT;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;HEPATITIS E INFECTION AND TREATMENT;HEPATOCELLULAR CARCINOMA;IMMUNOBIOLOGY OF DENDRITIC CELLS;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;INFLUENZA VIRUS RESEARCH AND EPIDEMIOLOGY;LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;ANALYSIS OF BRAIN FUNCTIONAL CONNECTIVITY NETWORKS;ATTENTION-DEFICIT/HYPERACTIVITY DISORDER;BIOLOGICAL PROPERTIES OF ALOE VERA AND RELATED COMPOUNDS","28;11;10;7;6;5;4;4;3;2;2;2;2;2;2;2;2;1;1;1","ANTIRETROVIRAL THERAPY;HIV;REGIMEN;RITONAVIR;HEPATITIS C;DARUNAVIR;DISCONTINUATION;ATAZANAVIR;RALTEGRAVIR;EMTRICITABINE;AUTOPHAGY;HIV INFECTION;CLINICAL ENDPOINT;LOPINAVIR;REVERSE-TRANSCRIPTASE INHIBITOR;RILPIVIRINE;TREATMENT;CONCORDANCE;DOLUTEGRAVIR;EFAVIRENZ","34;25;21;16;11;10;10;9;9;8;6;6;5;5;5;5;5;4;4;4","HIV-INFECTED PATIENTS;ANTIRETROVIRAL THERAPY;ANTIRETROVIRAL TREATMENT;HIVINFECTED PATIENTS;ANTIVIRAL ACTIVITY;CLINICAL PRACTICE;DRUG RESISTANCE;HIV PATIENTS;PATIENTS STARTING;PREGNANT WOMEN;VIRAL LOAD;VIROLOGICAL FAILURE;VIROLOGICALLY SUPPRESSED;ANTIRETROVIRAL DRUGS;ANTIRETROVIRAL REGIMEN;ANTIRETROVIRAL-NAIVE ADULTS;ATAZANAVIRRITONAVIR MONOTHERAPY;CLINICAL SAMPLES;COHORT STUDY;COMBINATION ANTIRETROVIRAL;DARUNAVIRRITONAVIR DRVR;DE NOVO;DUAL THERAPY;FUNCTION MONITORING;HIV- DRUG;HIV-POSITIVE PATIENTS;HIVHCV CO-INFECTED;HIVINFECTED INDIVIDUALS;ICONA COHORT;ICONA FOUNDATION","5;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CD COUNT;VIROLOGICAL FAILURE;VIRAL LOAD;ANTIRETROVIRAL THERAPY;HIV INFECTION;NAÏVE PATIENTS;PATIENTS STARTING;PATIENTS TREATED;TREATMENT FAILURE;ER STRESS;HIV- RNA;HR CI;MONOTHERAPY ARM;HIV RNA;MEDIAN AGE;SURVIVAL ANALYSIS;CD CELL;LOWER RISK;NONINFECTIVE SNAE;ODDS RATIO;VIROLOGICAL RESPONSE;ART INITIATION;ATVR MONOTHERAPY;CLINICAL PRACTICE;CLINICAL TRIALS;CURRENT CD;CYPA RS;DISCONTINUATION DUE;DRUG RESISTANCE;HIV PATIENTS","19;19;18;14;13;11;11;11;11;10;10;10;9;8;8;8;7;7;7;7;7;6;6;6;6;6;6;6;6;6",51,0.4,4.47,4,2.5,1,1,1,21.75,0,1,5,1,1,3,0,2,1,2,3,2.25,0,0,79.5,79.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,0,0,0.58,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY","1;1;1",NA,NA,"INFECTION","1","2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT","1",NA,NA,NA,NA,2,1876047.5,215645.92,3.5,9.5,6,1,19.5,324118.325757576,0.388746917365733,"ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI;ABSISKEY (FRANCE);BEN-GURION UNIVERSITY OF THE NEGEV;BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE;DEPARTMENT OF HEALTH;DÉLÉGATION PARIS 11;EUROPEAN RESEARCH AND PROJECT OFFICE;FEDERAL MINISTRY OF DEFENCE;INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT;INSTITUT PASTEUR;METABIOTA (UNITED STATES);MÉDECINS SANS FRONTIÈRES;NATIONAL CENTER FOR EPIDEMIOLOGY;PHILIPPS UNIVERSITY OF MARBURG;ROBERT KOCH INSTITUTE;UNIVERSITY OF LIVERPOOL;UNIVERSITY OF LJUBLJANA;UNIVERSITY OF MANITOBA","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","H2020-ADHOC-2014-20 (CALL FOR PROPOSAL);H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","2;2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY","2;1;1","BIODEFENSE;EMERGING INFECTIOUS DISEASES;INFECTIOUS DISEASES;PREVENTION;VACCINE RELATED;IMMUNIZATION;RARE DISEASES","2;2;2;2;2;1;1","INFECTION","1",NA,NA,NA,NA,NA,NA,"A01 CLINICAL MEDICINE","2","3 GOOD HEALTH AND WELL BEING","2",11,"PUBLIC LIBRARY OF SCIENCE","11","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;31 BIOLOGICAL SCIENCES;3105 GENETICS;3204 IMMUNOLOGY;36 CREATIVE ARTS AND WRITING;3601 ART HISTORY, THEORY AND CRITICISM;49 MATHEMATICAL SCIENCES","16;6;4;2;1;1;1;1;1","HIV/AIDS;INFECTIOUS DISEASES;BRAIN DISORDERS;CLINICAL RESEARCH;RARE DISEASES;EMERGING INFECTIOUS DISEASES;INFLUENZA;PEDIATRIC;PNEUMONIA & INFLUENZA;PREVENTION;VACCINE RELATED","3;3;2;2;2;1;1;1;1;1;1","INFECTION;GENERIC HEALTH RELEVANCE","5;1","7.1 INDIVIDUAL CARE NEEDS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;6.1 PHARMACEUTICALS","3;2;1","BIOMEDICAL;CLINICAL","2;2","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","4;1;1","KAPOSI'S SARCOMA;LIVER CANCER;NON-HODGKIN'S LYMPHOMA","2;1;1","3 GOOD HEALTH AND WELL BEING","1"
"IRCCS_SPALLANZANIROMA",2015,116,12.9310344827586,4.06034482758621,0.422413793103448,0.370689655172414,0.689655172413793,2.67613636363636,1.44117647058824,1.43333333333333,1.40350877192982,0.560344827586207,0,69,16,9,11,0.59,0.14,0.08,0.09,29.34,0.787395725720822,5.0206611570248,0.517241379310345,0.887931034482759,0.497,0.482,0.484,0.444,"MARIA ROSARIA CAPOBIANCHI;GIUSEPPE IPPOLITO;ANDREA ANTINORI;ANTONINO DI;NICOLA PETROSILLO;MAURO PIACENTINI;GIAN MARÍA FIMIA;ANTONELLA D’ARMINIO MONFORTE;VINCENZO PURO;RAFFAELLA LIONETTI;CARLO FEDERICO PERNO;CARMELA PINNETTI;CONCETTA CASTILLETTI;EMANUELE NICASTRI;MASSIMO ANDREONI;ENRICO GIRARDI;GIOVANNI GUARALDI;GIANPIERO D’OFFIZI;CHIARA AGRATI;DANIELE LAPA","23;20;18;15;12;10;10;9;9;9;9;7;7;7;7;7;6;6;6;6","GIUSEPPE IPPOLITO;MARIA ROSARIA CAPOBIANCHI;MAURO PIACENTINI;ANDREA ANTINORI;NICOLA PETROSILLO;GIAN MARÍA FIMIA;VINCENZO PURO;ANTONINO DI;RAFFAELLA LIONETTI;CHIARA TAIBI;CARLO FEDERICO PERNO;ANNA ROSA GARBUGLIA;DELIA GOLETTI;GIANPIERO D’OFFIZI;PIERLUCA PISELLI;ELISA BUSI RIZZI;DANIELE LAPA;CHIARA AGRATI;CONCETTA CASTILLETTI;SIMONE LANINI","2.15;2.13;1.73;1.54;1.38;1.37;1.28;1.27;0.85;0.68;0.65;0.64;0.61;0.6;0.58;0.56;0.55;0.55;0.54;0.54","MARIA ROSARIA CAPOBIANCHI;GIUSEPPE IPPOLITO;ANDREA ANTINORI;ANTONINO DI;NICOLA PETROSILLO;MAURO PIACENTINI;GIAN MARÍA FIMIA;VINCENZO PURO;RAFFAELLA LIONETTI;CARLO FEDERICO PERNO;CARMELA PINNETTI;CONCETTA CASTILLETTI;EMANUELE NICASTRI;ENRICO GIRARDI;GIANPIERO D’OFFIZI;CHIARA AGRATI;DANIELE LAPA;CHIARA TAIBI;MARZIA MONTALBANO;SIMONE LANINI","23;20;18;15;12;10;10;9;9;9;7;7;7;7;6;6;6;6;6;6","GIUSEPPE IPPOLITO;MARIA ROSARIA CAPOBIANCHI;MAURO PIACENTINI;ANDREA ANTINORI;NICOLA PETROSILLO;GIAN MARÍA FIMIA;VINCENZO PURO;ANTONINO DI;RAFFAELLA LIONETTI;CHIARA TAIBI;CARLO FEDERICO PERNO;ANNA ROSA GARBUGLIA;DELIA GOLETTI;GIANPIERO D’OFFIZI;PIERLUCA PISELLI;ELISA BUSI RIZZI;DANIELE LAPA;CHIARA AGRATI;CONCETTA CASTILLETTI;SIMONE LANINI","2.15;2.13;1.73;1.54;1.38;1.37;1.28;1.27;0.85;0.68;0.65;0.64;0.61;0.6;0.58;0.56;0.55;0.55;0.54;0.54","GIUSEPPE IPPOLITO;MARCO TRIPODI;ANTONINO DI;GIAN MARÍA FIMIA;CARMINE MANCONE;FRANCESCO DIELI;MARIA ROSARIA CAPOBIANCHI;ALESSIA LO DICO;ALICE CONIGLIARO;GIACOMO DE LEO;LAURA SAIEVA;MAURO MANNO;RICCARDO ALESSANDRO;SAMUELE RACCOSTA;SIMONA BUCCHERI;VIVIANA COSTA;MARCO CORAZZARI;MAURO PIACENTINI;NICOLA PETROSILLO;ANDREA ANTINORI","694;587;556;450;431;410;395;394;394;394;394;394;394;394;394;394;360;307;298;282","GIUSEPPE IPPOLITO;ANTONINO DI;MARCO TRIPODI;CARMINE MANCONE;GIAN MARÍA FIMIA;MARCO CORAZZARI;MARIA ROSARIA CAPOBIANCHI;NICOLA PETROSILLO;MAURO PIACENTINI;DELIA GOLETTI;SIMONE LANINI;ANDREA ANTINORI;FABIOLA CICCOSANTI;VINCENZO PURO;VALENTINA VANINI;CONCETTA CASTILLETTI;ANGELA MARIA COZZOLINO;EMANUELE NICASTRI;ALESSANDRA SACCHI;ANDREA FRUSTACI","656;539;491;431;431;360;357;298;288;274;260;244;239;182;161;158;156;150;141;120","MARIA ROSARIA CAPOBIANCHI;GIUSEPPE IPPOLITO;ANDREA ANTINORI;ANTONINO DI;NICOLA PETROSILLO;GIAN MARÍA FIMIA;RAFFAELLA LIONETTI;MAURO PIACENTINI;EMANUELE NICASTRI;CARMELA PINNETTI;VINCENZO PURO;CONCETTA CASTILLETTI;ENRICO GIRARDI;ANNA ROSA GARBUGLIA;DANIELE LAPA;DELIA GOLETTI;MARZIA MONTALBANO;CHIARA TAIBI;GIANPIERO D’OFFIZI;SIMONE LANINI","22;19;17;14;12;9;9;8;7;7;7;7;6;6;6;6;6;6;6;6","MEDICINE;BIOLOGY;PHYSICS;SOCIOLOGY;COMPUTER SCIENCE;CHEMISTRY;ENGINEERING;ECONOMICS;BUSINESS;GEOGRAPHY;POLITICAL SCIENCE;PSYCHOLOGY;HISTORY;GEOLOGY;MATERIALS SCIENCE;MATHEMATICS;PHILOSOPHY","93;66;11;10;9;8;8;5;4;4;3;3;2;1;1;1;1","INTERNAL MEDICINE;VIROLOGY;GENETICS;IMMUNOLOGY;PATHOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;CELL BIOLOGY;GASTROENTEROLOGY;SURGERY;INTENSIVE CARE MEDICINE;OPTICS;MICROBIOLOGY;PEDIATRICS;CANCER RESEARCH;FAMILY MEDICINE;DEMOGRAPHY;PSYCHIATRY;ELECTRICAL ENGINEERING;ENDOCRINOLOGY;PHARMACOLOGY;PROGRAMMING LANGUAGE;SOCIOECONOMICS","59;50;43;41;24;16;16;14;12;12;10;10;9;9;8;7;6;5;4;4;4;4;4","GENE;VIRUS;HUMAN IMMUNODEFICIENCY VIRUS (HIV);APOPTOSIS;DISEASE;OUTBREAK;POPULATION;CANCER;CONFIDENCE INTERVAL;INCIDENCE (GEOMETRY);COHORT;EPIDEMIOLOGY;IMMUNE SYSTEM;IN VITRO;REGIMEN;TRANSPLANTATION;TUBERCULOSIS;COHORT STUDY;ADVERSE EFFECT;SIERRA LEONE","29;28;25;12;12;12;10;9;9;9;8;8;8;8;8;8;8;7;6;6","VIRAL LOAD;EBOLA VIRUS;GENOTYPE;AUTOPHAGY;HAZARD RATIO;HEPATITIS B VIRUS;LIVER TRANSPLANTATION;VIRAL DISEASE;VIREMIA;HEPATITIS C VIRUS;INFECTIOUS DISEASE (MEDICAL SPECIALTY);MYCOBACTERIUM TUBERCULOSIS;SYPHILIS;T CELL;VIRAL REPLICATION;CARDIOMYOPATHY;CD8;CHRONIC HEPATITIS;CYTOTOXIC T CELL;ESCHERICHIA COLI;GENOME;PHYLOGENETIC TREE;TOLERABILITY","17;15;14;10;5;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3","ANTIRETROVIRAL THERAPY;RIBAVIRIN;MEN WHO HAVE SEX WITH MEN;CLADE;CORONAVIRUS DISEASE 2019 (COVID-19);EPITHELIAL–MESENCHYMAL TRANSITION;GENOTYPING;HERPESVIRIDAE;LATENT TUBERCULOSIS;MOLECULAR EPIDEMIOLOGY;WHOLE GENOME SEQUENCING;EBOLAVIRUS;HPV INFECTION;INTERFERON Γ;KLEBSIELLA PNEUMONIAE;LENTIVIRUS;MYELOID-DERIVED SUPPRESSOR CELL;ACINETOBACTER BAUMANNII;ACTIVE TUBERCULOSIS;ALPHA (FINANCE);AMPK;ANTIGEN-PRESENTING CELL;ANTIMICROBIAL STEWARDSHIP;APOBEC3G;ARTEMISININ;ARTESUNATE;ATG5;CD3;CD4 T CELL;CD90;COGNITIVE DECLINE;COLONOSCOPY;DEEP SEQUENCING;DIABETIC CARDIOMYOPATHY;DNA METHYLATION;E2F1;ETHAMBUTOL;EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS;GANCICLOVIR;GRAM-NEGATIVE BACTERIA;GRANZYME B;HAPLOTYPE;HBSAG;HEPACIVIRUS;HEPATITIS E;INTERLEUKIN 21;LAMIVUDINE;MATRIX-ASSISTED LASER DESORPTION/IONIZATION;MEASLES VIRUS;MICROVESICLES;MITOPHAGY;MULTILOCUS SEQUENCE TYPING;NECROPTOSIS;NITROTYROSINE;NS3;P38 MITOGEN-ACTIVATED PROTEIN KINASES;PERFORIN;PYRAZINAMIDE;PYRUVATE KINASE;SEROPREVALENCE;SEVERE MALARIA;SEXUAL TRANSMISSION;SINGLE-NUCLEOTIDE POLYMORPHISM;TIME-OF-FLIGHT MASS SPECTROMETRY;TISSUE TROPISM;TUBERCULOSIS DIAGNOSIS;UBIQUITIN LIGASE;VANCOMYCIN;VERBAL FLUENCY TEST;VIRAL QUASISPECIES","11;5;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;HIV INFECTIONS;FEMALE;MALE;ADULT;MIDDLE AGED;HEMORRHAGIC FEVER, EBOLA;ITALY;HIV-1;HEPACIVIRUS;RNA, VIRAL;ANTI-HIV AGENTS;AGED;ANTIVIRAL AGENTS;EBOLAVIRUS;;DNA, VIRAL;HEPATITIS C, CHRONIC;LATENT TUBERCULOSIS;MYCOBACTERIUM TUBERCULOSIS","98;91;61;60;53;43;39;39;31;22;22;21;17;16;16;15;15;15;15;15","EBOLA VIRUS RESEARCH AND OUTBREAKS;HEPATITIS C INFECTION AND TREATMENT;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;HEPATITIS B INFECTION AND TREATMENT;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;ROLE OF AUTOPHAGY IN DISEASE AND HEALTH;TUBERCULOSIS;MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;NATURAL KILLER CELLS IN IMMUNITY;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;CLOSTRIDIUM DIFFICILE INFECTION AND TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;INFECTION CONTROL IN HEALTHCARE SETTINGS;MACROPHAGE ACTIVATION AND POLARIZATION;VIRAL HEMORRHAGIC FEVERS AND ZOONOTIC INFECTIONS","15;10;8;7;5;5;5;5;3;3;3;2;2;2;2;2;2;2;2;2","HIV;ANTIRETROVIRAL THERAPY;HIV INFECTION;REGIMEN;AUTOPHAGY;HBV INFECTION;HEPATITIS C;VIREMIA;EPIDEMIOLOGY;TREATMENT;CONCORDANCE;DACLATASVIR;DISCONTINUATION;EBOLA VIRUS;ENDOPLASMIC RETICULUM;HEPATITIS B;HIV EPIDEMIOLOGY;HIV TRANSMISSION;MOLECULAR EPIDEMIOLOGY;MYCOBACTERIUM TUBERCULOSIS","18;11;10;8;7;5;5;5;4;4;3;3;3;3;3;3;3;3;3;3","EBOLA VIRUS;ANTIRETROVIRAL THERAPY;LIVER TRANSPLANT;HCV GENOTYPE;HIV PATIENTS;TRANSPLANT RECIPIENTS;VIRUS DISEASE;ACUTE HEPATITIS;BURKITTS LYMPHOMA;CANCER CELLS;CELLS ENHANCES;CHRONIC HEPATITIS;CIRRHOTIC PATIENTS;CLOSTRIDIUM DIFFICILE;COHORT STUDY;DACLATASVIR DCV;DIFFICILE INFECTION;EBV LYTIC;EBV-POSITIVE BURKITTS;ENHANCES EBV;ER STRESS;GENES EXPRESSION;GENOTYPE INFECTION;GLUCOSE METABOLISM;IMMUNOHISTOCHEMICAL ASPECTS;INITIATING ANTIRETROVIRAL;INTENSIVE CARE;LIVER TISSUE;LIVER TRANSPLANTATION;LOW-LEVEL VIREMIA","8;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","EBOLA VIRUS;GRAM NEGATIVE;RISK FACTORS;CELL DEATH;HIV INFECTION;NEGATIVE BACTERIA;ANTIRETROVIRAL THERAPY;HIV RNA;HIV- RNA;LT RECIPIENTS;SIERRA LEONE;ACTIVE TB;CANCER CELLS;EBOV VIREMIA;LT FAILURE;TRIPLE THERAPY;WEST AFRICA;CARBAPENEM-RESISTANT GRAM;CONFIDENCE INTERVAL;ER STRESS;HIV PATIENTS;INCREASED RISK;QUANTIFIABLE HIV-RNA;RR CI;STR PATIENTS;VΔ T-CELLS;AB SEROSTATUS;ANTI-HEV IGG;CD CELLS;CD T-CELL","14;10;10;9;9;9;7;7;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;4;4;4;4",57,0.49,4.6,5,2,1,1,1,2,0,1,5,0,0,4,0,2.5,2,1,3,2,0,0,65,65,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,2.78,881.38,5.77,1,0.11,56.56,0,0,1,0,4,0,0,3,1,5,3,0,0,0,0,1,0,9,0,0,7,0,1,0,0,0,1,0,0,0,"United States;Israel;Netherlands;Spain;United Kingdom","6;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY","9;7;3;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HIV/AIDS;INFECTIOUS DISEASES;EMERGING INFECTIOUS DISEASES;PREVENTION;VACCINE RELATED;BIODEFENSE;LUNG;ANTIMICROBIAL RESISTANCE;IMMUNIZATION;INFLUENZA;ORPHAN DRUG;PNEUMONIA;PNEUMONIA & INFLUENZA;RARE DISEASES;TUBERCULOSIS;UROLOGIC DISEASES","8;5;4;4;3;3;3;2;2;1;1;1;1;1;1;1;1;1","INFECTION","7","6.1 PHARMACEUTICALS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","7;1;1;1",NA,NA,NA,NA,7,6173735.71,389108.05,4.42857142857143,21,11,1,100.142857142857,1018831.16530196,0.113855959604082,"ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI;DEPARTMENT OF HEALTH;BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE;DÉLÉGATION PARIS 11;FRIEDRICH-LOEFFLER-INSTITUT;INSTITUT PASTEUR;PUBLIC HEALTH AGENCY OF SWEDEN;AIX-MARSEILLE UNIVERSITY;DEPARTMENT FOR ENVIRONMENT, FOOD AND RURAL AFFAIRS;ERASMUS MC;FINNISH INSTITUTE FOR HEALTH AND WELFARE;FRENCH NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO;INSTITUTO DE SALUD CARLOS III;ISTITUTO SUPERIORE DI SANITÀ;LEIDEN UNIVERSITY MEDICAL CENTER;NATIONAL CENTER FOR EPIDEMIOLOGY;ROBERT KOCH INSTITUTE;SCIENSANO (BELGIUM);STATENS SERUM INSTITUT","7;5;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","EUROPEAN COMMISSION","7","COALITION S;EC & ERC - EUROPEAN UNION","7;7","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-JTI-IMI2-2014-02-SINGLE-STAGE (CALL FOR PROPOSAL);IMI2-RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME);3RD HEALTH PROGRAMME (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME);H2020-EU.1.4.1.2. - INTEGRATING AND OPENING EXISTING NATIONAL AND REGIONAL  RESEARCH INFRASTRUCTURES OF EUROPEAN INTEREST (PROGRAMME);H2020-INFRAIA-2014-2015 (CALL FOR PROPOSAL);H2020-PHC-2014-SINGLE-STAGE (CALL FOR PROPOSAL)","4;3;3;2;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4206 PUBLIC HEALTH","6;4;2;1;1;1;1;1","INFECTIOUS DISEASES;PREVENTION;VACCINE RELATED;EMERGING INFECTIOUS DISEASES;BIODEFENSE;RARE DISEASES;BIOENGINEERING;BIOTECHNOLOGY;HIV/AIDS;IMMUNIZATION;NANOTECHNOLOGY;TUBERCULOSIS","5;5;5;4;3;2;1;1;1;1;1;1","INFECTION","7","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","3;1",NA,NA,NA,NA,"A06 AGRICULTURE, VETERINARY AND FOOD SCIENCE;A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;A05 BIOLOGICAL SCIENCES;C20 SOCIAL WORK AND SOCIAL POLICY","3;1;1;1;1","3 GOOD HEALTH AND WELL BEING","3",10,"PUBLIC LIBRARY OF SCIENCE","10","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;49 MATHEMATICAL SCIENCES;4905 STATISTICS;3207 MEDICAL MICROBIOLOGY;33 BUILT ENVIRONMENT AND DESIGN;46 INFORMATION AND COMPUTING SCIENCES;4612 SOFTWARE ENGINEERING","11;4;3;2;1;1;1;1","DIABETES;HIV/AIDS;INFECTIOUS DISEASES;PREVENTION;CARDIOVASCULAR","2;2;2;2;1","INFECTION;GENERIC HEALTH RELEVANCE","3;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","2;1",NA,NA,"CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH","3;2","LIVER CANCER","1",NA,NA
"IRCCS_SPALLANZANIROMA",2016,121,16.595041322314,3.83471074380165,0.31404958677686,0.305785123966942,0.661157024793388,2.52173913043478,1.1875,1.76190476190476,1.37931034482759,0.644628099173554,1,67,22,13,9,0.55,0.18,0.11,0.07,62.94,1.93769445989077,5.05523255813954,0.446280991735537,0.917355371900826,0.512,0.418,0.389,0.493,"GIUSEPPE IPPOLITO;ANTONINO DI;MARIA ROSARIA CAPOBIANCHI;ANDREA ANTINORI;ENRICO GIRARDI;EMANUELE NICASTRI;ALIMUDDIN ZUMLA;VINCENZO PURO;CARLO FEDERICO PERNO;CONCETTA CASTILLETTI;NICOLA PETROSILLO;MASSIMO ANDREONI;CARMELA PINNETTI;MARCO TRIPODI;MAURO PIACENTINI;GIAN MARÍA FIMIA;FRANCESCA CECCHERINI‐SILBERSTEIN;ANTONELLA D’ARMINIO MONFORTE;GIUSEPPE MARIA ETTORRE;RAFFAELLA LIONETTI","27;18;18;17;12;11;9;9;9;8;8;8;7;7;7;7;7;7;7;7","GIUSEPPE IPPOLITO;MARIA ROSARIA CAPOBIANCHI;ANNA ROSA GARBUGLIA;ENRICO GIRARDI;ANDREA ANTINORI;ANTONINO DI;GIAN MARÍA FIMIA;EMANUELE NICASTRI;VINCENZO PURO;MAURO PIACENTINI;NICOLA PETROSILLO;ALIMUDDIN ZUMLA;MANUELA ANTONIOLI;GIUSEPPE MARIA ETTORRE;CARMELA PINNETTI;CONCETTA CASTILLETTI;MARCO TRIPODI;FRANCESCO VAIRO;MAURO ZACCARELLI;DELIA GOLETTI","2.99;1.98;1.67;1.19;1.17;1.09;0.92;0.92;0.84;0.82;0.79;0.79;0.78;0.65;0.64;0.63;0.63;0.62;0.59;0.57","GIUSEPPE IPPOLITO;ANTONINO DI;MARIA ROSARIA CAPOBIANCHI;ANDREA ANTINORI;ENRICO GIRARDI;EMANUELE NICASTRI;VINCENZO PURO;CARLO FEDERICO PERNO;CONCETTA CASTILLETTI;NICOLA PETROSILLO;CARMELA PINNETTI;MARCO TRIPODI;MAURO PIACENTINI;GIAN MARÍA FIMIA;RAFFAELLA LIONETTI;GIANPIERO D’OFFIZI;MAURO ZACCARELLI;MARZIA MONTALBANO;DELIA GOLETTI;FABRIZIO PALMIERI","27;18;18;17;12;11;9;9;8;8;7;7;7;7;7;6;6;6;6;6","GIUSEPPE IPPOLITO;MARIA ROSARIA CAPOBIANCHI;ANNA ROSA GARBUGLIA;ENRICO GIRARDI;ANDREA ANTINORI;ANTONINO DI;GIAN MARÍA FIMIA;EMANUELE NICASTRI;VINCENZO PURO;MAURO PIACENTINI;NICOLA PETROSILLO;MANUELA ANTONIOLI;CARMELA PINNETTI;CONCETTA CASTILLETTI;MARCO TRIPODI;FRANCESCO VAIRO;MAURO ZACCARELLI;DELIA GOLETTI;RAFFAELLA LIONETTI;GIUSEPPINA LIUZZI","2.99;1.98;1.67;1.19;1.17;1.09;0.92;0.92;0.84;0.82;0.79;0.78;0.64;0.63;0.63;0.62;0.59;0.57;0.53;0.49","ANTONINO DI;MARTIN GABRIEL;ROMAN WÖLFEL;JOSEPH AKOI BORÉ;SOPHIE DURAFFOUR;EEVA KUISMA;DIDIER NGABO;JULIA HINZMANN;PIERRE FORMENTY;KATRIN SINGETHAN;CHRISTOPHER H. LOGUE;ELISA PALLASCH;SAKOBA KEÏTA;ANDREW RAMBAUT;GYTIS DUDAS;BOUBACAR DIALLO;N’FALY MAGASSOUBA;JANINE MICHEL;LIANA E. KAFETZOPOULOU;LISA L. CARTER","2384;2056;2056;2010;2010;1927;1819;1819;1556;1520;1476;1473;1473;1458;1458;1448;1448;1437;1437;1437","ANTONINO DI;ADRIANA AMMASSARI;GIUSEPPE IPPOLITO;MARCO TRIPODI;CARMINE MANCONE;CLAUDIA MONTALDO;MARIA ROSARIA CAPOBIANCHI;EMANUELE NICASTRI;TONINO ALONZI;LAURA SANTANGELO;CONCETTA CASTILLETTI;MAURO PIACENTINI;GIANPIERO D’OFFIZI;ANDREA ANTINORI;GIUSEPPINA LIUZZI;MARZIA MONTALBANO;MARCO IANNETTA;DELIA GOLETTI;ANDREA BAIOCCHINI;FABIOLA CICCOSANTI","2368;1269;1193;979;743;738;736;501;484;479;451;402;334;317;303;298;265;229;208;207","GIUSEPPE IPPOLITO;MARIA ROSARIA CAPOBIANCHI;ANTONINO DI;ANDREA ANTINORI;EMANUELE NICASTRI;ENRICO GIRARDI;CONCETTA CASTILLETTI;MARCO TRIPODI;MAURO PIACENTINI;RAFFAELLA LIONETTI;NICOLA PETROSILLO;CARMELA PINNETTI;FRANCESCO VAIRO;MAURO ZACCARELLI;RITA BELLAGAMBA;GIANPIERO D’OFFIZI;MARZIA MONTALBANO;VINCENZO PURO;DELIA GOLETTI;GIAN MARÍA FIMIA","23;19;17;16;11;10;8;7;7;7;7;6;6;6;6;6;6;6;5;5","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;SOCIOLOGY;GEOGRAPHY;ECONOMICS;POLITICAL SCIENCE;PHILOSOPHY;BUSINESS;HISTORY;PSYCHOLOGY;ENVIRONMENTAL SCIENCE;MATHEMATICS","103;63;12;9;8;8;8;7;6;6;4;2;2;2;1;1","INTERNAL MEDICINE;VIROLOGY;PATHOLOGY;IMMUNOLOGY;GENETICS;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;CELL BIOLOGY;INTENSIVE CARE MEDICINE;MICROBIOLOGY;SURGERY;GASTROENTEROLOGY;PEDIATRICS;FAMILY MEDICINE;PHARMACOLOGY;OPTICS;DEMOGRAPHY;ECOLOGY;PSYCHIATRY;COMPUTATIONAL BIOLOGY;ELECTRICAL ENGINEERING;NURSING","56;55;34;32;28;19;19;16;13;13;12;11;10;9;8;7;6;6;6;5;5;5","VIRUS;HUMAN IMMUNODEFICIENCY VIRUS (HIV);GENE;DISEASE;POPULATION;OUTBREAK;TUBERCULOSIS;REGIMEN;ANTIBIOTICS;IN VITRO;EPIDEMIOLOGY;APOPTOSIS;INCIDENCE (GEOMETRY);TRANSPLANTATION;BACTERIA;COHORT;HEPATITIS C;IMMUNE SYSTEM;TRANSMISSION (TELECOMMUNICATIONS);ANTIGEN;RETROSPECTIVE COHORT STUDY;SIERRA LEONE","32;26;25;24;15;14;14;10;9;9;8;7;7;7;6;6;6;6;6;5;5;5","VIRAL LOAD;EBOLA VIRUS;AUTOPHAGY;INFECTIOUS DISEASE (MEDICAL SPECIALTY);MYCOBACTERIUM TUBERCULOSIS;GENOTYPE;HEPATITIS C VIRUS;LIVER TRANSPLANTATION;ZIKA VIRUS;GENOME;CD8;CHRONIC HEPATITIS;HEPATITIS B VIRUS;MICROBICIDE;RNA;T CELL;CYTOTOXIC T CELL;PARKINSON'S DISEASE;VIRAL DISEASE;VIREMIA","21;17;7;7;7;6;6;6;6;5;4;4;4;4;4;4;3;3;3;3","ANTIRETROVIRAL THERAPY;CORONAVIRUS DISEASE 2019 (COVID-19);EBOLAVIRUS;LATENT TUBERCULOSIS;SEXUAL TRANSMISSION;HBSAG;RIBAVIRIN;ACTIVE TUBERCULOSIS;ANTIVIRAL THERAPY;CULTURE CONVERSION;GENOTYPING;LAMIVUDINE;LENTIVIRUS;MEROPENEM;MICROVESICLES;RNA-BINDING PROTEIN;SPUTUM CULTURE;ACINETOBACTER BAUMANNII;AEDES ALBOPICTUS;ALPHA-SYNUCLEIN;AMODIAQUINE;AMPK;ANABAENA;ANTIMYCOBACTERIAL;ANTIVIRAL TREATMENT;ARTEMISININ;ARTESUNATE;ATG8;ATP-BINDING CASSETTE TRANSPORTER;BAFILOMYCIN;BECN1;BK VIRUS;BROTH MICRODILUTION;CASPASE;CIRCULAR DNA;CYTOKINESIS;DISEASE MANAGEMENT;ELISPOT;ENTEROCOCCUS FAECALIS;EPITHELIAL–MESENCHYMAL TRANSITION;EZH2;GENOMICS;GP41;HAPLOTYPE;HEPACIVIRUS;HEPATITIS E;HEPATITIS E VIRUS;HERPESVIRIDAE;HLA-B;HOMEOTIC GENE;HOX GENE;IL-2 RECEPTOR;IMIPENEM;INHA;INTERNAL TRANSCRIBED SPACER;LEWY BODY;LONG NON-CODING RNA;MATRIX-ASSISTED LASER DESORPTION/IONIZATION;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;MICRONUCLEUS;MILAN CRITERIA;MITOCHONDRIAL FUSION;MITOPHAGY;MOST RECENT COMMON ANCESTOR;MYCOLIC ACID;NANOPORE SEQUENCING;NFKB1;NON-CODING RNA;NONTUBERCULOUS MYCOBACTERIA;PARATUBERCULOSIS;PARKIN;REPRESSOR;REVERSE TRANSCRIPTASE;RIBONUCLEOPROTEIN;RNA EDITING;SIDA;SINGLE-NUCLEOTIDE POLYMORPHISM;STABLE ISOTOPE LABELING BY AMINO ACIDS IN CELL CULTURE;STAPHYLOCOCCAL INFECTIONS;TELOMERASE REVERSE TRANSCRIPTASE;TNF INHIBITOR;TRANSCRIPTOME;TRANSPOSABLE ELEMENT;UBIQUITIN LIGASE;VANCOMYCIN;VIRAL ENCEPHALITIS;VIRAL EVOLUTION;VIRAL QUASISPECIES;WHOLE GENOME SEQUENCING;XERODERMA PIGMENTOSUM","14;6;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;HIV INFECTIONS;FEMALE;MALE;HEMORRHAGIC FEVER, EBOLA;ADULT;MIDDLE AGED;RNA, VIRAL;ANTI-HIV AGENTS;HIV-1;EBOLAVIRUS;ITALY;;TUBERCULOSIS;AGED;ANTI-BACTERIAL AGENTS;LIVER NEOPLASMS;RITONAVIR;VIRAL LOAD;YOUNG ADULT","89;65;53;53;48;45;43;33;31;30;27;27;24;23;20;20;17;17;17;17","EBOLA VIRUS RESEARCH AND OUTBREAKS;TUBERCULOSIS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;HEPATITIS C INFECTION AND TREATMENT;GLOBAL IMPACT OF ARBOVIRAL DISEASES;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;ROLE OF AUTOPHAGY IN DISEASE AND HEALTH;HEPATOCELLULAR CARCINOMA;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;MECHANISMS AND TREATMENT OF LIVER FIBROSIS;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;EUTROPHICATION AND HARMFUL ALGAL BLOOMS;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;HEPATITIS B INFECTION AND TREATMENT;HEPATITIS E INFECTION AND TREATMENT;INFLUENZA VIRUS RESEARCH AND EPIDEMIOLOGY;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS","16;12;9;8;6;6;4;3;3;3;3;2;2;2;2;2;2;2;2;2","HIV;ANTIRETROVIRAL THERAPY;REGIMEN;RITONAVIR;EPIDEMIOLOGY;HEPATITIS C;HIV EPIDEMIOLOGY;HIV INFECTION;TREATMENT;ZIKA VIRUS;DARUNAVIR;AUTOPHAGY;DIAGNOSIS;EBOLAVIRUS;MEDICAL MICROBIOLOGY;SEXUAL TRANSMISSION;ANTIVIRAL THERAPY;ATAZANAVIR;DISCONTINUATION;EMTRICITABINE","14;13;10;8;6;6;6;6;6;6;5;4;4;4;4;4;3;3;3;3","EBOLA VIRUS;VIRUS DISEASE;ZIKA VIRUS;CD T-CELL;EBOLA EPIDEMIC;ANTIRETROVIRAL THERAPY;ASYLUM SEEKERS;AUTOPHAGIC RESPONSES;COHORT STUDY;DX ASSAY;EAST RESPIRATORY;HEPATOCELLULAR CARCINOMA;HIV--INFECTED PATIENTS;HIV-INFECTED PATIENTS;INFECTIOUS DISEASES;LAZZARO SPALLANZANI;LIVER TRANSPLANTATION;LOW CD;MIDDLE EAST;NATIONAL INSTITUTE;OBSERVATIONAL STUDY;PEOPLE LIVING;QUANT DX;QUANTIFICATION ALGORITHM;RANDOMIZED TRIAL;RESPIRATORY SYNDROME;REVERSE TRANSCRIPTASE;SIERRA LEONE;SURGICAL SITE;SURVEILLANCE DATA","11;5;5;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","EBOLA VIRUS;CD T-CELL;ACTIVE TB;ROME ITALY;VIRAL LOAD;VIRUS DISEASE;EASTERN EUROPE;CONDOMLESS SEX;DISEASE EVD;HCV RNA;HIV- RNA;MONOTHERAPY ARM;WEST AFRICA;ATAZANAVIRRITONAVIR MONOTHERAPY;CARDIOVASCULAR RESPIRATORY;EBOLA TREATMENT;EVD OUTBREAK;GENOMIC SURVEILLANCE;GERIATRIC SCIENCES;HIV INFECTION;INTERNAL MEDICINE;LA SAPIENZA;NEPHROLOGIC ANESTHESIOLOGIC;PUBLIC HEALTH;RESPIRATORY NEPHROLOGIC;SAPIENZA UNIVERSITY;SECONDARY HYPERTENSION;SEMINAL FLUID;TRIPLE THERAPY;VIROLOGICAL RESPONSE","33;22;15;15;14;11;10;9;9;9;9;9;9;8;8;8;8;8;8;8;8;8;8;8;8;8;8;8;8;8",63,0.52,15.5,8.5,4,2,1.75,7,1.5,0,2,9,1,1,7,2,1.25,1,3,4.5,4.5,0,0,112,112,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,2,2515,1.18,0,0,26,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,2,0,0,1,1,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY","2;2;1;1","CLINICAL RESEARCH;EMERGING INFECTIOUS DISEASES;INFECTIOUS DISEASES;LUNG;PATIENT SAFETY;PREVENTION","1;1;1;1;1;1","INFECTION","2","5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","2;1","ANAL CANCER;HODGKIN'S DISEASE;KAPOSI'S SARCOMA;LUNG CANCER","1;1;1;1","3.3 CHEMOPREVENTION","1",3,8495064.67,289679.46,5,21.3333333333333,10,1,44.5,1102898.32019849,0.109710929633317,"ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI;DEPARTMENT OF HEALTH;DÉLÉGATION PARIS 11;INSERM TRANSFERT;KAROLINSKA INSTITUTET;PUBLIC HEALTH AGENCY OF SWEDEN;UNIVERSITY COLLEGE LONDON;ACADEMIC MEDICAL CENTER;AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT;ATOMIC ENERGY AND ALTERNATIVE ENERGIES COMMISSION;AUGUST PI I SUNYER BIOMEDICAL RESEARCH INSTITUTE;BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE;BIOMEDICAL PRIMATE RESEARCH CENTRE;CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX;CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST;ERASMUS MC;EUROVACC FOUNDATION;FIT BIOTECH (FINLAND);FRIEDRICH-LOEFFLER-INSTITUT;HOSPITAL CLÍNIC DE BARCELONA","3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","3","COALITION S;EC & ERC - EUROPEAN UNION","3;3","3RD HEALTH PROGRAMME (PROGRAMME);CSA - COORDINATION AND SUPPORT ACTION (FUNDING SCHEME);H2020-EU.1.4.1.1. - DEVELOPING NEW WORLD-CLASS RESEARCH INFRASTRUCTURES (PROGRAMME);H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-INFRADEV-1-2015-2 (CALL FOR PROPOSAL);H2020-PHC-2015-SINGLE-STAGE_RTD (CALL FOR PROPOSAL);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3507 STRATEGY, MANAGEMENT AND ORGANISATIONAL BEHAVIOUR;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;44 HUMAN SOCIETY","1;1;1;1;1;1;1;1","HIV/AIDS;INFECTIOUS DISEASES;PREVENTION;VACCINE RELATED;BIODEFENSE;BIOTECHNOLOGY;EMERGING INFECTIOUS DISEASES;IMMUNIZATION;RARE DISEASES;TUBERCULOSIS;VACCINE RELATED (AIDS)","2;2;2;2;1;1;1;1;1;1;1","INFECTION","2","3.4 VACCINES;5.1 PHARMACEUTICALS","1;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;C13 ARCHITECTURE, BUILT ENVIRONMENT AND PLANNING","1;1;1","3 GOOD HEALTH AND WELL BEING","1",8,"PUBLIC LIBRARY OF SCIENCE;AMERICAN CHEMICAL SOCIETY;TAYLOR & FRANCIS GROUP","6;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3107 MICROBIOLOGY;44 HUMAN SOCIETY;4403 DEMOGRAPHY","11;6;3;3;2;1;1;1","GENETICS;EMERGING INFECTIOUS DISEASES;INFECTIOUS DISEASES;ANTIMICROBIAL RESISTANCE;BIODEFENSE;BIOTECHNOLOGY;CHRONIC LIVER DISEASE AND CIRRHOSIS;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;HEPATITIS;HEPATITIS - C;HIV/AIDS;INFLUENZA;LIVER DISEASE;PNEUMONIA & INFLUENZA;PREVENTION;VACCINE RELATED","4;3;3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","INFECTION;ORAL AND GASTROINTESTINAL","4;1","6.1 PHARMACEUTICALS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","2;1;1;1;1;1","BIOMEDICAL;CLINICAL","4;3","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","3;2","LIVER CANCER;NOT SITE-SPECIFIC CANCER","1;1","3 GOOD HEALTH AND WELL BEING","1"
"IRCCS_SPALLANZANIROMA",2017,124,18.0564516129032,4.23387096774194,0.338709677419355,0.32258064516129,1.03225806451613,3.07017543859649,1.13513513513514,1.66666666666667,1.70666666666667,0.693548387096774,0,70,18,13,8,0.56,0.15,0.1,0.06,27.23,0.923690633431397,5.10754716981132,0.475806451612903,0.943548387096774,0.491,0.363,0.394,0.436,"ANDREA ANTINORI;MARIA ROSARIA CAPOBIANCHI;GIUSEPPE IPPOLITO;ANTONELLA D’ARMINIO MONFORTE;ADRIANA AMMASSARI;GIANPIERO D’OFFIZI;ANTONINO DI;CONCETTA CASTILLETTI;ENRICO GIRARDI;CARMELA PINNETTI;CLAUDIO MARIA MASTROIANNI;MASSIMO ANDREONI;CHIARA AGRATI;ANDREA DE LUCA;EMANUELE NICASTRI;NICOLA PETROSILLO;CARLO FEDERICO PERNO;ANTONELLA CASTAGNA;DELIA GOLETTI;RAFFAELLA LIONETTI","28;25;22;14;12;11;11;11;11;10;10;10;9;9;9;9;9;8;8;8","GIUSEPPE IPPOLITO;ANDREA ANTINORI;MARIA ROSARIA CAPOBIANCHI;NICOLA PETROSILLO;GIANPIERO D’OFFIZI;ROBERTO RAVASIO;ANTONELLA D’ARMINIO MONFORTE;ANNA ROSA GARBUGLIA;DELIA GOLETTI;ADRIANA AMMASSARI;RAFFAELLA LIONETTI;EMANUELE NICASTRI;GIOVANNI REZZA;CONCETTA CASTILLETTI;CHIARA AGRATI;CARMELA PINNETTI;ANTONINO DI;ANDREA DE LUCA;CLAUDIO MARIA MASTROIANNI;STEFANO RUSCONI","2.23;1.96;1.92;1.68;1.04;1;0.84;0.81;0.8;0.8;0.74;0.73;0.69;0.68;0.67;0.63;0.63;0.61;0.55;0.5","ANDREA ANTINORI;MARIA ROSARIA CAPOBIANCHI;GIUSEPPE IPPOLITO;ADRIANA AMMASSARI;GIANPIERO D’OFFIZI;ANTONINO DI;CONCETTA CASTILLETTI;ENRICO GIRARDI;CARMELA PINNETTI;CHIARA AGRATI;ANDREA DE LUCA;EMANUELE NICASTRI;NICOLA PETROSILLO;CARLO FEDERICO PERNO;DELIA GOLETTI;RAFFAELLA LIONETTI;MAURO ZACCARELLI;ANNA ROSA GARBUGLIA;FRANCESCA COLAVITA;ALESSANDRA SACCHI","28;25;22;12;11;11;11;11;10;9;9;9;9;9;8;8;7;7;6;6","GIUSEPPE IPPOLITO;ANDREA ANTINORI;MARIA ROSARIA CAPOBIANCHI;NICOLA PETROSILLO;GIANPIERO D’OFFIZI;ANNA ROSA GARBUGLIA;DELIA GOLETTI;ADRIANA AMMASSARI;RAFFAELLA LIONETTI;EMANUELE NICASTRI;CONCETTA CASTILLETTI;CHIARA AGRATI;CARMELA PINNETTI;ANTONINO DI;ANDREA DE LUCA;PIERLUCA PISELLI;ENRICO GIRARDI;MARZIA MONTALBANO;MARC A. LAZZARO;MAURO ZACCARELLI","2.23;1.96;1.92;1.68;1.04;0.81;0.8;0.8;0.74;0.73;0.68;0.67;0.63;0.63;0.61;0.49;0.47;0.47;0.43;0.43","ANDREA ANTINORI;GIUSEPPE IPPOLITO;MARIA ROSARIA CAPOBIANCHI;ANTONELLA D’ARMINIO MONFORTE;FABRIZIO PALMIERI;ALIMUDDIN ZUMLA;GIAN MARÍA FIMIA;EMANUELE NICASTRI;ANTON POZNIAK;DELIA GOLETTI;ANDREW CHENG;DEVI SENGUPTA;EDWIN DEJESUS;ELLEN KOENIG;ERIN QUIRK;HANS-JÜRGEN STELLBRINK;JACQUES REYNES;JIHAD SLIM;JOSEPH M. CUSTODIO;KIMBERLY WORKOWSKI","838;748;508;462;460;366;330;320;318;309;301;301;301;301;301;301;301;301;301;301","ANDREA ANTINORI;GIUSEPPE IPPOLITO;MARIA ROSARIA CAPOBIANCHI;FABRIZIO PALMIERI;EMANUELE NICASTRI;DELIA GOLETTI;ENRICO GIRARDI;GINA GUALANO;ALESSANDRA ROMAGNOLI;MARTINA DI RIENZO;CONCETTA CASTILLETTI;GILDA CUZZI;ANTONINO DI;CHIARA AGRATI;NICOLA PETROSILLO;GIANPIERO D’OFFIZI;ADRIANA AMMASSARI;FRANCESCO VAIRO;VALENTINA VANINI;MAURO PIACENTINI","797;636;469;460;320;309;287;277;273;273;248;224;221;197;190;173;170;162;153;151","ANDREA ANTINORI;MARIA ROSARIA CAPOBIANCHI;GIUSEPPE IPPOLITO;ADRIANA AMMASSARI;CONCETTA CASTILLETTI;GIANPIERO D’OFFIZI;ENRICO GIRARDI;ANTONINO DI;CARMELA PINNETTI;CHIARA AGRATI;EMANUELE NICASTRI;DELIA GOLETTI;NICOLA PETROSILLO;RAFFAELLA LIONETTI;MAURO ZACCARELLI;FRANCESCO VAIRO;FRANCESCA COLAVITA;LAVINIA FABENI;MIRELLA BIAVA;ALESSANDRA SACCHI","27;24;20;12;11;11;10;10;9;9;9;8;8;8;7;6;6;6;6;6","MEDICINE;BIOLOGY;SOCIOLOGY;ENGINEERING;ECONOMICS;COMPUTER SCIENCE;GEOGRAPHY;CHEMISTRY;PHYSICS;MATHEMATICS;PHILOSOPHY;PSYCHOLOGY;BUSINESS;ENVIRONMENTAL SCIENCE;GEOLOGY;HISTORY;MATERIALS SCIENCE","107;57;12;9;7;5;5;4;4;3;3;2;1;1;1;1;1","INTERNAL MEDICINE;VIROLOGY;IMMUNOLOGY;PATHOLOGY;GENETICS;GASTROENTEROLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;SURGERY;PEDIATRICS;DEMOGRAPHY;INTENSIVE CARE MEDICINE;MICROBIOLOGY;FAMILY MEDICINE;PHARMACOLOGY;CELL BIOLOGY;MECHANICAL ENGINEERING;ONCOLOGY;CANCER RESEARCH;PALEONTOLOGY","78;62;53;26;22;19;18;15;14;11;10;10;10;9;7;6;6;6;4;4","VIRUS;HUMAN IMMUNODEFICIENCY VIRUS (HIV);GENE;COHORT;DISEASE;HEPATITIS C;TUBERCULOSIS;IMMUNE SYSTEM;POPULATION;OUTBREAK;COHORT STUDY;CONFIDENCE INTERVAL;REGIMEN;ANTIBODY;ANTIBIOTICS;IN VITRO;FLOW CYTOMETRY;LOGISTIC REGRESSION;TRANSPLANTATION;EPIDEMIOLOGY;PROPORTIONAL HAZARDS MODEL","44;37;23;15;15;13;13;12;11;10;9;9;9;8;7;7;6;6;6;5;5","VIRAL LOAD;HEPATITIS C VIRUS;EBOLA VIRUS;MYCOBACTERIUM TUBERCULOSIS;GENOTYPE;HAZARD RATIO;VIREMIA;CD8;HEPATITIS B VIRUS;SEROLOGY;ZIKA VIRUS;INNATE IMMUNE SYSTEM;RNA;CYTOTOXIC T CELL;DENGUE VIRUS;DNA SEQUENCING;GENOME;ISCHEMIC STROKE;LIVER TRANSPLANTATION;PERIPHERAL BLOOD MONONUCLEAR CELL;SEROCONVERSION;SYPHILIS;T CELL;TOLERABILITY;VIRAL REPLICATION","24;19;10;10;7;6;6;5;5;5;5;4;4;3;3;3;3;3;3;3;3;3;3;3;3","ANTIRETROVIRAL THERAPY;RIBAVIRIN;EBOLAVIRUS;HBSAG;HEPACIVIRUS;LATENT TUBERCULOSIS;MEN WHO HAVE SEX WITH MEN;MODIFIED RANKIN SCALE;ACTIVE TUBERCULOSIS;BEDAQUILINE;CORONAVIRUS DISEASE 2019 (COVID-19);EBOLA VACCINE;GENOTYPING;LAMIVUDINE;SEROPREVALENCE;SEXUAL TRANSMISSION;VIRAL QUASISPECIES;ACINETOBACTER BAUMANNII;AEDES ALBOPICTUS;ANGIOSTRONGYLIASIS;ANTIBIOTIC STEWARDSHIP;ANTIVIRAL THERAPY;ARTEMISININ;ARTESUNATE;ATG8;AUTOPHAGOSOME;BECN1;C DIFFICILE;CD40;CD86;CEREBRAL MALARIA;CHEMOKINE RECEPTOR;COGNITIVE DECLINE;COMPLEMENTATION;CONDITIONING REGIMEN;CULTURE CONVERSION;DEEP SEQUENCING;ENDOVASCULAR COILING;ENTEROBACTER;ENTEROBACTER AEROGENES;EPITHELIAL–MESENCHYMAL TRANSITION;FRAMESHIFT MUTATION;GRANZYME B;HAPLOTYPE;HEMORRHAGIC CYSTITIS;HPV INFECTION;ILLUMINA DYE SEQUENCING;KAPOSI'S SARCOMA;LENTIVIRUS;LYMPHOPOIESIS;MEASLES VIRUS;MICROVESICLES;MILAN CRITERIA;MITOCHONDRIAL FUSION;MITOPHAGY;MULTI-DRUG-RESISTANT TUBERCULOSIS;MYCOLIC ACID;MYELOID-DERIVED SUPPRESSOR CELL;PARKIN;PERFORIN;PHYLOGENETIC RELATIONSHIP;PLAQUE REDUCTION NEUTRALIZATION TEST;PROGENITOR;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;REVERSE TRANSCRIPTASE;SANGER SEQUENCING;SELECTED REACTION MONITORING;SEXUALLY TRANSMITTED DISEASE;SHOTGUN SEQUENCING;SINGLE-NUCLEOTIDE POLYMORPHISM;SPUTUM CULTURE;TOLL-LIKE RECEPTOR;TRANSCRIPTOME;VANCOMYCIN;VECTOR (MOLECULAR BIOLOGY);VIRAL ENCEPHALITIS;VIRAL PHYLODYNAMICS;WHOLE GENOME SEQUENCING","19;13;5;3;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HIV INFECTIONS;HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;ITALY;HEPATITIS C, CHRONIC;ANTI-HIV AGENTS;ANTIVIRAL AGENTS;HIV-1;VIRAL LOAD;HEMORRHAGIC FEVER, EBOLA;HEPACIVIRUS;;EBOLAVIRUS;YOUNG ADULT;ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE;LIVER CIRRHOSIS;TREATMENT OUTCOME","107;100;73;72;57;51;45;43;39;31;28;27;26;26;22;21;21;19;19;19","HEPATITIS C INFECTION AND TREATMENT;EBOLA VIRUS RESEARCH AND OUTBREAKS;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;TUBERCULOSIS;GLOBAL IMPACT OF ARBOVIRAL DISEASES;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;HEPATITIS B INFECTION AND TREATMENT;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;CLOSTRIDIUM DIFFICILE INFECTION AND TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;HEPATOCELLULAR CARCINOMA;HERPESVIRUSES: EPIDEMIOLOGY, PATHOGENESIS, AND MANAGEMENT;RNA SEQUENCING DATA ANALYSIS;ROLE OF AUTOPHAGY IN DISEASE AND HEALTH;ATP SYNTHASE FUNCTION AND REGULATION;BIOLOGICAL, EPIDEMIOLOGICAL, AND CLINICAL ASPECTS OF ECHINOCOCCOSIS;BLOOD RHEOLOGY AND COAGULATION MECHANISMS","19;10;10;8;8;8;6;3;3;3;3;2;2;2;2;2;2;1;1;1","HIV;ANTIRETROVIRAL THERAPY;TREATMENT;HEPATITIS C;REGIMEN;SOFOSBUVIR;HIV EPIDEMIOLOGY;HIV INFECTION;RITONAVIR;PATHOGENESIS;VIREMIA;DACLATASVIR;DARUNAVIR;EBOLAVIRUS;HIV TRANSMISSION;ZIKA VIRUS;DASABUVIR;DIAGNOSIS;DISCONTINUATION;MYCOBACTERIUM TUBERCULOSIS","27;18;15;13;9;8;7;7;7;6;6;5;5;5;5;5;4;4;4;4","VIRUS INFECTION;EBOLA VIRUS;HIV INFECTION;CO-INFECTED PATIENTS;HIV-INFECTED PATIENTS;ANTIVIRAL AGENTS;HEPATOCELLULAR CARCINOMA;HUMAN IMMUNODEFICIENCY;RISK FACTORS;ADVANCED FIBROSIS;ANTIRETROVIRAL THERAPY;ANTIVIRAL TREATMENT;COHORT STUDY;CROSS-SECTIONAL STUDY;DIRECT-ACTING ANTIVIRAL;DISEASE CARDIOMYOPATHY;END-STAGE KIDNEY;FABRY DISEASE;FOUNDATION STUDY;HCV ANTIVIRAL;HIV PHYSICIANS;HIVHCV CO-INFECTED;INFECTION INDUCES;ITALIAN COMPASSIONATE;KIDNEY DISEASE;MULTICENTRE STUDY;NATIONAL STUDY;OBSERVATIONAL STUDY;PERSONS LIVING;PREGNANT WOMEN","6;5;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ACTIVE TB;EBOLA VIRUS;HIV INFECTION;ROME ITALY;INFECTIOUS DISEASES;TB PATIENTS;VIROLOGICAL CONTROL;ANTIRETROVIRAL TREATMENT;HCV GENOTYPE;AOR CI;HIV- DNA;PREGNANT WOMEN;TYPE DIABETES;VIRAL LOAD;COHORT STUDY;CONFIDENCE INTERVAL;PATIENTS TREATED;TRANSMISSION CLUSTERS;TUBERCULOSIS TB;WEST AFRICA;ANTIRETROVIRAL THERAPY;CD T-CELLS;COGNITIVE IMPAIRMENT;COX REGRESSION;HEPATOCELLULAR CARCINOMA;HIV DIAGNOSIS;HIV-POSITIVE PATIENTS;LOGISTIC REGRESSION;OBSERVATIONAL STUDY;PATIENTS ENROLLED","15;14;12;11;10;10;10;9;9;8;8;8;8;8;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6",72,0.58,5.64,7,1,1,1.75,2.5,1.5,0,1,9,0,0,6,1,1,2,2,4,3,0,0,80.5,80.5,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,5,0.95,8,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ALLOUCH AWATEF;GOUGEON MARIE-LISE;KROEMER GUIDO;PERFETTINI JEAN-LUC;PIACENTINI MAURO","1;1;1;1;1","ASSISTANCE PUBLIQUE HOPITAUX DE PARIS APHP;INSTITUT GUSTAVE ROUSSY (IGR);INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSERM;INSTITUT PASTEUR DE LILLE;ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE ""LAZZARO SPALLANZANI"" IRCCS;UNIVERSITE PARIS DESCARTES PARIS 5;UNIVERSITE PARIS SUD PARIS 11;UNIVERSITE PIERRE ET MARIE CURIE PARIS 6","1;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY","2;1;1","HIV/AIDS;INFECTIOUS DISEASES","1;1","5.1 PHARMACEUTICALS","1","A61K31/7088;C12N15/113","1;1","A61K31/165;A61K31/17;A61K31/395;A61K31/5517;A61K31/683;A61K31/7088;A61K31/713;A61K45/06;C12N15/113;C12N15/1132","1;1;1;1;1;1;1;1;1;1",1,5,500,0.65,0,0,48,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,"Italy","4","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","1;1","CLINICAL RESEARCH;INFECTIOUS DISEASES;LUNG;RARE DISEASES","1;1;1;1","INFECTION","1","6.1 PHARMACEUTICALS","1","LUNG CANCER","1",NA,NA,3,4120215.33,471013.2,5.33333333333333,10.6666666666667,6,1,4,1348016.91262828,0.0919869764528638,"ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI;ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;ASTRAZENECA (SWEDEN);ATOMIC ENERGY AND ALTERNATIVE ENERGIES COMMISSION;BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE;BIOMÉRIEUX (FRANCE);CENTRE HOSPITALIER RÉGIONAL ET UNIVERSITAIRE DE LILLE;DA VOLTERRA (FRANCE);DÉLÉGATION PARIS 11;EXCELLGENE (SWITZERLAND);FRAUNHOFER SOCIETY;FRENCH NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;GLAXOSMITHKLINE (BELGIUM);IFAKARA HEALTH INSTITUTE;ISTITUTO SUPERIORE DI SANITÀ;LEIDEN UNIVERSITY MEDICAL CENTER;MULTID ANALYSES (SWEDEN);NATIONAL LABORATORY OF HEALTH, ENVIRONMENT AND FOOD;OLIGOVAX (FRANCE);PFIZER (UNITED KINGDOM)","3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","3","COALITION S;EC & ERC - EUROPEAN UNION","3;3","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME);H2020-EU.2.1.1.1. - A NEW GENERATION OF COMPONENTS AND SYSTEMS: ENGINEERING OF ADVANCED EMBEDDED AND ENERGY AND RESOURCE EFFICIENT COMPONENTS AND SYSTEMS (PROGRAMME);H2020-JTI-IMI2-2015-08-SINGLE-STAGE (CALL FOR PROPOSAL);H2020-JTI-IMI2-2016-09-TWO-STAGE (CALL FOR PROPOSAL);IMI2-RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","2;2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY","3;3;2","BIODEFENSE;EMERGING INFECTIOUS DISEASES;INFECTIOUS DISEASES;PREVENTION;VACCINE RELATED;RARE DISEASES;ANTIMICROBIAL RESISTANCE;CLINICAL RESEARCH;IMMUNIZATION;ORPHAN DRUG;TUBERCULOSIS","3;3;3;3;3;2;1;1;1;1;1","INFECTION","3","2.4 SURVEILLANCE AND DISTRIBUTION;3.4 VACCINES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","1;1;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE;A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE;B12 ENGINEERING","1;1;1","3 GOOD HEALTH AND WELL BEING","2",39,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE","36;3","32 BIOMEDICAL AND CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;49 MATHEMATICAL SCIENCES;3204 IMMUNOLOGY;3202 CLINICAL SCIENCES;4905 STATISTICS;42 HEALTH SCIENCES;44 HUMAN SOCIETY;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;4406 HUMAN GEOGRAPHY;46 INFORMATION AND COMPUTING SCIENCES;3103 ECOLOGY;3105 GENETICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;37 EARTH SCIENCES;3704 GEOINFORMATICS;38 ECONOMICS;3801 APPLIED ECONOMICS;4203 HEALTH SERVICES AND SYSTEMS","47;11;10;9;7;5;4;4;3;2;2;2;1;1;1;1;1;1;1;1","HIV/AIDS;INFECTIOUS DISEASES;CLINICAL RESEARCH;MENTAL HEALTH;ANTIMICROBIAL RESISTANCE;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;GENETICS;HEMATOLOGY;HEPATITIS;HEPATITIS - C;LIVER DISEASE;LYMPHOMA;PREVENTION;RARE DISEASES","8;5;4;2;1;1;1;1;1;1;1;1;1;1;1;1;1","INFECTION","14","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS","5;1;1","CLINICAL;HEALTH SERVICES & SYSTEMS;BIOMEDICAL;POPULATION & SOCIETY","4;2;1;1","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH;BASIC SCIENCE;HEALTH SERVICES RESEARCH","16;3;1;1","NON-HODGKIN'S LYMPHOMA;HODGKIN'S DISEASE;CERVICAL CANCER;KAPOSI'S SARCOMA;LIVER CANCER;LUNG CANCER;NOT SITE-SPECIFIC CANCER","7;6;2;2;2;1;1","3 GOOD HEALTH AND WELL BEING","1"
"IRCCS_SPALLANZANIROMA",2018,128,17.0859375,3.9375,0.359375,0.3828125,0.546875,2.97633136094675,1.17948717948718,1.96,1.4,0.71875,2,69,23,12,8,0.54,0.18,0.09,0.06,25.42,0.833278586495576,5.22119815668203,0.4453125,0.90625,0.486,0.438,0.44,0.45,"ANDREA ANTINORI;GIUSEPPE IPPOLITO;ENRICO GIRARDI;MARIA ROSARIA CAPOBIANCHI;ANTONELLA D’ARMINIO MONFORTE;DELIA GOLETTI;CARLO FEDERICO PERNO;MASSIMO ANDREONI;FRANCESCA CECCHERINI‐SILBERSTEIN;ANTONIO DI BIAGIO;GIAN MARÍA FIMIA;GIANPIERO D’OFFIZI;CLAUDIO MARIA MASTROIANNI;EMANUELE NICASTRI;ADRIANA AMMASSARI;CRISTINA MUSSINI;FABRIZIO PALMIERI;MARIA MERCEDES SANTORO;ANTONELLA CASTAGNA;MAURO PIACENTINI","29;20;15;15;15;13;13;11;11;10;10;9;9;9;9;9;9;8;8;8","ANDREA ANTINORI;GIUSEPPE IPPOLITO;DELIA GOLETTI;MARIA ROSARIA CAPOBIANCHI;C. PELLICCIARI;GABRIELLA DE CARLI;ENRICO GIRARDI;EMANUELE NICASTRI;ANTONELLA D’ARMINIO MONFORTE;GIAN MARÍA FIMIA;ADRIANA AMMASSARI;FABRIZIO PALMIERI;TERESA CHIACCHIO;VALENTINA VANINI;GIANPIERO D’OFFIZI;MAURO PIACENTINI;CHIARA AGRATI;MARCO IANNETTA;ELISA PETRUCCIOLI;NICOLA GALEA","1.81;1.71;1.24;1.11;1;1;0.96;0.88;0.85;0.76;0.74;0.7;0.68;0.68;0.66;0.66;0.62;0.6;0.59;0.59","ANDREA ANTINORI;GIUSEPPE IPPOLITO;ENRICO GIRARDI;MARIA ROSARIA CAPOBIANCHI;DELIA GOLETTI;CARLO FEDERICO PERNO;GIAN MARÍA FIMIA;GIANPIERO D’OFFIZI;EMANUELE NICASTRI;ADRIANA AMMASSARI;FABRIZIO PALMIERI;MAURO PIACENTINI;ANDREA GORI;MARCO IANNETTA;TERESA CHIACCHIO;CONCETTA CASTILLETTI;PIERLUCA PISELLI;VALENTINA VANINI;ANNA ROSA GARBUGLIA;CARMELA PINNETTI","29;20;15;15;13;13;10;9;9;9;9;8;8;7;7;7;7;7;7;6","ANDREA ANTINORI;GIUSEPPE IPPOLITO;DELIA GOLETTI;MARIA ROSARIA CAPOBIANCHI;C. PELLICCIARI;GABRIELLA DE CARLI;ENRICO GIRARDI;EMANUELE NICASTRI;GIAN MARÍA FIMIA;ADRIANA AMMASSARI;FABRIZIO PALMIERI;TERESA CHIACCHIO;VALENTINA VANINI;GIANPIERO D’OFFIZI;MAURO PIACENTINI;CHIARA AGRATI;MARCO IANNETTA;ELISA PETRUCCIOLI;CRISTINA CHIMENTI;ANDREA FRUSTACI","1.81;1.71;1.24;1.11;1;1;0.96;0.88;0.76;0.74;0.7;0.68;0.68;0.66;0.66;0.62;0.6;0.59;0.59;0.59","CRISTINA MUSSINI;PIERLUIGI VIALE;ANDREA ANTINORI;ANNA MARIA CATTELAN;FRANCESCO MENICHETTI;MARIO TUMBARELLO;MATTEO BASSETTI;ALESSANDRO CAPONE;ANGELA RAFFAELLA LOSITO;CARLO TASCINI;ELDA RIGHI;MARGHERITA DIGAETANO;ANDREA GORI;GIULIANO RIZZARDINI;GIAN MARÍA FIMIA;GIUSTINO PARRUTI;ANTONIO DI BIAGIO;FRANCESCA RAFFAELLI;MASSIMO PUOTI;ROBERTO CAUDA","1026;715;681;611;581;581;581;580;580;580;580;580;507;484;479;461;455;441;402;394","ANDREA ANTINORI;ALESSANDRO CAPONE;MAURO PIACENTINI;GIUSEPPE IPPOLITO;GIAN MARÍA FIMIA;ANDREA GORI;MARIA ROSARIA CAPOBIANCHI;ENRICO GIRARDI;DELIA GOLETTI;FABIOLA CICCOSANTI;MARCO TRIPODI;LAURA FALASCA;GIULIA REFOLO;FABRIZIO PALMIERI;EMANUELE NICASTRI;VERONICA BORDONI;CONCETTA CASTILLETTI;TERESA CHIACCHIO;CHIARA AGRATI;MANUELA ANTONIOLI","641;580;369;335;322;313;294;270;252;233;199;190;175;163;153;149;147;140;134;127","ANDREA ANTINORI;GIUSEPPE IPPOLITO;MARIA ROSARIA CAPOBIANCHI;ENRICO GIRARDI;DELIA GOLETTI;EMANUELE NICASTRI;GIANPIERO D’OFFIZI;FABRIZIO PALMIERI;GIAN MARÍA FIMIA;ADRIANA AMMASSARI;MAURO PIACENTINI;ANNA ROSA GARBUGLIA;CARLO FEDERICO PERNO;CONCETTA CASTILLETTI;MARCO IANNETTA;VALENTINA VANINI;TERESA CHIACCHIO;CHIARA AGRATI;ELISA PETRUCCIOLI;VERONICA BORDONI","25;18;16;14;13;9;9;8;8;8;7;7;7;7;7;7;7;6;6;6","MEDICINE;BIOLOGY;ENGINEERING;CHEMISTRY;SOCIOLOGY;ECONOMICS;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;BUSINESS;GEOGRAPHY;POLITICAL SCIENCE;PHILOSOPHY;PSYCHOLOGY","115;61;14;11;10;8;8;7;6;4;4;4;3;3","INTERNAL MEDICINE;IMMUNOLOGY;PATHOLOGY;VIROLOGY;GENETICS;GASTROENTEROLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;MICROBIOLOGY;CELL BIOLOGY;PEDIATRICS;ELECTRICAL ENGINEERING;FAMILY MEDICINE;INTENSIVE CARE MEDICINE;CANCER RESEARCH;NURSING;OPTICS;PHARMACOLOGY;DEMOGRAPHY;ECONOMIC GROWTH","77;46;45;40;27;26;24;18;16;14;12;11;11;11;8;7;7;7;6;6","HUMAN IMMUNODEFICIENCY VIRUS (HIV);GENE;VIRUS;TUBERCULOSIS;COHORT;IMMUNE SYSTEM;DISEASE;HEPATITIS C;POPULATION;TRANSMISSION (TELECOMMUNICATIONS);EPIDEMIOLOGY;ANTIBIOTICS;CIRRHOSIS;CONFIDENCE INTERVAL;REGIMEN;APOPTOSIS;CANCER;INCIDENCE (GEOMETRY);COHORT STUDY;IN VITRO;PUBLIC HEALTH","38;29;25;20;16;16;15;12;12;11;10;9;9;9;9;8;7;7;6;6;6","VIRAL LOAD;MYCOBACTERIUM TUBERCULOSIS;HEPATITIS C VIRUS;GENOTYPE;HEPATITIS B VIRUS;INFECTIOUS DISEASE (MEDICAL SPECIALTY);AUTOPHAGY;CD8;HAZARD RATIO;CHRONIC HEPATITIS;CLOSTRIDIUM DIFFICILE;PERIPHERAL BLOOD MONONUCLEAR CELL;RNA;T CELL;CANCER CELL;CLINICAL ENDPOINT;ESCHERICHIA COLI;MUTATION;PROGRAMMED CELL DEATH;SEROLOGY;STAPHYLOCOCCUS AUREUS;SYPHILIS;TOLERABILITY;UNIVARIATE ANALYSIS","24;12;11;9;7;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","ANTIRETROVIRAL THERAPY;LATENT TUBERCULOSIS;CORONAVIRUS DISEASE 2019 (COVID-19);LAMIVUDINE;RIBAVIRIN;ACTIVE TUBERCULOSIS;HEPACIVIRUS;IMMUNOGENIC CELL DEATH;MEN WHO HAVE SEX WITH MEN;ANTIVIRAL TREATMENT;ARTESUNATE;CLADE;EPITHELIAL–MESENCHYMAL TRANSITION;GENOTYPING;HBSAG;HEPATITIS E;HEPATITIS E VIRUS;IL-2 RECEPTOR;KLEBSIELLA PNEUMONIAE;LYMPHOCYTE SUBSETS;MOLECULAR EPIDEMIOLOGY;PLASMODIUM VIVAX;SANGER SEQUENCING;SEXUAL TRANSMISSION;TRANSIENT ELASTOGRAPHY;TUBERCULOSIS DIAGNOSIS;VACCINIA;VANCOMYCIN","23;7;5;5;5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;HIV INFECTIONS;MALE;ADULT;FEMALE;MIDDLE AGED;ITALY;HIV-1;ANTI-HIV AGENTS;;TUBERCULOSIS;AGED;MYCOBACTERIUM TUBERCULOSIS;ANTI-RETROVIRAL AGENTS;ANIMALS;RNA, VIRAL;YOUNG ADULT;HEPATITIS C, CHRONIC;LEUKOCYTES, MONONUCLEAR;NEOPLASMS","97;91;66;60;60;53;41;36;30;29;26;24;23;18;17;17;17;16;16;16","TUBERCULOSIS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;HEPATITIS C INFECTION AND TREATMENT;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;CLOSTRIDIUM DIFFICILE INFECTION AND TREATMENT;GLOBAL IMPACT OF ARBOVIRAL DISEASES;EBOLA VIRUS RESEARCH AND OUTBREAKS;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;EPIDEMIOLOGY AND PATHOBIOLOGY OF MONKEYPOX VIRUS INFECTION;EPIDEMIOLOGY AND PATHOGENESIS OF PNEUMOCYSTIS PNEUMONIA;HEPATITIS E INFECTION AND TREATMENT;MALARIA;NATURAL KILLER CELLS IN IMMUNITY;ROLE OF AUTOPHAGY IN DISEASE AND HEALTH;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS","16;12;9;7;6;6;4;4;3;3;3;3;2;2;2;2;2;2;2;2","HIV;ANTIRETROVIRAL THERAPY;TREATMENT;HEPATITIS C;REGIMEN;EMTRICITABINE;HIV TRANSMISSION;RITONAVIR;DIAGNOSIS;DISCONTINUATION;MYCOBACTERIUM TUBERCULOSIS;ACTIVE TUBERCULOSIS;DARUNAVIR;INTERQUARTILE RANGE;SOFOSBUVIR;ABACAVIR;ADHERENCE TO MEDICATION;ATAZANAVIR;CLINICAL ENDPOINT;DELPHI METHOD","17;16;16;12;9;7;6;6;5;5;5;4;4;4;4;3;3;3;3;3","ANTIRETROVIRAL THERAPY;ANTIVIRAL AGENTS;CLOSTRIDIUM DIFFICILE;COHORT STUDY;HEPATOCELLULAR CARCINOMA;PATIENTS TREATED;REVERSE TRANSCRIPTASE;AGENTS PREDICTS;CARCINOMA DEVELOPMENT;DIFFICILE INFECTION;DIRECT ANTIVIRAL;DRUG RESISTANCE;EUROPEAN UNION;HIV-INFECTED PATIENTS;LATENT TUBERCULOSIS;PREDICTS HEPATOCELLULAR;SERUM ALPHAFETOPROTEIN;TRANSCRIPTASE INHIBITORS;TRANSPLANT RECIPIENTS;VIRUS INFECTION;ACUTE HEPATITIS;ANTIRETROVIRAL AGENTS;ANTIVIRAL SIGNALING;ASYLUM SEEKERS;CLINICAL OUTCOMES;DENDRITIC CELLS;DIAGNOSTIC-CLINICAL MANAGEMENT;DIRECTACTING ANTIVIRALS;DISIPROXIL FUMARATEEMTRICITABINE;EBOLA VIRUS","5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","ITALY SEARCH;CYSTIC FIBROSIS;CONSULTING FEE;ROME ITALY;RESEARCH SUPPORT;SAN RAFFAELE;ACTIVE TB;INVESTIGATOR RESEARCH;ITALY DEPARTMENT;EUROPEAN INSTITUTE;FIBROSIS SAN;INSTITUTE MILAN;MEDICINE UNIVERSITY;MILAN ITALY;RAFFAELE SCIENTIFIC;SCIENTIFIC INSTITUTE;SPEAKER HONORARIUM;CD COUNT;PARIS FRANCE;TB PATIENTS;TREATMENT FAILURE;EASTERN PIEDMONT;HEALTH SCIENCES;NOVARA ITALY;PATIENTS TREATED;PIEDMONT NOVARA;SCIENCES UNIVERSITY;SPEAKERS BUREAU;AHR CI;CD T-CELLS","36;24;23;21;19;19;16;16;16;13;13;13;13;13;13;13;13;12;12;12;12;11;11;11;11;11;11;11;10;10",77,0.6,5.05,8,1,1,1,3,2,0,1.5,9,0,1,6.5,1,1.75,1.5,2,5,2,0,0,68,68,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,5,0.99,9,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"GOUGEON MARIE LISE;KROEMER GUIDO;PAOLETTI AUDREY;PERFETTINI JEAN LUC;PIACENTINI MAURO","1;1;1;1;1","ASSISTANCE PUBLIQUE HOPITAUX DE PARIS APHP;INSTITUT GUSTAVE ROUSSY (IGR);INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSERM;INSTITUT PASTEUR DE LILLE;ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE ""LAZZARO SPALLANZANI"" IRCCS;UNIVERSITE PARIS DESCARTES PARIS 5;UNIVERSITE PARIS DIDEROT PARIS 7;UNIVERSITE PARIS SUD PARIS 11;UNIVERSITE PIERRE ET MARIE CURIE PARIS 6","1;1;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;48 LAW AND LEGAL STUDIES;4806 PRIVATE LAW AND CIVIL OBLIGATIONS","1;1;1",NA,NA,NA,NA,"A61K31/00;A61K38/00;A61K48/00;A61P31/00;A61P35/00;A61P37/00","1;1;1;1;1;1","A61K31/7034;A61K31/7072;A61K31/7076;A61K31/7084;A61K38/177;A61K48/00;A61P29/00;A61P31/00;A61P35/00;A61P37/00","1;1;1;1;1;1;1;1;1;1",3,1.5,618,1.88,0,0,31.33,0,0,0,0,2,0,1,0,0,2,0,0,0,0,0,0,0,3,0,0,2,1,0,0,0,0,0,0,0,0,"Italy;United States","5;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","3;1;1;1;1;1","CHRONIC LIVER DISEASE AND CIRRHOSIS;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;GENETICS;HEPATITIS;HEPATITIS - C;INFECTIOUS DISEASES;LIVER DISEASE","1;1;1;1;1;1;1;1;1;1","INFECTION","2","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS","2;1","ANAL CANCER;KAPOSI'S SARCOMA;LIVER CANCER;NON-HODGKIN'S LYMPHOMA","1;1;1;1","2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;3.3 CHEMOPREVENTION;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1;1;1",1,9997501,499875.05,7,20,12,1,103,752613.822945743,0.170073942435718,"BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE;CENTRE DE RECHERCHE MÉDICALES DE LAMBARÉNÉ;CHARITÉ - UNIVERSITY MEDICINE BERLIN;CHATHAM HOUSE;FONDATION CONGOLAISE POUR LA RECHERCHE MÉDICALE;IFAKARA HEALTH INSTITUTE;INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT;IRRUA SPECIALIST TEACHING HOSPITAL;ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI;KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY;NATIONAL INSTITUTE FOR MEDICAL RESEARCH;NIGERIA CENTRE FOR DISEASE CONTROL;NJALA UNIVERSITY;ROYAL VETERINARY COLLEGE;SOKOINE UNIVERSITY OF AGRICULTURE;UGANDA NATIONAL HEALTH RESEARCH ORGANISATION;UNIVERSITY COLLEGE LONDON;UNIVERSITY OF GHANA;UNIVERSITY OF KHARTOUM;UNIVERSITY OF TÜBINGEN","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN & DEVELOPING COUNTRIES CLINICAL TRIALS PARTNERSHIP","1",NA,NA,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY","1;1;1","BIODEFENSE;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;EMERGING INFECTIOUS DISEASES;INFECTIOUS DISEASES;PREVENTION;VACCINE RELATED","1;1;1;1;1;1;1","INFECTION","1",NA,NA,NA,NA,NA,NA,"C14 GEOGRAPHY AND ENVIRONMENTAL STUDIES","1",NA,NA,18,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;KARGER PUBLISHERS","16;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;3204 IMMUNOLOGY;34 CHEMICAL SCIENCES;46 INFORMATION AND COMPUTING SCIENCES;4610 LIBRARY AND INFORMATION STUDIES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS;3202 CLINICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;42 HEALTH SCIENCES;44 HUMAN SOCIETY;4403 DEMOGRAPHY","11;4;3;2;2;2;2;1;1;1;1;1;1;1","HIV/AIDS;INFECTIOUS DISEASES;RARE DISEASES;TUBERCULOSIS;EMERGING INFECTIOUS DISEASES;GENETICS;PREVENTION;VACCINE RELATED;ANTIMICROBIAL RESISTANCE;BIODEFENSE;BIOTECHNOLOGY;CHRONIC LIVER DISEASE AND CIRRHOSIS;CLINICAL RESEARCH;DIGESTIVE DISEASES;HEPATITIS;LIVER DISEASE;ORPHAN DRUG;SUBSTANCE MISUSE","4;4;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1","INFECTION","4","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","2;2;1;1","BIOMEDICAL;CLINICAL","2;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","5;2;1","LIVER CANCER;NOT SITE-SPECIFIC CANCER","1;1",NA,NA
"IRCCS_SPALLANZANIROMA",2019,117,19.5726495726496,4.28205128205128,0.358974358974359,0.393162393162393,0.666666666666667,2.77777777777778,1.13513513513514,1.91666666666667,1.41818181818182,0.726495726495726,1,65,21,6,10,0.56,0.18,0.05,0.09,31.09,1.27834906488834,5.37521663778163,0.461538461538462,0.957264957264957,0.487,0.488,0.386,0.457,"ANDREA ANTINORI;GIUSEPPE IPPOLITO;ENRICO GIRARDI;MARIA ROSARIA CAPOBIANCHI;ANTONELLA D’ARMINIO MONFORTE;CARLO FEDERICO PERNO;CARMELA PINNETTI;ANTONINO DI;MASSIMO ANDREONI;MARIA MERCEDES SANTORO;ANTONELLA CASTAGNA;FRANCESCA CECCHERINI‐SILBERSTEIN;CHIARA AGRATI;ALESSANDRO COZZI‐LEPRI;MASSIMO PUOTI;STEFANO RUSCONI;DELIA GOLETTI;CONCETTA CASTILLETTI;ANDREA DE LUCA;NICOLA PETROSILLO","37;22;17;17;16;14;12;12;12;11;11;11;10;10;9;9;9;8;8;8","GIUSEPPE IPPOLITO;ANDREA ANTINORI;MARIA ROSARIA CAPOBIANCHI;ENRICO GIRARDI;CARLOALBERTO REDI;DELIA GOLETTI;ANTONINO DI;CHIARA AGRATI;CRISTINA CHIMENTI;ANDREA FRUSTACI;FRANCESCO VAIRO;GIAN MARÍA FIMIA;CONCETTA CASTILLETTI;ELEONORA CIMINI;CARMELA PINNETTI;NICOLA PETROSILLO;ALIMUDDIN ZUMLA;MARIA MERCEDES SANTORO;STEFANO RUSCONI;ANNALISA MONDI","1.95;1.92;1.2;1.04;1;0.94;0.84;0.74;0.73;0.73;0.69;0.69;0.66;0.65;0.63;0.63;0.61;0.56;0.55;0.55","ANDREA ANTINORI;GIUSEPPE IPPOLITO;ENRICO GIRARDI;MARIA ROSARIA CAPOBIANCHI;CARLO FEDERICO PERNO;CARMELA PINNETTI;ANTONINO DI;CHIARA AGRATI;DELIA GOLETTI;CONCETTA CASTILLETTI;NICOLA PETROSILLO;ELEONORA CIMINI;GIULIA MARCHETTI;FRANCESCA COLAVITA;GINA GUALANO;FABRIZIO PALMIERI;VERONICA BORDONI;FRANCESCO VAIRO;ANNALISA MONDI;FABRIZIO CARLETTI","37;22;17;17;14;12;12;10;9;8;8;8;8;7;7;7;7;7;7;7","GIUSEPPE IPPOLITO;ANDREA ANTINORI;MARIA ROSARIA CAPOBIANCHI;ENRICO GIRARDI;CARLOALBERTO REDI;DELIA GOLETTI;ANTONINO DI;CHIARA AGRATI;CRISTINA CHIMENTI;ANDREA FRUSTACI;FRANCESCO VAIRO;GIAN MARÍA FIMIA;CONCETTA CASTILLETTI;ELEONORA CIMINI;CARMELA PINNETTI;NICOLA PETROSILLO;ANNALISA MONDI;CARLO FEDERICO PERNO;FRANCESCA COLAVITA;ANNA ROSA GARBUGLIA","1.95;1.92;1.2;1.04;1;0.94;0.84;0.74;0.73;0.73;0.69;0.69;0.66;0.65;0.63;0.63;0.55;0.54;0.53;0.5","AMANDA CLARKE;AGATHE LEÓN;ALISON RODGER;FÉLIX GUTIÉRREZ;HANS‐JÜRGEN STELLBRINK;HEIKO JESSEN;JOHANNES R. BOGNER;JORGE DEL ROMERO;NNEKA NWOKOLO;NORBERT H. BROCKMEYER;OLAF DEGEN;PEP COLL;VICENTE ESTRADA;ANDREA ANTINORI;JÜRGEN K. ROCKSTROH;ADRIANE SKALETZ‐ROROWSKI;ALYSON KNOTT;ANDERS BLAXHULT;ANDREW PHILLIPS;ANJA HÜFNER","1684;1558;1558;1558;1558;1558;1558;1558;1558;1558;1558;1558;1558;1511;936;779;779;779;779;779","ANDREA ANTINORI;NICOLA PETROSILLO;MARIA ROSARIA CAPOBIANCHI;GIUSEPPE IPPOLITO;ANNA ROSA GARBUGLIA;FABRIZIO PALMIERI;MANUELA ANTONIOLI;GINA GUALANO;GUIDO GRANATA;ANNALISA MONDI;ANTONINO DI;MAURO PIACENTINI;GIAN MARÍA FIMIA;CHIARA AGRATI;MARIA ADRIANA CATALDO;CARMELA PINNETTI;VERONICA BORDONI;FABIOLA CICCOSANTI;CONCETTA CASTILLETTI;FRANCESCO VAIRO","1511;464;410;321;299;251;244;235;157;143;140;134;131;108;108;101;101;98;96;93","ANDREA ANTINORI;GIUSEPPE IPPOLITO;MARIA ROSARIA CAPOBIANCHI;ENRICO GIRARDI;CARMELA PINNETTI;CHIARA AGRATI;ELEONORA CIMINI;NICOLA PETROSILLO;ANTONINO DI;VERONICA BORDONI;FABRIZIO PALMIERI;ANNALISA MONDI;GINA GUALANO;ANNA ROSA GARBUGLIA;ALESSANDRA SACCHI;CONCETTA CASTILLETTI;FRANCESCO VAIRO;DELIA GOLETTI;CARLO FEDERICO PERNO;FRANCESCA COLAVITA","37;20;13;11;10;10;8;8;8;8;7;7;7;6;6;6;6;6;5;5","MEDICINE;BIOLOGY;PHYSICS;SOCIOLOGY;CHEMISTRY;COMPUTER SCIENCE;POLITICAL SCIENCE;ECONOMICS;ENGINEERING;GEOGRAPHY;MATHEMATICS;BUSINESS;HISTORY","100;62;10;7;6;6;5;4;4;4;3;2;1","INTERNAL MEDICINE;VIROLOGY;IMMUNOLOGY;GENETICS;PATHOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;MICROBIOLOGY;INTENSIVE CARE MEDICINE;CELL BIOLOGY;PHARMACOLOGY;GASTROENTEROLOGY;SURGERY;FAMILY MEDICINE;OPTICS;ENDOCRINOLOGY;PEDIATRICS;LAW;NURSING;ONCOLOGY","67;44;41;32;31;21;19;17;12;10;10;9;9;8;8;6;6;5;5;5","HUMAN IMMUNODEFICIENCY VIRUS (HIV);GENE;VIRUS;TUBERCULOSIS;POPULATION;REGIMEN;ADVERSE EFFECT;COHORT;DISEASE;ANTIBIOTICS;IMMUNE SYSTEM;BACTERIA;HEPATITIS C;INCIDENCE (GEOMETRY);CONFIDENCE INTERVAL;APOPTOSIS;COHORT STUDY;DRUG RESISTANCE;EPIDEMIOLOGY;IN VITRO;ODDS RATIO;OUTBREAK","30;26;20;18;11;11;10;10;10;9;9;8;8;8;7;6;6;6;6;6;6;6","VIRAL LOAD;MYCOBACTERIUM TUBERCULOSIS;T CELL;AUTOPHAGY;HEPATITIS B VIRUS;INFECTIOUS DISEASE (MEDICAL SPECIALTY);GENOTYPE;TOLERABILITY;VIRAL DISEASE;VIRAL REPLICATION;ANTIBIOTIC RESISTANCE;BACTEREMIA;CHRONIC HEPATITIS;CLINICAL ENDPOINT;EBOLA VIRUS;GENOME;HAZARD RATIO;HEPATITIS C VIRUS;PERIPHERAL BLOOD MONONUCLEAR CELL;PHENOTYPE","23;11;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3","ANTIRETROVIRAL THERAPY;LAMIVUDINE;LATENT TUBERCULOSIS;REVERSE TRANSCRIPTASE;BEDAQUILINE;CORONAVIRUS DISEASE 2019 (COVID-19);EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS;RIBAVIRIN;ACINETOBACTER BAUMANNII;AGROBACTERIUM;ALPHAVIRUS INFECTION;AMPK;ANTIMICROBIAL STEWARDSHIP;ARTEMISININ;AUTOPHAGOSOME;BACTERIAL OUTER MEMBRANE;BORRELIA;CD38;CD4 T CELL;CEFTAZIDIME;CETUXIMAB;CHEMOKINE RECEPTOR;CLADE;CULTURE CONVERSION;DNA METHYLATION;DNA VACCINATION;EARLY PREGNANCY LOSS;ELISPOT;ENTEROBACTERIACEAE;EPITHELIAL–MESENCHYMAL TRANSITION;FRAMINGHAM HEART STUDY;GENETICALLY MODIFIED CROPS;GENOMICS;GP41;HEPATITIS E;HEPATITIS E VIRUS;HUMAN MICROBIOME PROJECT;KRAS;LENTIVIRUS;LMNA;LYMPHATIC FILARIASIS;LYMPHOCYTE SUBSETS;MEN WHO HAVE SEX WITH MEN;MICROVESICLES;MULTI-DRUG-RESISTANT TUBERCULOSIS;MYELOID-DERIVED SUPPRESSOR CELL;NKG2D;ORGANELLE BIOGENESIS;PAPILLOMAVIRIDAE;PERFORIN;PLACENTA;PLASMODIUM VIVAX;PRAZIQUANTEL;PROPIDIUM IODIDE;RESTRICTIVE CARDIOMYOPATHY;RUBELLA;SEROPREVALENCE;SEROSTATUS;SEXUAL TRANSMISSION;SIDA;TRANSMISSIBILITY (STRUCTURAL DYNAMICS);UBIQUITIN LIGASE;VANCOMYCIN;VIRAL ENTRY;VIRIDANS STREPTOCOCCI;WEIGHT CHANGE;WHOLE GENOME SEQUENCING;ZIDOVUDINE","22;5;4;4;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HIV INFECTIONS;HUMANS;MALE;FEMALE;ADULT;ANTI-HIV AGENTS;ITALY;MIDDLE AGED;HIV-1;;VIRAL LOAD;AGED;TREATMENT OUTCOME;HEPATITIS C, CHRONIC;ANTITUBERCULAR AGENTS;ANTI-RETROVIRAL AGENTS;ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE;COINFECTION;DRUG RESISTANCE, VIRAL;ANTI-BACTERIAL AGENTS","96;86;60;57;54;50;49;48;37;30;23;21;17;16;14;13;13;13;13;12","EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;TUBERCULOSIS;HEPATITIS C INFECTION AND TREATMENT;GLOBAL IMPACT OF ARBOVIRAL DISEASES;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;ROLE OF AUTOPHAGY IN DISEASE AND HEALTH;EBOLA VIRUS RESEARCH AND OUTBREAKS;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;BIOLOGICAL, EPIDEMIOLOGICAL, AND CLINICAL ASPECTS OF ECHINOCOCCOSIS;DIAGNOSIS AND TREATMENT OF PROSTHETIC JOINT INFECTIONS;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GLOBAL BURDEN OF ANTIMICROBIAL RESISTANCE;MALARIA;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;BIOLOGICAL AGENTS FOR BIOTERRORISM;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;DIAGNOSIS AND TREATMENT OF SPINAL INFECTIONS","18;13;8;5;5;4;4;3;3;2;2;2;2;2;2;2;2;1;1;1","ANTIRETROVIRAL THERAPY;HIV;REGIMEN;HEPATITIS C;HIV INFECTION;TREATMENT;EMTRICITABINE;DOLUTEGRAVIR;INTEGRASE INHIBITOR;DIAGNOSIS;LIVER DISEASE;MYCOBACTERIUM TUBERCULOSIS;RALTEGRAVIR;TOLERABILITY;ABACAVIR;AUTOPHAGY;BACTEREMIA;CLINICAL ENDPOINT;DISCONTINUATION;ELVITEGRAVIR","19;19;11;8;8;7;6;5;5;4;4;4;4;4;3;3;3;3;3;3","ADVERSE EVENTS;ANTIRETROVIRAL THERAPY;VIRUS INFECTION;ANTIRETROVIRAL REGIMENS;COHORT STUDY;EBOLA VIRUS;HIV INFECTION;INFECTIOUS DISEASES;INTENSIVE CARE;LATENT TUBERCULOSIS;MULTICENTER STUDY;MULTIDRUG-RESISTANT TUBERCULOSIS;PATIENTS RECEIVING;ADULT PATIENTS;AFFECT OUTCOME;CHRONIC HEPATITIS;CLINICAL PRACTICE;CONSENSUS DOCUMENT;CURE DRUG;DRUG RELATED;DRUG-RESISTANT TUBERCULOSIS;EANM EBJIS;ESCMID ENDORSEMENT;HIV- INFECTION;HUMAN IMMUNODEFICIENCY;ICONA COHORT;ICONA FOUNDATION;IMMUNODEFICIENCY VIRUS;INFECTED PATIENTS;JOINT PAPER","5;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","TUBERCULOSIS INFECTION;INFECT DIS;LATENT TUBERCULOSIS;ACTIVE TB;DIS S-SABSTRACT;PDF SCOPUS;WORLD HEALTH;HEALTH ORGANIZATION;INFECTIOUS DISEASES;LEFT VENTRICULAR;ADVERSE EVENTS;HCV INFECTION;HIV POSITIVE;PREGNANCY LOSS;ART INITIATION;CELL COUNT;ROME ITALY;BLASTOCYSTIS SP;CONDUCTION TISSUE;DRUG REACTIONS;ENDOMYOCARDIAL BIOPSY;GLOBAL TB;RISK FACTORS;VΔ T-CELLS;ADVERSE DRUG;ALCOHOL CONSUMPTION;HIV INFECTION;HIV- RNA;INSTI TREATMENT;REGRESSION ANALYSIS","25;22;22;19;18;17;15;14;14;14;13;12;12;11;10;10;10;9;9;9;9;9;9;9;8;8;8;8;8;8",71,0.61,7.78,6,1,6,0,2,1,0,1.5,8,1,1,6,1.75,12.5,1,2,4.25,1.5,0,0,65,65,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,4.5,1832.5,2.42,1,0.25,23.75,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,3,0,1,2,2,0,0,0,0,0,0,0,0,"United States","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;3204 IMMUNOLOGY","4;3;2;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HIV/AIDS;INFECTIOUS DISEASES;PREVENTION;ANTIMICROBIAL RESISTANCE;BEHAVIORAL AND SOCIAL SCIENCE;EMERGING INFECTIOUS DISEASES;IMMUNIZATION;MENTAL HEALTH;PEDIATRIC;PEDIATRIC AIDS;SEXUALLY TRANSMITTED INFECTIONS;VACCINE RELATED","2;2;2;2;2;1;1;1;1;1;1;1;1;1","INFECTION","4","5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS;2.4 SURVEILLANCE AND DISTRIBUTION;5.2 CELLULAR AND GENE THERAPIES","3;3;1;1","ANAL CANCER;KAPOSI'S SARCOMA;LIVER CANCER;LUNG CANCER","1;1;1;1","2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER","1",4,4489344,335219.97,4.25,13,10.75,1,15,1004139.26665204,0.116517702161073,"ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI;PUBLIC HEALTH AGENCY OF SWEDEN;AIX-MARSEILLE UNIVERSITY;DEPARTMENT OF HEALTH;DÉLÉGATION PARIS 11;ERASMUS MC;INSERM TRANSFERT;ROBERT KOCH INSTITUTE;ACADEMIC MEDICAL CENTER;BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE;CORIS BIOCONCEPT (BELGIUM);CUMHURIYET UNIVERSITY;EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK - ERIC;FINNISH INSTITUTE FOR HEALTH AND WELFARE;HEALTH SERVICE EXECUTIVE;HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO;INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT;INSTITUT PASTEUR DE DAKAR;INSTITUTO DE SALUD CARLOS III;KAROLINSKA INSTITUTET","4;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","4","COALITION S;EC & ERC - EUROPEAN UNION","4;4","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME);3RD HEALTH PROGRAMME (PROGRAMME);CSA - COORDINATION AND SUPPORT ACTION (FUNDING SCHEME);H2020-EU.1.4.1.1. - DEVELOPING NEW WORLD-CLASS RESEARCH INFRASTRUCTURES (PROGRAMME);H2020-JTI-IMI2-2015-08-SINGLE-STAGE (CALL FOR PROPOSAL)","2;2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;4206 PUBLIC HEALTH;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;46 INFORMATION AND COMPUTING SCIENCES","2;2;2;1;1;1","INFECTIOUS DISEASES;PREVENTION;BIODEFENSE;EMERGING INFECTIOUS DISEASES;RARE DISEASES;VACCINE RELATED","2;2;1;1;1;1","INFECTION","2","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1",NA,NA,NA,NA,"A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;A05 BIOLOGICAL SCIENCES;A06 AGRICULTURE, VETERINARY AND FOOD SCIENCE;B11 COMPUTER SCIENCE AND INFORMATICS","1;1;1;1","17 PARTNERSHIPS FOR THE GOALS;3 GOOD HEALTH AND WELL BEING","1;1",14,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;SPRINGER NATURE","10;2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;38 ECONOMICS;3501 ACCOUNTING, AUDITING AND ACCOUNTABILITY;3507 STRATEGY, MANAGEMENT AND ORGANISATIONAL BEHAVIOUR;3801 APPLIED ECONOMICS;44 HUMAN SOCIETY;48 LAW AND LEGAL STUDIES;51 PHYSICAL SCIENCES;5106 NUCLEAR AND PLASMA PHYSICS","15;7;4;2;2;2;1;1;1;1;1;1;1","INFECTIOUS DISEASES;CLINICAL RESEARCH;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;HIV/AIDS;LIVER DISEASE;RARE DISEASES;ANTIMICROBIAL RESISTANCE;BIOTECHNOLOGY;CANCER;CHRONIC LIVER DISEASE AND CIRRHOSIS;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;GENETICS;HEPATITIS;HEPATITIS - C;PATIENT SAFETY;TUBERCULOSIS","3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","INFECTION","5","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","5;4;1","CLINICAL;BIOMEDICAL","3;2","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","9;1","LIVER CANCER","2",NA,NA
"IRCCS_SPALLANZANIROMA",2020,173,19.364161849711,5.15028901734104,0.364161849710983,0.352601156069364,0.705202312138728,3.61788617886179,1.28571428571429,2.25925925925926,1.54430379746835,0.867052023121387,2,94,30,4,10,0.54,0.17,0.02,0.06,41.08,1.63005877499273,6.79080459770114,0.479768786127168,0.959537572254335,0.625,0.474,0.433,0.509,"GIUSEPPE IPPOLITO;ANDREA ANTINORI;MARIA ROSARIA CAPOBIANCHI;EMANUELE NICASTRI;NICOLA PETROSILLO;CHIARA AGRATI;ALIMUDDIN ZUMLA;CONCETTA CASTILLETTI;LUISA MARCHIONI;ELEONORA LALLE;FRANCESCO VAIRO;FRANCESCA COLAVITA;FABRIZIO PALMIERI;ANTONINO DI;DELIA GOLETTI;LICIA BORDI;ENRICO GIRARDI;ANTONELLA D’ARMINIO MONFORTE;MARKUS MAEURER;GIANPIERO D’OFFIZI","42;37;33;32;28;26;23;19;19;19;19;16;16;15;15;15;15;15;14;11","NICOLA PETROSILLO;GIUSEPPE IPPOLITO;MARIA ROSARIA CAPOBIANCHI;ANDREA ANTINORI;EMANUELE NICASTRI;ROMINA VERARDO;ANDREA FRUSTACI;CRISTINA CHIMENTI;CHIARA AGRATI;ALIMUDDIN ZUMLA;MARIA ALFARANO;FRANCESCO VAIRO;ELEONORA LALLE;ANTONINO DI;LUISA MARCHIONI;DELIA GOLETTI;CONCETTA CASTILLETTI;ELISA MARIA LORI;MARIA ADRIANA CATALDO;LICIA BORDI","4.35;2.47;2.4;1.89;1.68;1.64;1.57;1.53;1.48;1.31;1.25;1.21;1.17;1.1;1.1;1.1;1.01;1;0.94;0.92","GIUSEPPE IPPOLITO;ANDREA ANTINORI;MARIA ROSARIA CAPOBIANCHI;EMANUELE NICASTRI;NICOLA PETROSILLO;CHIARA AGRATI;CONCETTA CASTILLETTI;LUISA MARCHIONI;ELEONORA LALLE;FRANCESCO VAIRO;FRANCESCA COLAVITA;FABRIZIO PALMIERI;ANTONINO DI;DELIA GOLETTI;LICIA BORDI;ENRICO GIRARDI;ANTONELLA D’ARMINIO MONFORTE;GIANPIERO D’OFFIZI;ROMINA VERARDO;ALESSANDRA D’ABRAMO","42;37;33;32;28;26;19;19;19;19;16;16;15;15;15;15;15;11;11;11","NICOLA PETROSILLO;GIUSEPPE IPPOLITO;MARIA ROSARIA CAPOBIANCHI;ANDREA ANTINORI;EMANUELE NICASTRI;ROMINA VERARDO;ANDREA FRUSTACI;CRISTINA CHIMENTI;CHIARA AGRATI;FRANCESCO VAIRO;ELEONORA LALLE;ANTONINO DI;LUISA MARCHIONI;DELIA GOLETTI;CONCETTA CASTILLETTI;MARIA ADRIANA CATALDO;LICIA BORDI;FABRIZIO PALMIERI;FRANCESCA COLAVITA;ENRICO GIRARDI","4.35;2.47;2.4;1.89;1.68;1.64;1.57;1.53;1.48;1.21;1.17;1.1;1.1;1.1;1.01;0.94;0.92;0.83;0.8;0.77","GIUSEPPE IPPOLITO;EMANUELE NICASTRI;MARIA ROSARIA CAPOBIANCHI;ALIMUDDIN ZUMLA;ANDREA ANTINORI;CHIARA AGRATI;LUISA MARCHIONI;NICOLA PETROSILLO;ELEONORA LALLE;MARKUS MAEURER;FABRIZIO PALMIERI;CONCETTA CASTILLETTI;LICIA BORDI;FRANCESCA COLAVITA;FRANCESCO VAIRO;DELIA GOLETTI;LAURA SCORZOLINI;GIANPIERO D’OFFIZI;ALESSANDRA D’ABRAMO;ELEONORA CIMINI","3326;3015;2184;2140;1989;1899;1814;1689;1508;1443;1442;1436;1025;997;997;921;871;815;794;787","GIUSEPPE IPPOLITO;EMANUELE NICASTRI;MARIA ROSARIA CAPOBIANCHI;ANDREA ANTINORI;LUISA MARCHIONI;CHIARA AGRATI;NICOLA PETROSILLO;ELEONORA LALLE;FABRIZIO PALMIERI;CONCETTA CASTILLETTI;DELIA GOLETTI;ELEONORA CIMINI;ALESSANDRA VERGORI;FRANCESCO VAIRO;LICIA BORDI;GIANPIERO D’OFFIZI;FRANCESCA COLAVITA;ANTONINO DI;LAURA SCORZOLINI;PAOLA SOGNAMIGLIO","3281;2897;1957;1809;1767;1655;1546;1294;1277;1222;815;787;783;774;706;692;678;676;612;602","GIUSEPPE IPPOLITO;ANDREA ANTINORI;MARIA ROSARIA CAPOBIANCHI;EMANUELE NICASTRI;NICOLA PETROSILLO;CHIARA AGRATI;ELEONORA LALLE;CONCETTA CASTILLETTI;FRANCESCO VAIRO;LUISA MARCHIONI;DELIA GOLETTI;FRANCESCA COLAVITA;ANTONINO DI;LICIA BORDI;FABRIZIO PALMIERI;ALESSANDRA VERGORI;FABRIZIO CARLETTI;ENRICO GIRARDI;ROMINA VERARDO;FRANCESCO MESSINA","38;31;30;29;25;22;17;17;16;16;14;13;13;12;12;11;11;11;11;9","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;SOCIOLOGY;POLITICAL SCIENCE;ENGINEERING;GEOGRAPHY;CHEMISTRY;BUSINESS;ECONOMICS;MATHEMATICS;PSYCHOLOGY;HISTORY;PHILOSOPHY;MATERIALS SCIENCE","163;73;18;14;14;13;10;9;8;6;6;5;3;2;2;1","INTERNAL MEDICINE;VIROLOGY;PATHOLOGY;IMMUNOLOGY;GENETICS;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;MICROBIOLOGY;PEDIATRICS;FAMILY MEDICINE;BIOCHEMISTRY;LAW;NURSING;CARDIOLOGY;DEMOGRAPHY;OPTICS;SURGERY;EMERGENCY MEDICINE;CANCER RESEARCH;GASTROENTEROLOGY","107;66;56;44;34;25;20;20;17;16;14;13;13;12;12;12;12;11;10;10","DISEASE;OUTBREAK;HUMAN IMMUNODEFICIENCY VIRUS (HIV);GENE;VIRUS;TUBERCULOSIS;POPULATION;PNEUMONIA;PUBLIC HEALTH;ANTIBIOTICS;COHORT;INCIDENCE (GEOMETRY);REGIMEN;IMMUNE SYSTEM;RETROSPECTIVE COHORT STUDY;ANTIBODY;MYOCARDITIS;CANCER;COHORT STUDY;HEART FAILURE;LUNG;RESPIRATORY SYSTEM;TRANSMISSION (TELECOMMUNICATIONS)","66;29;28;26;20;18;16;12;12;11;11;11;11;10;10;9;9;8;7;7;7;7;7","INFECTIOUS DISEASE (MEDICAL SPECIALTY);2019-20 CORONAVIRUS OUTBREAK;VIRAL LOAD;MYCOBACTERIUM TUBERCULOSIS;CLINICAL ENDPOINT;GENOTYPE;SEROLOGY;SPUTUM;CARDIOMYOPATHY;CHIKUNGUNYA;HAZARD RATIO;PHYLOGENETIC TREE;VASCULITIS;VIRAL DISEASE;ANTIBIOTIC RESISTANCE;AUTOPHAGY;CANCER CELL;CARBAPENEM;CYTOTOXIC T CELL;DOWNREGULATION AND UPREGULATION;EPIGENETICS;GENE EXPRESSION;PHYLOGENETICS;POISSON REGRESSION;RESPIRATORY TRACT INFECTIONS;SYPHILIS;VIRAL MYOCARDITIS;VIRAL REPLICATION;VIRAL SHEDDING","54;24;18;8;6;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","CORONAVIRUS DISEASE 2019 (COVID-19);ANTIRETROVIRAL THERAPY;ANTIMICROBIAL STEWARDSHIP;AEDES ALBOPICTUS;BEDAQUILINE;CHIKUNGUNYA FEVER;CLADE;DISEASE MANAGEMENT;EPITHELIAL–MESENCHYMAL TRANSITION;EZH2;HEPATITIS E VIRUS;LATENT TUBERCULOSIS;MEN WHO HAVE SEX WITH MEN;MOLECULAR EPIDEMIOLOGY;NECROTIZING VASCULITIS;SEROPREVALENCE;SEROSTATUS;SIDA;ACTIVE TUBERCULOSIS;ANGIOTENSIN RECEPTOR BLOCKERS;ANTIBIOTIC STEWARDSHIP;ARTEMISININ;ARTESUNATE;AUTOPHAGOSOME;BECN1;BLASTOCYST;C DIFFICILE;CATENIN;CEFTAZIDIME;CERVICAL INTRAEPITHELIAL NEOPLASIA;CLOCK;DENDROGRAM;DIFFUSE ALVEOLAR DAMAGE;DNA METHYLATION;ENTEROBACTERIACEAE;EPSTEIN–BARR VIRUS INFECTION;FABRY'S DISEASE;FORAMEN OVALE (HEART);HBSAG;HEMATOPOIETIC STEM CELL;HEPATITIS E;HERPESVIRIDAE;HISTONE H3;HOX GENE;HUMAN METAPNEUMOVIRUS;IMATINIB MESYLATE;INDUCED PLURIPOTENT STEM CELL;INJURY SEVERITY SCORE;KLEBSIELLA PNEUMONIAE;LAMIVUDINE;LENTIVIRUS;LONG NON-CODING RNA;LYMPHOPOIESIS;MASS CYTOMETRY;METHYLTRANSFERASE;MHC CLASS I;MYELOID-DERIVED SUPPRESSOR CELL;NONTUBERCULOUS MYCOBACTERIA;PARTNER NOTIFICATION;PD-L1;PERFORIN;PERMISSIVENESS;PHOSPHOLIPIDOSIS;POLYARTERITIS NODOSA;POLYMORPHISM (COMPUTER SCIENCE);PRIMAQUINE;PSYCHOLOGICAL REPRESSION;RAFT;RESPIRATORY RATE;RIBAVIRIN;RNA EXTRACTION;SALMONELLA ENTERICA;SEXUAL TRANSMISSION;SINGLE-NUCLEOTIDE POLYMORPHISM;SOD2;SPUTUM CULTURE;TAKOTSUBO SYNDROME;TRANSCRIPTOME;TREE OF LIFE (BIOLOGY);VECTOR (MOLECULAR BIOLOGY);VIRAL ENTRY;VIRAL QUASISPECIES;WHOLE GENOME SEQUENCING","53;9;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;CORONAVIRUS INFECTIONS;PNEUMONIA, VIRAL;HIV INFECTIONS;MALE;COVID-19;FEMALE;BETACORONAVIRUS;MIDDLE AGED;ADULT;SARS-COV-2;ITALY;AGED;HIV-1;PANDEMICS;RNA, VIRAL;ANTI-HIV AGENTS;TUBERCULOSIS, PULMONARY;CHIKUNGUNYA FEVER","87;82;52;49;48;48;47;46;38;34;33;31;30;24;20;18;16;14;14;13","CORONAVIRUS DISEASE 2019;CORONAVIRUS DISEASE 2019 RESEARCH;TUBERCULOSIS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;GLOBAL IMPACT OF ARBOVIRAL DISEASES;CLOSTRIDIUM DIFFICILE INFECTION AND TREATMENT;GLOBAL BURDEN OF ANTIMICROBIAL RESISTANCE;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;DIAGNOSTIC METHODS FOR COVID-19 DETECTION;NEUROLOGICAL MANIFESTATIONS OF COVID-19 INFECTION;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;COMPUTATIONAL METHODS IN DRUG DISCOVERY;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;EPIGENETIC MODIFICATIONS AND THEIR FUNCTIONAL IMPLICATIONS;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;GLOBAL EPIDEMIOLOGY OF HIV AND DRUG USE;HEPATITIS C INFECTION AND TREATMENT","17;14;13;7;7;6;6;5;5;5;4;4;3;2;2;2;2;2;2;2","2019-20 CORONAVIRUS OUTBREAK;HIV;PANDEMIC;CORONA VIRUS;CORONAVIRUS;REGIMEN;CLINICAL CHARACTERISTICS;MYOCARDITIS;ANTIRETROVIRAL THERAPY;ENDOMYOCARDIAL BIOPSY;CLINICAL ENDPOINT;MYCOBACTERIUM TUBERCULOSIS;BETACORONAVIRUS;CLOSTRIDIOIDES;HIV EPIDEMIOLOGY;ANTIMICROBIAL STEWARDSHIP;CARDIOVASCULAR MAGNETIC RESONANCE;DISCONTINUATION;HIV INFECTION;PREPAREDNESS","22;19;18;14;12;10;8;8;7;7;6;6;5;5;5;4;4;4;4;4","HIV INFECTION;CLOSTRIDIOIDES DIFFICILE;COVID- PATIENTS;DIFFICILE INFECTION;ACUTE RESPIRATORY;CORONARY VASCULITIS;CORONAVIRUS DISEASE;COVID- DISEASE;CHIKUNGUNYA OUTBREAK;CLINICAL MANAGEMENT;COHORT STUDY;CONDUCTION TISSUE;DISEASE COVID-;HUMAN IMMUNODEFICIENCY;IMMUNODEFICIENCY VIRUS;LONGITUDINAL DESCRIPTIVE;MULTICENTER STUDY;MYCOBACTERIUM TUBERCULOSIS;PHYLOGENETIC ANALYSIS;RESPIRATORY SYNDROME;SARS-COV- INFECTION;SEVERE ACUTE;ACTION STRENGTHENING;ACUTE HIV;ANTIMICROBIAL RESISTANCE;ARRHYTHMIC PHENOTYPE;BLOOD COUNT;BLOODSTREAM INFECTIONS;CANCER CELLS;CARBAPENEM-RESISTANT GRAM-NEGATIVE","6;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","PUBMED SCOPUS;SARS-COV- INFECTION;ROME ITALY;INFECT DIS;COVID- PATIENTS;CROSSREF PUBMED;GILEAD SCIENCES;ACUTE RESPIRATORY;INFECTIOUS DISEASES;SPALLANZANI ROME;WORLD HEALTH;HEALTH ORGANIZATION;MYCOBACTERIUM TUBERCULOSIS;CORONAVIRUS DISEASE;MD GILEAD;NATIONAL INSTITUTE;REFERENCE METHOD;RESPIRATORY SYNDROME;SAN GALLICANO;SEVERE ACUTE;VIRAL LOAD;CD COUNT;COVID- AG;DERMATOLOGIC INSTITUTE;GALLICANO DERMATOLOGIC;INSTITUTE IRCCS;SEVERE COVID-;SUSCEPTIBILITY TESTING;AG FIA;COVID- DISEASE","60;30;29;23;22;22;19;18;18;18;18;17;17;16;16;15;15;15;15;15;15;14;14;14;14;14;14;14;13;13",112,0.65,11.06,11.25,2.75,1.25,0,3,2,1,1,11.25,1,1,10.75,1,2.5,2,4.5,7.75,5,0,0,133.75,133.75,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,5,0.56,9,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"GOUGEON MARIE-LISE;KROEMER GUIDO;PAOLETTI AUDREY;PERFETTINI JEAN-LUC;PIACENTINI MAURO","1;1;1;1;1","ASSISTANCE PUBLIQUE HOPITAUX DE PARIS APHP;INSTITUT GUSTAVE ROUSSY (IGR);INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSERM;INSTITUT PASTEUR DE LILLE;ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE ""LAZZARO SPALLANZANI"" IRCCS;UNIVERSITE PARIS DESCARTES PARIS 5;UNIVERSITE PARIS DIDEROT PARIS 7;UNIVERSITE PARIS SUD PARIS 11;UNIVERSITE PIERRE ET MARIE CURIE PARIS 6","1;1;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;48 LAW AND LEGAL STUDIES;4806 PRIVATE LAW AND CIVIL OBLIGATIONS","1;1;1",NA,NA,NA,NA,"A61K31/00;A61K38/00;A61K48/00;A61P31/00;A61P35/00;A61P37/00","1;1;1;1;1;1","A61K31/7034;A61K31/7072;A61K31/7076;A61K31/7084;A61K38/177;A61K48/00;A61P29/00;A61P31/00;A61P35/00;A61P37/00","1;1;1;1;1;1;1;1;1;1",10,1.75,1214.29,4.9,7,0.7,68.8,1,0,1,2,6,0,0,0,0,7,0,0,0,0,0,0,0,10,0,0,7,3,0,0,0,0,0,0,0,0,"United States","5","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;3204 IMMUNOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","10;6;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;INFECTIOUS DISEASES;PREVENTION;AGING;HIV/AIDS;LUNG;PNEUMONIA;PNEUMONIA & INFLUENZA;VACCINE RELATED;BIOTECHNOLOGY;CARDIOVASCULAR;EMERGING INFECTIOUS DISEASES;IMMUNIZATION;ORPHAN DRUG;PATIENT SAFETY;RARE DISEASES","6;6;4;4;2;2;2;2;2;2;1;1;1;1;1;1;1","INFECTION;INFLAMMATORY AND IMMUNE SYSTEM","6;1","6.1 PHARMACEUTICALS","9",NA,NA,NA,NA,6,3955557.67,375317.83,3.33333333333333,10.6666666666667,5.5,0.833333333333333,115.8,1497254.69990961,0.115544803439551,"ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI;AIX-MARSEILLE UNIVERSITY;AUSTRIAN INSTITUTE OF TECHNOLOGY;BARCELONA SUPERCOMPUTING CENTER;BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE;BIOGENE (UNITED KINGDOM);CENTRE DE COOPÉRATION INTERNATIONALE EN RECHERCHE AGRONOMIQUE POUR LE DÉVELOPPEMENT;CHARITÉ - UNIVERSITY MEDICINE BERLIN;CINECA;COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION;DEPARTMENT FOR ENVIRONMENT, FOOD AND RURAL AFFAIRS;DEPARTMENT OF HEALTH;DOMPÉ (ITALY);DÉLÉGATION PARIS 11;ELETTRA SINCROTRONE TRIESTE;ERASMUS MC;FEDERAL MINISTRY OF DEFENCE;FONDATION MÉRIEUX;FORSCHUNGSZENTRUM JÜLICH;FRAUNHOFER SOCIETY","6;3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;TELETHON FOUNDATION","5;1","COALITION S;EC & ERC - EUROPEAN UNION","5;5","RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME);H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-JTI-IMI2-2020-21-SINGLE-STAGE (CALL FOR PROPOSAL);H2020-SC1-PHE-CORONAVIRUS-2020 (CALL FOR PROPOSAL);H2020-EU.1.4.1.2. - INTEGRATING AND OPENING EXISTING NATIONAL AND REGIONAL  RESEARCH INFRASTRUCTURES OF EUROPEAN INTEREST (PROGRAMME)","5;4;2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;34 CHEMICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY","5;3;2;2;1;1","INFECTIOUS DISEASES;PREVENTION;CLINICAL RESEARCH;EMERGING INFECTIOUS DISEASES;BIODEFENSE;BIOENGINEERING;VACCINE RELATED;AUTOIMMUNE DISEASE;CARDIOVASCULAR;HEART DISEASE;PNEUMONIA & INFLUENZA;RARE DISEASES","4;4;3;3;2;2;2;1;1;1;1;1","INFECTION;GENERIC HEALTH RELEVANCE","3;1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);5.1 PHARMACEUTICALS","3;2;1;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE;A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;A06 AGRICULTURE, VETERINARY AND FOOD SCIENCE","3;1;1;1",NA,NA,18,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE","17;1","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;40 ENGINEERING;38 ECONOMICS;44 HUMAN SOCIETY;51 PHYSICAL SCIENCES;3105 GENETICS;3801 APPLIED ECONOMICS;4004 CHEMICAL ENGINEERING;42 HEALTH SCIENCES;4205 NURSING;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4403 DEMOGRAPHY;47 LANGUAGE, COMMUNICATION AND CULTURE;4705 LITERARY STUDIES;49 MATHEMATICAL SCIENCES;4901 APPLIED MATHEMATICS;5106 NUCLEAR AND PLASMA PHYSICS","6;4;4;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1","INFECTIOUS DISEASES;BIODEFENSE;EMERGING INFECTIOUS DISEASES;GENETICS;PREVENTION;VACCINE RELATED","2;1;1;1;1;1","INFECTION","1",NA,NA,NA,NA,"CLINICAL MEDICINE AND SCIENCE","3","NOT SITE-SPECIFIC CANCER","1","3 GOOD HEALTH AND WELL BEING","1"
"IRCCS_SPALLANZANIROMA",2021,184,20.8532608695652,6.69021739130435,0.418478260869565,0.380434782608696,0.559782608695652,4.34982332155477,1.42592592592593,2.05882352941176,1.45070422535211,0.902173913043478,0,79,30,5,6,0.43,0.16,0.03,0.03,24.66,1.59934536991473,7.07927677329626,0.407608695652174,0.945652173913043,0.604,0.351,0.466,0.492,"ANDREA ANTINORI;GIUSEPPE IPPOLITO;MARIA ROSARIA CAPOBIANCHI;EMANUELE NICASTRI;CONCETTA CASTILLETTI;CHIARA AGRATI;GIANPIERO D’OFFIZI;DELIA GOLETTI;ENRICO GIRARDI;NICOLA PETROSILLO;FABRIZIO PALMIERI;LUISA MARCHIONI;ALESSANDRA VERGORI;ROBERTA GAGLIARDINI;ROBERTA NARDACCI;FRANCA DEL NONNO;ANTONELLA D’ARMINIO MONFORTE;FRANCESCA COLAVITA;GINA GUALANO;GIULIA MATUSALI","48;44;43;33;28;26;23;23;22;20;20;18;16;14;13;13;13;12;12;12","ANDREA ANTINORI;GIUSEPPE IPPOLITO;MARIA ROSARIA CAPOBIANCHI;DELIA GOLETTI;EMANUELE NICASTRI;ENRICO GIRARDI;CONCETTA CASTILLETTI;NICOLA PETROSILLO;FRANCA DEL NONNO;CHIARA AGRATI;DANIELE COLOMBO;ROBERTA NARDACCI;LAURA FALASCA;GIANPIERO D’OFFIZI;LUISA MARCHIONI;FABRIZIO PALMIERI;ROBERTA GAGLIARDINI;LINDA PETRONE;ANTONELLA D’ARMINIO MONFORTE;LAURA TIMELLI","2.9;2.65;2.62;2.01;1.92;1.85;1.6;1.58;1.5;1.43;1.37;1.28;1.25;1.2;1.16;1.11;0.85;0.84;0.84;0.8","ANDREA ANTINORI;GIUSEPPE IPPOLITO;MARIA ROSARIA CAPOBIANCHI;EMANUELE NICASTRI;CONCETTA CASTILLETTI;CHIARA AGRATI;GIANPIERO D’OFFIZI;DELIA GOLETTI;ENRICO GIRARDI;NICOLA PETROSILLO;FABRIZIO PALMIERI;LUISA MARCHIONI;ALESSANDRA VERGORI;ROBERTA GAGLIARDINI;ROBERTA NARDACCI;FRANCA DEL NONNO;FRANCESCA COLAVITA;GINA GUALANO;GIULIA MATUSALI;DANIELE LAPA","48;44;43;33;28;26;23;23;22;20;20;18;16;14;13;13;12;12;12;11","ANDREA ANTINORI;GIUSEPPE IPPOLITO;MARIA ROSARIA CAPOBIANCHI;DELIA GOLETTI;EMANUELE NICASTRI;ENRICO GIRARDI;CONCETTA CASTILLETTI;NICOLA PETROSILLO;FRANCA DEL NONNO;CHIARA AGRATI;DANIELE COLOMBO;ROBERTA NARDACCI;LAURA FALASCA;GIANPIERO D’OFFIZI;LUISA MARCHIONI;FABRIZIO PALMIERI;ROBERTA GAGLIARDINI;LINDA PETRONE;LAURA TIMELLI;ANNA ROSA GARBUGLIA","2.9;2.65;2.62;2.01;1.92;1.85;1.6;1.58;1.5;1.43;1.37;1.28;1.25;1.2;1.16;1.11;0.85;0.84;0.8;0.79","GIUSEPPE IPPOLITO;EMANUELE NICASTRI;MARIA ROSARIA CAPOBIANCHI;ANDREA ANTINORI;CONCETTA CASTILLETTI;CHIARA AGRATI;MASSIMO FANTONI;DELIA GOLETTI;MATTEO BASSETTI;FRANCESCO CASTELLI;A. CINGOLANI;ALESSANDRA VERGORI;FRANCESCA MONTAGNANI;ARIANNA EMILIOZZI;MASSIMILIANO FABBIANI;SILVIA MESCHI;FRANCESCA COLAVITA;FABRIZIO PALMIERI;LUISA MARCHIONI;AGGELIKI RAPTI","2062;1549;1311;1086;1024;848;714;698;694;658;584;537;511;497;497;473;469;463;434;430","GIUSEPPE IPPOLITO;EMANUELE NICASTRI;MARIA ROSARIA CAPOBIANCHI;ANDREA ANTINORI;CONCETTA CASTILLETTI;CHIARA AGRATI;DELIA GOLETTI;SILVIA MESCHI;FABRIZIO PALMIERI;FRANCESCA COLAVITA;LUISA MARCHIONI;GIULIA MATUSALI;DANIELE LAPA;ALESSANDRA VERGORI;GINA GUALANO;GIANPIERO D’OFFIZI;FRANCA DEL NONNO;NICOLA PETROSILLO;ROBERTA NARDACCI;GILDA CUZZI","2050;1549;1278;1078;1024;839;666;473;458;436;434;429;395;362;333;328;327;308;307;302","ANDREA ANTINORI;MARIA ROSARIA CAPOBIANCHI;GIUSEPPE IPPOLITO;EMANUELE NICASTRI;CONCETTA CASTILLETTI;CHIARA AGRATI;DELIA GOLETTI;ENRICO GIRARDI;GIANPIERO D’OFFIZI;NICOLA PETROSILLO;FABRIZIO PALMIERI;LUISA MARCHIONI;ALESSANDRA VERGORI;FRANCA DEL NONNO;ROBERTA GAGLIARDINI;ROBERTA NARDACCI;GIULIA MATUSALI;DANIELE LAPA;DANIELE COLOMBO;GINA GUALANO","46;45;43;33;28;25;22;22;22;19;19;18;15;13;13;13;12;12;11;11","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;CHEMISTRY;GEOGRAPHY;SOCIOLOGY;POLITICAL SCIENCE;ECONOMICS;PSYCHOLOGY;BUSINESS;PHILOSOPHY;HISTORY;MATHEMATICS","167;81;16;13;12;10;6;6;5;4;4;3;3;1;1","INTERNAL MEDICINE;VIROLOGY;IMMUNOLOGY;PATHOLOGY;GENETICS;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;MICROBIOLOGY;OPTICS;SURGERY;PEDIATRICS;ENDOCRINOLOGY;CELL BIOLOGY;EMERGENCY MEDICINE;PHARMACOLOGY;COMPUTATIONAL BIOLOGY;RADIOLOGY;ELECTRICAL ENGINEERING;PALEONTOLOGY","133;80;78;49;36;26;25;18;17;13;13;11;10;9;8;8;8;7;7;6;6","DISEASE;GENE;VIRUS;HUMAN IMMUNODEFICIENCY VIRUS (HIV);OUTBREAK;ANTIBODY;IMMUNE SYSTEM;POPULATION;COHORT;PNEUMONIA;TUBERCULOSIS;CONFIDENCE INTERVAL;INCIDENCE (GEOMETRY);EPIDEMIOLOGY;LOGISTIC REGRESSION;LUNG;RETROSPECTIVE COHORT STUDY;COHORT STUDY;HEPATITIS C;IN VITRO;ODDS RATIO;VACCINATION","83;36;33;30;26;25;24;22;20;18;16;13;12;10;9;9;9;8;8;8;8;8","INFECTIOUS DISEASE (MEDICAL SPECIALTY);VIRAL LOAD;2019-20 CORONAVIRUS OUTBREAK;MYCOBACTERIUM TUBERCULOSIS;HEPATITIS C VIRUS;GENOTYPE;SEROLOGY;NEUTRALIZING ANTIBODY;CLINICAL ENDPOINT;GENE EXPRESSION;HAZARD RATIO;TITER;IMMUNOGENICITY;INNATE IMMUNE SYSTEM;MONOCLONAL ANTIBODY;POISSON REGRESSION;RNA;ANDROGEN;ARDS;CD8;COINFECTION;CUMULATIVE INCIDENCE;DOWNREGULATION AND UPREGULATION;LIVER TRANSPLANTATION;PERIPHERAL BLOOD MONONUCLEAR CELL;STAPHYLOCOCCUS AUREUS;UBIQUITIN;VIRAL DISEASE","66;26;23;11;10;8;8;6;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","CORONAVIRUS DISEASE 2019 (COVID-19);ANTIRETROVIRAL THERAPY;LATENT TUBERCULOSIS;TRANSCRIPTOME;HEPACIVIRUS;MONOCLONAL;RIBAVIRIN;SEROPREVALENCE;SEX HORMONE-BINDING GLOBULIN;ACTIVE TUBERCULOSIS;DNA METHYLATION;KLEBSIELLA PNEUMONIAE;LENTIVIRUS;LYMPHOCYTE SUBSETS;MITOGEN-ACTIVATED PROTEIN KINASE KINASE;MOLECULAR EPIDEMIOLOGY;SUPAR;TOLL-LIKE RECEPTOR;VIRAL QUASISPECIES;AMPK;ANDROGEN RECEPTOR;ANTIBODY TITER;ANTIVIRAL THERAPY;ANTIVIRAL TREATMENT;ATG8;AUTOPHAGOSOME;BAG3;CEFTAZIDIME;CHANCRE;CLADE;CLAVULANIC ACID;CLOSTRIDIUM DIFFICILE TOXIN A;COALESCENT THEORY;COXSACKIEVIRUS;CXCL10;DANIO;DIFFUSE ALVEOLAR DAMAGE;DIROFILARIA;DIROFILARIA REPENS;DNA VACCINATION;ECHOVIRUS;ENDOMEMBRANE SYSTEM;EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS;FOLD CHANGE;FUSION MECHANISM;GENE MUTATION;GENITAL HERPES;GENOTYPING;HEPATITIS E;HEPATITIS E VIRUS;HERPESVIRIDAE;HONEYCOMBING;HSP70;IMIPENEM;IMMUNOGLOBULIN A;IMMUNOLOGICAL MEMORY;INDUCED PLURIPOTENT STEM CELL;INTERFERON Γ;IRF3;ISG15;LAMIVUDINE;MEMORY B CELL;MEROPENEM;MG132;MILAN CRITERIA;MULTI-DRUG-RESISTANT TUBERCULOSIS;MULTILOCUS SEQUENCE TYPING;NITROFURANTOIN;NONALCOHOLIC FATTY LIVER DISEASE;P-SELECTIN;PNEUMOCOCCAL VACCINE;PNEUMOCYSTIS PNEUMONIA;PROTEOBACTERIA;RESTRICTIVE CARDIOMYOPATHY;RIBONUCLEOPROTEIN;RNA EDITING;RNA-BINDING PROTEIN;RUBELLA;SECRETORY PATHWAY;SEROSTATUS;SIDA;SIRTUIN 1;SKIN INFECTION;SPUTUM CULTURE;STAT;STAT PROTEIN;SYPHILIS SERODIAGNOSIS;TISSUE TROPISM;TORQUE TENO VIRUS;TRANSPOSABLE ELEMENT;TREPONEMA;UBIQUITIN LIGASE;USHER SYNDROME;VANCOMYCIN;VP40;WHOLE GENOME SEQUENCING","66;19;8;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","COVID-19;HUMANS;;SARS-COV-2;MALE;FEMALE;HIV INFECTIONS;MIDDLE AGED;ADULT;AGED;ITALY;ANTIBODIES, VIRAL;ANTIVIRAL AGENTS;RNA, VIRAL;HIV-1;TUBERCULOSIS;ANIMALS;YOUNG ADULT;LATENT TUBERCULOSIS;SPIKE GLYCOPROTEIN, CORONAVIRUS","122;99;82;76;55;47;44;41;35;31;26;23;20;20;19;18;16;16;15;15","CORONAVIRUS DISEASE 2019 RESEARCH;CORONAVIRUS DISEASE 2019;TUBERCULOSIS;HEPATITIS C INFECTION AND TREATMENT;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;DIAGNOSTIC METHODS FOR COVID-19 DETECTION;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;GLOBAL IMPACT OF ARBOVIRAL DISEASES;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;CLOSTRIDIUM DIFFICILE INFECTION AND TREATMENT;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;APPLICATIONS OF DEEP LEARNING IN MEDICAL IMAGING;BIOLOGICAL BASIS AND CLINICAL MANAGEMENT OF SYPHILIS;DIVERSITY AND FUNCTION OF GUT MICROBIOME;EPIDEMIOLOGY AND PATHOGENESIS OF RESPIRATORY VIRAL INFECTIONS;HEPATITIS E INFECTION AND TREATMENT;IMPACT OF COVID-19 ON MENTAL HEALTH","29;24;13;10;8;6;6;5;4;4;3;3;3;3;2;2;2;2;2;2","2019-20 CORONAVIRUS OUTBREAK;PANDEMIC;HIV;HIV INFECTION;TREATMENT;CLINICAL CHARACTERISTICS;CORONAVIRUS;HEPATITIS C;IMMUNITY;ANTIVIRAL TREATMENT;REGIMEN;ANTIBODY;ANTIRETROVIRAL THERAPY;HIV EPIDEMIOLOGY;HIV TRANSMISSION;CLINICAL ENDPOINT;CORONA VIRUS;DIAGNOSIS;DOLUTEGRAVIR;PATHOGENESIS","19;18;17;10;9;8;8;8;8;7;7;6;6;6;6;5;5;5;5;5","COVID- PATIENTS;SARS-COV- INFECTION;ANTIRETROVIRAL THERAPY;HOSPITALIZED PATIENTS;COHORT STUDY;COVID- PANDEMIC;LAZIO REGION;PEOPLE LIVING;CENTRAL ITALY;CLINICAL PROGRESSION;CLOSTRIDIOIDES DIFFICILE;COVID- PNEUMONIA;HIVHCV COINFECTED;INTENSIVE CARE;ITALIAN SOCIETY;LIVER TRANSPLANTATION;MULTICENTER STUDY;ANTIGEN TEST;CARE UNIT;CEREBROSPINAL FLUID;COINFECTED PATIENTS;COMBINATION ANTIRETROVIRAL;CONVALESCENT COVID-;CORIST STUDY;CORONAVIRUS DISEASE;COVID- DISEASE;COVID- INPATIENTS;COVID- THERAPY;DE NOVO;DIFFICILE INFECTION","13;9;6;5;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","COVID- PATIENTS;SARS-COV- INFECTION;ROME ITALY;ITALY SEARCH;BAMBINO GESÙ;CHILDRENS HOSPITAL;GESÙ CHILDRENS;HOSPITAL ROME;IRCCS BAMBINO;GENE THERAPY;PEDIATRIC HEMATO-ONCOLOGY;THERAPY IRCCS;ACUTE RESPIRATORY;IMMUNE RESPONSE;SEVERE COVID-;CORONAVIRUS DISEASE;COVID- PANDEMIC;DISEASE COVID-;HELA CELLS;HIV RNA;BIOLOGY UNIVERSITY;DISEASE PROGRESSION;IL- IL-;INDEPENDENT EXPERIMENTS;COPENHAGEN DENMARK;INTENSIVE CARE;ITALY DEPARTMENT;CSF HIV;CT VALUES;DIALYSIS PATIENTS","63;46;42;40;26;26;26;26;26;21;21;21;19;18;17;15;15;15;15;15;14;14;14;14;13;13;13;12;12;12",122,0.66,8.6,9,1,1.75,0,5,2,0,1,11.75,2,0,8.25,1,5,1.5,2.75,8,5,0,0,61.5,59,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,4.33,3723.33,2.19,2,0.33,17.5,0,0,1,1,4,0,0,0,0,3,0,0,0,0,0,0,0,6,0,0,3,3,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","6;2;2;2;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;INFECTIOUS DISEASES;PATIENT SAFETY;COMPLEMENTARY AND INTEGRATIVE HEALTH;HIV/AIDS;IMMUNIZATION;PREVENTION;VACCINE RELATED","3;3;2;2;1;1;1;1;1","INFECTION","4","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS","4;1","NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER","1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","2",3,8996252,398208.81,4.33333333333333,26.3333333333333,13.6666666666667,1,36.5,1470751.14623962,0.125106140811412,"ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI;NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT;SCIENSANO (BELGIUM);AIDS AND CLINICAL IMMUNOLOGY RESEARCH CENTER;AMSTERDAM UMC LOCATION VUMC;BARCELONA SUPERCOMPUTING CENTER;BIOBANKING AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE - ERIC;CENTER FOR ADVANCED STUDIES RESEARCH AND DEVELOPMENT IN SARDINIA;CENTRE FOR GENOMIC REGULATION;CENTRO HOSPITALAR DE LISBOA OCIDENTAL;CONSORTIUM OF EUROPEAN SOCIAL SCIENCE DATA ARCHIVES - ERIC;DEPARTMENT OF HEALTH;EMPIRICA - COMMUNICATION AND TECHNOLOGY RESEARCH;ERASMUS MC;EU-OPENSCREEN ERIC;EURO-BIOIMAGING ERIC;EUROPEAN ADVANCED TRANSLATIONAL RESEARCH INFRASTRUCTURE - ERIC;EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK - ERIC;EUROPEAN INSTITUTE OF ONCOLOGY;EUROPEAN MOLECULAR BIOLOGY LABORATORY","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","3","COALITION S;EC & ERC - EUROPEAN UNION","3;3","HORIZON-RIA - HORIZON  RESEARCH AND INNOVATION ACTIONS (FUNDING SCHEME);3RD HEALTH PROGRAMME (PROGRAMME);HORIZON-HLTH-2021-CORONA-01 (CALL FOR PROPOSAL);HORIZON-INFRA-2021-EMERGENCY-01 (CALL FOR PROPOSAL);HORIZON.1.3 - RESEARCH INFRASTRUCTURES (PROGRAMME);HORIZON.2.1 - HEALTH (PROGRAMME)","2;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;44 HUMAN SOCIETY;4407 POLICY AND ADMINISTRATION;46 INFORMATION AND COMPUTING SCIENCES;4604 CYBERSECURITY AND PRIVACY","1;1;1;1;1;1","BIODEFENSE;EMERGING INFECTIOUS DISEASES;INFECTIOUS DISEASES;PREVENTION;VACCINE RELATED;CLINICAL RESEARCH;HIV/AIDS;IMMUNIZATION;PATIENT SAFETY","2;2;2;2;2;1;1;1;1","INFECTION;GENERIC HEALTH RELEVANCE","2;1","2.4 SURVEILLANCE AND DISTRIBUTION","1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE;A05 BIOLOGICAL SCIENCES;C20 SOCIAL WORK AND SOCIAL POLICY","1;1;1","3 GOOD HEALTH AND WELL BEING;16 PEACE, JUSTICE AND STRONG INSTITUTIONS","2;1",18,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE;TAYLOR & FRANCIS GROUP","8;4;3;3","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;46 INFORMATION AND COMPUTING SCIENCES;31 BIOLOGICAL SCIENCES;3213 PAEDIATRICS;36 CREATIVE ARTS AND WRITING;3602 CREATIVE AND PROFESSIONAL WRITING;3101 BIOCHEMISTRY AND CELL BIOLOGY;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;33 BUILT ENVIRONMENT AND DESIGN;3303 DESIGN;37 EARTH SCIENCES;3704 GEOINFORMATICS","21;6;3;2;2;2;2;1;1;1;1;1;1;1","PREVENTION;INFECTIOUS DISEASES;LUNG;EMERGING INFECTIOUS DISEASES;RARE DISEASES;BIOTECHNOLOGY;CLINICAL RESEARCH;TUBERCULOSIS;ARTHRITIS;AUTOIMMUNE DISEASE;BRAIN DISORDERS;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COMPARATIVE EFFECTIVENESS RESEARCH;DENTAL/ORAL AND CRANIOFACIAL DISEASE;DIGESTIVE DISEASES;GENETICS;HIV/AIDS;IMMUNIZATION;NEURODEGENERATIVE","8;6;5;4;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","INFECTION;CANCER;GENERIC HEALTH RELEVANCE;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL","2;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;5.1 PHARMACEUTICALS","8;2;2;1;1","BIOMEDICAL;CLINICAL","7;1","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE","6;4","NOT SITE-SPECIFIC CANCER;CERVICAL CANCER;HEAD AND NECK CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER","4;1;1;1;1","3 GOOD HEALTH AND WELL BEING","1"
"IRCCS_SPALLANZANIROMA",2022,186,18.9516129032258,6.75806451612903,0.403225806451613,0.349462365591398,0.43010752688172,4.04180064308682,1.6304347826087,2.16666666666667,1.77777777777778,0.870967741935484,0,75,40,8,7,0.4,0.22,0.04,0.04,23.73,2.65781511319743,6.99798927613943,0.376344086021505,0.96236559139785,0.584,0.495,0.498,0.497,"EMANUELE NICASTRI;ANDREA ANTINORI;ENRICO GIRARDI;CHIARA AGRATI;FRANCESCO VAIA;FRANCESCA COLAVITA;DELIA GOLETTI;GIULIA MATUSALI;CONCETTA CASTILLETTI;SILVIA MESCHI;ROBERTA GAGLIARDINI;FABRIZIO MAGGI;ALESSANDRA VERGORI;VALENTINA MAZZOTTA;MARIA ROSARIA CAPOBIANCHI;VINCENZO PURO;DANIELE LAPA;PIERLUCA PISELLI;STEFANIA CICALINI;LINDA PETRONE","44;41;34;32;29;27;26;22;21;17;16;16;16;16;16;15;14;13;13;13","EMANUELE NICASTRI;ANDREA ANTINORI;ENRICO GIRARDI;CHIARA AGRATI;DELIA GOLETTI;FRANCESCO VAIA;FRANCESCA COLAVITA;CONCETTA CASTILLETTI;ANDREA FRUSTACI;FABRIZIO MAGGI;MARIA ROSARIA CAPOBIANCHI;GIULIA MATUSALI;GIUSEPPE SBERNA;CRISTINA CHIMENTI;MARCO TRIPODI;MATTEO ANTONIO RUSSO;ANNA ROSA GARBUGLIA;CECILIA BATTISTELLI;ROMINA VERARDO;ALESSANDRA VERGORI","2.78;2.31;1.97;1.76;1.75;1.54;1.51;1.17;1.16;1.12;1.11;1.05;0.99;0.98;0.98;0.97;0.94;0.92;0.83;0.83","EMANUELE NICASTRI;ANDREA ANTINORI;ENRICO GIRARDI;CHIARA AGRATI;FRANCESCO VAIA;FRANCESCA COLAVITA;DELIA GOLETTI;GIULIA MATUSALI;CONCETTA CASTILLETTI;SILVIA MESCHI;ROBERTA GAGLIARDINI;FABRIZIO MAGGI;ALESSANDRA VERGORI;VALENTINA MAZZOTTA;MARIA ROSARIA CAPOBIANCHI;VINCENZO PURO;DANIELE LAPA;PIERLUCA PISELLI;STEFANIA CICALINI;LINDA PETRONE","44;41;34;32;29;27;26;22;21;17;16;16;16;16;16;15;14;13;13;13","EMANUELE NICASTRI;ANDREA ANTINORI;ENRICO GIRARDI;CHIARA AGRATI;DELIA GOLETTI;FRANCESCO VAIA;FRANCESCA COLAVITA;CONCETTA CASTILLETTI;ANDREA FRUSTACI;FABRIZIO MAGGI;MARIA ROSARIA CAPOBIANCHI;GIULIA MATUSALI;GIUSEPPE SBERNA;CRISTINA CHIMENTI;MARCO TRIPODI;ANNA ROSA GARBUGLIA;ROMINA VERARDO;ALESSANDRA VERGORI;LICIA BORDI;ROBERTA GAGLIARDINI","2.78;2.31;1.97;1.76;1.75;1.54;1.51;1.17;1.16;1.12;1.11;1.05;0.99;0.98;0.98;0.94;0.83;0.83;0.81;0.78","ANDREA ANTINORI;FABRIZIO MAGGI;CRISTINA MUSSINI;SILVIA NOZZA;ABRAHAM GOORHUIS;ACHYUTA NORI;ANNAMARIA CATTELAN;ANN‐BRIT EG HANSEN;CHLOE ORKIN;CHRISTIAN HOFFMANN;CHRISTOPH BOESECKE;CLAIRE PINTADO;DARRELL H. S. TAN;DAVIDE MOSCHESE;ELENA SENDAGORTA;FERNANDO MALTÊZ;IAIN REEVES;JEZER I. LEZAMA;JOHANNES NEMETH;JOHN THORNHILL","2935;2018;1665;1651;1643;1643;1643;1643;1643;1643;1643;1643;1643;1643;1643;1643;1643;1643;1643;1643","ANDREA ANTINORI;FABRIZIO MAGGI;FRANCESCO VAIA;ENRICO GIRARDI;EMANUELE NICASTRI;DANIELE LAPA;VALENTINA MAZZOTTA;STEFANIA CICALINI;VINCENZO PURO;FRANCESCA COLAVITA;ALESSANDRA MARANI;ANNA ROSA GARBUGLIA;GIULIA MATUSALI;CHIARA AGRATI;SILVIA MESCHI;FABRIZIO CARLETTI;ROBERTA GAGLIARDINI;CARMELA PINNETTI;SERENA VITA;ALESSANDRA D’ABRAMO","2925;2009;1316;1279;1229;1118;1098;1026;949;871;852;827;802;771;746;738;615;613;606;603","EMANUELE NICASTRI;ANDREA ANTINORI;ENRICO GIRARDI;FRANCESCO VAIA;CHIARA AGRATI;FRANCESCA COLAVITA;DELIA GOLETTI;GIULIA MATUSALI;CONCETTA CASTILLETTI;SILVIA MESCHI;ALESSANDRA VERGORI;FABRIZIO MAGGI;ROBERTA GAGLIARDINI;MARIA ROSARIA CAPOBIANCHI;VALENTINA MAZZOTTA;DANIELE LAPA;VINCENZO PURO;ANNA ROSA GARBUGLIA;LINDA PETRONE;CARMELA PINNETTI","43;40;35;29;29;25;25;21;20;17;16;15;15;15;14;14;14;13;13;13","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;COMPUTER SCIENCE;CHEMISTRY;PSYCHOLOGY;SOCIOLOGY;GEOGRAPHY;ECONOMICS;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE;ART;BUSINESS;GEOLOGY;HISTORY;MATERIALS SCIENCE","162;81;18;15;14;9;9;9;8;7;7;3;3;1;1;1;1;1","INTERNAL MEDICINE;VIROLOGY;IMMUNOLOGY;PATHOLOGY;GENETICS;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;PEDIATRICS;GASTROENTEROLOGY;FAMILY MEDICINE;OPTICS;SURGERY;COMPUTATIONAL BIOLOGY;DEMOGRAPHY;ECOLOGY;MICROBIOLOGY;CELL BIOLOGY;ELECTRICAL ENGINEERING;ONCOLOGY;PSYCHIATRY","114;82;78;53;44;31;24;15;15;13;12;11;10;9;9;9;9;8;8;8;8","DISEASE;GENE;VIRUS;IMMUNE SYSTEM;OUTBREAK;HUMAN IMMUNODEFICIENCY VIRUS (HIV);POPULATION;ANTIBODY;VACCINATION;TUBERCULOSIS;COHORT;PNEUMONIA;INCIDENCE (GEOMETRY);EPIDEMIOLOGY;RETROSPECTIVE COHORT STUDY;TRANSMISSION (TELECOMMUNICATIONS);IN VITRO;LOGISTIC REGRESSION;TRANSPLANTATION;CANCER;MECHANICAL VENTILATION","77;41;32;29;29;28;26;21;20;18;16;14;11;9;9;9;8;8;8;7;7","INFECTIOUS DISEASE (MEDICAL SPECIALTY);2019-20 CORONAVIRUS OUTBREAK;VIRAL LOAD;MYCOBACTERIUM TUBERCULOSIS;GENOME;RECOMBINANT DNA;HEPATITIS B VIRUS;CD8;POLYMERASE CHAIN REACTION;SEROLOGY;T CELL;LIVER TRANSPLANTATION;PHYLOGENETIC TREE;TITER;CARDIOMYOPATHY;GENOTYPE;HEPATITIS C VIRUS;MUTATION;NEUTRALIZING ANTIBODY;PHENOTYPE;VIREMIA","60;24;17;9;8;8;7;6;6;6;6;5;5;5;4;4;4;4;4;4;4","CORONAVIRUS DISEASE 2019 (COVID-19);ANTIRETROVIRAL THERAPY;VACCINIA;LATENT TUBERCULOSIS;BOOSTER DOSE;LAMIVUDINE;REVERSE TRANSCRIPTASE;RIBAVIRIN;SUPAR;WHOLE GENOME SEQUENCING;AMPLICON;CLADE;ELISPOT;EPITHELIAL–MESENCHYMAL TRANSITION;ESTROGEN RECEPTOR;GENOTYPING;HBSAG;HEALTH FACILITY;HEPATITIS DELTA;LENTIVIRUS;PROVIRUS;SEXUAL TRANSMISSION;SINGLE-NUCLEOTIDE POLYMORPHISM","59;11;7;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;COVID-19;;HIV INFECTIONS;SARS-COV-2;ANTIBODIES, VIRAL;TUBERCULOSIS;HIV-1;FEMALE;ITALY;MALE;ADULT;RNA, VIRAL;ANTI-HIV AGENTS;COVID-19 VACCINES;VACCINATION;PANDEMICS;BNT162 VACCINE;IMMUNOGLOBULIN G;ANTIBODIES, NEUTRALIZING","115;96;68;63;58;25;24;21;20;20;20;18;18;16;14;14;13;11;11;10","CORONAVIRUS DISEASE 2019 RESEARCH;CORONAVIRUS DISEASE 2019;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;TUBERCULOSIS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND PATHOBIOLOGY OF MONKEYPOX VIRUS INFECTION;HEPATITIS C INFECTION AND TREATMENT;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;DIAGNOSTIC METHODS FOR COVID-19 DETECTION;HEPATITIS B INFECTION AND TREATMENT;CLOSTRIDIUM DIFFICILE INFECTION AND TREATMENT;DIVERSITY AND FUNCTION OF GUT MICROBIOME;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;IMPACT OF COVID-19 INFECTION ON PREGNANCY OUTCOMES;LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;MANAGEMENT OF VENTILATOR-ASSOCIATED PNEUMONIA IN ICU PATIENTS;MOLECULAR MECHANISMS OF AMYLOIDOSIS;POLYOMAVIRUS-ASSOCIATED CARCINOGENESIS AND CLINICAL MANIFESTATIONS","34;21;10;10;7;7;4;4;3;3;3;3;2;2;2;2;2;2;2;2","2019-20 CORONAVIRUS OUTBREAK;HIV;PANDEMIC;VACCINES;ANTIRETROVIRAL THERAPY;ANTIVIRAL TREATMENT;HIV TRANSMISSION;IMMUNITY;MONKEYPOX;HIV EPIDEMIOLOGY;HIV INFECTION;REGIMEN;T CELL IMMUNITY;TREATMENT;DOLUTEGRAVIR;MONKEYPOX VIRUS;NASOPHARYNGEAL SWAB;SALIVA TESTING;CLINICAL CHARACTERISTICS;CORONAVIRUS","21;17;14;10;9;9;7;7;7;6;6;6;6;6;5;5;5;5;4;4","COVID- PATIENTS;COVID- PNEUMONIA;IMMUNE RESPONSE;LAZIO REGION;REGION ITALY;SARS-COV- INFECTION;COHORT STUDY;COVID- PANDEMIC;PEOPLE LIVING;T-CELL IMMUNE;VIRAL LOAD;COVID- VACCINATION;HOSPITALIZED PATIENTS;HUMAN IMMUNODEFICIENCY;IMMUNE ACTIVATION;IMMUNE RESPONSES;IMMUNODEFICIENCY VIRUS;LATENT TUBERCULOSIS;MRNA VACCINATION;MRNA VACCINE;OBSERVATIONAL STUDY;PREGNANT WOMEN;TUBERCULOSIS INFECTION;ACUTE RESPIRATORY;AIRWAY EPITHELIUM;ANGIOTENSIN-CONVERTING ENZYME;ANTIRETROVIRAL THERAPY;BACTERIAL RESISTANCE;BILIARY LESIONS;BNTB VACCINATION","7;6;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2","COVID- PATIENTS;SARS-COV- INFECTION;MONKEYPOX VIRUS;PUBMED GOOGLE;ROME ITALY;SITE PUBMED;PUBMED SCOPUS;IMMUNE RESPONSE;OMICRON VARIANT;SCHOLARCROSSREFSEARCH ADS;T-CELL RESPONSE;ADS PUBMED;INFECTIOUS DISEASES;ACUTE RESPIRATORY;CD COUNT;CROSSREF PUBMED;DELTA VARIANT;GOOGLE SCHOLARCROSSREFSEARCH;HEALTH CARE;HIV- DNA;ITALY SEARCH;LOGISTIC REGRESSION;SARS-COV- VARIANTS;COVID- PANDEMIC;PUBLIC HEALTH;TUBERCULOSIS TB;DAY DAY;STATISTICALLY SIGNIFICANT;SYMPTOM ONSET;UNVACCINATED PATIENTS","37;35;29;29;26;23;19;18;16;16;16;15;15;14;13;13;13;13;13;13;13;13;13;12;12;12;11;11;11;11",102,0.55,11.15,12,1,2,0,58.75,0,1,1,14,1.5,0,10,5.5,7.75,2,4,8,3.5,0,0,24.75,24.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,2,28,1.01,0,0,7.33,0,0,2,0,0,0,1,0,0,1,0,0,0,0,0,0,0,3,0,0,1,2,0,0,0,0,0,0,0,0,"United States","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","3;3","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;LYMPHOMA;PATIENT SAFETY;RARE DISEASES","1;1;1;1;1;1;1","CANCER;INFECTION","1;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.2 CELLULAR AND GENE THERAPIES","2;1;1","NON-HODGKIN'S LYMPHOMA","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",1,20998624,145823.78,4,144,32,1,7,1244090.07593839,0.14950685934835,"AARHUS UNIVERSITY;AIX-MARSEILLE UNIVERSITY;AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT;ANTONI VAN LEEUWENHOEK HOSPITAL;ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE;ATOMIC ENERGY AND ALTERNATIVE ENERGIES COMMISSION;AUGUST PI I SUNYER BIOMEDICAL RESEARCH INSTITUTE;AVIA-GIS (BELGIUM);BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE;BIOBANKING AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE - ERIC;BIOMEDICAL PRIMATE RESEARCH CENTRE;BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS;BRAC UNIVERSITY;CENTRE DE COOPÉRATION INTERNATIONALE EN RECHERCHE AGRONOMIQUE POUR LE DÉVELOPPEMENT;CENTRO AGRICOLTURA AMBIENTE (ITALY);CHARITÉ - UNIVERSITY MEDICINE BERLIN;CHARLES UNIVERSITY;COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION;DEPARTMENT FOR ENVIRONMENT, FOOD AND RURAL AFFAIRS","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","HORIZON-INFRA-2021-EMERGENCY-02 (CALL FOR PROPOSAL);HORIZON-RIA - HORIZON  RESEARCH AND INNOVATION ACTIONS (FUNDING SCHEME);HORIZON.1.3 - RESEARCH INFRASTRUCTURES (PROGRAMME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;46 INFORMATION AND COMPUTING SCIENCES","1;1;1","EMERGING INFECTIOUS DISEASES","1","INFECTION","1","2.4 SURVEILLANCE AND DISTRIBUTION","1",NA,NA,NA,NA,"A05 BIOLOGICAL SCIENCES","1",NA,NA,19,"SPRINGER NATURE;FRONTIERS;PUBLIC LIBRARY OF SCIENCE;TAYLOR & FRANCIS GROUP","8;6;3;2","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;3202 CLINICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS;3107 MICROBIOLOGY;34 CHEMICAL SCIENCES;46 INFORMATION AND COMPUTING SCIENCES;3203 DENTISTRY;3204 IMMUNOLOGY;3208 MEDICAL PHYSIOLOGY;3401 ANALYTICAL CHEMISTRY;37 EARTH SCIENCES;3704 GEOINFORMATICS;4612 SOFTWARE ENGINEERING","20;11;6;5;3;2;2;2;2;2;1;1;1;1;1;1;1","INFECTIOUS DISEASES;CLINICAL RESEARCH;BIODEFENSE;EMERGING INFECTIOUS DISEASES;PREVENTION;VACCINE RELATED;BIOTECHNOLOGY;IMMUNIZATION;LUNG;PNEUMONIA;PNEUMONIA & INFLUENZA;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIABETES;DIGESTIVE DISEASES;HEPATITIS;HEPATITIS - B;HIV/AIDS;LIVER DISEASE;NUTRITION;RARE DISEASES","8;7;5;5;5;5;4;4;2;2;2;1;1;1;1;1;1;1;1;1","INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;METABOLIC AND ENDOCRINE","7;1;1","3.4 VACCINES;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION","4;1;1;1","CLINICAL;BIOMEDICAL","5;2","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","12;2","LIVER CANCER;NOT SITE-SPECIFIC CANCER","1;1","3 GOOD HEALTH AND WELL BEING","4"
"IRCCS_SPALLANZANIROMA",2023,146,18.4109589041096,6.24657534246575,0.458904109589041,0.452054794520548,0.547945205479452,3.41573033707865,1.31372549019608,2.53846153846154,1.53846153846154,0.910958904109589,0,63,23,12,6,0.43,0.16,0.08,0.04,6.85,1.56266833622324,6.61208053691272,0.267123287671233,0.945205479452055,0.592,0.488,0.502,0.5,"FABRIZIO MAGGI;ANDREA ANTINORI;ENRICO GIRARDI;EMANUELE NICASTRI;VALENTINA MAZZOTTA;FRANCESCO VAIA;GIULIA MATUSALI;ALESSANDRA VERGORI;ROBERTA GAGLIARDINI;DELIA GOLETTI;ANNA ROSA GARBUGLIA;LAVINIA FABENI;ANTONELLA D’ARMINIO MONFORTE;FRANCESCA COLAVITA;CARMELA PINNETTI;ROMINA VERARDO;ANNALISA MONDI;SILVIA MESCHI;ANDREA FRUSTACI;FABRIZIO CARLETTI","44;43;30;27;22;21;18;16;15;14;14;13;13;11;11;11;11;10;10;10","FABRIZIO MAGGI;ANDREA ANTINORI;ENRICO GIRARDI;ROMINA VERARDO;ANNA ROSA GARBUGLIA;ANDREA FRUSTACI;EMANUELE NICASTRI;FRANCESCO VAIA;GIULIA MATUSALI;DELIA GOLETTI;VALENTINA MAZZOTTA;VERDIANA ZULIAN;MARIA CHIARA GATTO;LAVINIA FABENI;DANIELE FOCOSI;CRISTINA CHIMENTI;ALESSANDRA VERGORI;ROBERTA GAGLIARDINI;MARIA ALFARANO;ROSSELLA SCIALLA","3.56;2.88;1.92;1.79;1.75;1.69;1.47;1.3;1.16;1.07;1.04;0.94;0.91;0.9;0.89;0.88;0.81;0.77;0.76;0.7","FABRIZIO MAGGI;ANDREA ANTINORI;ENRICO GIRARDI;EMANUELE NICASTRI;VALENTINA MAZZOTTA;FRANCESCO VAIA;GIULIA MATUSALI;ALESSANDRA VERGORI;ROBERTA GAGLIARDINI;DELIA GOLETTI;ANNA ROSA GARBUGLIA;LAVINIA FABENI;FRANCESCA COLAVITA;CARMELA PINNETTI;ROMINA VERARDO;ANNALISA MONDI;SILVIA MESCHI;ANDREA FRUSTACI;FABRIZIO CARLETTI;CHIARA AGRATI","44;43;30;27;22;21;18;16;15;14;14;13;11;11;11;11;10;10;10;9","FABRIZIO MAGGI;ANDREA ANTINORI;ENRICO GIRARDI;ROMINA VERARDO;ANNA ROSA GARBUGLIA;ANDREA FRUSTACI;EMANUELE NICASTRI;FRANCESCO VAIA;GIULIA MATUSALI;DELIA GOLETTI;VALENTINA MAZZOTTA;VERDIANA ZULIAN;MARIA CHIARA GATTO;LAVINIA FABENI;CRISTINA CHIMENTI;ALESSANDRA VERGORI;ROBERTA GAGLIARDINI;MARIA ALFARANO;ROSSELLA SCIALLA;CARLA FONTANA","3.56;2.88;1.92;1.79;1.75;1.69;1.47;1.3;1.16;1.07;1.04;0.94;0.91;0.9;0.88;0.81;0.77;0.76;0.7;0.69","VALENTINA MAZZOTTA;ANTONELLA D’ARMINIO MONFORTE;ANDREA ANTINORI;FABRIZIO MAGGI;SILVIA NOZZA;CRISTINA MUSSINI;CHLOE ORKIN;ACHYUTA NORI;ADRIÀ MENDOZA;AGNÈS LIBOIS;ALBA CATALÀ;ALBERTO CASTILLO;ALBERTO DOS SANTOS DE LEMOS;ALEXANDRA CALMY;ALMA LETICIA RODRÍGUEZ GUZMÁN;ALVARO FURTADO COSTA;ANDREA ALEMANY;ANGELICA GARCÍA TELLO;ANIRUDDHA HAZRA;ANJA MÖNCH","419;308;298;287;270;265;263;261;261;261;261;261;261;261;261;261;261;261;261;261","VALENTINA MAZZOTTA;FABRIZIO MAGGI;ANDREA ANTINORI;EMANUELE NICASTRI;ENRICO GIRARDI;FRANCESCO VAIA;GIULIA MATUSALI;CARMELA PINNETTI;DELIA GOLETTI;FRANCESCA COLAVITA;ROBERTA GAGLIARDINI;ANNALISA MONDI;FABRIZIO CARLETTI;SERENA VITA;SILVIA MESCHI;DANIELE LAPA;SIMONE LANINI;LAVINIA FABENI;ELIANA SPECCHIARELLO;ALESSANDRA AIELLO","419;284;280;210;186;173;154;110;103;99;94;87;87;86;78;70;70;69;65;62","FABRIZIO MAGGI;ANDREA ANTINORI;ENRICO GIRARDI;EMANUELE NICASTRI;VALENTINA MAZZOTTA;FRANCESCO VAIA;GIULIA MATUSALI;ROBERTA GAGLIARDINI;ALESSANDRA VERGORI;CARMELA PINNETTI;ANNALISA MONDI;ANNA ROSA GARBUGLIA;DELIA GOLETTI;LAVINIA FABENI;FRANCESCA COLAVITA;FABRIZIO CARLETTI;ROMINA VERARDO;SILVIA MESCHI;ALESSIA BECCACECE;CESARE ERNESTO MARIA GRUBER","43;39;30;27;22;21;18;16;15;15;14;14;13;12;11;11;11;10;9;9","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;SOCIOLOGY;COMPUTER SCIENCE;ENGINEERING;ECONOMICS;GEOGRAPHY;MATHEMATICS;POLITICAL SCIENCE;PSYCHOLOGY;BUSINESS;PHILOSOPHY","133;62;13;10;9;8;6;5;5;5;2;2;1;1","INTERNAL MEDICINE;IMMUNOLOGY;VIROLOGY;GENETICS;PATHOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;CARDIOLOGY;SURGERY;GASTROENTEROLOGY;PEDIATRICS;MICROBIOLOGY;DEMOGRAPHY;INTENSIVE CARE MEDICINE;OPTICS;COMPUTATIONAL BIOLOGY;CELL BIOLOGY;PHARMACOLOGY;DERMATOLOGY;CANCER RESEARCH;EMERGENCY MEDICINE;FAMILY MEDICINE;RADIOLOGY","94;73;60;35;33;22;22;13;13;12;12;11;8;8;8;7;6;6;5;4;4;4;4","DISEASE;GENE;VIRUS;IMMUNE SYSTEM;ANTIBODY;HUMAN IMMUNODEFICIENCY VIRUS (HIV);OUTBREAK;VACCINATION;POPULATION;COHORT;INCIDENCE (GEOMETRY);TUBERCULOSIS;HEART FAILURE;REGIMEN;COHORT STUDY;EPIDEMIOLOGY;IN VITRO;INFLAMMATION;LUNG;BACTERIA;CONFIDENCE INTERVAL;DRUG RESISTANCE;LOGISTIC REGRESSION;OBSERVATIONAL STUDY;PNEUMONIA;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY","49;34;29;27;23;23;20;19;18;12;9;9;8;8;7;7;7;6;6;5;5;5;5;5;5;5;5","INFECTIOUS DISEASE (MEDICAL SPECIALTY);VIRAL LOAD;TITER;2019-20 CORONAVIRUS OUTBREAK;CARDIOMYOPATHY;GENOTYPE;GENOME;HEPATITIS B VIRUS;HEPATITIS C VIRUS;IMMUNITY;MUTATION;POLYMERASE CHAIN REACTION;CLINICAL ENDPOINT;FABRY DISEASE;MICRORNA;NEUTRALIZING ANTIBODY;PERIPHERAL BLOOD MONONUCLEAR CELL;RECOMBINANT DNA;SEROCONVERSION;VIRAL DISEASE","34;22;11;9;8;8;6;5;5;5;5;5;4;4;4;4;4;4;4;4","CORONAVIRUS DISEASE 2019 (COVID-19);ANTIRETROVIRAL THERAPY;BOOSTER DOSE;HBSAG;VACCINIA;WHOLE GENOME SEQUENCING;ANTIBODY TITER;HERPESVIRIDAE;RESTRICTIVE CARDIOMYOPATHY;REVERSE TRANSCRIPTASE;RIBAVIRIN;SECUKINUMAB;TORQUE TENO VIRUS;ADENOSINE RECEPTOR;AL AMYLOIDOSIS;AMPLICON;ANTIGENIC DRIFT;ANTISYNTHETASE SYNDROME;ANTIVIRAL THERAPY;APOBEC;AUTOPHAGOSOME;BECK ANXIETY INVENTORY;BECN1;CD3;CEFTAZIDIME;CHIKUNGUNYA FEVER;CTGF;CYCLIN-DEPENDENT KINASE 1;DIGITAL POLYMERASE CHAIN REACTION;DISEASE MANAGEMENT;EL TOR;FRAMESHIFT MUTATION;GENE FLOW;GENITAL WARTS;HISTONE DEACETYLASE;HOST ADAPTATION;IMMUNOGLOBULIN M;KIDNEY TRANSPLANT;KLEBSIELLA;KLEBSIELLA PNEUMONIA;KLEBSIELLA PNEUMONIAE;LENTIVIRUS;LONG TERMINAL REPEAT;MACROPHAGE INFLAMMATORY PROTEIN;MEN WHO HAVE SEX WITH MEN;MICROARRAY;MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR;MICROVESICLES;MODEL FOR END-STAGE LIVER DISEASE;MOLECULAR CLOCK;MOLECULAR EPIDEMIOLOGY;MULTILOCUS SEQUENCE TYPING;MYCOBACTERIUM ABSCESSUS;NKG2D;OMALIZUMAB;PARKIN;PHLEBOVIRUS;PITTSBURGH SLEEP QUALITY INDEX;PLK1;POINT MUTATION;POLYMORPHISM (COMPUTER SCIENCE);PRENATAL DIAGNOSIS;PROCTITIS;PYRIN DOMAIN;RNA INTERFERENCE;SANGER SEQUENCING;SCHISTOSOMA HAEMATOBIUM;SCHISTOSOMA MANSONI;SIDA;SINGLE-NUCLEOTIDE POLYMORPHISM;SPINDLE APPARATUS;STREPTOCOCCUS INTERMEDIUS;STREPTOCOCCUS PYOGENES;SUMO PROTEIN;TOLL-LIKE RECEPTOR;UBIQUITIN LIGASE;USUAL INTERSTITIAL PNEUMONIA;VECTOR (MOLECULAR BIOLOGY);VIRAL PATHOGENESIS;VIRAL PHYLODYNAMICS;VIRAL QUASISPECIES","34;14;3;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;HIV INFECTIONS;COVID-19;SARS-COV-2;ITALY;ANTI-HIV AGENTS;FEMALE;MALE;HIV-1;VIRAL LOAD;ADULT;MPOX (MONKEYPOX);RETROSPECTIVE STUDIES;ANTIBODIES, VIRAL;TORQUE TENO VIRUS;TUBERCULOSIS;COVID-19 VACCINES;PYRIDONES;RILPIVIRINE","85;60;46;42;28;20;17;14;14;11;11;9;9;9;8;8;8;7;7;7","CORONAVIRUS DISEASE 2019 RESEARCH;EPIDEMIOLOGY AND PATHOBIOLOGY OF MONKEYPOX VIRUS INFECTION;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;HEPATITIS C INFECTION AND TREATMENT;TUBERCULOSIS;VIRAL DISEASES IN LIVESTOCK AND POULTRY;CORONAVIRUS DISEASE 2019;GLOBAL IMPACT OF ARBOVIRAL DISEASES;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;MOLECULAR MECHANISMS OF AMYLOIDOSIS;HEPATITIS B INFECTION AND TREATMENT;LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;NEUROLOGICAL MANIFESTATIONS OF COVID-19 INFECTION;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;DIAGNOSIS AND MANAGEMENT OF KAWASAKI DISEASE;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;DIAGNOSTIC METHODS FOR COVID-19 DETECTION;EPIDEMIOLOGY AND PATHOGENESIS OF RESPIRATORY VIRAL INFECTIONS;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;MANAGEMENT AND EPIDEMIOLOGY OF INFECTIVE ENDOCARDITIS","24;13;8;6;5;5;4;4;4;4;3;3;3;3;2;2;2;2;2;2","2019-20 CORONAVIRUS OUTBREAK;ANTIRETROVIRAL THERAPY;IMMUNITY;REGIMEN;HIV;TREATMENT;DOLUTEGRAVIR;HIV INFECTION;PANDEMIC;VACCINES;CLINICAL ENDPOINT;SEROCONVERSION;VIRAL TRANSMISSION;ANTIVIRAL THERAPY;ANTIVIRAL TREATMENT;BOOSTER DOSE;CARDIAC AMYLOIDOSIS;CONCORDANCE;DIAGNOSIS;DILATED CARDIOMYOPATHY","8;8;8;8;7;6;5;5;5;5;4;4;4;3;3;3;3;3;3;3","PEOPLE LIVING;SARS-COV- INFECTION;TRANSPLANT RECIPIENTS;COHORT STUDY;HIV INFECTION;IMMUNE RESPONSE;LAZIO REGION;MPOX VIRUS;OBSERVATIONAL STUDY;COVID- MRNA;COVID- PATIENTS;FABRY DISEASE;LIVER TRANSPLANT;MRNA VACCINE;REGION ITALY;TUBERCULOSIS INFECTION;ACUTE HIV;ADVANCED HIV;ANTIBODY RESPONSE;AUTOCHTHONOUS DENGUE;BOOSTER DOSE;CARDIAC RECOVERY;CHANGING HCV;CONDUCTION TISSUE;COVID- VACCINES;CROSS-SECTIONAL ANALYSIS;DISEASE CARDIOMYOPATHY;ELECTRICAL INSTABILITY;HCV PATIENT;HUMORAL IMMUNE","6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","SARS-COV- INFECTION;VIRAL LOAD;CD COUNT;PERSONAL FEES;WRITING REVIEW;EDITING SUPPORTING;IMMUNE RESPONSE;DATA CURATION;IMMUNE RESPONSES;SUPPORTING WRITING;BOOSTER DOSE;CARDIOVASCULAR RISK;ENDOMYOCARDIAL BIOPSY;HIV INFECTION;LEFT VENTRICULAR;PEOPLE LIVING;PROJECT ADMINISTRATION;ACUTE RESPIRATORY;ANTIRETROVIRAL THERAPY;CONDUCTION TISSUE;COVID- PATIENTS;DISEASE SEVERITY;PATIENTS TREATED;ADMINISTRATION SUPPORTING;CD CELL;COVID- PNEUMONIA;HUMORAL RESPONSE;IMMUNE SYSTEM;MYOCARDIAL INFLAMMATION;OBSERVATIONAL STUDY","23;17;16;15;14;13;13;11;11;11;10;10;10;10;10;10;10;9;9;9;9;9;9;8;8;8;8;8;8;8",80,0.55,3.7,5.25,1,1.75,0,8,0,1,0,5.25,1.75,0,5,0,1,1,2,4,2.25,0,0,7,7,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,8,0.88,2,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BECCARI ANDREA ROSARIO;BORDI LICIA;IACONIS DANIELA;MANELFI CANDIDA;MATUSALI GIULIA;NICASTRI EMANUELE;SCORZOLINI LAURA;TALARICO CARMINE","1;1;1;1;1;1;1;1","DOMPE FARMACEUTICI SPA;ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE ""LAZZARO SPALLANZANI"" IRCCS","1;1","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY","1;1;1",NA,NA,NA,NA,"A61K31/4535;A61P31/14","1;1","A61K31/4535;A61P31/14","1;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,6183822,363754.24,5,17,8,1,1,987988.189663883,0.147775045822835,"BIOMEDICAL PRIMATE RESEARCH CENTRE;DEPARTMENT OF HEALTH;FRENCH NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;INSTITUT PASTEUR;ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI;LEIDEN UNIVERSITY MEDICAL CENTER;LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE;MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY;PASTEUR INSTITUTE OF LILLE;PAUL SABATIER UNIVERSITY;STATENS SERUM INSTITUT;TUBERCULOSIS VACCINE INITIATIVE;UNIVERSITY OF BASEL;UNIVERSITY OF LEICESTER;UNIVERSITY OF OXFORD;UNIVERSITY OF ULM;UNIVERSITY OF ZARAGOZA","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","HORIZON-HLTH-2022-DISEASE-06-TWO-STAGE (CALL FOR PROPOSAL);HORIZON-RIA - HORIZON  RESEARCH AND INNOVATION ACTIONS (FUNDING SCHEME);HORIZON.2.1 - HEALTH (PROGRAMME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY","1;1;1","BIODEFENSE;BIOTECHNOLOGY;EMERGING INFECTIOUS DISEASES;HIV/AIDS;IMMUNIZATION;INFECTIOUS DISEASES;LUNG;ORPHAN DRUG;PREVENTION;RARE DISEASES;TUBERCULOSIS;TUBERCULOSIS VACCINE;VACCINE RELATED","1;1;1;1;1;1;1;1;1;1;1;1;1","INFECTION","1","3.4 VACCINES","1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1","3 GOOD HEALTH AND WELL BEING","1",16,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;TAYLOR & FRANCIS GROUP","11;3;2","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;49 MATHEMATICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;48 LAW AND LEGAL STUDIES;3103 ECOLOGY;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;4203 HEALTH SERVICES AND SYSTEMS;4905 STATISTICS;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;37 EARTH SCIENCES;40 ENGINEERING;47 LANGUAGE, COMMUNICATION AND CULTURE;4705 LITERARY STUDIES;4802 ENVIRONMENTAL AND RESOURCES LAW","12;6;5;4;3;3;2;2;2;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;INFECTIOUS DISEASES;PREVENTION;EMERGING INFECTIOUS DISEASES;GENETICS;PATIENT SAFETY;IMMUNIZATION;RARE DISEASES;VACCINE RELATED;BIOTECHNOLOGY;BRAIN DISORDERS;CYSTIC FIBROSIS;DIGESTIVE DISEASES;HEPATITIS;HEPATITIS - B;HUMAN GENOME;LIVER DISEASE;LUNG;NEUROSCIENCES;ORPHAN DRUG","6;6;6;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1","INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;CONGENITAL","9;2;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;3.4 VACCINES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","3;1;1;1;1;1","BIOMEDICAL;CLINICAL","2;1","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH","3;3;3",NA,NA,"3 GOOD HEALTH AND WELL BEING","6"
"IRCCS_SPALLANZANIROMA",2024,119,21.2016806722689,5.8655462184874,0.571428571428571,0.445378151260504,0.630252100840336,2.97021276595745,1.41666666666667,3.11764705882353,1.59574468085106,0.798319327731092,0,58,23,6,2,0.49,0.19,0.05,0.02,0.94,0.984798587062994,4.68120085775555,0.369747899159664,0.974789915966387,0.564,0.449,0.493,0.489,"ANDREA ANTINORI;ENRICO GIRARDI;FABRIZIO MAGGI;VALENTINA MAZZOTTA;EMANUELE NICASTRI;ANTONELLA D’ARMINIO MONFORTE;ROBERTA GAGLIARDINI;LOREDANA SARMATI;ALESSANDRA VERGORI;GIULIA MATUSALI;ALESSANDRO COZZI‐LEPRI;ILARIA MASTROROSA;DELIA GOLETTI;A. CINGOLANI;ANNALISA MONDI;CARLA FONTANA;PIETRO GIORGIO SPEZIA;ANTONELLA CASTAGNA;MARIA LETIZIA GIANCOLA;ANTONIO DI BIAGIO","41;38;34;25;23;16;15;15;15;15;12;12;11;10;10;9;9;9;9;8","FABRIZIO MAGGI;ENRICO GIRARDI;ANDREA ANTINORI;EMANUELE NICASTRI;VALENTINA MAZZOTTA;GIULIA MATUSALI;STEFANIA CICALINI;ANDREA FRUSTACI;DELIA GOLETTI;DANIELE FOCOSI;ROBERTA GAGLIARDINI;GUIDO GRANATA;ANNA ROSA GARBUGLIA;ROMINA VERARDO;CARLA FONTANA;EMANUELA FRUSTACI;ILARIA MASTROROSA;PIETRO GIORGIO SPEZIA;ALESSANDRA D’ABRAMO;ANTONELLA D’ARMINIO MONFORTE","2.87;2.22;2.18;1.44;1.34;1;0.95;0.86;0.83;0.79;0.79;0.76;0.75;0.74;0.66;0.63;0.59;0.59;0.56;0.56","ANDREA ANTINORI;ENRICO GIRARDI;FABRIZIO MAGGI;VALENTINA MAZZOTTA;EMANUELE NICASTRI;ROBERTA GAGLIARDINI;ALESSANDRA VERGORI;GIULIA MATUSALI;ILARIA MASTROROSA;DELIA GOLETTI;ANNALISA MONDI;CARLA FONTANA;PIETRO GIORGIO SPEZIA;MARIA LETIZIA GIANCOLA;LAVINIA FABENI;ALESSANDRA D’ABRAMO;CARMELA PINNETTI;GILDA CUZZI;ANDREA FRUSTACI;ANNA ROSA GARBUGLIA","41;38;34;25;23;15;15;15;12;11;10;9;9;9;8;8;7;7;7;7","FABRIZIO MAGGI;ENRICO GIRARDI;ANDREA ANTINORI;EMANUELE NICASTRI;VALENTINA MAZZOTTA;GIULIA MATUSALI;STEFANIA CICALINI;ANDREA FRUSTACI;DELIA GOLETTI;ROBERTA GAGLIARDINI;GUIDO GRANATA;ANNA ROSA GARBUGLIA;ROMINA VERARDO;CARLA FONTANA;ILARIA MASTROROSA;PIETRO GIORGIO SPEZIA;ALESSANDRA D’ABRAMO;ALESSANDRA VERGORI;SILVIA PAUCIULLO;MARIA LETIZIA GIANCOLA","2.87;2.22;2.18;1.44;1.34;1;0.95;0.86;0.83;0.79;0.76;0.75;0.74;0.66;0.59;0.59;0.56;0.54;0.52;0.5","ENRICO GIRARDI;ANDREA ANTINORI;FABRIZIO MAGGI;EMANUELE NICASTRI;ÁNGELA CANO;ROBERTA GAGLIARDINI;GIULIA MATUSALI;LOREDANA SARMATI;ANNALISA MONDI;PIERLUIGI VIALE;SERENA VITA;VALENTINA MAZZOTTA;ALESSANDRO COZZI‐LEPRI;CARMELA PINNETTI;FRANCESCO GIUSEPPE DE ROSA;DANIELE LAPA;DELIA GOLETTI;GEORGE Ν. DALEKOS;CARLA FONTANA;ALESSANDRA VERGORI","39;28;27;23;22;20;18;17;16;16;16;16;15;15;15;14;14;14;13;12","ENRICO GIRARDI;FABRIZIO MAGGI;ANDREA ANTINORI;EMANUELE NICASTRI;ROBERTA GAGLIARDINI;GIULIA MATUSALI;SERENA VITA;ANNALISA MONDI;VALENTINA MAZZOTTA;CARMELA PINNETTI;DANIELE LAPA;DELIA GOLETTI;ASSUNTA NAVARRA;CARLA FONTANA;RAFFAELE STRIPPOLI;SILVIA MESCHI;ALESSANDRA VERGORI;ANTONIO DICARO;NICOLA PETROSILLO;STEFANIA NOTARI","36;27;25;23;19;18;16;15;15;14;14;14;12;12;12;12;11;11;11;11","ENRICO GIRARDI;ANDREA ANTINORI;FABRIZIO MAGGI;EMANUELE NICASTRI;VALENTINA MAZZOTTA;GIULIA MATUSALI;ROBERTA GAGLIARDINI;ALESSANDRA VERGORI;DELIA GOLETTI;CARMELA PINNETTI;CARLA FONTANA;ANNALISA MONDI;LAVINIA FABENI;MARIA LETIZIA GIANCOLA;PIETRO GIORGIO SPEZIA;SERENA VITA;ANDREA FRUSTACI;ALESSANDRA D’ABRAMO;ANNA ROSA GARBUGLIA;GILDA CUZZI","35;35;33;23;22;13;13;12;11;10;9;8;8;8;8;8;7;7;7;7","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ENGINEERING;COMPUTER SCIENCE;POLITICAL SCIENCE;BUSINESS;GEOGRAPHY;PSYCHOLOGY;MATERIALS SCIENCE;PHILOSOPHY;SOCIOLOGY;ART;ECONOMICS;ENVIRONMENTAL SCIENCE;GEOLOGY;HISTORY;MATHEMATICS","109;55;8;7;7;6;5;4;4;3;2;2;2;1;1;1;1;1;1","INTERNAL MEDICINE;VIROLOGY;IMMUNOLOGY;PATHOLOGY;GENETICS;BIOCHEMISTRY;MICROBIOLOGY;ENVIRONMENTAL HEALTH;PEDIATRICS;INTENSIVE CARE MEDICINE;SURGERY;GASTROENTEROLOGY;PHARMACOLOGY;CARDIOLOGY;FAMILY MEDICINE;PALEONTOLOGY;CANCER RESEARCH;CELL BIOLOGY;ELECTRICAL ENGINEERING;LAW;NEUROSCIENCE;OPTICS;PSYCHIATRY","69;55;44;32;26;15;14;11;11;10;9;7;7;6;6;5;4;4;4;4;4;4;4","DISEASE;GENE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);VIRUS;COHORT;OUTBREAK;COHORT STUDY;ANTIBODY;TUBERCULOSIS;VACCINATION;IMMUNE SYSTEM;ANTIBIOTICS;POPULATION;TRANSPLANTATION;CANCER;CLINICAL TRIAL;DRUG;DRUG RESISTANCE;PROPORTIONAL HAZARDS MODEL;TRANSMISSION (TELECOMMUNICATIONS)","39;24;24;24;15;14;12;9;9;9;8;7;6;6;5;5;5;5;5;5","INFECTIOUS DISEASE (MEDICAL SPECIALTY);VIRAL LOAD;2019-20 CORONAVIRUS OUTBREAK;GENOTYPE;HEPATITIS B VIRUS;MYCOBACTERIUM TUBERCULOSIS;POLYMERASE CHAIN REACTION;RECOMBINANT DNA;ENZYME REPLACEMENT THERAPY;FABRY DISEASE;HEPATITIS C VIRUS;ANTIBIOTIC RESISTANCE;CARDIOMYOPATHY;GENOME;IMMUNOGENICITY;LIVER TRANSPLANTATION;MYCOBACTERIUM;PERIPHERAL BLOOD MONONUCLEAR CELL;SYPHILIS;CLINICAL ENDPOINT;ENTEROVIRUS;HAZARD RATIO;INFECTIVITY;KIDNEY TRANSPLANTATION;METASTASIS;PHENOTYPE;PLACEBO;PLASMODIUM FALCIPARUM;REAL-TIME POLYMERASE CHAIN REACTION;RENAL TRANSPLANT;SEROLOGY;SMALLPOX;TIGECYCLINE;TITER;UNIVARIATE ANALYSIS;VIRAL DISEASE;VIREMIA","25;19;9;6;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);ANTIRETROVIRAL THERAPY;HBSAG;VACCINIA;TORQUE TENO VIRUS;GENOTYPING;MEN WHO HAVE SEX WITH MEN;MYCOBACTERIUM ABSCESSUS;REACTOGENICITY;REVERSE TRANSCRIPTASE;SIDA;ACINETOBACTER BAUMANNII;ACTIN CYTOSKELETON;ANTIBIOTIC STEWARDSHIP;ANTIMICROBIAL STEWARDSHIP;ANTIMYCOBACTERIAL;APOBEC;BK VIRUS;BOOSTER DOSE;BROTH MICRODILUTION;BRUTON'S TYROSINE KINASE;CANDIDA KRUSEI;CASPOFUNGIN;CHEMOIMMUNOTHERAPY;CUTANEOUS LYMPHOMA;DIGITAL POLYMERASE CHAIN REACTION;DOUBLE BLIND;ENTEROVIRUS 71;EPITHELIAL–MESENCHYMAL TRANSITION;FRONTOTEMPORAL DEMENTIA;GLOBOTRIAOSYLCERAMIDE;HEPATITIS DELTA;HUMAN VIROME;IBRUTINIB;KLEBSIELLA PNEUMONIAE;LAMIVUDINE;LYMPHOPLASMACYTIC LYMPHOMA;MERKEL CELL POLYOMAVIRUS;MEROPENEM;MYCOBACTERIUM KANSASII;MYELOID-DERIVED SUPPRESSOR CELL;NONTUBERCULOUS MYCOBACTERIA;PEMPHIGOID;PHLEBOVIRUS;PLASMODIUM VIVAX;POLYMORPHISM (COMPUTER SCIENCE);PRAZIQUANTEL;PROPIDIUM MONOAZIDE;REVERSION;RPOB;SAPS II;SEXUAL TRANSMISSION;SINGLE-NUCLEOTIDE POLYMORPHISM;TOLL-LIKE RECEPTOR;TRANSCRIPTOME;TRANSVERSION;VANCOMYCIN;VECTOR (MOLECULAR BIOLOGY);VIRAL HEMORRHAGIC FEVER;VIRAL QUASISPECIES;WHOLE GENOME SEQUENCING","24;11;4;4;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;HIV INFECTIONS;COVID-19;SARS-COV-2;AGED;ITALY;VIRAL LOAD;ANTI-HIV AGENTS;BIOMARKERS;ANTIVIRAL AGENTS;COHORT STUDIES;HIV-1;CROSS-SECTIONAL STUDIES;CYTOKINES;DNA, VIRAL","63;56;30;28;27;24;19;17;15;13;11;11;9;8;7;7;6;5;5;5","CORONAVIRUS DISEASE 2019 RESEARCH;EPIDEMIOLOGY AND PATHOBIOLOGY OF MONKEYPOX VIRUS INFECTION;TUBERCULOSIS;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;VIRAL DISEASES IN LIVESTOCK AND POULTRY;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;DIAGNOSTIC METHODS FOR COVID-19 DETECTION;EMERGING ZOONOTIC DISEASES AND ONE HEALTH APPROACH;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;HEPATITIS C INFECTION AND TREATMENT;BIOLOGICAL, EPIDEMIOLOGICAL, AND CLINICAL ASPECTS OF ECHINOCOCCOSIS;CORONAVIRUS DISEASE 2019;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HEPATITIS B INFECTION AND TREATMENT;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;MACROPHAGE ACTIVATION AND POLARIZATION;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA","9;7;7;6;6;5;4;4;3;3;3;3;3;2;2;2;2;2;2;1","HIV;2019-20 CORONAVIRUS OUTBREAK;TREATMENT;PANDEMIC;ANTIRETROVIRAL THERAPY;HIV INFECTION;ANTIVIRAL TREATMENT;HIV TRANSMISSION;IMMUNE RESPONSES;IMMUNITY;MONKEYPOX;MONKEYPOX VIRUS;MYCOBACTERIUM ABSCESSUS;REGIMEN;TORQUE TENO VIRUS;VACCINES;CARDIOMYOPATHIES;CARDIOVASCULAR MAGNETIC RESONANCE;CLINICAL CHARACTERISTICS;CLINICAL ENDPOINT","11;10;7;6;5;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2","COHORT STUDY;ICONA COHORT;ITALIAN MULTICENTRE;LIVER TRANSPLANTATION;TENO VIRUS;TORQUE TENO;TRANSPLANT RECIPIENTS;BICTEGRAVIREMTRICITABINETENOFOVIR ALAFENAMIDE;BOOSTER DOSE;CARDIOMYOCYTE REGENERATION;CELL RESPONSE;CENTRAL ITALY;CLINICAL OUTCOMES;COMBINATION THERAPY;COVID- PANDEMIC;COVID- PATIENTS;COVID- PNEUMONIA;DISEASE CARDIOMYOPATHY;DRUG RESISTANCE;ENZYME REPLACEMENT;FABRY DISEASE;HIV INFECTION;HUMAN MYOCARDITIS;INTRAVENOUS METRONIDAZOLE;MONKEYPOX VIRUS;MRNA VACCINATION;MULTICENTER STUDY;MULTICENTRE COHORT;MULTIPLE SCLEROSIS;NEWLY DIAGNOSED","7;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","COVID- PATIENTS;TTV VIREMIA;VIRAL LOAD;DAY MORTALITY;COVID- PANDEMIC;CD COUNT;COMBINATION THERAPY;MONOCLONAL ANTIBODIES;VIREMIA LOG;ANTIRETROVIRAL THERAPY;DIGITAL HEALTH;LEFT VENTRICULAR;SARS-COV- INFECTION;BREAKTHROUGH INFECTIONS;COX REGRESSION;IMMUNE RESPONSE;LOGISTIC REGRESSION;MEDIAN AGE;NERVOUS SYSTEM;RISK FACTORS;AMPLT MGDL;BEMPEDOIC ACID;CRYPTIC HBV-DNA;DNA DAMAGE;DNA METHYLATION;ELECTRON MICROSCOPY;HIGHLY SENSITIVE;HIV INFECTION;HIV PATIENTS;HIV PWH","15;11;10;9;8;7;7;7;7;6;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,3193004.5,198195.76,3,15,11,1,0,726783.114347961,0.163735229466306,"DÉLÉGATION PARIS 11;INSTITUTO DE SALUD CARLOS III;ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI;MEDICAL UNIVERSITY OF GRAZ;NATIONAL INSTITUTE OF HEALTH DR. RICARDO JORGE;PUBLIC HEALTH AGENCY OF SWEDEN;AIX-MARSEILLE UNIVERSITY;BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE;CHARITÉ - UNIVERSITY MEDICINE BERLIN;COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION;DEPARTMENT OF HEALTH;ERASMUS MC;EUROPEAN MOLECULAR BIOLOGY LABORATORY;FEDERAL DEPARTMENT OF DEFENCE, CIVIL PROTECTION AND SPORTS;FRIEDRICH-LOEFFLER-INSTITUT;INSTITUT PASTEUR;KU LEUVEN;LEIBNIZ INSTITUTE DSMZ – GERMAN COLLECTION OF MICROORGANISMS AND CELL CULTURES;NATIONAL HEALTH LABORATORY SERVICE;NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT","2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","HORIZON-INFRA-2023-DEV-01 (CALL FOR PROPOSAL);HORIZON.1.3 - RESEARCH INFRASTRUCTURES (PROGRAMME);HORIZON-CSA - HORIZON COORDINATION AND SUPPORT ACTIONS (FUNDING SCHEME);HORIZON-RIA - HORIZON  RESEARCH AND INNOVATION ACTIONS (FUNDING SCHEME)","2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3507 STRATEGY, MANAGEMENT AND ORGANISATIONAL BEHAVIOUR;48 LAW AND LEGAL STUDIES","1;1;1;1;1","INFECTIOUS DISEASES","1","INFECTION","2",NA,NA,NA,NA,NA,NA,"B11 COMPUTER SCIENCE AND INFORMATICS;C18 LAW","1;1","3 GOOD HEALTH AND WELL BEING","1",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
